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Abstract

Abstract
Alzheimer’s disease (AD), the commonest form of dementia, is a chronic,
progressive neurodegenerative disease which manifests clinically as a slow
global decline in cognitive function, including deterioration of memory,
reasoning, abstraction, language and emotional stability, culminating in a
patient with end-stage disease, totally dependent on custodial care. With an
ageing population, there is predicted to be a marked increase in the number of
people diagnosed with AD in the coming decades, making this a significant
challenge to socio-economic policy and aged care. Currently there is no cure for
AD and while current therapies may temporarily ameliorate symptoms, death
usually occurs approximately 8 years after diagnosis. Attention is now being
directed to the discovery of biomarkers that may not only facilitate presymptomatic diagnosis but provide an insight into aberrant biochemical
pathways that may reveal potential therapeutic targets. AD pathogenesis
develops over many years before clinical symptoms appear, providing the
opportunity to develop therapy that could slow or stop disease progression well
before any clinical manifestations develop.
Research and understanding of AD pathology has been driven in recent years
by advances in technologies, enabling the precise investigation of the lipidome;
the repertoire of lipid species present in cells and tissues that reflect the net
effect of gene and protein expression, which in turn are influenced by the
cellular

environment.

Lipidomic studies have identified abnormal lipid

metabolism as a key component of the pathological processes which lead to the
development of AD. Therefore, lipidomic studies are crucial for advancing the
understanding of AD pathology and for identifying potential therapeutic targets;
these studies may also facilitate biomarker discovery. Many studies have
reported abnormal lipid profiles in both AD plasma and brain tissue.
This thesis investigated plasma lipid species using a “shotgun” lipidomics
approach by electrospray ionisation tandem mass spectrometry (ESI/MS/MS).
Additionally, Phospholipid Transfer Protein (PLTP); a protein involved in lipid
metabolism was assayed using a commercial kit. The utility of these analytes as
potential AD biomarkers was investigated by testing plasma samples from the
i
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highly characterised Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
The study cohort comprised over 1000 participants at inception who were
classified as either healthy control (n=733), mild cognitive impairment (MCI,
n=125) or AD (n=204): Samples from the baseline and 18 month follow-up time
points were utilised. Plasma PLTP activity levels were measured in a subset of
the baseline samples (n=259). Lipid and PLTP measurements were analysed in
conjunction with supplementary neuroimaging and blood biomarker data
collected as part of the AIBL study.
The thesis identified significant differences in several plasma lipids between
clinical classification groups, including several ceramide, sphingomyelin (SM),
phosphatidylethanolamine (PE), phosphatidylcholine (PC) and plasmalogen
species. Additionally, a panel of lipids was identified which could distinguish AD
participants from healthy controls with a sensitivity and specificity of 80%.
Plasma PLTP activity was significantly lower in AD and MCI groups compared
to healthy controls, and levels correlated with plasma Aβ in all groups and
cerebral Aβ in the healthy controls.
The results of this thesis validate and extend previous findings reported in the
literature. The current findings provide evidence to indicate that several lipid
species and PLTP show promise as potential blood biomarkers of AD. Further
investigation using a targeted lipidomics platform and prospective longitudinal
follow-up is warranted.
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1.1

Alzheimer’s Disease – Background

Alzheimer’s disease (AD) is the commonest form of dementia, initially identified
by Alois Alzheimer in 1906. It is a chronic, progressive neurodegenerative
disease manifesting clinically as a disturbance in multiple higher functions of the
brain, including memory, thinking, orientation, comprehension, calculation,
learning capacity, language and judgement.
It can also be accompanied by deterioration in emotional control, motivation or
social behaviour [1, 2]. In advanced stages, care by family members and carers
is required to assist with daily living and ultimately an inability to recognise
family members exacerbates the huge emotional burden. On average, the
disease progresses from initial mild symptoms to severe dementia over a period
of about eight years, with many sufferers requiring institutional care for several
years.
The greatest risk factor for AD is age and so with an ageing population, there is
predicted to be a marked increase in the number of AD cases in the coming
decades; in both the developed and developing world [3, 4]. In Australia,
approximately 300,000 people are suffering from dementia, with this figure
expected to be close to 1 million by 2050 [5].
Current estimates put a direct cost of $AUD3.2 billion to the healthcare system
in Australia with a predicted increase to $AUD6billion within the next five years
[6]. This represents a major economic burden to an already stretched
healthcare budget. According to the Alzheimer’s Association in the US, unpaid
care by family members and caregivers in 2009 represented $144 billion. These
alarming

statistics

emphasise

the

importance

of

gaining

a

greater

understanding of the pathophysiology of AD with the aim of developing tests
that will identify those at risk before the clinical hallmarks of AD manifest.
Currently, post mortem examination of the affected brain still provides the most
affirmative diagnosis of AD, however with advances in brain imaging (amyloid
ligand positron emission tomography (PET)), amyloid beta (Aβ) can now be
visualised ante-mortem. This may assist in identifying pre-clinical stages of
disease. Ultimately early diagnosis, identification of those at risk and the
1
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development of intervention strategies offers the best chance of significantly
reducing the number of AD cases.
1.1.1

AD Pathology – hallmarks of disease

In AD, the rate at which nerve cells deteriorate and die rapidly increases, greatly
outstripping renewal and repair mechanisms resulting in shrinkage of several
areas of the brain [7]. The causes and factors leading to disease progression
are poorly understood but AD pathology is characterised by the presence of
senile plaques, beta-amyloid (Aβ) deposits and neurofibrillary tangles in the
cerebral cortex and sub-cortical grey matter.
An interesting and until recently often overlooked feature of AD pathology,
originally described by Alois Alzheimer, is an increased number of “lipoid
granules” in the AD brain [8]. Despite this observation, understanding the
connection between abnormal lipid metabolism and AD has progressed slowly,
although renewed interest in this area of AD pathology is gaining momentum
due to the technological advances in lipid analyses.
There is much debate in the literature as to which of these hallmarks are
causative and which result from other patho-physiological processes. Multiple
factors have been implicated in the aetiology and pathogenesis of AD. These
factors include genetic defects, abnormal lipid metabolism, energy metabolism
deficits and mitochondrial defects, inflammation, abnormal amyloid precursor
protein processing, deficiency of neurotrophic factors, glutamate excitotoxicity,
free-radical induced neuron degeneration and trace element toxicity. It is
unlikely that any of these factors are isolated, but when combined with
imbalances in neurotransmitters and hormones and impaired hepatic metabolic
and detoxification pathways, a complex web of dysfunctional biochemistry is
established, resulting in the characteristic AD pathology [7].
1.1.2

Amyloid Plaques

Amyloid plaques are a characteristic feature of AD and contain aggregates of
Aβ, a 4kDa peptide of 39-43 amino acids normally found in the brain, albeit at
low concentrations [9]. The plaques when visualised at post-mortem are
typically spherical and range from 10-150nm [10] (see Figure 1.1A). Aβ is a
2
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protein fragment cleaved by the action of secretase enzymes from its larger
parent protein called amyloid precursor protein (APP). APP is located in the
plasma (outer) membrane of brain cells, including neurons, glial cells and the
endothelial cells of the blood brain barrier. APP is an abundant protein in the
central nervous system but is also ubiquitously expressed in the peripheral
tissues such as epithelium, muscle and circulating cells. Platelets are a rich
source of APP and contain concentrations similar to that of brain cells [11].
The APP protein undergoes proteolytic cleavage by enzymes termed BACE
(beta site APP cleaving enzyme) and the α- and γ-secretases which act via two
competing pathways which depend on the localisation of APP to lipid rafts and
feedback loops controlling gene transcription for the appropriate enzymes (see
Section 1.5 and reviewed in [12].
One product of APP cleavage is Aβ of which two main forms of Aβ are
secreted; Aβ40 and Aβ42 consisting of 40 and 42 amino acids respectively. Aβ42
accounts for approximately 10% of secreted Aβ, but is the main form found in
amyloid plaques, suggesting a more pathological role for Aβ42 due to its ability
to aggregate and polymerise into amyloid fibrils more readily than Aβ40 [9]. An
overproduction or reduced clearance of Aβ is considered a key component of
AD and

alterations in A kinetics may contribute to the induction of

inflammation, oxidation and neurotoxicity, turning a physiologically relevant
protein into a potentially toxic one [13].
Evidence also suggests that soluble oligomers of Aβ known as amyloid beta
derived diffusible ligands (ADDLs) accumulate and initiate a toxic cascade
before plaque deposition and neuronal death occurs. This may explain the
inconsistencies observed with plaque burden and cognitive deficits [14].
There is no doubt that the evidence suggests a key role for A in the
neuropathology of AD, but the amyloid hypothesis as the sole driver has been
challenged by recent studies using immunisation with pre-aggregated A1-42,
demonstrating that in spite of almost complete elimination of senile plaques
from the AD brain, cognitive decline still progressed [15]. This evidence has
also been corroborated by the failure in clinical trials of the gamma-secretase
inhibitor semagacestat, which reduced A production, but failed to retard
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disease progression [16]. However, the patients used in these trials had
advanced disease, where any increased clearance of Aβ may have occurred
too late to influence cognitive decline. Further trials are required that target early
stage disease. Moreover, it has been suggested that A deposition merely
represents a protective response to some other pathophysiological process or is
involved with the chelation of potentially oxidative transition metals [17]. A more
detailed section on APP processing, Aβ generation and lipids is presented later
in the chapter (see Section 1.5.1).
1.1.3

Neurofibrillary tangles

Affected areas of the AD brain have significantly lower neuronal numbers and
the remaining neurons possess reduced numbers of dendrite branches and
synaptic densities. Neurofibrillary tangles (NFTs) arise within individual neurons
as depositions of abnormally twisted filaments (see Figure 1B).
The tau protein in neurons is normally organised in a linear fashion into
microtubules, which give structural integrity and are involved in intracellular
transport [18]. Phosphorylation of tau is part of the normal process of assembly
of microtubules, conferring stability. However, in AD the tau proteins become
hyper-phosphorylated or glycosylated, causing them to twist and form tangles,
which adversely affects neuronal function and results in loss of intracellular
communication [19-21].
The phosphorylation and dephosphorylation of tau, as with other proteins, is
tightly regulated by various kinases and phosphatases and dysregulation of
these processes may contribute to the accumulation of NFTs.
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Figure 1.1: Pathological hallmarks of Alzheimer’s disease. A) Amyloid plaques. B)
Neurofibrillary tangles. C) Cerebral amyloid angiopathy (CAA). Amyloid plaques and NFTs
are stained brown in 1A and 1B. Amyloid can also deposit in the cerebral and meningeal blood
vessels as seen in 1C, where it appears to be associated with increased inflammation and risk
of cerebral haemorrhage [22, 23]. However, both amyloid plaques and CAA can be seen in both
cognitively normal individuals and in AD [24].
(Images adapted from coloradodementia.org and angiopathy.org)

1.1.4

Abnormal Lipid Metabolism

Abnormal lipid metabolism is emerging as a very important pathophysiological
process in the development of AD. This is logical, as the adverse effects of
abnormal lipid metabolism on neuronal biochemistry are numerous; affecting
membrane lipid composition and a myriad of cellular signals generated by lipid
mediators. The link between AD and lipid metabolism was firmly established
when carriage of the apolipoprotein Eε4 allele (APOEε4) was identified as a
major risk factor for AD [25].
In recent years a greater understanding of the interaction between lipids,
amyloidogenesis and tau pathology has emerged, with most classes of lipids
being implicated. This makes sense as lipids are key components of
membranes, providing an environment conducive for fluidity and ion
permeability as well as regulating trafficking and proteolytic activity of key
membrane-bound proteins (including APP, beta site APP cleaving enzyme,
(BACE) and γ-secretase) involved in APP processing and AD [26].
Lipids may also affect the pathogenicity of Aβ by influencing its tendency to
aggregate [27]. Lipid mediators are generated from phospholipids, sphingolipids
and cholesterol by activation of phospholipases, sphingomyelinases and
cytochrome p450-dependent oxygenases respectively, which exert numerous
effects on cellular function. These effects involve modulation of enzyme activity,
5
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neural cell differentiation, immune responses, inflammation, oxidation, cell
migration, mitogenesis and apoptosis and therefore imbalances in any of these
mediators would predictably contribute to AD pathology [28].
Later sections (Section 1.5) will outline the specifics of abnormal lipid
metabolism and how this directly contributes to AD pathology when the
homeostatic mechanisms become dysfunctional. This outline will be followed by
individual discussions of the many integrated factors affecting lipid metabolism,
bearing in mind the significant cross-talk and interaction of these regulatory
factors. These sections have been separated in an attempt to simplify a highly
complex and integrated system. As with other degenerative diseases, there are
many feedback mechanisms and points of control required to maintain
homeostasis, which when altered, synergistically combine to accelerate
pathology.
1.2

Current diagnostic strategies

Current primary care approaches only detect AD once symptoms are already
present, highlighting the need for a pre-symptomatic test. A primary care doctor
relies upon determining a history of cognitive and behavioural change often with
the help of an informant close to the patient.
Other causes of cognitive decline including head trauma, stroke, cancer,
hormone, endocrine and nutrient abnormalities must be excluded by various
testing. If a diagnosis of AD is suspected, the patient can then be referred to a
specialist centre where various cognitive, physical and neurological tests can be
performed alongside brain imaging.
Neuropsychological tests are used to assess memory, problem solving,
communication and mood. Many population studies use a combination of these
tests to improve sensitivity. In reality, no one test or imaging technique provides
a definitive diagnosis and in practice combinations of assessment methods are
used. The National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDSARDA) established AD diagnostic criteria 27 years ago with a reported
sensitivity and specificity of 81% and 70% respectively. To ensure flexibility in
the criteria so that they may be used by both general healthcare providers and
6
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specialist investigators, a recent revision of these criteria by the National
Institute on Aging and the Alzheimer’s Association (NIA/AA) now incorporates
pre-clinical and mild cognitive impairment (MCI) stages [29].
Imaging and other biomarkers are also integrated into research settings to
enhance specificity of diagnosis while key clinical criteria remain the main
diagnostic tool in clinical practice. Emerging biomarker research and validation
is expected to enhance the specificity of these diagnostic criteria. The following
sections outline some of the tests commonly used in current diagnostic
strategies, including those used in the well characterised Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of ageing; the cohort utilised in this study.
1.2.1

Neuropsychological Tests

A battery of neuropsychological tests can be employed to assess the level of
cognitive impairment. These tests investigate the ability to acquire and
remember new information, ability to plan and reason, visuospatial abilities and
language functions. Testing can also help the doctor and family understand the
impact of the disorder on the everyday functioning of the patient. There are
several tests widely used, each having its own strengths and weaknesses.
Relevant tests with respect to AIBL are briefly described below.
1.2.2

Mini Mental State Examination (MMSE)

The MMSE assesses global cognition and represents a commonly used test to
evaluate memory problems as well as assisting with diagnosis of dementia and
assessing progression and severity. The test involves a brief 30 point
questionnaire probing memory, orientation and arithmetic functions [30]. MMSE
scores range from 0 to 30 points: Table 1.1 facilitates interpretation.
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Table 1.1: Mini-Mental State Examination (MMSE) scores and interpretation.

MMSE Score

Interpretation

0-9

Severe AD

10-19

Moderate AD

20-23

Mild cognitive impairment (MCI)

24-30

Normal cognition

Corrections to the score may have to be applied to account for age and
education level, highlighting a limitation of this test, as a well educated person
may score highly even when cognitive impairment is present. Equally a less
educated, cognitively normal person may score in the lower range [31].
Consideration of an individual’s hearing, reading, writing and drawing ability is
also required when interpreting the scores, however despite these limitations,
the MMSE is a useful tool. The MMSE is also capable of differentiating other
types of dementia as AD patients typically score lower on orientation than
Parkinson’s, Lewy body and vascular dementia cases [32].
1.2.3

Clinical Dementia Rating (CDR) scale

The CDR is a scale used to assess the severity of dementia. Developed by
John Morris in 1997 at the Washington University School of Medicine, a
structured interview assesses the effects of cognitive loss on everyday activities
[33]. Memory, orientation, judgement, problem solving, community affairs,
personal care, home and hobbies are assessed and an algorithm applied to
obtain a combined score of 0 to 3 as follows:
Table 1.2: Clinical Dementia Ratio (CDR) scale and interpretation.

Total Score

Dementia

0

None

0.5

Very mild

1

Mild

2

Moderate

3

Severe
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The CDR is capable of detecting very mild cognitive deficits but it is however
time consuming and a subjective measure. Despite its limitations it is widely
accepted as a valid tool for assessing cognitive function.
1.2.4

Alzheimer’s Disease Assessment Scale – Cognitive subscale
(ADAS-Cog)

This test was specifically designed to evaluate the severity of cognitive decline
and behavioural changes in AD [34] . This test is similar to the MMSE and uses
a structured scale to probe executive functioning (the ability to carry out daily
tasks, planning and decision making), memory, attention, language and
orientation [35]. Executive functioning loss is an early event in AD.
1.2.5

Neuroimaging

Neuroimaging is an essential component of dementia diagnosis [35, 36].
Structural imaging with computed tomography (CT) or magnetic resonance
imaging (MRI) is routinely used in the clinical evaluation of patients with AD.
These techniques are used to exclude other causes of dementia such as
normal-pressure hydrocephalus, vascular dementia, or intracranial mass. In
addition, the degree of atrophy can be assessed [37].
Cortical atrophy is a consistent finding in AD, particularly within the medial
temporal

lobe

structures

including

the

hippocampus,

amygdala

and

parrahippocampal gyrus [38] (see Figure 1.2). Due to its high resolution (50100μm), MRI can assist with diagnosis of AD by assessing specific brain region
volumes, for example hippocampal atrophy.
Further, a recent study has shown good correlation between MRI determined
grey matter volumes and total tau/Aβ levels in cerebrospinal fluid (CSF; a highly
sensitive differential diagnostic test for AD) and explored the utility of MRI as a
predictor of CSF total tau/Aβ levels. [39]. Structural changes are likely to be a
feature of late stage disease and are predicted by functional changes seen with
positron emission tomography (PET).
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1.2.6

Positron Emission Tomography (PET)

PET is an imaging technique that enables three dimensional imaging and
assessment of functional processes in the body by detecting gamma rays
indirectly emitted by a positron emitting tracer such as 18F-fluorodeoxyglucose
(FDG) or Pittsburgh compound B (PiB) [40, 41]. FDG is an analogue of glucose
and is used to assess metabolic activity and regional glucose uptake, which is
reduced in regions of the brain in those with AD [35].
The use of tracers has enabled a more robust differential diagnosis of AD from
other dementias, due to the identification of the PiB compound ([N-methyl-11C]
2-(4’-methylaminophenyl)-6-hydroxybenzothiazole). PiB directly binds to Aβ and
can be used to assess brain Aβ burden [42]. However, individuals can
accumulate Aβ and remain cognitively stable, and therefore PET imaging can
facilitate interpretation of other measures but currently cannot be used alone as
a predictor of cognitive decline (see Figure 1.2).
In addition, these imaging tests are currently limited to specialist or research
centres and are expensive to perform, so the need for the development of
other, cheaper and more accessible predictive tests is crucial.
This study aims to identify a blood lipid biomarker panel which can facilitate
development of a definitive diagnostic test ante-mortem.
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Figure 1.2: Age-matched AIBL Study participants. The AD brain on the right shows cortical
atrophy and high concentrations of bound PiB (yellow/red), indicating a high amyloid load in
these regions. The healthy brain on the left shows minimal shrinkage and a small amount of
bound PiB.
Image courtesy of Professor Chris Rowe, Austin Health, Heidelberg, Victoria.

1.3

AD Risk factors

AD can be familial or sporadic. Familial Alzheimer’s disease (FAD) is rare,
accounting for less than 5% of all cases and symptoms usually manifest before
age 65. In FAD, the major risk factor is possession of a mutant allele in one of
three currently identified genes, which is inherited in an autosomal dominant
fashion. However other as yet undiscovered genes may also be involved [43].
The genes currently known to carry mutations in FAD are those coding for APP,
Presenilin 1 (PS1) and Presenilin 2 (PS2). Following APP cleavage by BACE,
the membrane-bound complex γ-secretase generates Aβ [9]. The presenilin
genes code for the presenilin proteins that in association with nicastrin, Aph1
(anterior pharynx defective-1) and PEN-2 (presenilin enhancer-2) form the γsecretase complex [44]. The many mutations identified in these three genes
represent a fully penetrant risk factor for developing AD, and while rare
compared to the more common sporadic form, provide a useful model for
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studying patho-physiological processes. There are several known risk factors
for sporadic AD; the more common form accounting for over 95% of all cases
and typically affecting those over 65 years. These known risk factors will be
discussed below.
1.3.1

Age

Advances in medical technology, control of infectious diseases and better living
standards have resulted in an increase in the elderly population. This ensures
an increase in age-related degenerative diseases, including age-related
dementia; of which AD is the most common type. The following graph illustrates
the advancing age of the Australian population since 1901.

Figure 1.3: Life expectancy at birth, 1901-10 to 2008-10 in the Australian population.

The prevalence of AD at age 65 years is estimated to be approximately 5% and
this rises dramatically to 20% for those over 80 years [3]. The multiple factors
that are an inevitable part of the ageing process, such as abnormal lipid
metabolism, mitochondrial defects, inflammation, oxidation, imbalances in
neurotransmitters and hormones, compromised immune function, reduced
hepatic detoxification capacity, digestive disorders and nutrient deficiencies,
likely contribute to AD pathogenesis.
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Apolipoprotein E ε4 allele (APOEε4)

1.3.2

The late onset form of AD accounts for the majority of AD cases (as defined
previously); with age and possession of the APOEε4 genotype being the
predominant risk factors [45]. In humans the APOE gene is located on
chromosome 19q13.2 [46] and encodes for a 299 amino acid protein of which
there are three isoforms; ε2, ε3 and ε4, resulting from the substitution of a
cysteine with an arginine residue at codons 112 and 158 [47, 48]. Despite the
amino acid difference at only one or two codons, the effect on risk of developing
various diseases is quite marked due to conformational changes and the
influence this has on binding capacity to lipids, proteins and receptors [48, 49].
The following table shows allele frequencies in caucasian and Australian
populations and their influence on disease risk.
Table 1.3: Apolipoprotein E (APOE) gene frequency and disease risk [50-53].

Genotype
112

158

Cys

Allele
Frequency

Disease Association
↑ and ↓ risk for atherosclerosis [54]
and ↑ risk for Parkinson’s Disease
[55]

APOEε2

(Cys

)

7%

APOEε3

(Cys112 Arg158)

79%

Considered neutral
↑ risk for atherosclerosis, AD,
cognitive impairment,

APOEε4

(Arg112 Arg158)

14%

↓ hippocampal volume, faster
progression of multiple sclerosis,
cerebrovascular disease and sleep
apnoea [25, 56-61]

Cys: Cysteine, Arg: Arginine.

The locus within an apolipoprotein gene cluster on chromosome 19 was first
shown to be an AD risk factor in 1993 [25]. ApoE was implicated, based on the
facts that apoE is present in plaques and NFT, it binds to Aβ, and it is also the
commonest brain apolipoprotein.
Further studies then demonstrated a strong allelic association between AD and
the APOEε4 allele [56, 62]. It is estimated that being homozygous for APOEε4
increases the risk of developing AD by the age of 75 by ten to thirty times
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compared to non-carriers of APOEε4 [53]. APOEε2 appears to be protective in
terms of AD risk [53].
Apolipoprotein E (apoE) is the protein encoded by these genes and is an
essential lipid transporter and component of triglyceride rich particles, such as
chylomicrons and very low density lipoproteins (VLDL). ApoE is required for
triglyceride catabolism, is involved with cholesterol metabolism in an isoformdependent way and transports phospholipids and fat soluble vitamins (see
Section 1.7 for more details). The importance of apoE was highlighted when it
was

demonstrated

that

familial

dysbetalipoproteinaemia

(type

III

hyperlipoproteinaemia) resulted from defects in the APOE gene affecting the
function of the apoE protein. As clearance of chylomicrons and VLDL is
impaired, elevated plasma cholesterol and triglycerides result, thereby
increasing risk of cardiovascular and cerebrovascular disease, which are
themselves risk factors for AD [63].
In the central nervous system, apoE is produced by astrocytes and microglia
and neurons express apoE receptors, which are part of the low density
lipoprotein receptor (LDLR) family, responsible for lipid transport among brain
cells [64]. ApoE is a ligand for cell surface lipoprotein receptors, including those
that chaperone APP and it has been shown to be directly involved in APP
processing.
Studies have shown that when apoE is added to cell cultures a decrease in the
secretion of Aβ is observed, with a rise in the APP C-terminal fragments;
suggesting inhibition of γ-secretase and a subsequent reduction in Aβ
generation [65]. There are several known mechanisms for clearing Aβ from the
brain, and defects in any mechanism will contribute to an increase in brain Aβ
load. The Aβ peptide can be cleaved directly by proteolytic enzymes, such as
neprilysin and insulin degrading enzyme (IDE) [66]. Alternatively, Aβ can be
internalised in apoE containing lipoprotein particles which can bind to low
density lipoprotein receptor-related protein 1 (LRP1) receptors present on
microglia, astrocytes and neurons – these particles are then endocytosed and
transported to lysosomes for breakdown and recycling [67, 68].
Aβ can also be cleared in a similar manner by receptor-mediated transport into
the periphery, following binding to LRP1-receptors on the blood brain barrier
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(BBB). This results in efflux from the brain into the systemic circulation for
processing by the liver and excretion via the bile [69]. Aβ40 is transported across
the BBB via LRP1 much faster than Aβ42 [70].
The interaction of apoE-associated particles with Aβ peptides may facilitate the
conversion of soluble to fibrillar Aβ when both apoE particles and Aβ are
increased [71]. The APOEε4 isoform has the lowest affinity for Aβ binding and
is the least effective in promoting both Aβ clearance and cholesterol efflux [72].
It is also the most immuno-reactive and least antioxidant form; all factors by
which APOEε4 increases the risk for AD [73]. Recent studies also suggest that
APOEε4 contributes to Aβ induced apoptosis in neuronal cells by forming a
reactive intermediate that can insert into the lysosomal membrane causing
destabilisation and lysosomal leakage [74, 75].
The APOEε4 allele is associated with high membrane cholesterol levels, which
therefore promotes amyloidogenic APP processing. APOEε4 is also associated
with a reduction in mRNA for the neuronal sortilin-related receptor
(SorLA/LR11), a neuronal sorting protein that reduces APP trafficking to BACE
and γ-secretase [76].
The amount of lipid carried by apoE appears to influence Aβ metabolism. Free
Aβ is efficiently transported across the BBB but this transport is slowed in the
presence of apoE. In addition, the reduced efflux of Aβ is influenced both by the
degree of lipidation of the apoE and the isoform, with APOEε4 showing the
greatest inhibition [77]. Apolipoprotein J, (ApoJ), the other main lipoprotein
secreted by glial cells, promotes the transport of Aβ across the BBB [70].
Studies have shown that when Aβ binds to APOEε4 the transport of Aβ is
redirected from LRP1 to the VLDL receptor (another member of the LDLR
family) resulting in brain retention of Aβ as the binding affinity of the Aβ-apoE
complexes is much lower for VLDL receptors compared to LRP1 [77].
Polymorphisms in the LRP1 gene itself have also been shown to increase risk
of AD [78, 79].
Differences in apoE levels between healthy controls and AD patients have been
reported in plasma and cerebrospinal fluid (CSF), although the results have
been inconsistent [80-83]. Plasma apoE levels measured in the highly
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characterised Australian Imaging, Biomarkers and Lifestyle (AIBL) study of
ageing cohort have recently been shown to be lower in AD, which also
correlated to brain Aβ load determined by PiB-PET imaging [84].
1.3.3

Diet and Nutrition

The type and amount of food eaten has a major influence on plasma lipid
profiles and therefore any lipid biomarker panel. Dietary habits and nutritional
status are also emerging as key components of chronic degenerative diseases,
including AD. This is further compounded by the fact that AD is an age-related
disorder with a general decline of digestive function, absorptive capacity and
assimilation of nutrients.
Atrophic gastritis is common in older people and can affect absorption of key
nutrients such as vitamin B12 and folate [85, 86], which have been associated
with hyperhomocysteinaemia and increased risk of AD [87, 88]. This can also
affect protein absorption and therefore the supply of essential amino acids,
such as tryptophan and tyrosine, which are required for the synthesis of
neurotransmitters such as serotonin and catecholamines [89].
There is an age related decline in metabolic rate [90] and coupled with a
decrease in physical activity, elderly people tend to eat less and may consume
inadequate micronutrients. Additionally, co-morbidities often exist, requiring
pharmaceutical agents that may further compromise nutrient status. The wellestablished risk factors for developing AD are elevated cholesterol and
dyslipidaemia, obesity, diabetes, hypertension, depression, cardiovascular and
cerebrovascular disease (reviewed in [91, 92]), all of which are biochemically
connected and are influenced by diet and possible nutrient deficiencies.
An increase in AD incidence is reported in populations who have a high intake
of saturated fat, trans-fatty acids, refined sugar, processed foods, and total
calories [93]. High fish consumption is inversely correlated with the
development of dementia and moderate alcohol consumption appears to offer a
protective effect [93-95].
Many studies have confirmed the link between high fat/high sugar (HFS) diets
and declining cognitive function, strongly suggesting a role for insulin resistance
and diet-induced endocrine abnormalities [96-99]. Diets that contain high
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saturated fat, cholesterol, added sugar, including high fructose corn syrup
(HFCS), and high glycaemic load foods contribute to dyslipidaemia [100, 101].
Animal studies have shown that a diet high in fat and refined sugar influences
brain structure and function via regulation of neurotrophins [102]. Until recently
it was assumed that the adverse effects of such diets on AD were a direct result
of the negative influence on insulin sensitivity, metabolism and cardiovascular
health. While these are major contributing factors, these studies have shown a
direct effect of such diets on the brain.
Neuronal plasticity is the brain’s ability to compensate for challenges by
influencing synapse formation and neurite growth. A HFS diet has been shown
in animals to decrease brain plasticity via regulation of brain-derived
neurotrophic factor (BDNF) [102]; a major mediator of neuronal plasticity and
contributor to learning and memory capabilities [103, 104]. Animals that learn a
spatial memory task faster have been shown to have more BDNF mRNA and
protein in the hippocampus, and after feeding a HFS for two months, the
hippocampal levels of BDNF were reduced and the animals demonstrated
reduced spacial learning performance [102].
In contrast to the standard western diet, comprising high fat, high refined sugar,
low fibre and high salt, the Mediterranean diet has been shown to reduce the
risk for AD [105, 106]. This eating style focuses on high intakes of vegetables,
legumes, fruits, cereals and unsaturated fatty acids (mainly as oleic acid 18:1n9, the monounsaturated fatty acid found in olive oil). The focus is also on high
fibre, non-refined carbohydrates, making this a low glycaemic eating plan which
helps prevent insulin resistance.
The intake of saturated fatty acids found in animal products is low, and fish
intake is moderately high. Fish contains high levels of omega-3 fatty acids,
docosahexaenoic acid (DHA 22:6n-3) and eicosapentaenoic acid (EPA 20:5n3). Intake of dairy products is low to moderate, with those being consumed
mainly in the form of cheese or yoghurt. Meat and poultry intake is also low and
there is regular consumption of wine, usually with meals [105, 107].
The Mediterranean diet also contains numerous nutrients and plant
phytochemicals that are anti-inflammatory, anti-oxidant and beneficial to health.
For example low dietary intake of antioxidants may contribute to increased
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oxidative stress, a feature of AD [93, 108]. Some of these nutrients and plant
phytochemicals are now being shown to have a powerful influence on gene
transcription factors that influence energy homeostasis, lipid metabolism and
possibly longevity [109-113]. A meta-analysis involving twelve studies with a
total of over 1.5 million people, followed for a period of 3 to 18 years showed a
greater adherence to the Mediterranean eating style was associated with a
reduced risk of mortality and morbidity, including AD [114]. The beneficial
effects were seen in many markers of coagulation and inflammation, including
homocysteine, C-reactive protein, interleukin-6, white cell count and fibrinogen.
Blood lipids and blood pressure were also affected, all of which are risk factors
for both cardiovascular disease and AD [115].
1.3.4

Specific nutrients and AD risk

The above section discussed general dietary considerations and risk for both
metabolic disease and AD. Specific nutrient deficiencies in the elderly may
exacerbate existing pathology in the brain, particularly in the presence of other
risk factors [116].
The formation and maintenance of neurons relies on an adequate supply of the
building blocks and cofactors required for normal functioning of biochemical and
neurotransmitter pathways, all of which must be obtained from the diet [117]. In
addition, mitochondrial decay due to oxidation is a feature of brain ageing and
neurodegenerative disease and an adequate supply of nutrients that protect
mitochondrial enzymes and mitochondrial membranes is crucial to support
cellular energy generation and prevent neurological decline [118].
Vitamins, minerals and other metabolites act as critical cofactors for the
synthesis of mitochondrial enzymes and other pathways and therefore diets that
supply inadequate amounts of micronutrients can accelerate mitochondrial
decay and neurodegeneration [119]. Nutrients supporting mitochondrial function
include B vitamins, vitamin C, cysteine, ubiquinone (CoQ10), lipoic acid,
sulphur, iron, copper, zinc, manganese and magnesium [119]. Deficiencies of
several nutrients have been linked to dementia, including B vitamins, vitamin E,
vitamin A, zinc, essential fatty acids, vitamin D and magnesium.
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There have been several studies that have looked at various nutrient
deficiencies in mild cognitive impairment (MCI). It is probably more ‘useful’ to
study this group in terms of nutrient deficiencies because of the challenges
faced in ensuring adequate dietary intakes associated with different stages of
AD and possibly the increased nutrient requirement of a chronic disease
process [120-123]. Table 1.4 summarises the effect of various nutrients on lipid
metabolism and the known association with AD.
Various nutrients influence lipid metabolism and also have specific effects on
lipid related AD pathology. The importance of methylation pathways in
phospholipid, sphingolipid and sterol metabolism is discussed in Section 1.3.5,
following Table 1.4, as dietary intakes of vitamins B6, B12 and folate influence
these

pathways.

Additionally

epigenetic

modifications

controlling

gene

expression can be adversely affected. Abnormal methylation pathways can
elevate plasma homocysteine levels; a risk factor for developing AD. The
interaction of dietary choline with phospholipid metabolism will also be
discussed in Section 1.3.5..
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Table 1.4: Summary of specific nutrients involved in lipid metabolism that also influence AD pathology.
Nutrient

Influence on Lipid Metabolism

Influence on AD

Vitamin B1
(thiamine)

Coenzyme for pentose phosphate pathway for production of pentose
sugars and NADPH synthesis required for fatty acid synthesis [89].

Thiamine dependent processes reduced in AD brain [125, 126].

High fat diets increase thiamine requirement [89].
Thiamine a cofactor for transketolase, pyruvate dehyrodgenase, αketoglutarate dehydrogenase - involved in energy generation and lipid
/ glucose metabolism [124].

Recent metabolomic study showed up-regulation of pentose phosphate
pathway in those who progressed to AD [127].
Thiamine deficiency associated with dementia [128] and increased CSF
phosphorylated tau [129].
Nerve cell damage resulting from reduction in these enzymes [124].
Thiamine dependent enzymes reduced in AD brain [130-132] causing
increased oxidative stress. Thiamine deficiency induced oxidative stress
promotes Aβ accumulation by regulating BACE maturation [133, 134].

Vitamin B2
(riboflavin)

Precursor of FMN and FAD, redox cofactors for mitochondrial ATP
generation and therefore lipid metabolism [118].
Riboflavin reduces oxidised glutathione, restoring antioxidant capacity
and prevents lipid peroxidation [135]. FAD is cofactor for MTHFR
which converts homocysteine to methionine in methylation pathways –
involved with PL, SL metabolism [118, 136, 137].

Abnormal ATP production and hypometabolism [135, 138].
Reduced glutathione and uric acid and increased homocysteine related to
cognitive decline [139-141].

Vitamin B3
(niacin)

Required for formation of the ubiquitous redox coenzymes NAD and
NADP, for mitochondrial ATP generation and numerous other
biochemical processes involved with lipid metabolism [89].

Niacin deficiency and dementia are linked – important for DNA synthesis and
repair, myelination, dendritic growth, cellular calcium signalling and antioxidation [142-145]. Trials using niacin have shown improvement in cognitive
scores [145, 146].

Vitamin B6
(pyridoxine),

Coenzyme for several reactions in one carbon metabolism, including
synthesis of PC [136]. SAH in methylation pathway is a potent inhibitor
of PEMT, required for PC production [147].

Nutrient insufficiency can increase plasma homocysteine, a risk factor for AD
[139, 150, 151]. Abnormal methylation can increase gene expression of highly
methylated APP, leading to increased Aβ production [152, 153].

Adenosylcobalamin (Vit B12 metabolite) is a mitochondrial cofactor for
the production of succinylCoA for preventing incorporation of odd
chain fatty acids into PLs and SLs [148].

Important for preventing incorporation of odd chain fatty acids into myelin
which can affect nerve conduction [148].

Vitamin B12
(cobalamin)
Folate

Folate is associated with DHA release from the liver via PC and tissue
concentrations of DHA are associated with folate status [149].

In animals dietary folate deficiency causes depletion of DHA in neural tissue
[154].

20

Vitamin E
(tocopherols)

Prevents lipid peroxidation [155, 156]. Transported by PLTP to tissues;
our studies show lower PLTP activity levels (unpublished data – see
Chapter 5). Intracellular accumulation of ceramides and cholesterol
can be blocked by vitamin E [157].

Lower levels associated with AD [159]. In neuronal cultures vitamin E inhibits
Aβ-induced lipid peroxidation and cell death [160, 161].

Gene array studies in rats have associated vitamin E deficiency with
down-regulation of genes involved with lipid metabolism and Aβ
clearance, including growth hormone, thyroid hormones, melatonin
and dopaminergic neurotransmission [158].

Genes affecting Aβ clearance and advanced glycation end products are downregulated in vitamin E deficiency [165].

Zinc

Cofactor for desaturase enzymes involved in PUFA metabolism [166168].

Insulin degrading enzyme is a zinc metallopeptidase, which breaks down Aβ
[169].

Vitamin D

Linked to insulin sensitivity [170] and sex steroid production [171,
172].

Vitamin D up-regulates NPD1 production from DHA and GDNF, promoting
neuronal survival [173].

Vitamin A

Studies in rats have shown vit A deficiency decreases liver content of
PLs [174], probably due to lower PC synthesis and reduced availability
of fatty acids. This may be explained by low activation by the Retinoid
X receptor (RXR) of peroxisome proliferator-activated receptor α
(PPARα) which regulates lipid metabolism [175]. Affects delivery of
PLs to other tissues.

Vitamin A involved in production of α-secretase and acetylcholine reduces
excessive microglial activation [177, 178]. Retinoic acid is a powerful modulator
of excessive inflammation via suppression of IL-6 and TNFα, both of which are
induced by Aβ [178].

Elevated ceramides and cellular cholesterol abnormalities are a feature of AD
[162-164].

Vitamin A insufficiency may contribute to the hypometabolism seen in AD [176,
179].

Essential cofactor for protein kinase C-delta (PKC-delta), a nutritional
sensor regulating energy homeostasis [176].

Abbreviations: ATP: Adenosine Triphosphate, APP: Amyloid Precursor Protein, BACE: Beta site APP Cleaving Enzyme, CSF: Cerebrospinal Fluid, DHA:
Docosahexaenoic Acid, DNA: Deoxyribonucleic Acid, FAD: Flavin Adenine Dinucleotide, FMN: Flavin Mononucleotide, GDNF: Glial Derived Neurotrophic
Factor, IL-6: Interleukin 6, MTHFR: Methylenetetrahydrofolate Reductase, NAD: Nicotinamide Adenine Dinucleotide, NADP: Nicotinamide Adenine
Dinucleotide Phosphate, NPD1: Neuroprotectin D1, PC: Phosphatidylcholine, PEMT: Phosphatidylethanolamine Methyl Transferase, PL: Phospholipid, PLTP:
Phospholipid Transfer Protein, PUFA: Polyunsaturated Fatty Acid, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, SAH: S-adenosyl
Homocysteine, SL: Sphingolipid, TNF-α: Tumour Necrosis Factor alpha.
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1.3.5

Homocysteine, choline and methylation pathways

Homocysteine is a sulphur containing amino acid that exists at a critical
biochemical intersection in the ubiquitous methionine cycle, whose function is to
generate one carbon methyl groups for transmethylation reactions and
synthesise cysteine and taurine [155] (see Figure 1.4). Methionine is converted
to S-adenosyl-methionine (SAMe), which is the most important methyl donor in
the body and is critical for stabilising many macromolecules such as myelin and
DNA. Methylation of DNA is an epigenetic modification that controls gene
expression, including the highly methylated APP gene [152]. Methylation via
SAMe is involved with synthesis of numerous compounds including
phosphatidylcholine, melatonin, serotonin, nor-adrenalin, Coenzyme Q10 and
carnitine [136]. SAMe is a crucial component of both phase I and phase II
detoxification pathways in the liver, providing the methyl group directly. In
addition a balanced methionine cycle is required to supply taurine for bile acid
synthesis and cysteine for both sulphur conjugation and for the formation of
glutathione, which is both an antioxidant and a vital phase I and II component
[136]. All these processes are crucial for both normal neurological and normal
metabolic function.
The link between elevated homocysteine and AD risk has been firmly
established in several studies [139, 150, 151] and homocysteine levels are also
correlated to vitamin B6, B12 and folate status [180-182], but the exact
mechanisms behind the elevated homocysteine and connected metabolites
remain to be fully elucidated. It is probable that elevated homocysteine
promotes AD by more than one mechanism and that while homocysteine serves
as a surrogate marker for nutrient status; which when deficient can promote
neurological damage in its own right, evidence suggests that homocysteine has
direct actions on the brain. Cerebral microangiopathy has been demonstrated in
stroke associated hyperhomocysteinaemia [183] and endothelial dysfunction,
oxidative damage and neuronal DNA damage are all reported consequences of
elevated homocysteine [184-186]. There also appears to be an enhancement of
Aβ mediated neurotoxicity and apoptosis where homocysteine levels are
elevated [187, 188] and homocysteic acid, which is a metabolite of
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homocysteine, is possibly an NMDA agonist itself, causing excitotoxicty and
apoptosis [189, 190].

Figure 1.4: Methylation pathway depicting interaction with phospholipids and
sphingolipids. After donating the methyl group SAMe is converted into homocysteine via Sadenosylhomocysteine (SAH). The homocysteine is then broken down by one of three
pathways. Firstly it can be converted back to methionine by accepting a methyl group from
methylcobalamin (vitamin B12), secondly, it can be converted to methionine by accepting a
methyl group from trimethylglycine (betaine) or thirdly it can be converted to cysteine and
taurine via serine and activated vitamin B6 [155]. The catabolism of homocysteine depends on
an adequate supply of vitamin B6, folate and vitamin B12. The majority of the essential nutrient
choline is present in phosphatidylcholine (PC) and sphingomyelin (SM), major components of all
cell membranes. Additionally, PC and SM are precursors for the signalling molecules ceramide,
platelet activating factor and sphingophosphorylcholine [137]. Choline is required for synthesis
of the neurotransmitter, acetylcholine and as it is oxidised to betaine (trimethylglycine), plays a
crucial role as a methyl donor in the methionine/homocysteine pathway.

The conversion of S-adenosylhomocysteine (SAH) to homocysteine is a
reversible reaction and so elevated homocysteine can also lead to an increase
in SAH which is a potent inhibitor of methyltransferase enzymes (including
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phosphatidylethanolamine

methyltransferase

(PEMT)

required

for

phosphatidylcholine (PC) production), further reducing the capacity of SAMe to
participate

in

methylation

reactions:

This

adversely

affects

numerous

biochemical processes [147]. The APP gene is highly methylated and
decreased methylation may increase expression leading to increased Aβ
production [152, 153]. A link between elevated SAH and polyunsaturated fatty
acid metabolism has also been established in AD [191]. The connection
between homocysteine and lipid metabolism has been further highlighted as
homocysteine-induced

endoplasmic

reticulum

stress

interferes

with

phospholipid metabolism. This has the effect of activating sterol regulatory
element binding proteins (SREBPs) associated with increased expression of
genes involved with cholesterol and triglyceride uptake and intracellular
accumulation of cholesterol (see Section 1.5) [192]. A regulatory feedback
circuit has been identified where SREBP-1 controls the production of SAMe and
therefore PC production, which is dependent on methylation reactions, and
giving merit to the notion that nutritional or genetic factors limiting the production
of SAMe or PC, may activate SREBP-1 and contribute to metabolic dysfunction
[193]. The inhibition of methyltransferase enzymes by SAH is very important in
the brain as the alternate pathway for homocysteine catabolism via
trimethylglycine (betaine) has no activity [87] (see Figure 1.4). Central nervous
system cells can’t export SAH and therefore conversion to homocysteine and
extracellular transport is the only way to remove SAH, causing a subsequent
rise in plasma homocysteine. This raises the possibility that SAH could be the
toxic metabolite, at least in some tissues [147] and that the question of elevated
homocysteine and increased disease risk has been difficult to answer with
certainty.
Dietary fat and cholesterol are transported to the liver via chylomicrons and then
packaged into VLDL in the liver for delivery to other tissues. PC is an essential
component of these lipoproteins and deficiency of choline and PC results in fat
accumulation in the liver. Requirement for choline depends on the status of
other methyl group donors such as folate and SAMe. When dietary choline is
inadequate, the liver has a back-up pathway to provide choline from PE via a
three step methylation pathway by SAMe;

a reaction catalysed by
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Phosphatidylethanolamine-N-methyl transferase (PEMT) [194]. Deficiencies of
nutrients involved in this pathway, could reduce the availability of choline.
Interestingly,

oestrogen

induces

endogenous

synthesis

of

choline

by

upregulating PEMT, which may put postmenopausal women at risk of choline
deficiency, when dietary intakes are inadequate [195]. Additionally disturbed
choline transport is suggested to play a role in various neurological disorders,
including AD [196]. Loss of cholinergic neurons is a feature of AD and various
choline transporters have been investigated as potential targets for increased
choline delivery to the neurons for acetylcholine synthesis [196-198]. Studies
have shown that one of the choline transport systems in erythrocytes is
abnormal in patients with AD [199].
1.3.6

Dietary fatty acids

Apart from dietary fatty acids being an energy generating nutrient, the amount
and type of fat is important for determining disease risk due to the diverse
function of lipids in general; the structure and function of which is influenced by
the fatty acids they contain. It has already been stated that the Mediterranean
style diet, which is low in saturated fat and cholesterol, high in monounsaturated
and polyunsaturated fats and low glycaemic load is beneficial. High saturated
fat intake is strongly associated with the development of dyslipidaemia, insulin
resistance, obesity, diabetes, vascular disease and metabolic abnormalities; all
risk factors for AD [200-202]. Saturated and trans fatty acid intakes are
positively correlated with increased cholesterol levels and unfavourable shifts in
low density lipoprotein: high density lipoprotein (LDL:HDL) ratios [203-205].
Excess palmitic acid can also upregulate ceramide production, which is
considered a major contributor to dyslipidaemia and insulin resistance [206,
207] (see Figure 1.15).
The most commonly consumed fatty acids are myristic (14:0 – 14 carbon chain
length with no unsaturated/double bonds), palmitic (16:0), stearic (18:0), oleic
(18:1) and linoleic (18:2). Each of these fatty acids affects plasma cholesterol
levels differently due to their impact on the LDL receptor, the activity of which is
regulated by the sterol content of the cell via SREBP [89]. When the sterol
content of the cell is low, a fragment of SREBP is cleaved by a protease which
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acts as a transcription factor to activate the LDL receptor gene. Dietary fatty
acids and cholesterol can increase the sterol regulatory pool by their effects on
the enzyme acylCoA-cholesterol acyl transferase (ACAT) [202, 208]. The
activity of this enzyme is determined in part by the amount and type of dietary
fatty acid, which therefore affects plasma cholesterol levels [89]. The saturated
fatty acid, palmitic acid partially inhibits cholesteryl ester (CE) formation by
ACAT, therefore increasing the amount of free cholesterol. As the sterol
regulatory pool increases, SREBP cleavage is inhibited leading to the reduced
expression and activity of the LDL receptor. In contrast, if the liver cells are
enriched with monounsaturated fats (MUFA) and polyunsaturated fats (PUFA),
ACAT activity is increased as it is a preferred substrate and CE formation is
promoted [209]. Short and medium chain saturated fatty acids (4:0, 6:0, 8:0 and
10:0), are rapidly oxidised to acetyl CoA in the liver and do not alter the
concentration of free cholesterol or cholesteryl esters and therefore have no
effect on the LDL receptor. Stearic acid (18:0) has been shown to be neutral in
respect to its effect on plasma cholesterol levels and saturated fatty acids in
general inhibit CE formation and reduce LDL receptor number and activity,
therefore increasing plasma cholesterol levels [202].
Dietary trans fatty acids are known to contribute to dyslipidaemia and
associated increased disease risk [210] and have been linked to brain ageing
and impaired cognition [211, 212]. Most naturally occurring fatty acids have
double bonds in a cis configuration which allows the chain to bend. The trans
bond imparts a rigid structure which is similar to saturated fatty acids and
increased consumption from processed and fast foods can lead to
dyslipidaemia [210] [213]. Trans fatty acids alter membrane fluidity and
responses of various membrane receptors through their incorporation into
membrane phospholipids. As fatty acids are ligands for nuclear receptors, such
as peroxisome proliferator activated receptors (PPARs), liver X receptor (LXR)
and SREBP, regulation of gene transcription can be altered [214-216], directly
modulating metabolic and inflammatory responses in an adverse way. The
effects on lipid metabolism are due to several mechanisms. Firstly, trans fatty
acids alter the secretion, composition and size of apolipoprotein B-100
produced in the liver. This decreases the rate of LDL catabolism. The
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catabolism of ApoAI is increased, which reduces plasma HDL cholesterol.
Trans fatty acids increase the cellular accumulation and secretion of free
cholesterol and cholesterol esters by the liver [217]. The effects on reducing
HDL are thought to be due to an increase in cholesteryl ester transfer protein
(CETP) which transfers cholesterol esters from HDL to LDL and VLDL [218].
Additionally the fluidity, determined by the fatty acid at the sn-2 of PC is a major
regulator of lecithin:cholesterol acyltransferase (LCAT), which is required for the
formation of mature HDL. Trans fatty acids reduce fluidity and can therefore
reduce activity of LCAT [219].
Lipids form the membrane bilayer and are important signalling molecules via the
generation of second messengers [63, 89]. The diet provides fatty acids, or the
precursors for their synthesis, and therefore influences structure and function of
all lipids. Of particular importance are the long chain polyunsaturated fatty acids
(PUFAs) and the ratio of the omega-3 and omega-6 series, which have
opposing effects in terms of the signalling molecules generated. They are
competitive substrates for the enzymes involved in PUFA metabolism [89],
which makes the relative amounts important in terms of the signals generated.
The PUFAs are converted via the action of cyclooxygenase and lipoxygenase
enzymes to prostaglandins, leukotrienes, thromboxanes and other metabolites
which are important mediators of cellular function and therefore the signalling
molecules generated are partly influenced by dietary intakes [220].The omega-6
fatty acids are more inflammatory, atherogenic and pro-thrombotic than the
omega-3 series [89].There are two essential fatty acids that have to be obtained
from the diet as humans lack the delta-12 and delta-15 desaturase enzymes to
produce them from other fatty acids [221, 222]. Linoleic acid (18:2n-6) is
abundant in plants, seeds and nuts and is the precursor for the omega-6 series
of eicosanoids. Alpha-linolenic acid (ALA) (18:3n-3) is the precursor for the
important eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),
which is the most abundant PUFA in the central nervous system (CNS), and is
particularly associated with phosphatidylethanolamine species [223].
Deficiency of the essential fatty acids is rare, but conversion of ALA by the
action of elongase and desaturase enzymes to the longer chain PUFAs is
limited and also affected by hormone imbalances, diet and nutrient deficiencies
27

Chapter 1: Review of the Literature – Lipids and AD
[224-226]. High intakes of omega-6 fatty acids and arachidonic acid (AA) from
meat

can

elevate

pro-inflammatory

eicosanoids

and

up-regulate

pro-

inflammatory cytokines. Levels of the non-enzymatically derived isoprostanes,
which are vasoconstrictive, are also elevated in AA enriched diets [227].
Conversely, diets enriched in DHA from fish and fish oil are more antiinflammatory, anti-thrombotic and vasodilatory and have neuroprotective effects
in terms of synaptic function and plasticity via generation of docosanoids [220,
228]. The ratio of dietary AA to DHA would appear to influence several
diseases, including AD, and may be important in designing nutrition-based
strategies for disease prevention [229]. The brain relies on a supply of AA and
DHA from the periphery, which are delivered via plasma lipoproteins and
lysophospholipids. Unesterified AA and DHA can also enter the brain where
they are esterified into the sn-2 position of phospholipids following activation by
long chain fatty acyl CoA synthase (LC-FACS) [89].
DHA and EPA are important in reducing plasma triglyceride levels as they
regulate the activity of various nuclear receptors resulting in a repartitioning of
fatty acids away from storage as triglycerides and towards oxidation. These
receptors include LXR, hepatocyte nuclear factor 4α, farnesoid X-activated
receptor (FXR), and PPARs. Each of these receptors is in turn regulated by
SREBP-1c [230]. EPA and DHA reduce SREBP-1c which is the main genetic
switch controlling lipogenesis. This reduces the amount of free fatty acids
available for VLDL synthesis. EPA and DHA are highly unsaturated and are
prone to peroxidation which stimulates the degradation of apolipoprotein B
(ApoB), required for VLDL synthesis and their presence in lipoproteins may also
enhance postprandial chylomicron clearance by stimulating lipoprotein lipase
activity [230].
The carbohydrate responsive element binding protein (ChREBP) is a
transcription factor that responds to glucose levels and is involved in hepatic
lipid synthesis by the transcription of genes involved in lipogenesis, such as
fatty acid synthase and acetylCoA carboxylase [231]. ChREBP activity can be
inhibited or normalised by omega-3 fatty acids [230, 231].
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1.3.7

Dietary Carbohydrates

The amount and type of dietary carbohydrate has a significant impact on lipid
profiles and the risk of developing AD risk factors such as cardiovascular
disease and type 2 diabetes. Long term consumption of high glycaemic load,
refined carbohydrates and simple sugars can lead to insulin resistance and
metabolic syndrome [101, 232]. Insulin resistance and metabolic syndrome are
also known risk factors for dyslipidaemia and AD. Insulin resistance results in
an atherogenic lipid profile which also includes a decrease in LDL particle size
and a postprandial accumulation of triglyceride rich remnant lipoproteins.
Adipose tissue becomes resistant to the anti-lipolytic effects of insulin which
increases the concentration of circulating free fatty acids. The combination of
high insulin and free fatty acids acts on the liver to increase the synthesis and
secretion of VLDL causing hypertriglyceridaemia. Once the plasma triglyceride
pool is increased the transfer rate of cholesterol ester by CETP from HDL to
VLDL increases. This then reduces the HDL levels. The fractional catabolic rate
of apolipoprotein A-1 is also increased with high triglycerides [233-235]. The
composition of the LDL particles is also abnormal in insulin resistance as
cholesterol ester depletion results in a small dense LDL [236]. This is due to the
action of CETP which mediates the exchange of VLDL triglyceride for
cholesterol ester in LDL. This triglyceride rich, cholesterol ester depleted LDL
interacts with lipoprotein or hepatic lipase which hydrolyses the triglyceride to
produce small, dense LDL [236]. Excess consumption of simple sugars,
including fructose, can also have adverse effects on lipid metabolism. The liver
rapidly absorbs and metabolises fructose and exposure to large amounts of
fructose leads to lipogenesis and triglyceride accumulation. The accumulation of
triglycerides contributes to reduced insulin sensitivity, hepatic insulin resistance
and impaired glucose intolerance [237] .
From Section 1.3.3 it is clear that diet and specific nutrients contribute to AD
risk indirectly by increasing AD related risk factors such as cardiovascular
disease and type 2 diabetes, but also contributing directly to many lipid-related
processes involved in AD pathology.
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1.3.8

Lifestyle

Apart from dietary considerations, data from observational studies indicate that
several lifestyle factors can reduce the risk of developing AD (reviewed in [238,
239], including physical activity, mental stimulation, being a non-smoker, and
social interaction. Intensity of physical activity has been investigated and
positively associated with improved cognition [240] whilst higher levels of total
physical activity have been shown to be linked to biological and imaging
markers of AD [241]. Being physically active has known beneficial effects on
body composition, insulin sensitivity and lipid profiles. Although a topic of
intense scientific debate, the beneficial effects of physical activity on metabolic
disease and ageing are thought to be mediated via sirtuins (SIRTs) [242].
SIRTs are NAD-dependent histone deacetylases which are activated by cellular
stresses to enhance cellular defense and repair pathways and to mediate
adaptive responses to changing energy requirements and physical activity. This
is achieved by deacetylation and transcriptional control of numerous genes
involved in lipid and glucose metabolism [243]. Additionally Sirt1, has been
shown to attenuate amyloidogenic processing of APP both in cell culture
models and in transgenic mice [244, 245], suggesting a possible mechanistic
link between physical activity and improved markers of AD pathology.
1.3.9

Hormones

As balance and levels of hormones inevitably changes with ageing, many
studies have examined the role of hormones in the pathogenesis of AD. Due to
the highly integrated nature of the endocrine system, the metabolic,
reproductive, adrenal, thyroid, gut-derived, adipocyte-derived and appetite
regulating hormones all have a role to play in terms of their direct effects on AD
pathology, but also their indirect effects due to altered metabolism. Specifically,
all these hormones have a marked effect on lipid homeostasis.
1.3.10

Sex Steroids and Gonadotropins

The first clue as to hormonal involvement in AD is the reported gender
differences in AD risk, with a higher prevalence reported in women, although in
general women have a greater life expectancy [246, 247]. This observation also
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appears to be study group specific with gender differences being reported in
Swedish, Chinese, French and European populations but not within several
large American studies, including the Framingham and Rochester studies [248].
This highlights the complex nature and long duration of the neurodegeneration
seen in AD, with associated co-morbidities and hormonal influences
complicating the picture. It has also been reported that AD pathology and
cognitive deficits are more severe in women, which has prompted the
investigation of sex steroids and risk of AD [249, 250]. The results of studies
into the use of hormone replacement therapy in women to reduce the risk of AD
have been conflicting. The Women’s Health Initiative Memory Study (WHIMS)
showed an almost two-fold increased risk of AD and deficits in cognitive
functioning in older women (over 65 years), but with no effect in younger
women [251, 252]. The Women’s Health Initiative Memory Study of Younger
Women (WHIMSY), included 1326 participants, and concluded that hormone
therapy given to postmenopausal women at ages 50-55 years resulted in no
differences in global cognitive function scores or individual cognitive domains
[252]. Some studies of women who had been on hormone replacement (HRT)
in their 50s found that the HRT did reduce the risk of dementia (whereas there
was no effect if the women in the studies were in their 70s), suggesting that
oestrogen needs to be taken early, perhaps to reduce early pathogenic
mechanisms. Several reasons for these conflicting results include the type of
hormone used, form of delivery and the combination with progesterone. Many
past studies have used conjugated equine oestrogens and/or synthetic
progestins. Studies are required that use bio-identical forms of these hormones.
A recent systematic review of data recommended that hormone therapy should
not be used for dementia prevention [253]. Animal studies into the nonreproductive roles of oestrogen have highlighted neuroprotective and
neurotrophic/synaptic

plasticity

roles

and

effects

on

attenuating

Aβ

accumulation [249]. In premenopausal women, oestrogen may protect against
dietary choline deficiency because oestrogen induces the endogenous
synthesis of choline from PE via the enzyme PE methyl transferase (PEMT)
[195].
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Testosterone has also been shown to have similar neuroprotective properties,
which are likely mediated by the direct action of dihydrotestosterone (DHT) or
via aromatisation to oestrogen [250]. Further, an age related decline in
testosterone production occurs normally after about the third decade which
correlates with cognitive decline. Sex steroid production is regulated by the
complex feedback loops of the hypothalamic-pituitary-gonadal axis (HPG),
involving the pituitary gonadotrophins, luteinising hormone (LH) and follicle
stimulating hormone (FSH). Increasing gonadotrophin levels, as occurs with
age, are now being shown to contribute to AD, with APP processing and Aβ
production, and neuronal cell cycle abnormalities reported [254-256]. A recent
study investigating the association between gonadotrophins, testosterone,
plasma Aβ levels and brain amyloid burden (as determined by PiB retention) in
the AIBL cohort, demonstrated involvement of testosterone and LH at different
stages of disease in men and recommended consideration of their effects when
investigating other potential biomarkers for AD [257].
1.3.11

Metabolic Hormones

In recent years numerous reports have highlighted the strong relationship
between dementia and metabolic disorders that include dyslipidaemia, obesity,
diabetes, cardiovascular disease and hypertension (reviewed in [179, 258262]). While the mechanisms that underpin this association are beyond the
scope of this chapter, it is important to emphasise that the above conditions
rarely occur in isolation, and the complex network of metabolic dysfunction
which occurs in these conditions has been shown to influence many aspects of
AD pathogenesis and neurodegeneration. For example, insulin is required for
blood glucose regulation in the periphery and the brain. When peripheral insulin
resistance (IR) develops metabolic dysfunction results and brain insulin
signalling is altered affecting glucose utilisation, Aβ and tau pathology,
vasculature,

mitochondrial

function,

inflammation,

oxidation,

neuronal

maintenance and plasticity [98, 179, 263, 264]. A neurodegenerative cycle
consisting of AD pathogenesis, insulin resistance and inflammation has often
been described. The components of this cycle have elevated ceramide levels
as a common factor, suggesting these toxic lipids may represent the link
between all these pieces of the AD puzzle [207, 265]. The literature is teeming
32

Chapter 1: Review of the Literature – Lipids and AD
with reports and studies into the effects of hormones on AD, with virtually all
known metabolic hormones being involved, including insulin, thyroid, cortisol
(and other non-sex steroids), growth hormone, leptin, ghrelin, adiponectin and
vitamin D to name a few. For example, thyroid hormones have a profound effect
on lipid profiles [266] and direct effects on cognition [267] and patients with AD
and other neurodegenerative diseases have chronically elevated cortisol levels,
suggesting dysregulation of the hypothalamic-pituitary-adrenal axis [268].
Furthermore, leptin is an adipose tissue-derived hormone, involved in energy
storage and availability, and the hormone orexin (also called hypocretin) is a
neurotransmitter that regulates arousal, wakefulness, and appetite; and orexin
dysregulation, insulin resistance and leptin resistance, which can all occur with
obesity, have all been linked to neurodegeneration [269].
1.4

Lipids and Lipidomics

Lipidomic approaches have greatly improved understanding of the mechanisms
of disease and have lead to the development of biomarkers and therapeutic
strategies for a wide range of conditions including cardiovascular disease,
metabolic disease and cancer [270-272]. Altered lipid metabolism has clearly
been established as a contributor to neurodegenerative disease. The nervous
system has the second highest concentration of lipids, exceeded only by
adipose tissue. Lipids in the nervous system also show enormous structural
diversity and by studying lipid profiles, insight into the biochemical pathways
that alter levels of individual species is obtained, leading to a greater
understanding of pathology. The lipid profiling part of this project for the
identification of a lipid blood biomarker focuses on analysing phospholipid and
sphingolipid species.
Cell membranes are dynamic and require continuous remodelling of
phospholipids for function. A major factor determining the shape of
phospholipids is the nature of the side group and the fatty acids linked to sn-1
and sn-2 positions of the glycerol backbone (see Figures 1.5 and 1.6). The
length of the carbon chain and number of double bonds of the fatty acid
determines the length and shape. The molecular shape of the phospholipid in
the membrane bilayer is also influenced by the compatibility between the size of
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its polar head group and the hydrophobic tail [273]. A huge variety of lipid
species arise from the various combinations of fatty acids with backbone
structures such as glycerol and sphingoid bases [274] (see Figures 1.5 and
1.6). The most common class of lipids consist of fatty acids linked by either an
ester bond to glycerol (a trihydric alcohol) or other alcohols such as cholesterol
or by amide bonds to sphingoid bases. In addition they may contain alkyl
moieties other than fatty acids, phosphoric acid, organic bases, carbohydrates
and various other components, which can be released by various hydrolytic
processes [275].

PE:Phosphatidylethanolamine, PC: Phosphatidylcholine, PG: Phosphatidylglycerol, PI:
Phosphatidylinositol, PS: Phosphatidylserine, PA: Phosphatidic Acid.
Fig 1.5: General structure of phospholipids. The fatty acids at positions sn-1 and sn-2 can
vary in chain length and number of double bonds. In this example, the fatty acid at the sn-1
position contains 16 carbon atoms and has no double/unsaturated bonds (palmitic acid). The
example at the sn-2 position contains 18 carbon atoms and has 4 unsaturated/double bonds
(stearidonic acid). The linkage of the sn-1 acyl group determines the subclass. i.e. ester linkage
forms phosphatidyl species, where a vinyl ether linkage forms the plasmenyl or plasmalogen
species. The linkage of the side group to the phosphate (P) group at the sn-3 position
determines the phospholipid species. If X=ethanolamine, phosphatidylethanolamine (PE) or
ethanolamine plasmalogen will be formed.
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Fig 1.6: General structure of sphingolipids. The fatty acid can vary in chain length and
number of double bonds. In this example the fatty acid has 16 carbon atoms (C) and no
unsaturated/double bonds (palmitic acid). The group attached at X determines the sphingolipid
species. For example if X is hydrogen, ceramide is formed.

It is evident that many neurological disorders involve complex interactions
between proteins and lipids, and in AD, lead to the increased formation of
protein deposits [276]. A key development in the study of lipids and
neurodegenerative disease has been in the advancement of technologies to
determine profiles of lipids and their interacting partners. This is of major
importance, as it is known that cellular signalling and membrane trafficking are
often regulated by peripheral proteins, which reversibly interact with membrane
lipid molecules in highly regulated spatial and temporal fashions. Lipidomic
research has particular relevance to biomarker development. In the case where
there is great overlap with AD and other conditions involving altered lipid
metabolism, such as cardiovascular disease and diabetes, there are new
technologies that may help distinguish between them, including computational
biology, cellular lipid mapping, and single molecule imaging [270, 277]. This will
be of value as specific lipid classes and sub-classes are believed to play an
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important role in AD, and many changes in brain lipid composition have been
reported [273].
1.5

Lipidomics and AD

The specific relevance of each lipid class and their contribution to known
pathological processes in AD will be described in the following sections. It is
apparent that disturbances in lipid metabolism in general have an effect on AD
pathology and the discovery of blood lipid biomarkers may help predict some of
these pathological changes at an early stage of disease or even pre-clinically.
1.5.1

Lipids, APP processing and Aβ

Amyloid precursor protein (APP) is a transmembrane protein expressed by
many tissues and is concentrated in the synapses of neurons [278]. While its
primary function remains to be elucidated it is thought to be involved with
synapse formation, neural plasticity and iron export [279, 280]. APP expression
is up-regulated during neuronal differentiation, following neural injury and this
protein is involved in cell surface protein signalling [278]. APP has also been
shown to have ferroxidase activity which catalyses the oxidation of iron during
iron transport. Accumulated Aβ may trap zinc, which inhibits this enzyme and
subsequent transport of iron. Imbalances in redox metals are a contributor to
increased oxidative stress and AD pathology [280]. As previously mentioned in
Section 1.1.2, APP can be processed by two different pathways, depending on
the localisation of APP to lipid rafts and feedback loops controlling gene
transcription for the appropriate enzymes (see Figure 1.7); processes which are
influenced by membrane composition.
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? cholesterol sensor

LRP1

α: α-secretase, β: Beta site APP cleaving enzyme, γ: γ-secretase, N and C: N and C terminals
of APP, AICD: APP intracellular domain, C99: carboxyterminal fragment (CTF) 99, C83: CTF
83, APPsβ and APPsα: secreted APP β and α respectively, NPD1: neuroprotectin D1, LTP:
long term potentiation, LRP1: LDL-receptor related protein 1.

Figure 1.7: APP processing - The non-amyloidogenic and amyloidogenic pathways and
relationship to cholesterol. The non-amyloidogenic processing of APP involves cleavage by α
and γ secretases resulting in generation of a secreted form of APP (APPsα), CTF83, AICD and
P3. APPsα has neuroprotective properties via its effect on NPD1 production, enhancing LTP
and neurite outgrowth. The amyloidogenic processing of APP involves cleavage by β and γ
resulting in generation of secreted APPβ (APPsβ), CTF99 and Aβ. Under certain conditions the
Aβ42 can be overproduced or inefficiently cleared. A toxic cascade of neuro-inflammation and
oxidation ensues resulting in neuronal death. The AICD can translocate to the nucleus to
suppress or transcribe several genes. By suppression of LRP1 it may act as a cellular
cholesterol sensor. The biological relevance of the CTFs and P3 remain to be determined.
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The APP protein undergoes proteolytic cleavage (see Figure 1.7) in the nonamyloidogenic pathway by α-secretase or in the amyloidogenic pathway by beta
site APP cleaving enzyme (BACE), formerly known as β-secretase [281]. In
both cases, initial cleavage is followed by an additional cleavage by γ-secretase
[282]. Several enzymes including ADAM 10, ADAM 17 (a disintegrin and
metalloproteinase 10 or 17) and TACE (tumour necrosis factor α-converting
enzyme) show α-secretase activity [9]. α-secretase cleaves within the Aβ
domain of APP liberating a soluble APP fragment (APPsα), which precludes the
formation of Aβ and has neurotrophic and neuroprotective properties [282]. The
soluble APP fragment (APPsα) is thought to be neuro-protective by promoting
neuronal cell survival and repair following cellular injury. An up-regulation of the
enzymes phospholipase A2 (PLA2) and/or 15-lipoxygenase, required for the
biosynthesis of DHA-derived neuroprotectin D1 (NPD1), may elicit this
neurotrophic activity and represent a complimentary cell survival mechanism
activated early in AD pathogenesis [283]. APP is processed by BACE and γsecretase in the amyloidogenic pathway to release the Aβ peptide. Under
certain conditions these peptides can become potent, self aggregating
neurotoxins when they accumulate as a result of increased production or poor
clearance [13]. The fate of APP in terms of processing is determined by its
location within the cell membrane and cellular compartments and the upregulation of enzymes in response to various signals, which in turn appear to be
influenced by factors including genetic make-up, diet, nutritional status, lifestyle
and hormonal status.
APP clusters in cholesterol-rich lipid rafts in the membranes of neurons,
astrocytes and microglia [284]. Lipid rafts are domains within the plasma
membrane bilayer consisting of cholesterol, glycosphingolipids and protein
receptors. These specialised regions compartmentalise cellular processes and
act as organising centres for assembly of signalling molecules. Rafts also
influence membrane fluidity and are involved with membrane protein and
receptor trafficking and the regulation of neurotransmitters [285]. When the
cholesterol content of the rafts increases, the activity of α-secretase decreases
and the activity of BACE increases, thereby promoting amyloidogenic
processing of APP [284]. The immediate precursor to Aβ is the C-terminal
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domain of APP called C99 (see Figure 1.7 – APP processing), the product of
BACE cleavage of APP and has an affinity for cholesterol. The localisation of
APP/C99 is therefore directed to the cholesterol-rich rafts, where the BACE and
γ-secretase are concentrated, thereby increasing amyloidogenic processing of
APP [284]. The α-secretase and BACE are concentrated in different areas of
the cell [286]. Optimal α-secretase activity is found in cell surface regions that
contain few lipid rafts, in particular fluid regions with a high DHA content [286].
When APP accumulates at the cell surface, it is more likely to be cleaved by αsecretase. When APP is shifted inside the cell to the Golgi apparatus,
endosome or lysosome, BACE activity predominates and Aβ is more likely to be
produced. Evidence is emerging which suggests cholesterol and low density
lipoprotein receptors (LDLR) influence where APP accumulates [287].
Dysregulation of APP processing occurs early in the disease process, possibly
as a result of cardiovascular risk factors such as insulin resistance, lipid
dysregulation, inflammation, hormonal imbalances and oxidative stress,
resulting in overproduction of Aβ42, Aβ aggregation (causing toxicity and further
oxidative stress) and eventually fibril and plaque deposition, as well as NFT
formation [9]. This is the basis of the “amyloid hypothesis”, which states that Aβ
accumulation is central in the aeitology of AD [288]. Cholesterol and plasma
membrane lipids have roles in regulating APP metabolism [45] and although Aβ
is proposed as a main driver for AD, the BACE and γ-secretases that generate
it are up-regulated by high membrane cholesterol levels. This suggests that a
possible physiological role for Aβ is to recycle brain cholesterol and promote its
efflux into the systemic circulation and thus protect against elevated brain
cholesterol [289].
Aβ increases cholesterol efflux from cells by assembling high-density
lipoprotein-like particles during secretion [290]; this assembly being mediated by
the ATP-binding cassette transporter 1 (ABCA1) [289]. Animal studies have
reported that Aβ containing lipoproteins are excreted much more efficiently than
those without Aβ [69, 289]. Evidence supports the notion that the products of
the amyloidogenic processing of APP (Aβ and AICD) act to lower cellular
cholesterol levels [284]. Aβ stimulates the release of cholesterol and other lipids
from cells via lipoproteins [289]. Aβ may also reduce biosynthesis of cholesterol
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and other lipids by inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMG-CoA reductase); the rate-limiting enzyme in the cholesterol biosynthesis
pathway [291]. Additionally, AICD can translocate to the nucleus where it
suppresses transcription of the gene encoding LDL-receptor related protein
(LRP1); a major apoE receptor in the brain mediating cellular cholesterol uptake
via endocytosis [292]. In this way APP may act as a cellular cholesterol sensor
by creating a negative-feedback loop (see Figure 1.7) as it has been shown that
the C-terminal (mostly intracellular) domain of APP specifically binds membrane
cholesterol, thus favouring lipid raft localisation and promoting amyloidogenic
processing, the products of which (in particular AICD, as mentioned) reduce
apoE-mediated cholesterol uptake and synthesis [284]. In normal neurons the
optimal amount of cholesterol present in the membrane confers “stiffness”
which influences raft structure and the interaction between BACE and APP and
thus influences Aβ generation [293]. Statins, inhibitors of hydroxymethyl coenzyme A-reductase, are widely prescribed for their cholesterol lowering ability.
Statins reduce the production of cholesterol and isoprenoid intermediates
including geranylgeranyl and farnesyl pyrophosphate. In experimental models
of AD, statins also reduce the production of Aβ by reducing membrane
cholesterol,

disrupting

secretase

enzyme

function

and

by

reducing

neuroinflammation. However these results have been questioned as some of
the studies used levels of statins that resulted in unnaturally low levels of
membrane cholesterol, thus disrupting normal membrane function.
In 2000, the protein Seladin 1 was found to be down-regulated in AD-affected
brain regions, this protein was later found to be an enzyme (DHCR24) that
converts desmosterol into cholesterol. Interestingly, 17β-oestradiol increases
Seladin 1 levels as well as membrane cholesterol levels, and is known to
protect cells against Aβ aggregate-induced toxicity [294]. In support of this,
other cell culture studies have shown that a reduction in membrane cholesterol
and associated reduction in rigidity facilitates the interaction of exogenous Aβ
with the membrane, allowing the opening of Ca2+ pores and subsequent
excitotoxicity [295], demonstrating a derailment of normal physiological control.
However more recently, another study has found the levels of the cholesterol
precursor desmosterol are lower in AD-affected brain regions compared to age40
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matched controls, suggesting Seladin 1 activity may not be the limiting step or
factor [296]. It is likely that there is an optimum level for membrane cholesterol,
above or below which membrane protein metabolism is disrupted, and further
studies are needed to clarify all these aspects of brain cholesterol metabolism.
1.5.2

Cholesterol and metabolites

The brain contains almost 25% of total body cholesterol, the majority of which is
unesterified and is present in myelin and the plasma membranes of neurons
and astrocytes [297]. Unlike fatty acids which are also synthesised by the liver
and delivered to the CNS [298], brain cholesterol is mainly synthesised de novo
by glial cells, reflecting the importance of adequate amounts and lack of
reliance on peripheral supply for maintenance of brain function [297]. When
released from degenerating neurons and glial cells, cholesterol is actively
recycled by astrocytes. Cholesterol dysregulation in the brain is suggested as
an important factor for Aβ overload [45, 284], with both increased and reduced
levels influencing neurodegeneration [162, 299, 300]. Cholesterol homeostasis
is maintained by a complex interplay of synthesis, transport and metabolic
pathways. Cholesterol and other lipids are transported in the CNS as
lipoproteins. Lipoproteins in the CNS resemble plasma HDL in terms of size,
density and composition; the major difference being that CNS HDL contains
apoE as its predominant protein compared to apoAI in plasma HDL. ApoE is
abundantly synthesised by microglia and astrocytes [301]. Normally small
amounts of cholesterol can be delivered from the periphery through the small
HDL, which can cross the blood brain barrier (BBB). ApoAI is not synthesised in
the brain, but low levels are found in the CSF, supporting the fact that
peripheral HDL, or at least apoAI can cross the BBB [302]. The larger peripheral
LDL and VLDL are thought to be excluded by the BBB, however recent
evidence challenges this concept as it has been shown that frequent,
persistent, post-prandial elevated plasma cholesterol can result in significant
amounts of cholesterol and therefore the Aβ they contain being delivered to the
CNS. This is suggested to be a consequence of vascular injury, inflammation
and subsequent impairment of BBB function [179, 303], thereby contributing to
increased Aβ load. The cholesteryl esters released from degenerating nerve
cells are hydrolysed by cholesterol esterase. The free cholesterol is cleared by
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binding, mainly to apoE, which delivers cholesterol back to neurons [63].
Excess free cellular cholesterol is converted into cholesteryl esters by acyl
CoA:cholesterol acyl transferase 1 (ACAT1) [304].
Cholesterol equilibrium is maintained by a negative feedback loop between free
cholesterol, Aβ and HMG-CoA reductase. Inhibition of HMG-CoA reductase by
statins has been shown in animal models to reduce Aβ [305] but clinical trial
results in terms of reducing AD risk have been inconsistent [306]. ACAT
inhibition is also a therapeutic target to reduce Aβ as increasing levels of
cholesteryl ester enhances Aβ release in cultured cells [307].
Cholesterol homeostasis is maintained in the brain by a balance between
synthesis and removal. Brain cholesterol is metabolised by conversion to 24-Shydroxycholesterol (24SHC) by 24-cholesterol hydroxylase (CYP46A10), an
enzyme found almost exclusively in the brain [45]. 24SHC readily crosses the
blood brain barrier and is excreted by the liver [45]. Since most of the circulating
24SHC originates from the brain, plasma levels may reflect cholesterol turnover
in the CNS [303]. In a mouse model of AD, genetic ablation of ACAT1 also
increases 24SHC, suggesting a potential role for this oxysterol in decreasing
amyloidogenesis [308]: The increased free cholesterol being metabolised into
24SHC, which crosses the BBB and is removed from the CNS, may explain
this. 27-hydroxycholesterol (27HC) is a peripheral cholesterol metabolite that
can also cross the BBB [309]. Brain levels of oxysterols are key regulators of
brain cholesterol via their influence on gene expression, in particular sterol
regulatory element binding protein (SREBP), LDL receptor and HMGCoA
reductase [310]. Recent studies have also suggested that α-secretase and
BACE activity are regulated by 24HSC and 27HC. In cultured neuroblastoma
cell lines 24HSC was shown to decrease BACE and increase α-secretase
activity, thereby reducing amyloidogenic APP processing [311].

This would

suggest that the balance between free cholesterol and cholesteryl esters might
represent a key factor in regulating amyloidogenesis [307]. Cholesterol efflux
may also control generation of Aβ via the ATP-binding cassette transporter
(ABCA1) [310, 312].
The cross regulation of lipid pathways is also highlighted by studies showing
that oxysterols activate glycerophospholipid and sphingomyelin synthesis by
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activating CTP:phosphocholine cytidyltransferase (CCT); the rate limiting step in
the Kennedy pathway for PC synthesis [313], possibly to protect cells from
excess sterol accumulation (see Figure 1.9). Membrane composition is
determined by the co-ordinated synthesis, breakdown and efflux of cholesterol,
phospholipids and sphingolipids, ensuring membrane integrity and preventing
the accumulation of bioactive lipids, such as ceramides and diacylglycerol
(DAG), which can be detrimental to the cell [313]. An inability of PC synthesis to
proceed at the same pace as cholesterol accumulation can lead to activation of
the endoplasmic reticulum (ER) unfolded protein response and apoptosis [314].
Cellular cholesterol homeostasis is regulated by two main nuclear ligandactivated transcription factors; liver-X-receptors (LXR) and sterol regulatory
element binding proteins (SREBPs), which activate over thirty genes involved in
synthesis, uptake and processing of cholesterol, fatty acids, triglycerides and
phospholipids [64, 315, 316]. SREBP-2 functions to increase cellular cholesterol
whereas LXRs (LXRα/LXRβ) facilitate reverse cholesterol transport (RCT)
leading to cholesterol removal via the liver. SREBP-2 is activated when the
cellular sterol pool is decreased. SREBP-2 is present as an inactive precursor in
the ER bound to SREBP cleavage-activating protein (SCAP). SCAP is retained
in the ER when bound to Insigs (insulin induced gene) and prevents transport of
the SCAP/SREBP complex to the Golgi apparatus. Sterols mediate feedback
inhibition of SREBP-2 via Insigs and when cholesterol levels decrease the
SCAP/SREBP-2 complex moves to the Golgi apparatus for proteolytic
cleavage. An active fragment is then released which enters the nucleus and
binds to sterol response elements on the promoter region of target genes such
as HMGCoAR and the LDL receptor gene, leading to increased cholesterol
synthesis and uptake [312, 317]. Insigs also inactivate HMGCoAR within the ER
by promoting ubiquitination and degradation when sterols accumulate [317].
Diabetes and the associated impairment of insulin signaling have been shown
to suppress key enzymes in the cholesterol biosynthesis pathway by inhibition
of SREBP-2 in the brain. Reduced synaptosomal membrane cholesterol
synthesis results, with associated defects in neuronal function [318]. LXRs form
dimers with the retinoid-X-receptor (RXR) which result in gene transcription
[319]. In the CNS LXRβ is more abundant [320] and acts as a cholesterol
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sensor to prevent cellular cholesterol overload. LXRs stimulate cholesterol
efflux by promoting gene expression to increase transporters (ABCA1 and
ABCG) and apoE in the CNS and apoAI in the periphery for transport back to
the liver. The main physiological LXR activators are oxysterols, which can be
intermediates in the cholesterol synthesis pathway, intermediates of the steroid
hormone synthesis pathway or cholesterol breakdown pathways [321]. LXRs
also suppress several inflammatory genes coding for cytokines such as tumour
necrosis factor (TNFα), interleukins IL-6 and IL-1β and enzymes such as
cyclooxygenase-2 and inducible nitric oxide synthase, suggesting reciprocal
regulation of lipid metabolism and inflammation [322]. LXR agonists could
potentially alleviate AD pathology by simultaneously acting on brain lipid
metabolism and therefore Aβ deposition, while reducing inflammation; both
being pieces of the AD puzzle [323].
ABCA1 regulates both the levels and amount of lipid associated with apoE by
promoting the efflux of excess intracellular cholesterol and its subsequent
binding to lipoproteins, including unlipidated apoE [324]. Studies using cultured
cells have shown that increasing levels of ABCA1 lowers Aβ, and in a mouse
model of AD, deletion of the ABCA1 gene leads to a substantial reduction in
both brain and peripheral apoE, leading to increased Aβ deposits [325,
326].This increase in Aβ deposition could be mediated by an increase in the
degradation of poorly lipidated apoE; a process paralleled in the periphery by
increased renal catabolism of poorly lipidated plasma apoAI [327]. The degree
of lipidation of apoE may be more important for Aβ metabolism and
amyloidogenesis than total brain levels of apoE. ABCA1 mediated lipidation of
apoE is reported to assist with degradation of Aβ by both the extracellular
insulin degrading enzyme (IDE) secreted by microglia and astrocytes, and the
intracellular neprilysin in microglia [328]. In vitro studies have shown that
APOEε4 is the least efficient at promoting Aβ degradation and microglial Aβ
catabolism is impaired in the absence of both ABCA1 and apoE [328].
Phospholipid transfer protein (PLTP) plays a major role in lipid metabolism and
Aβ clearance by modulating apoE secretion by astrocytes and through its
influence on ABC transporters, reverse cholesterol transport (RCT) and
lipoprotein modelling (see Section 1.7 and Chapter 5).
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1.5.3

Phospholipids

All human cells are contained by a plasma membrane which is composed of a
lipid bilayer with embedded proteins. This lipid bilayer is fluid and selectively
restricts the exchange of compounds between the extracellular fluid and the
intracellular compartments. The main lipids in the bilayer are phospholipids
(phosphatidylcholine,

PC;

phosphatidylethanolamine,

PE;

and

phosphatidylserine, PS) with the polar head groups facing the aqueous media
and the fatty acyl chains forming the hydrophobic core. Another major
component is the sphingolipid, sphingomyelin (SM). PC is the most abundant in
most cell types and the sphingolipids are generally the most variable [63, 89,
275]. The bilayer composition is also asymmetric with PC and SM being more
abundant in the outer leaflet and PS and PE higher in the inner leaflet. PS has a
net negative charge which contributes to membrane potential and binds
positively charged molecules. Phosphatidylinositol (PI) is only found in the inner
membrane and is a signalling intermediate for hormones and neurotransmitters
[275].
The fluidity of the membrane is highly dependent on cholesterol, which is
interspersed between the phospholipids. The unsaturated fatty acid chains of
the phospholipids are in the cis conformation which forms a pocket for
cholesterol by binding its hydrophilic OH group and therefore the hydrophobic
steroid nucleus is anchored in the membrane core. This interaction prevents the
hydrophobic chains from packing too closely together and allows protein and
lipids that are not bound to structural proteins to move laterally and rotate within
the membrane [275]. The fluidity of the membrane is partially determined by the
fatty acid composition of the diet, particularly the unsaturated fatty acids. This
maybe one of the reasons why high consumption of trans fatty acids is
detrimental to one’s health as it reduces fluidity of the membranes [210, 213].
Membrane composition is non-uniform, and is dynamic, such that sections of
the membrane can bud off into vesicles to remove membrane components to
other parts of the cell. The membrane also accepts vesicles formed in the Golgi
apparatus and other parts of the cell to enable delivery of new and recycled
components back to the membrane. Individual fatty acids can be hydrolysed
from the membrane lipids by various enzymes and replaced as required [329].
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Flippase enzymes (P4 ATPases) transfer lipids between membrane leaflets and
are required for maintenance of membrane asymmetry [330]. Loss of
asymmetry on the extracellular surface of a cell is proposed to be an early
marker of apoptosis, such as the appearance of PS on the outer leaflet where it
is not normally present [331]. Aβ is capable of initiating this response in neurons
and this mechanism has been proposed to contribute to Aβ toxicity [332].
Additionally, genome wide association studies in AD have identified a SNP in
ATP8B4 (cation transport ATPase) as a potential AD risk factor, resulting in P4
ATPase deficiency [333].
PLs make up more than 60% of the total brain lipids, with the majority being
incorporated into cell membranes. The six most abundant phospholipids in the
brain are PC, PE, PS, PI, SM and ethanolamine plasmalogen. Studies have
shown that the phospholipid profile of the brain is consistent: it is not
significantly altered by different metabolic conditions. Thus, alterations in the
profile may reflect changes in membrane biology [334]. Using

31

PNMR

spectroscopy, the following phospholipid composition was determined in various
fractions of the healthy brain [334].

PC: phosphatidylcholine, PE: phosphatidylethanolamine, PS: phosphatidylserine,
phosphatidylinositol, SM: sphingomyelin, PlsEtn: plasmalogen ethanolamine

PI:

Figure 1.8: Phospholipid distribution in healthy brain. This figure shows the predominance
of PE and PC in all three regions, with SM also being a major component of white matter and
myelin. Plasmalogen species are notably abundant in white matter and myelin.
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Changes in composition and metabolism of several phospholipids have been
described in brain tissue from AD patients when compared to age-matched
control brains, including phosphatidylcholine (PC), phosphatidylethanolamine
(PE), phosphatidylinositol (PI) and plasmalogens [270, 335, 336]. Various
groups have reported differences in lipid biochemistry in both brain tissue [337339] and plasma [120, 127, 272]. A recent lipidomic study of the metabolic
syndrome and obesity showed these conditions were associated with elevated
plasma LysoPC, PC and PE species as well as reduced ether phospholipids
(plasmalogens) [340]. In AD, lower peripheral ethanolamine plasmalogen
(PlsEtn) has been reported, and these levels not only appear to correlate with
disease severity, but also linear regression models suggest that serum PlsEtn
levels decrease years before clinical symptoms appear, thus providing a
potential early disease marker [341].
Glycerophospholipids are a source of lipid mediators, including arachidonic acid
(AA) and docosahexaenoic acid (DHA), which are released from membrane
phospholipids by the action of phospholipases. Variations in phospholipid
metabolising

enzymes,

such

as

phospholipase

A 2,

phospholipase

C,

phospholipase D and phosphoinositidases have also been reported in AD [342,
343]. Initially most PLs have a saturated fatty acid at the sn-1 position and an
unsaturated fatty acid at the sn-2 position of the glycerol backbone. However
due to cellular requirements, the fatty acid distribution is constantly in flux by
remodelling that occurs through the action of various phospholipases. Once
synthesised, the PLs bud off from the ER in vesicles and are then orientated in
the various cellular membranes by the action of flippase and floppase enzymes
[344, 345]. All nucleated cells are capable of de novo synthesis of PLs by two
pathways. The predominant “Kennedy” pathway occurs in the endoplasmic
reticulum (ER) membrane from cytosolic precursors in most cells or alternatively
synthesis occurs via activated diacylglycerol (DAG) described in Figure 1.9.
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Figure 1.9: Phospholipid synthesis and connection with sphingolipid and cholesterol
metabolism. ACh: Acetylcholine, CDP:cytidine diphosphate, CCT:CTP-phosphocholine
cytidyltransferase, SAH: S-adenosyl homocysteine, HCy: Homocysteine, Meth: Methionine,
SAMe: S-adenosyl methionine, PEMT: phosphatidylethanolamine methyltransfersase, SM:
sphingomyelin, PAF: platelet activating factor, DAG: diacylglycerol
All nucleated cells are capable of de novo synthesis of PLs by two pathways. The predominant
“Kennedy” pathway occurs in the endoplasmic reticulum (ER) membrane from cytosolic
precursors in most cells and utilises a cytidine-diphosphate (CDP)-activated polar head group
(choline or ethanolamine) for attachment to the phosphate of phosphatidic acid. Alternatively a
CDP-activated diacylglycerol is attached to an inactivated polar head group (glycerol, serine or
inositol) [63, 275, 346]. The importance of the methylation pathway is highlighted to provide
methyl groups for PC production from PE when dietary sources are inadequate to meet
demand. The cross regulation of steroid, PL and SL pathways is shown by oxysterol activation
of CCT, the rate limiting step in PC synthesis to maintain optimal steroid to PL ratios in the
membrane.
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1.5.4

Phosphatidylcholine (PC)

Choline is phosphorylated by choline kinase to phosphocholine. Cytidine di
phosphate (CDP) is then added to form CDP-choline. CDP-choline then reacts
with diacylglycerol to form PC (catalysed by choline phosphotransferaseCPT1). This process is referred to as the Kennedy pathway for de novo
synthesis of PC (see Figure 1.9). The liver has a back up pathway via the
second most abundant PL, PE to provide choline when dietary sources of this
essential compound are low. This pathway involves a three step methylation by
SAMe, catalysed by PEMT [194, 196, 347] (see Figure 1.9). PC is required for
the secretion of VLDL from hepatocytes and is a major source of the second
messengers DAG, PA, LysoPA, LysoPC, platelet activating factor and AA for
eicosanoid synthesis. PC is also a direct substrate for the formation of SM via
sphingomyelin synthase which transfers the choline-phosphate group to
ceramide [348].
1.5.5

Phosphatidylethanolamine (PE)

Ethanolamine cannot be synthesised and therefore must be obtained from
dietary lipids. PE is synthesised via the Kennedy pathway described above and
by the carboxylation of PS [346] (see Figure 1.9). Additionally LysoPE can be
acylated by a LysoPE-acyltransferase [349]. PE species make up 45% of the
total brain PLs (see Figure 1.8), where its conical shape and ability to form
reversed non-lamellar structures, facilitate membrane fusion and fission;
processes that are particularly important in the brain [349, 350]. PE also confers
curvature to the cell membrane which influences structure, folding and activity
of membrane proteins [346]. As the nitrogen group on ethanolamine can be
positively charged, PE is a zwitterion, enabling establishment of hydrogen
bonds with various amino acid residues and thereby anchoring proteins. Like
PC, PE is a precursor to many signalling molecules, such as DAG, FAs and PA.
Ethanolamine is also a precursor for anandamide (an N-acyl ethanolamine),
which is a ligand for cannabinoid receptors in the brain [351].
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1.5.6

Phosphatidylserine (PS)

The brain is enriched with PS compared to other tissues where the brain PS
acyl chains are highly enriched with DHA [352, 353]. As shown in Figure 1.9,
PS is an important precursor for mitochondrial PE by conversion via PS
carboxylase. PS is mainly located on the inner leaflet of the membrane bilayer
and is thought to become an apoptotic signalling molecule when relocated to
the outer leaflet. This surface exposure is a recognition signal for phagocytic
removal [354, 355].
1.5.7

Plasmalogens

Plasmalogens are a sub-class of phospholipid characterised by a vinyl-ether
linkage at the sn-1 position and an acyl linkage at sn-2 of the glycerol
phospholipid backbone. Plasmalogens contribute to membrane integrity and are
involved in many cellular processes such as vesicle formation and membrane
fusion, ion transport and the generation of secondary signal mediators such as
platelet activating factor [63]. The presence of the vinyl ether bond imparts
antioxidant properties which reduces free radical based cellular damage as the
products of enol ether oxidation do not propagate the oxidation of
polyunsaturated fatty acids (PUFA); a benefit in the CNS with PUFAs in
abundance and a high metabolic rate. Studies have shown a significant loss of
plasmalogen in post mortem AD brains [337, 356, 357]. Ethanolamine
plasmalogen (PlsEtn) is a subclass of PE and plays important roles as a
reservoir for AA release, in the facilitation of membrane fusion and as an
antioxidant [337]. PlsEtn is a major component of neuronal membranes,
accounting for approximately 30% of the total phospholipids and 90% of the PE
species [339]. Plasmalogens and their precursors are synthesised in the liver
and transported to the brain bound to transport proteins. The PlsEtn species in
grey matter contain mainly arachidonate and docosahexaenoate, whereas
PlsEtn in the white matter contain mainly monounsaturated acyl chains at the
sn-2 position. Plasmalogen deficiency in the grey matter may be directly related
to neurodegeneration as deficiency leads to membrane instability [358].
Plasmalogens are key regulators of cholesterol and studies have shown that
plasmalogen deficient cells exhibit lower HDL-mediated cholesterol efflux and
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impaired LDL-mediated transport [359-361]. This results in an increase in free
cellular cholesterol and reduced levels of cholesteryl esters via suppression of
sterol-O-acyltransferase gene expression and therefore reduced levels of the
enzyme it encodes: acyl-coenzyme A:cholesterol acyl transferase (ACAT).
ACAT is a critical membrane bound cholesterol processing enzyme which
promotes the formation of cholesteryl esters and increases LDL receptor
expression [356]. The synthesis of plasmalogens is dependent on peroxisomes
to generate 1-alkyl-glyceryl ether lipid precursors and peroxisomal function
decreases with age. A recent study showed that decreased plasmalogen
precursor levels in the CNS correlate with functional decline in AD [357].
1.5.8

Phosphatidylinositol (PI)

Phosphatidylinositol (PI) is an important membrane constituent and participates
in essential metabolic processes via a number of phosphorylated metabolites. It
is abundant in brain tissue, comprising 10% of phospholipid species. PI has a
characteristic high content of stearic acid (C18:0) linked to sn-1, and
arachidonic acid (C20:4) linked to sn-2 [274]. This makes PI a primary source of
arachidonic acid required for eicosanoid synthesis via the action of
phospholipase A2 [274]. Phosphoinositol phosphates (PIPs) have roles in both
signal transduction, by generation of second messengers (diacylglycerol (DAG)
and inositiol triphosphate) and as membrane docking sites for protein signalling,
such as the insulin receptor [63]. PI changes have been linked to several
diseases, including diabetes and cancer [362]. Evidence suggests that
alterations in PI metabolism may play a role in AD too as PI kinases play a key
role in the transport and sorting of newly synthesised proteins, thus affecting the
intracellular trafficking of APP [363]. Phosphatidylinositol 4,5-biphosphate (PIP2)
is important in the regulation of ion channels and membrane trafficking. In
familial forms of AD, presenilin mutations cause an imbalance in PIP2
metabolism, with studies suggesting that this imbalance may contribute to Aβ42
generation by modulating the trafficking of γ-secretase [364]. It is suggested
that PIP2 competitively interferes with γ-secretase cleavage of APP [365] and in
fact an inverse correlation between cellular PIP2 and secreted Aβ42 has been
demonstrated in cultured fibroblasts [364]. An increased turnover of PIP2 by
increased phopholipase C (PLC) activity has also been shown in familial AD
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resulting from presenilin mutations, as PLC inhibitors cause a reduction in Aβ42
secretion [364]. On the other hand, PLC hydrolysis of PIP2 produces
diacyglycerol (DAG) which has been shown to stimulate α-secretase and
therefore promote the non-amyloidogenic processing of APP [366]. It would
appear therefore that in familial AD at least, that PI metabolism is disturbed
when presenilin mutations are present. Phosphatidylinositol 3-kinase (PI3K) is a
key enzyme involved in PI metabolism and in vitro and in vivo studies using
wortmannin, an inhibitor of phosphatidylinositol 3-kinase, have reported the
inhibitor reduces levels of Aβ: This provides further evidence for a role for PI in
AD [367, 368]. Epidemiological studies have shown an increased risk of
dementia in patients with diabetes mellitus (DM) and the role of insulin receptor
dysfunction in AD is an active area of AD research [369]. Hyperphosphorylation
of the tau protein is a key step in the formation of neurofibrillary tangles. This
phosphorylation is catalysed by various protein kinases, including glycogen
synthase kinase 3β (GSK3β) [369]. This enzyme is negatively controlled by the
PI-3-kinase/phospho-Akt pathway, which is stimulated by insulin. This suggests
one possible mechanism by which impaired insulin signalling contributes to AD
pathology. A recent study found reduced PI3K activity in peripheral blood
mononuclear cells in AD compared to age matched controls [369], supporting a
role for this enzyme in contributing to the pathogenesis of AD. Identification and
quantification of phosphatidylinositol phosphate (PIP) and phosphatidylinostiol
biphosphate (PIP2) with different fatty acid compositions may uncover
abnormalities in PI metabolism in AD [370].
1.5.9

Phospholipases

Phospholipids are constantly being remodelled in terms of their fatty acyl chains
and polar head groups and also in the generation of second messengers. This
occurs through the action of various phospholipase enzymes as illustrated in
the following figure.
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Phospholipase B (lysophospholipase) has
both PLA1 and PLA2 activity.

Fig 1.10: Phospholipase enzymes and site of action.
PLA1: phospholipase A1, PLA2: phospholipase A2, PLC: phospholipase C, PLD: phospholipase
D, R1 and R2: fatty acyl chains, R3: phospholipid head group

Phospholipase D (PLD), which hydrolyses PC to produce phosphatidic acid
(PA) and choline, has also been implicated in AD pathology [343]. With the
creation of animal models to study PLD, this enzyme is emerging as a key
player in regulating phospholipid metabolism and is now a therapeutic target for
several brain disorders, including AD, due to its multiple roles in signal
transduction pathways [343]. PLD1 has been shown to be involved with APP
and presenilin intracellular trafficking and PLD2 involved with Aβ signalling.
Ablation of PLD2 in a transgenic model of AD, has been shown to be
neuroprotective [343]. In addition, elevated levels of PL degradation products
have also been described [371] suggesting that the delicate equilibrium of PL
metabolism is disturbed in AD. PLD is also involved in the generation of N-acyl
ethanolamines

(endocannabinoids)

from

their

precursors,

N-acyl

PEs.

Endocannabinoids are lipid signalling molecules that are implicated in a diverse
range of processes including pain, cognition, appetite, inflammation, memory
and hippocampal neurogenesis [372-374].
Increased expression or activation of PLA2 in AD has recently been measured
in CSF and was shown to correspond to an increase in PL breakdown products,
particularly PE [375]. The resulting defects in membrane structure can expose
membrane bound proteins, such as APP to abnormal processing, and the
production of Aβ and is consistent with the reported co-localisation of PLA2 with
amyloid plaques [376]. Activation of various phospholipases can lead to
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alterations in membrane fluidity, permeability and ion balance resulting in
oxidative stress [377]. The release of AA and DHA is highly regulated and the
fate of both is determined by numerous signals. These polyunsaturated fatty
acids (PUFAs) can undergo oxidation by both enzymatic and non-enzymatic
pathways, producing an array of interconnected lipid mediators that influence
oxidative stress and neuro-inflammation; key components of AD pathology [28].
Glycerophospholipid degradation products generated enzymatically include
eicosanoids, lysophospholipids, docosanoids, platelet activating factor (PAF),
and endocannabinoids [28]. Many of these mediators are pro-inflammatory and
their generation activates astrocytes and microglia to release inflammatory
cytokines such as tumour necrosis factor (TNF), interleukin 1 (IL1) and
interleukin 6 (IL6). These cytokines in turn promote and intensify further
oxidative stress and neuroinflammation, by up-regulating various isoforms of
PLA2, cyclooxygenases (COX) and nitric oxide synthases (NOS) [378]. It is
suggested that Aβ accumulation itself may increase cytosolic PLA2 (cPLA2)
activity

[379].

Ceramide

and

ceramide-1-phosphate,

generated

from

sphingolipids, have also been shown to stimulate cPLA2 [380]. The Ca2+independent PE-PLA2 isoform may contribute to neural damage by decreasing
plasmalogen levels causing increased membrane permeability, Ca2+ flux and
excitotoxicity [377]. The increased Ca2+ flux also promotes the relocation of
cPLA2 from the cytosol to the plasma and nuclear membranes where it
accelerates the breakdown of PC [28]. As Ca2+ levels increase further, the
secretory isoform of PLA2 is activated (sPLA2), exacerbating neural cell injury
[28]. Increased levels of lipid mediators derived from AA and DHA by the action
of PLA2 can result in abnormal and imbalanced signalling leading to
neurodegeneration. The proportion of AA and DHA in PLs varies in different
regions of the brain, with AA being more evenly distributed throughout grey and
white matter and DHA more concentrated at synaptic membranes [381]. PL
balance is maintained through regulated hydrolysis by phospholipases and
synthesis by reacylation and deacylation. There is also some de novo synthesis
in the brain [28].
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1.5.10

Phospholipid derived metabolites

The following figure shows the different actions of the PL derived metabolites
involving arachidonic acid and docosahexaenoic acid.

Figure 1.11: Phospholipid derived metabolites from the action of PLA2.
PLA2: phospholipase A2, AA: arachidonic acid (20:4), DHA: docosahexaenoic acid (22:6),
BDNF: brain-derived neurotrophic factor, COX-1 and 2: cyclooxygenase-1 and 2, 15-LO-1: 15lipoxygenase-1. Bcl-2: B cell lymphoma-2 regulatory proteins.
The free AA and DHA are released from membrane phospholipids. Cyclooxygenases or
lipoxygenases transform these into eicosanoids from AA and docosanoids from DHA. The
eicosanoids are potent inflammatory, vasoconstricting and platelet aggregating compounds
important in immunity and wound healing. The docosanoids, including neuroprotectin D1
suppress inflammation and promote neuronal cell survival via production of anti-apoptotic
proteins and suppression of pro-apoptotic proteins, such as those of the Bcl-2 family.
Docosanoid production is promoted by neurotrophins, such as BDNF. Non-enzymatic
transformation of AA and DHA also occurs (depending on the redox state of the cell) to produce
neuroprostanes and isoprostanes respectively: These can exacerbate oxidative stress and
damage to cell membranes.

55

Chapter 1: Review of the Literature – Lipids and AD
1.5.11

AA and metabolites

AA is the most important omega-6 fatty acid in the brain, present as free fatty
acid and enriched in phospholipids [382]. The brain relies on a steady supply of
AA from the plasma via lipoproteins and LysoPLs as very little linoleic acid (LA),
the essential fatty acid precursor of AA, is present in brain and even when
present, it is not readily converted to AA [383]. AA has several important
physiological effects as it can increase neuronal firing and enhance synaptic
transmission and long term potentiation (LTP), thus influencing learning and
memory. It is still not clear how AA does this, but one suggestion has been that
AA

rapidly

increases

the

level

of

α-amino-3-hydroxy-5-methyl-4-

isoxazaolepropionic acid receptors (AMPAR) at the neuronal surface, which
might increase neuronal activity by increasing currents through Ca2+-permeable
AMPAR [384]. AA may also influence brain function indirectly via the generation
of eicosanoids (such as prostaglandins), which regulate inflammation, blood
clotting and vascular tone (see Figure 1.11) [385]. Increases in neuronal activity
must be matched by increased delivery of oxygen and nutrients through the
neurovascular unit of the BBB, and PLA2- and AA- derived mediators play an
important role in this regulation [386, 387]. AA also regulates the activity of
many enzymes, including choline transferase and protein kinases A and C,
involved with acetylcholine production and glucose/lipid metabolism respectively
[388]. Glutamate excitotoxicity can be enhanced by AA and its inflammatory
mediators, as activated microglia impair the astrocytic ability to sequester
glutamate and therefore imbalances in AA or its metabolites contribute to
neuronal damage [389, 390].
1.5.12

DHA and metabolites

DHA is a major component of neural membrane lipids where it has both a
structural and functional role. The fluidity of the membrane is crucial for
membrane protein interaction, speed of signal transduction, neurotransmission
and the formation of lipid rafts. DHA has the unique ability to shift its shape
millions of times per second, which provides membrane fluidity [286]. DHA is
mainly obtained from the diet, although small amounts can be made by a series
elongation and desaturation reactions of its precursor -linolenic acid (18:3n-3):
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This process occurs in the liver and astrocytes with the final elongation and
saturation reaction occurring in peroxisomes; function of which is known to
decline with age. However endogenous production of DHA is not sufficient to
meet the brain’s neuroprotective needs. Regardless of the source, DHA is
rapidly internalised by neurons and incorporated mainly into PS and PE [391].
Evidence from animal studies demonstrates that DHA exerts a protective effect
against several pathological signs of AD, including Aβ accumulation and
hyperphosphorylation of tau. DHA has been shown to attenuate Aβ generation
and increase synthesis of the DHA derived messenger, neuroprotectin D1
(NPD1) [392].
DHA is a direct signalling molecule as it binds and activates various nuclear
receptors, including peroxisome proliferator-activated receptors (PPARs),
retinoid X receptors (RXR) and sterol regulatory-element binding protein
(SREBP). These nuclear receptors activate genes involved in anti-inflammatory
processes, lipid metabolism and other brain functions. DHA can specifically bind
RXR, regulating pathways involved in synaptic plasticity and memory [393].
PUFAs bind to PPARs more readily than saturated or monounsaturated fatty
acids. The RXR receptor, normally regulated by retinoic acid, can also be
activated by DHA. Retinoic acid signalling is involved in synaptic plasticity and
memory, and abnormal retinoid metabolism has recently been suggested as a
possible contributor to AD pathology [176, 394, 395].
Total DHA levels are decreased in the AD brain [396]. This deficiency may be
due to enhanced free radical – mediated lipid peroxidation, decreased dietary
intakes and/or impaired liver DHA shuttling to the brain [283]. It is generally
assumed that fatty acid transport into the brain occurs from the non-esterified
pool (NEFA), bound to albumin. Albumin also binds lysophospholipids, mainly
lysophosphatidylcholine (LysoPC). In addition to the LysoPC generated by the
action of phospholipase enzymes, it is also produced when lecitihin cholesterol
acyl transferase (LCAT) transfers the acyl chain from the sn-2 position of HDLphosphatidylcholine to free cholesterol to form cholesteryl ester in HDL. Studies
have shown that DHA uptake by the brain is around 10 times more efficient
when incorporated into LysoPC compared to the NEFA form. LysoPC-DHA may
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therefore represent a privileged form of DHA transport into the brain and may
have implications for abnormal lipid metabolism and reduced HDL [397].
Studies with primary neurons in culture, stressed by Aβ and interleukin-1β (IL1β) have shown up-regulation of PLA2 [286] and may explain the increase in
unesterified DHA seen in AD. The bioavailability of unesterified DHA is a highly
regulated event. Once DHA is freed from membrane phospholipids it can go
down two different pathways – one protective and one damaging (see Figure
1.11). The pathway taken appears to be influenced by the redox balance of
cells [398]. DHA is the most unsaturated fatty acid, making it a target for primary
lipid peroxidation. During periods of excessive oxidative stress, DHA may be
non-enzymatically

oxidised

into

neuroprostanes

[352].

Generation

of

docosanoids from DHA is an emerging area of research. Resolvins and
neuroprotectins are derived from DHA by the action of 15-lipoxygenase and
maresins are formed by the action of 14-lipoxygenase and are so called
because they “resolve” inflammation and promote “protection” of cells against
injury [274]. It would therefore appear that the beneficial actions of DHA in the
brain are a result of direct maintenance of neuronal plasma membrane fluidity
and through the generation of docosanoids. The docosanoids are similar in
structure to eicosanoids and appear to antagonise the potent inflammatory and
immunoregulatory functions of the omega-6 generated counterpart [399].
Therefore deficits in DHA or its metabolites may contribute to the inflammatory
signalling, apoptosis and neuronal dysfunction seen in AD [286]. Resolvins
have been shown to block TNF induced cytokine release from microglial cells
and regulate leucocyte infiltration in the brain [400].
A major DHA derived mediator is neuroprotectin D1 (NPD1) or 10R,17Sdihydroxy-docosa-4Z,7Z,11E,15E,19Z hexaenoic acid. NPD1 is synthesised as
an alarm response to oxidative stress and by neurotrophic activation in an
attempt to maintain cellular integrity and promote brain cell survival and repair,
through anti-apoptotic and anti-inflammatory signalling [286, 401]. Recent
evidence suggests that synthesis of NPD1 is activated by growth factors and
neurotrophins. NPD1 is also being shown to interact with the mechanisms
associated with APP and A peptide [286]. Both DHA and NPD1 promote nonamyloidogenic processing of APP and decrease the rate of Aβ generation.
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NPD1 has been shown to specifically down regulate A1-42-induced expression
of the pro-inflammatory cyclooxygenase-2 (COX-2) and BACE1, while activating
ADAM10 and increasing production of the neuro-protective sAPP [402]: This
diminishes Aβ-mediated pro-inflammatory, pro-apoptotic and pathogenic
consequences. NPD1 also reduces brain cell damage by shifting the balance
from expression of apoptotic proteins such as caspase-3, to expression of the
anti-apoptotic, survival promoting members of the Bcl-2 gene family during
oxidative stress [403] (see Figure 1.11).

Animal and in vitro studies have

helped to clarify the mechanisms of NPD1 protection and have shown that
along with DHA it also interacts with PPARγ, a transcription factor regulating
lipid metabolism, inflammation and insulin sensitivity [402]. Studies using the
PPARγ agonist rosiglitazone (Avandia), the irreversible antagonist GW9662
and overexpression of PPARγ demonstrated that NPD1- mediated down
regulation of BACE and Aβ42 peptide release are PPARγ activation dependent
[402]. PPARγ activation leads to anti-inflammatory, anti-amyloidogenic and antiapoptotic actions, as does NPD1. The molecular mechanisms of the Aβlowering effects by PPARγ remain unclear, although several mechanisms have
been proposed:

Induction of

Aβ ubiquitination,

leading

to

enhanced

degradation, is one possible mechanism. Alternatively, Aβ clearance may be
enhanced by improved insulin sensitivity and increased insulin degrading
enzyme activity in the brain, which plays a major role in degrading Aβ [404].
Additional studies have also shown that NPD1’s stimulation of nonamyloidogenic pathways can also be PPARγ-independent.
1.5.13

Lysophospholipids and Platelet Activating Factor (PAF)

Lysophospholipids are transiently produced during phospholipid metabolism by
the action of PLA2 and include LysoPC, LysoPE, LysoPS, LysoPI, LysoPA and
Lysoplasmalogens [63]. Apart from being intermediates of PL metabolism, at
high concentrations they influence membrane permeability and interact with
membrane bound enzymes and other membrane lipids, affecting various
functions and growth factors [28]. LysoPLs can be reacylated to restore PLs to
membranes or acetylated to form platelet activating factor (PAF); a potent
inflammatory lipid with multiple signalling roles [405]. LysoPC is involved in
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microglial and immune activation in the brain, where activated microglia help
clear cellular debris in areas where senile plaques and neurofibrillary tangles
are accumulating [28]. Analysis of CSF in AD patients has shown LysoPC to be
significantly reduced compared to controls, indicating abnormal PC metabolism
with resulting alterations in membrane fluidity, permeability, ion homeostasis
and promotion of oxidative stress [371]. However, a recent study contradicted
these findings by reporting an increase in the LysoPC:PC ratio in both
nanometer particle fractions (more representative of brain tissue) and
supernatant fractions of CSF in AD [375], which was accompanied by increased
PLA2 activity. LysoPA is involved in neurotransmitter action, including
stimulation of noradrenaline and dopamine release [406].
1.5.14

Non-enzymatic derived lipid mediators

Non-enzymatic degradation of glycerophospholipids results in the formation of
isoprostanes, neuroprostanes, isofurans, neurofurans, isoketals, neuroketals, 4hydroxynonenal (4-HNE), 4-hydroxyhexanal (4-HHE) and malondialdehyde
[407]. These prostaglandin-like compounds trigger further reactive oxygen
species (ROS) generation, exacerbating damage to cellular membranes.
Neuroprostane-containing phospholipids adversely affect neuronal function by
interfering with membrane function [408]. AA peroxidation results in the
formation of 4-HNE, which is highly reactive and increases the expression and
activity of BACE1 [28]. Measurement of F4-neuroprostanes (derived from DHA)
and hydroxynonenal (HNE) reflect the general state of oxidative stress and lipid
peroxidation in ‘stressed’ brain cells and these molecules may be useful
biomarkers for neurodegeneration [409]. Notably F4-neuroprostanes are
elevated in the cortex of AD brains [410] and may therefore serve as a potential
biomarker for the specific oxidation of DHA [352].
1.5.15

Sphingolipids

Sphingolipids,

including

sphingomyelin,

ceramides,

sulphatides

and

glycosphingolipids are key components of lipid rafts and therefore affect APP
processing and Aβ binding and aggregation. Ceramides are central
components of sphingolipid metabolism and are core constituents of most
sphingolipids, which are either synthesised from fatty acyl CoA and serine,
60

Chapter 1: Review of the Literature – Lipids and AD
sphingosine or produced by enzymatic hydrolysis of other sphingolipids [63].
The following figure depicts sphingolipid metabolism.

Figure 1.12: Sphingolipid metabolism.
Sphingolipid synthesis begins with ceramide which can be formed de novo from palmitoyl-CoA
and serine or be produced from other sphingolipids by the action of various enzymes. Ceramide
reacts with phosphatidylcholine (PC) to form sphingmyelin (SM) and can react with uridine
diphosphate (UDP) sugars to form cerebrosides (usually galactose or glucose).
Galactoceramide (cerobroside) can react with 3’-phosphoadenosine 5’-phosphosulphate
(PAPS, an active sulphur donor) to form sulphatides. Additional sugars may be added to
ceramide to form globosides (glycoSLs). Gangliosides are produced by the addition of Nacetylneuraminic acid. (Figure adapted from [411]).
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Sphingomyelin (SM) and glycosphingolipids, in particular gangliosides, are
abundant in the brain and are major components of neuronal membranes.
Sphingolipids are also directly involved with APP processing, which in turn
affects cholesterol and sphingomyelin metabolism. This suggests a cross
regulation of both processes and a link between Aβ-regulated cholesterol and
sphingomyelin metabolism, with γ-secretase activity controlling various
enzymes involved in lipid metabolism [291]. Inhibition of sphingomyelinase, the
enzyme that converts sphingomyelin to ceramide, results in SM accumulation,
which in turn reduces Aβ secretion due to inhibition of γ-secretase. Studies
have shown that activation of neutral sphingomyelinase (SMase) by Aβ42
reduces SM and increases ceramide. However, Aβ40 lowers cholesterol by
inhibition of HMGCoA reductase and reducing de novo cholesterol synthesis.
The reduced membrane cholesterol and SM produced by Aβ affects γsecretase activity and therefore normally provides a feedback mechanism [291]
(see Figure 1.13): This suggests a role for sphingolipids as γ-secretase
modulators. Additionally the presence of a sphingolipid binding sequence on Aβ
has been identified that increases affinity of Aβ to bind lipid rafts rich in
cholesterol and sphingolipids [412]. This binding sequence may have
implications for aggregation and processing of Aβ, which can influence
pathogenicity as studies have shown that Aβ aggregation requires an
environment rich in SM [291].
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Figure 1.13: Interactions between Cholesterol, Sphingolipids and APP processing.
APP: Amyloid Precursor Protein, γ: Gamma secretase complex, β: Beta site APP cleaving
enzyme (BACE), Chol: Cholesterol, SM: Sphingomyelin, MAOS: Membrane Associated
Oxidative Stress, SMase: Sphingomyelinase, HMGCoR: 3-hydroxy-3-methyl-glutaryl-CoA
reductase.
APP, BACE and γ-secretase are concentrated in lipid rafts which are rich in Cholesterol and
SM. Cholesterol increases the activities of BACE and γ-secretase, increasing production of
Aβ42, which can directly activate SMase resulting in increased ceramide production.
Additionally, age-related increases in oxidative stress and Aβ42 induce membrane-associated
oxidative stress which also activates SMase. An increase in ceramides can impair synaptic
function and damage neurons. Aβ40 inhibits HMGCoAR, the rate limiting step in the cholesterol
biosynthesis pathway. An increase in the Aβ42/Aβ40 ratio will therefore increase levels of
cholesterol and decrease SM in membranes.

SM is a major source of ceramides and sphingomyelinases which hydrolyse
phosphocholine from sphingomyelin to produce ceramides, are activated by
inflammatory cytokines and oxidative stress [157]. Ceramides are potent
second messengers that regulate diverse cellular processes. They activate
enzymes involved in stress signalling and are linked to caspase activation and
pro-apoptotic signalling via reactive oxygen intermediates. In early stages of
AD, marked decreases in sulphatides have been described, apparently not due
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to deficiencies in production, but rather due to greater conversion to ceramides,
which are a class of potential degradation products of sulphatides [413].
Accumulation of ceramide, with increased brain and CSF levels has been
reported at the earliest clinically recognisable stages of AD [273, 337].
Ceramide levels have been found to be more than three-fold higher in white
matter of the AD brain compared to normal control brain. It appears that gene
expression changes in the early stages of AD shift sphingolipid metabolism
towards accumulation of ceramide, depletion of glycosphingolipids and a
reduction in the anti-apoptotic signalling molecule, sphingosine-1-phosphate
[335]. Lipid metabolism is tightly connected to APP processing, and Aβ42 may
activate sphingomyelin catabolism causing accumulation of ceramide which
exacerbates neurodegeneration [414]. Adverse consequences result from
ceramide accumulation, including up-regulation of cytokines, reactive oxygen
species generation, mitochondrial dysfunction and apoptosis [415]. Ceramides
act directly on mitochondria to induce membrane permeability transition and the
release of cytochrome c, thereby compromising ATP generation and promoting
cell death [157]. Ceramides have also been shown to increase APP processing
by BACE, by enhancing BACE stability through the formation of ceramideenriched platforms in the lipid rafts [416] (see Figure 1.14). The substantial
elevation of ceramide in the AD brain might also be a consequence of
sulphatide degradation and an increase in synthesis or catabolism of SM and/or
cerebroside (see Figure 1.12) [337].
Sialylation of glycoceramides produces gangliosides, which are currently
receiving considerable attention as accelerators of AD pathology [27, 411, 417].
Aβ is thought to exert its toxic affects by interacting with cell membranes and
membrane proteins, which alters the folding of the peptide. The abnormal Aβ
then interferes with cell signalling and membrane integrity and reacts with other
components, which promote aggregation [418]. A possible mechanism by which
Aβ assembles into insoluble fibrils is through binding to the ganglioside GM1.
The conformation of Aβ from random coils to structures with increased β-sheet
content results when Aβ is bound to GM1 [27]. In this way, the membrane
bound GM1 acts as a seed for Aβ aggregation. This process is increased with
ageing and appears to be facilitated by cholesterol rich environments, such as
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lipid rafts [419]. Aβ bound to gangliosides in plaques may also escape immune
surveillance and indirectly promote further plaque formation by decreasing
microglial clearance of Aβ [420].
Sulphatides are a class of myelin-specialised glycosphingolipids, involved in
various cellular processes, including cell growth, protein trafficking, signal
transduction, cell-cell recognition, neuronal plasticity and cellular integrity [421].
Studies have shown that apoE is associated with sulphatide transport and
mediates sulphatide homeostasis in the CNS through lipoprotein metabolism
pathways. Alterations in apoE mediated sulphatide trafficking have been shown
to deplete sulphatide in the brain, and CNS levels of sulphatide have been
shown to be apoE isoform dependent, with the lowest levels observed with
APOEε4 [71]. An increased rate of apoE/sulphatide containing particle uptake
and increased expression of lipoprotein receptors can lead to increased
breakdown of sulphatide, depleting sulphatide from the myelin sheath.
Sulphatide containing apoE-associated particles facilitate Aβ clearance. This
may represent a further mechanism through which APOEε4 increases the risk
for AD [71]. Studies with APP transgenic mice have demonstrated that
clearance of increased Aβ production requires increased apoE, which
collectively increases sulphatide trafficking and degradation [71].
Serum SM and ceramide levels were measured in women as part of the
longitudinal WHASII study of cognitive impairment and the results suggest that
these lipids may be used as biomarkers of memory impairment and disease
progression [163, 422]. However, this study gave conflicting results between
cross sectional and longitudinal data. Lower levels of serum ceramide and SM
were found to be associated with memory impairment cross-sectionally, but
higher ceramide levels were found to be associated in the longitudinal data
[163, 423]. The potential reasons for these differences will be explored in
Chapters 3 and 4. The potential link between ceramides and AD pathology can
be summarised in the following figure:

65

Chapter 1: Review of the Literature – Lipids and AD

Figure 1.14: The potential mechanisms for both direct and indirect effects of increased
ceramides influencing AD risk.
CSF: Cerebrospinal Fluid.
Elevated plasma ceramides are a feature of diabetes mellitus (DM), atherosclerosis, insulin
resistance (IR) and metabolic dysfunction; all risk factors for developing Alzheimer’s disease
(AD). (reviewed in [207, 265]). Additionally it is hypothesised that the existence of a
liver/peripheral-brain axis of neurodegeneration results in the increased production and delivery
of ceramides across the blood brain barrier (BBB): This provides a possible explanation for the
cognitive impairment seen in DM and non-alcoholic steatohepatitis (NASH) [165]. In the central
nervous system, the elevated ceramides have direct effects on AD pathology by stabilising beta
site APP cleaving enzyme (BACE) and increasing Aβ generation [416]. Ceramides may also
induce brain insulin resistance, which alters brain glucose metabolism and interferes with
numerous signalling pathways involved with synapse maintenance and brain plasticity [263,
265]. (Figure adapted from [424]).

A recent probe into the plasma lipidome of individuals with metabolic syndrome
and obesity showed various changes including increased ceramide species
[340].
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1.6

Control of lipid metabolism

Section 1.3.3 discussed diet and nutrition as risk factors for developing AD. The
composition of the diet and nutrient status has profound effects on lipid
metabolism through their influence on the endocrine system and energy
homeostasis via transcription factors regulating metabolic gene expression,
including SIRT1, adenosine monophosphate kinase (AMPK) and PPAR-gamma
coactivator 1-α (PGC1α) (reviewed in [425-427]). A recent publication has also
shown that metabolic stress modulates BACE gene transcription via effects on
SIRT1, PPARγ and PGC1α in neurons [428]. Due to the integrated nature of the
endocrine system, virtually all hormones will have some influence on lipid
metabolism and therefore influence a myriad of cellular functions. These
hormones therefore, may need consideration when interpreting blood lipid
profiles. Insulin is a master hormone regulating glucose uptake and utilisation,
but it also has many other effects on metabolism in general and acts as a
signalling molecule for a vast array of cellular processes. As previously
described, it has wide ranging effects on the CNS and is considered a key
player in the AD picture [98, 179]. The effects of insulin on cholesterol
metabolism via gene expression changes in SREBP and HMGCoAR have also
been described in previous sections. Insulin has a major influence on peripheral
plasma lipid profiles due to its affect on directing metabolism towards energy
storage. When insulin resistance is present increased circulating free fatty acids
(FFA) result from increased adipose tissue lipolysis as insulin normally inhibits
this process. The increased FFAs eventually lead to increased VLDL secretion,
increased cholesterol and an associated increased amyloid burden [260].
Insulin has also been shown to induce fatty acid desaturase expression in
monocytes and may provide an explanation of the increased inflammation
promoted by post-prandial hyperinsulinaemia when the dietary omega-6 to
omega-3 ratio is high [429]. Of particular relevance to lipidomics is the emerging
evidence to suggest an association between insulin resistance and ceramides;
where toxic ceramides may be the intermediate that links excess dietary
saturated fatty acids and inflammatory cytokines with insulin resistance [265]:
This is depicted in the following diagram.

67

Chapter 1: Review of the Literature – Lipids and AD

Fig 1.15: Ceramides – the toxic intermediate linking metabolic dysfunction, inflammatory
cytokines and insulin resistance? TNFα: tumour necrosis factor alpha, CoA: Coenzyme A.
NFκB: nuclear factor kappa B, iNOS: inducible nitric oxide synthase, NO: nitric oxide, Bcl2: B cell
lymphoma 2 anti-apoptotic proteins, IRS-1: insulin receptor substrate-1, PI3-K:
phosphatidylinositol-3 kinase, Akt/PKB: serine/threonine-specific protein kinase.
When adipose tissue exceeds its storage capacity, adipokines increase inflammation which
increases ceramides. This inhibits insulin signalling, further increasing lipolysis and increasing
the release of fatty acids for ceramide synthesis. Ceramide promotes apoptosis and the
elevated saturated fatty acids inhibit the Bcl2 family of anti-apoptotic proteins.

1.7

Lipoprotein metabolism and phosholipid transfer protein
(PLTP)

Lipoproteins are complexes of protein and lipids that solubilise lipids so they
can be transported in the circulation between tissues. Lipoproteins are
synthesised in the intestines from dietary lipids or in the liver from endogenous
lipids and can also be remodelled from precursor lipoproteins under the
influence of various metabolic signals. Lipoproteins are generally spherical
structures, typically consisting of a neutral lipid core of cholesteryl esters and
triglycerides and a surface layer of phospholipids, unesterified cholesterol and
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various apolipoproteins. These apolipoproteins not only solubilise the lipids but
also act as ligands for cell surface receptors and cofactors for plasma enzymes.
High LDL, VLDL and low HDL are known risk factors for vascular disease,
diabetes and AD [430-432] and dyslipidaemia has been shown to be more
prevalent in AD patients with BBB impairment [433]. Lipoproteins are very
dynamic and are constantly being modified by the action of enzymes, lipid
transfers and apolipoprotein exchange. This ensures specific lipid delivery to
different tissues [63, 89]. Lipoprotein metabolism and the associated lipid
transfer proteins are shown in the following figure:

Figure 1.16: Lipoprotein metabolism and lipid transfer proteins.
CM: Chylomicrons, LPL: Lipoprotein lipase, CR: Chylomicron remnants, PLTP: Phospholipid
transfer protein, Chol: Cholesterol, PL: Phospholipid, ABC-1: ATP binding Cassette Transporter
1, HDL: High density lipoprotein, LDL: Low density lipoprotein, VLDL: Very low density
lipoprotein, IDL: Intermediate density lipoprotein, SR-B1: Scavenger receptor B1, CETP:
Cholesteryl ester transfer protein, LCAT: Lecithin-Cholesterol acyl transferase, VitE: Vitamin E,
LPS: Lipopolysaccharide
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CM are assembled from dietary fat in the intestine and enter the circulation. At
the same time lipid poor apolipoprotein AI (apoAI) is secreted from the intestine
and reaches the circulation. The triglycerides of CM undergo lipolysis by
lipoprotein lipase and the surface remnants (phospholipids and apolipoproteins)
of the CR are transferred via PLTP to apoAI. The CRs are then taken up by the
LDL/remnant receptor in the liver. Triglyceride rich lipoproteins (VLDL) are
secreted by the liver. VLDLs also contain a large amount of cholesteryl ester
and

are

enriched

with

apolipoprotein

B100

(apoB100)

and

phosphatidylethanolamine (PE). The CE is transferred from HDL by CETP and
moves most of the CEs to apoB containing lipoproteins which can be cleared by
the liver. LPL hydrolyses the TG of VLDL to form IDL, which are further modified
by hepatic lipase to form LDL. The surface PLs and protein remnants at each
stage are transferred to HDL via PLTP. Lipid poor apoAI acquire free
cholesterol and phospholipids via ABCA-1 mediated efflux from the liver and
peripheral cells (and from VLDL and CR via PLTP) to form nascent pre-β HDL,
which progressively acquire additional PL and cholesterol via ABCA-1 efflux
from tissues. The cholesterol acquired by these discoid nascent HDL is then
esterified by LCAT (synthesised and secreted by the liver), which the HDL
obtains from the circulation. If the cholesterol is not modified within the HDL
particle it can move out again so conversion to CEs ensures that cholesterol is
trapped within HDL as CEs move to the centre of the HDL, producing the more
spherical -HDL. The activity of LCAT is crucial for maintaining a steady
gradient of free cholesterol allowing the HDL to accept additional cholesterol
from other sources. CETP also enriches HDL with TG which enhances lipolysis
of PLs and TG by hepatic lipase leading to smaller HDL3 and preβ-HDL. Large
mature HDL particles enriched with CE are removed from the circulation by the
liver scavenger receptor-B1 (SR-B1). PLTP, by transferring PLs and
apolipoproteins is constantly remodelling HDL for reverse cholesterol transport.
It also transfers vitamin E and lipopolysaccharides from and to HDL3
respectively.
In plasma there are two main lipid transfer proteins; cholesterol ester transfer
protein (CETP) and phospholipid transfer protein (PLTP). CETP is secreted
mainly by the liver and circulates bound to HDL. It redistributes cholesteryl
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esters from HDL to TG rich lipoproteins (CM and VLDL) and transfers TGs from
VLDL and CM to LDL and HDL [434]. PLTP facilitates the transfer of
phospholipids from TG rich lipoproteins to HDL and together with CETP is
important in reverse cholesterol transport by modifying the size and function of
HDL. The physiological relevance of PLTP is highlighted in PLTP-deficient
mice, which demonstrate a total absence of PL transfer from VLDL to HDL and
markedly reduced PLTP and HDL levels [435, 436]. The lack of substrate
specificity of PLTP is also highlighted by its ability to transfer DAG, which are
released by lipoprotein lipase in capillary endothelium and during lipolysis in
adipose tissue [437]. DAG is also transported by HDL. PLTP also facilitates the
transport of other lipophilic substances such as -tocopherol [438]. Dietary tocopherol (Vitamin E) is incorporated in CM and transported to the liver where
it is packaged into VLDL. Vitamin E is important in preventing LDL oxidation
and subsequent uptake of oxidised LDL by vascular endothelium [439]. PLTP
deficiency in the brain has been shown to result in reduced -tocopherol and an
increase in oxidative injury, leading to neurological dysfunction [440]. This
suggests that PLTP is a local transporter of -tocopherol and may transport tocopherol across the BBB. A major function of PLTP is to maintain the plasma
sub species of HDL [441, 442] and the CNS HDL like lipoproteins [443]. The
literature regarding the role of PLTP in disease is not straightforward and
conflicting. Most studies have been conducted in relation to atherosclerosis and
metabolic disease and are contradictory with some finding higher PLTP activity
levels and increased risk of disease [444, 445] and others finding lower levels
associated with disease [446, 447]. These conflicting results may be due to
study design as some were prospective and others cross-sectional. Assay
methodology may also contribute to the disparate results as there are notable
differences in the assays used. The protective or disease promoting effects of
PLTP remain unclear as HDL cholesterol levels vary in response to PLTP gene
overexpression or deficiency [448, 449]. It may be that the effect of PLTP on
disease depends on the background lipid profile, metabolic landscape, comorbidities, medication use and dietary considerations. Research into PLTP
and disease is gaining momentum. The emerging diverse roles and involvement
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in both lipid metabolism and AD pathology certainly make this a protein of
enormous interest and an intriguing addition to the lipidomic part of this study.
1.8

Lipidomics and AD biomarkers

The remarkable diversity of plasma lipids was recently highlighted by a study
which measured over 500 distinct lipid species in a pooled human plasma
sample [450]. The greatest challenge when studying the CNS is to ascertain
direct links between blood-based analytes and neuronal biochemistry. The BBB
separates the CNS from the periphery but in terms of lipids, some are excluded
and others are not. In addition, ageing and inflammation can disrupt the integrity
of the BBB and complicate the picture. Metabolic dysfunction, which is common
in ageing and present as a risk factor for AD, can also disturb normal lipoprotein
metabolism resulting in abnormal lipid transfer between the periphery and the
CNS [302, 443]. CSF is thought to be the most relevant sample for studying the
CNS but its collection, however, is an invasive procedure, requiring specialised
clinicians and is therefore not appropriate for large population screening and
follow-up. Conversely, blood is an easily obtainable and convenient sample to
use for this study with the additional benefit of accessing samples from a highly
characterised cohort of ageing where lipid profiles can be assessed in the
context of other AD-related biomarkers such as cerebral amyloid load.
Diagnostic strategies were discussed in detail earlier in this chapter (see
Section 1.2). Ante-mortem diagnosis of AD is currently made using
neuropsychological assessments and neuroimaging in some cases. Imaging of
the brain for amyloid burden enables AD to be identified pre-clinically, but is not
feasible for large population screening and some individuals can accumulate Aβ
but remain cognitively stable. [36, 41, 42]. Definitive diagnosis can only be
made by examination of the brain post-mortem and therefore the need for the
development of biomarkers to enable early diagnosis and monitoring of disease
progression ante-mortem is a priority. Such biomarkers will enable therapeutic
and intervention strategies to be implemented prior to manifestation of
irreversible neurodegeneration.
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A biomarker can be defined as:
“A characteristic that is objectively measured and evaluated as an indicator of
normal biologic processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention (an indicator of disease status, both clinical and
sub-clinical)”. [451].
In addition an appropriate AD biomarker should be able to detect
neuropathology, should be accurate, non-invasive, reliable, reproducible and
inexpensive. It should also be validated in confirmed AD and non-AD cases
[452]. The development of a blood-based biomarker would represent a huge
leap forward in terms of meeting the non-invasive, simple to perform and
inexpensive criteria. However, due to the complex nature of AD and presence of
co-morbidities, it is unlikely that a single biomarker will be identified offering
sensitivity and specificity of greater than 80%. It is more likely that a panel of
biomarkers will be identified comprising lipids, proteins and gene variants. This
study aims to contribute towards the identification of such a panel.
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1.9

Hypotheses
1. AD patients have abnormal plasma lipid profiles.
2. Altered plasma lipid profiles will reflect altered cerebral Aβ deposits.
3. Lipid profiling of plasma will yield sensitive and specific markers of AD.
4. Plasma PLTP activity levels are different between AD patients and
healthy controls.

1.10

Aims of the study

These hypotheses will be addressed by the following specific aims:
1. To determine plasma lipid profiles of baseline and 18 month follow up
AIBL samples using electrospray ionisation mass spectrometry (ESIMS/MS).
2. To determine differences in plasma lipid profiles between healthy
controls and AD, by using a shotgun lipidomics approach. In particular
plasma levels of phosphatidylcholine (PC), phosphatidylethanolamine
(PE),

phosphatidylserine

(PS),

phosphatidylinositol

(PI),

phosphatidylglycerol (PG), sphingomyelin (SM), lysophospholipids,
ceramides and plasmalogens will be measured.
3. In addition, lipoprotein metabolism will be investigated using the
measurement of phospholipid transfer protein (PLTP) activity.
4. To correlate candidate lipid biomarkers to disease progression, using
standard uptake value ratios (SUVR).
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Chapter 2 - Materials and Methods
This chapter describes the ethics, research design, the study cohort,
biomarkers (blood and imaging) and genotypes that have been used for the
work described in this thesis. The overall aim of the methods used was to
evaluate associations between blood lipid biomarkers and other Alzheimer
disease (AD)-related variables of interest and to investigate the potential of a
biomarker panel as an early predictive test for AD.
2.1

Ethics

The Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) is
approved by research ethics committees from the major participating
institutions: St Vincent’s Health, Austin Health, Hollywood Private Hospital and
Edith Cowan University. All participants were provided with information and
consent documentation outlining all procedures which included information on
potential risks and benefits associated with participation in the study. After
being provided with this documentation, a signed consent form was obtained
from each participant before commencement of data collection. This project
involved utilisation of previously collected blood samples and analysis of
supplementary AIBL data (neuroimaging, genotypes, clinical classifications and
blood analyte measurements) and therefore no participant interaction was
involved.
2.2

Study Population

The AIBL volunteer database was created as a joint venture between leading
Australian

researchers

in

Alzheimer’s

disease

and

the

Australian

Commonwealth Scientific Industrial and Research Organisation (CSIRO) in
2005 [453]. The aims of this collaboration were to recruit a cohort of Australian
subjects aged 60 years and over (n = 1112) and to collect comprehensive
information including cognitive function status, amyloid brain load, blood
biomarkers and lifestyle habits. This information has been collected every 18
months since study inception. Only baseline and 18 month time point data and
blood samples were used for this study. The cohort consisted of three main
groups:
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Cognitively healthy controls (HC) which can further be divided into nonmemory complainers (NMC) and subjective memory complainers (SMC)



Individuals with mild cognitive impairment (MCI)



Individuals with early-stage AD

Figure 2.1 illustrates the cohort breakdown by clinical classification at baseline
and 18 month follow-up.

Figure 2.1: AIBL cohort at baseline and 18 months. There were 1,112 baseline samples.
These were classified as 211 AD, 133 MCI and 768 healthy controls (372 non-memory
complainers (NMC) + 396 subjective memory complainers (SMC)). 115 of the baseline
participants did not return for 18 month follow-up and of these 28 were deceased. There were
968 18 month follow-up samples which were classified as 196 AD, 81 MCI and 691 healthy
controls (317 NMC + 374 SMC). One participant in the MCI group was reclassified as non-AD
dementia due to Parkinson’s Disease (PDD). The arrows and associated numbers reflect the
individuals moving between groups.
Schematic adapted from an image provided by the AIBL Study Scientific Management
Committee.

Several high impact studies investigating cognitive function in the aged,
lifestyle, neuroimaging and blood biomarkers of AD have been published
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utilising data from the AIBL study: A list of these publications can be found at
www.aibl.csiro.au.
2.2.1

Recruitment, eligibility screening and exclusion criteria

Volunteers for this study were recruited in Melbourne and Perth, Australia, via
media advertisements (television, radio and newspapers). Over 4000
individuals responded who then underwent eligibility screening by telephone to
obtain basic demographics (contact details, sex and age). In addition,
information regarding medical history, with specific information related to
eligibility was obtained. Information on alcohol intake was also collected. All
AIBL volunteers were aged 60 years and above at baseline, and excluded if
they had a history of non-AD dementia, schizophrenia, bipolar disorder,
significant current depression (geriatric depression scale score or “GDS” > 5),
Parkinson’s disease, cancer within the last two years (except basal cell skin
carcinoma), symptomatic stroke, insulin-dependent diabetes, uncontrolled
diabetes mellitus or current regular alcohol consumption exceeding four
standard drinks per day for men or two per day for women. There was no
maximum age for inclusion.
2.2.2

Classification of Study Population

Classification of individuals into AD, MCI or cognitively healthy groups was
made by utilising all available information, including medical history, memory
complaints, information from family and neuropsychological test data. A
consensus diagnosis was assigned for each participant by a clinical review
panel, which included consideration of diagnostic criteria, DSM-IV diagnosis
(Diagnostic and Statistical Manual of Mental Disorders, version IV) and ICD-10
diagnosis (International Statistical Classification of Disease) [454]. Where
appropriate, ICD-10 dementia severity rating, NINCDS-ADRDA (National
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association) AD diagnosis (probable or
possible) and MCI classifications were applied. Diagnosis of individuals with
MCI was made according to the internationally agreed criteria [455, 456] and
these participants had also reported memory difficulties either personally or
through an informant. The clinical review panel comprised a neurologist, a
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geriatrician,

neuropsychologists

and

geriatric

psychiatrists

to

ensure

consistency of diagnoses.
2.2.3

Study visit

All participants who met the inclusion criteria were scheduled for a study visit at
one of three locations in Melbourne and one location in Perth. On the morning
of the appointment, measurements of pulse, blood pressure, height, weight and
abdominal circumference were obtained. Following these measurements, an
80mL blood sample (following an overnight fast) was collected from the
antecubital vein using standard venipuncture technique. Following blood
collection, participants were given a light breakfast and then required to
complete a medical history questionnaire. A series of cognitive and mood
assessments were then performed. Separate appointments were made for the
purpose of undertaking brain scans. All procedures were repeated at the 18
month follow up assessment.
2.2.4

Demographics, medical history and medication use

A detailed questionnaire regarding demographic information, medical history,
medication use and lifestyle (alcohol consumption and smoking) was completed
by each participant. Demographic information included marital status, country of
birth, primary language spoken, living arrangements, handedness, occupation
(past/present), primary source of income, years of education, pet ownership and
participation in community activities. Medical questions included current or past
history of cardiovascular disease, hypertension, stroke, diabetes, visual defects
(including colour deficiency), cancer, history of falls, thyroid/parathyroid disease,
gastrointestinal complaints, arthritis, kidney disease, liver disease, joint
replacement, epilepsy, serious head injury, neurological disorders, depression,
anxiety and psychiatric disorders. Current medication use including name, dose
and frequency was also recorded.
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2.3

Blood Biomarkers

2.3.1

Sample collection [453]

At baseline and 18 month follow-up, 80mL of fasted blood was collected. From
each participant, three different blood collection tubes were used:


Lithium heparin



EDTA with added prostaglandin E1 (Sapphire Biosciences, 33.3ng/mL)



Serum tubes

27mL of the 80mL collected was sent to either PathWest Laboratory Medicine,
Nedlands, Western Australia or Melbourne Health, Victoria for analysis of full
blood count, erythrocyte sedimentation rate, urea and electrolytes, creatinine,
androgen levels, globulin levels, sex hormone binding globulin (SHBG),
glomerular

filtration

rate,

calcium,

liver

function

tests,

serum

lipids,

homocysteine, serum and red cell folate, B12, glucose, insulin, caeruloplasmin,
ferritin/transferrin/iron, oestradiol, luteinising hormone, thyroid function tests
(thyroid stimulating hormone, free thyroxine, free triiodothyronine) and prostate
specific antigen (males only). 0.5mL of whole blood was sent for apolipoprotein
E (APOE) genotyping (see Section 2.3.2). The remaining blood was
fractionated into the following components:


Serum



Plasma



Platelets



Red blood cells



White blood cells (in distilled water)



White blood cells in RNA later, (Ambion, Thermo Fisher Scientific,
Waltham, MA, USA).

These blood fractions were stored in NUNC cryovials (Nalge Nunc International,
Rochester, NY, USA) in liquid nitrogen in aliquots which ranged in size from
0.25mL to 1.0mL.
The EDTA plasma samples were used for lipid extraction and profiling.
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2.3.2

DNA extraction and APOE genotyping

DNA was extracted from 200μL of whole blood using a Qiagen Blood Mini-Kit
(Qiagen, Hilden, Germany). 200μL of whole blood was added to 200μL of buffer
containing proteinase K, pulse vortexed for 15 seconds and then incubated for
10 minutes at 56°C. After centrifugation, 200μL of absolute ethanol was added
to the tube. The mixture was then applied to the QIAamp Mini Spin Column and
centrifuged for 1 minute at 6,000g. The filtrate was discarded and the QIAamp
Mini Spin Column placed into a clean tube, followed by the addition of 500μL of
buffer and centrifugation for 1 minute at 6,000g. Again the filtrate was discarded
and the QIAamp Mini Spin Column placed into a clean tube with the addition of
500μL of buffer and centrifugation for 3 minutes at 20,000g. The column was
placed into a clean tube with the addition of 200μL distilled water and incubated
at room temperature for 1 minute before centrifugation at 6,000g for 1 minute.
The extracted DNA was genotyped by the following published method [457]:
PCR reaction:
200nM primer

Forward:

5’ GCCTACAAATCGGAACTGGA 3’

Reverse:

5’ ACCTGCTCCTTCACCTCGT 3’

1 unit Platinum Taq Polymerase (Invitrogen, Carlsbad, CA, USA)
1.5mM Magnesium chloride
200μM deoxyribonucleotide triphosphate
94°C 7 secs denaturation
(94°C for 30 secs, 55°C for 30 secs, 72°C for 30 secs) x 30 cycles
Sequencing with the forward primer was carried out with BDV3.1 on a 3130-xl
genetic analyser (Applied Biosystems, Foster City, CA, USA).
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The APOE genotype was then determined using the following fragments:
Table 2.1: APOE genotype and fragment size as determined by DNA sequencing.

Genotype
ε2/ε2
ε2/ε3
ε2/ε4
ε3/ε3
ε3/ε4
ε4/ε4

Fragment Size (bp)
91 + 83
91 + 83 + 48 + 35
91 + 83 + 72 + 48 + 35
91 + 48 + 35
91 + 72 + 48 + 35
72 + 48 + 35

bp: base pairs.

APOE genotyping was undertaken and the protocol provided by Dr Simon
Laws.
2.3.3

Sample extraction for lipid profiling

A modified Bligh and Dyer method was used [458].
900µL of ice-cold organic solvent mixture (chloroform/methanol 1:2 v/v) was
added to 150µL of plasma (in duplicate) and vortexed for 15 seconds. The
samples were then incubated in a vacuum (Desi-Vac Container) on ice inside a
4°C dark room with agitation at 180rpm for one hour. After incubation, 250µL of
ice-cold water and 300µL of ice-cold chloroform were added to the sample to
break the phase. The samples were then vortexed for 15 seconds and
incubated on ice for one minute and then vortexed again for 15 seconds. The
samples were subsequently centrifuged at 9,000rpm for 2 minutes at 4°C. The
lower organic phase was transferred into a clean eppendorf tube and 500µL of
ice cold chloroform added to the original tube for a second extraction. After
vortexing for 15 seconds this sample was placed in a vacuum on ice inside a
4°C dark room with agitation at 180rpm for 30-60 minutes. Following
centrifugation the lower organic phase was removed and added to the original
extracted lower phase. The pooled organic phases from both extractions were
dried in a Savant SpeedVac® (Thermo Fisher Scientific, Scoresby, Victoria,
Australia). The dried, extracted lipids were stored at -80°C until required for
analysis.
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2.3.4

For

Sample preparation for shotgun lipidomics (direct-flow
injection)
analysis

the

dried

samples

were

reconstituted

in

100L

of

chloroform/methanol (1:1 v/v). The sample was vortexed and centrifuged at
12,000 rpm for 2 minutes. Following centrifugation 80L was added to 120L of
chloroform/methanol (1:1 v/v). The sample was again centrifuged at 12,000 for
2 minutes. 80L was then transferred into a sample vial with 80L of the
working internal standard mix (shown in Table 2.2) and loaded on to the
analyser. For the positive mode samples a further dilution was required. 10μl of
the prepared sample (already spiked with internal standard) was removed from
the vial and mixed in a separate vial with 80μl of chloroform/methanol (1:1 v/v).
The internal standard mix was prepared as outlined in Table 2.2.
Table 2.2: Internal Standards used to prepare mix for lipid profiling.

Standard
DMPE
DMPG
DMPS
DMPA
diC8PI
DMPC
GluCer
SM
C17Cer
LysoPE
LysoPG
LysoPI

[Stock mg/mL]
0.2
0.2
0.5
0.1
0.25
0.2
0.1
0.5
0.1
0.1
0.1
0.1

[Working μg/mL]
5
2
2
1
2
10
2
6
2
0.5
0.5
0.5

DMPE:
1,2-dimyristoyl-glycero-3-phosphoethanolamine,
DMPG:
dimyristoylphosphatidylglycerol, DMPS: dimyristoyl-phosphatidylserine, DMPA: dimyristoyl-phosphatidic
acid, diC8PI: dioctanoyl-phosphatidylinositol, DMPC: dimyristoyl-phosphatidylcholine, GluCer:
C8-Glucosylceramide, SM: C-12 sphingomyelin, C17Cer: C17-ceramide, LysoPE:
Lysophosphatidylethanolamine,
LysoPG:
Lysophosphatidylglycerol,
LysoPI:
Lysophosphatidylinositol.

The diC8-PI was supplied by Echelon Bioscience Inc, USA. All other lipids were
supplied by Avanti Polar Lipids, Alabaster, Alabama, USA.
The working mix was stored wrapped in foil at -80°C

82

Chapter 2 – Materials and Methods
2.3.5

Shotgun lipid profiling by mass spectrometry

Electrospray ionisation mass spectrometry (ESI-MS) was performed on an
Applied Biosystems (Foster City, CA, USA) high performance FlashQuant™
workstation

that

incorporates

a

4000Q

Trap

Instrument

(a

triple

quadrupole/linear ion trap liquid chromatography-tandem mass spectrometer
(MS/MS) and a Shimadzu High Performance Liquid Chromatography (HPLC)
(Shimadzu, Kyoto, KYT, Japan) autosampler to quantify individual polar lipids
[370]. This method combines triple quadrupole scan modes with linear ion trap
scans, therefore allowing multiple analyses. The sample was mixed with
chloroform/methanol (1:1 v/v) in the autosampler and then injected into the
mass spectrometer via loop injections with the mobile phase which was
chloroform/methanol (1:1 v/v), at a flow rate of 0.25mL/min. In the ESI chamber,
the analyte is volatilised by the tiny charged capillary and the sample propelled
out of the capillary in the form of an aerosol. Nitrogen gas was used as the
carrier gas. The sample then passes through to the second chamber (MSI) and
then through the collision induced dissociation (CID) chamber where further
fragmentation of the analyte occurs (see Figure 2.2). The MS2 chamber is a
quadrupole ion trap, which acts as a mass-selective filter, trapping and
sequentially ejecting the ions.

Figure 2.2: Schematic of method used for lipid profiling.
ESI: Electrospray ionisation, MS1: mass spectrometer chamber 1, CID: Collison induced
dissociation chamber, MS2: Quadrupole ion trap.

83

Chapter 2 – Materials and Methods
In the example used in the figure, the parent lipid is detected at 885.8 m/z
(mass to charge) and after passing through the CID a unique fragment at 241.1
m/z is detected. The resultant mass to charge ratio of 885.8/241.1 identifies this
as phosphatidylinositol (PI 38:4), where the sn-1 and sn-2 side chains contain
fatty acids with a sum of 38 carbons and 4 double bonds.
Each individual sample is spiked with a known quantity of commercially
available internal standard as described in Table 2.2. Multiple reaction
monitoring (MRM) transitions were used for quantitative analyses and were set
up based on product and precursor ion analysis of various lipid head groups.
The signal intensity of each MRM value was normalised to the signal intensity of
the spiked internal standards and the sum of the individual lipid species before
being corrected for molecular weight.
2.3.6

Phospholipid Transfer Protein (PLTP) Activity Assay

A commercially available PLTP activity assay kit was purchased from Roar
Biomedical, Inc. Audubon Biomedical Centre, 3960 Broadway, New York, USA
and was utilised according to the manufacturer’s protocol. PLTP mediates the
transfer of an exogenous fluorescent substrate in this assay. Briefly, frozen
plasma samples were thawed on ice and then centrifuged at 12,000rpm for 10
minutes at 4°C. A 96 well black microtitre plate (Nalge Nunc International,
Rochester, NY, USA) was placed on wet ice to cool. A grand mix was prepared
containing 4200μL of 1 x assay buffer and 300μL of donor particle. 45μL of this
grand mix was added to each well of the microtitre plate. 5μL of sample or an
assay blank (5μL of 1 x assay buffer) was added to the wells. All plasma
samples, control samples and blanks were run in duplicate. 50μL of the
acceptor particle was then added using an 8 tip multichannel pipette. The plate
was covered and incubated in a 37°C water bath for 20 minutes. Following
incubation, the plate cover was removed and the fluorescence read at 37°C
using an Enspire Multimode Plate Reader (Perkin Elmer, Waltham, MA, USA)
with the excitation and emission wavelengths set at 465nm and 535nm
respectively.
While the plate containing the samples, controls and blanks was incubating a
standard curve was prepared for a concentration range of 0-80 picomoles. Six
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tubes were labelled S0 to S5, each containing 1mL of isopropanol, with tube S5
containing an additional 1mL. 5μL of PLTP donor particle was added to tube S5
which was vortexed to adequately disperse the donor particle in the
isopropanol. 1mL of S5 was transferred to S4, 1mL of S4 transferred to S3, 1mL
of S3 transferred to S2, 1mL of S2 transferred to S1, with vortex mixing after
each addition. S0 is the isopropanol blank. 100μL of each standard was
pipetted, in duplicate, into two rows of a black microtitre plate (separate to the
sample plate) and fluorescence read (Ex:465 nm; Em:535 nm) at 37°C. A
standard curve was created by plotting the fluorescence intensity versus the
picomole concentrations of the standards read. The fluorescence intensity units
transferred during the incubation time were determined by subtracting the assay
blank (assays performed without plasma, but using 5μL 1x assay buffer) from
the fluorescence values of the samples and then applied to the standard curve
to obtain a PLTP activity level.
2.3.7

Plasma beta amyloid

Plasma Aβ1-40 and Aβ1-42 were measured according to the manufacturer’s
protocol by a commercial kit (INNO_BIA plasma Aβ assay, Innogenetics, Inc.,
Gent, Belgium). Briefly, the thawed plasma samples were diluted 1:3 using the
supplied buffer. Coated beads were vortexed and sonicated for 3 minutes,
diluted 100 times in diluent and protected from light. The pre-made standards
and controls were thawed at room temperature and loaded onto the plate after
vortexing. All standards, controls and plasma samples were run in duplicate.
For the measurement of Aβ1-40 and A1-42, Conjugate 1A was diluted 100 times
with Conjugate Diluent. A 96-well polyvinylidene fluoride microfilter plate was
washed once with Wash Solution, followed by addition of 100μL of the diluted
bead mix to each well. The contents of the plate were aspirated by vacuum and
25μL of diluted Conjugate 1A was then added to each well. 75μL of standards,
controls and diluted plasma was then added to the appropriate well. Assay
blanks used Diluent only in place of sample. The plate was covered with foil and
incubated at 4°C overnight on an orbital plate shaker. Following overnight
incubation, the Detection Conjugate was diluted 100x in Diluent and protected
from light. The plate was aspirated by vacuum and washed three times with
wash solution. 100μL of diluted Detection Conjugate was then added to each
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well. The plate was covered with foil and incubated at room temperature for 1
hour on an orbital plate shaker. Following incubation, the wells were aspirated
and washed 3 times with Wash Solution. 100μL of Reading Solution was added
to each well and the plate covered with foil and placed on an orbital plate
shaker for at least 2 minutes to a maximum of 5 minutes. The plates were read
using a Luminex xMAP reader system (Bio-Plex 200 System, Bio-Rad). A
minimum of 100 beads per region were read for each sample. Data analysis
was performed using a 5-PL logarithmic equation built into the instrument
software, which automatically calculated for dilution factors. The plasma Aβ142:Aβ1-40

ratio was calculated. The ratio is preferred to measurement of Aβ1-42

alone as Aβ1-40 is taken into account as an internal reference. Dr Alan Rembach
provided the protocol and performed the plasma Aβ assay.
2.3.8

Plasma apolipoprotein E (apoE)

Plasma apoE was measured according to the manufacturer’s protocol by a
commercial kit (ApoE4/Pan ApoE ELISA, MBL co., Ltd., Woburn, USA). This
sandwich enzyme-linked immunosorbent assay (ELISA) kit measures the
amount of total ApoE using purified polyclonal antibodies against ApoE. Briefly,
thawed plasma samples were diluted 1:500 using the Assay Diluent. Working
concentrations of the standards were prepared from solutions of the provided
calibrator, which was reconstituted 1:10 with the assay diluent. All standards,
controls and plasma samples were run in duplicate. Standards or thawed,
diluted plasma samples were loaded into microwell strips that were coated with
anti-Human Pan-ApoE antibody. The plates were covered and incubated at
37°C for 1 hour. Following incubation the plate was washed four times with
wash solution. 100μL of a peroxidase conjugated anti-ApoE polyclonal antibody
was then added and incubated at 37°C for 1 hour. The plates were again
washed before the addition of 100μL of the peroxide substrate, followed by
further incubation at 37°C for 30 minutes. To terminate the enzyme reaction and
stabilise the developed colour, 100μL of an acid solution was added to each
well. The optical density of each well was measured at 450nm using a BMG
microplate reader. Concentrations of Pan-ApoE were determined from a
standard curve based on reference standards. The sensitivity of the assay is
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8ng/mL. The ApoE assay was performed and the protocol provided by Dr Veer
Gupta.
2.3.9

High Density Lipoprotein (HDL) cholesterol - subfractions

Plasma HDL cholesterol sub-fractions were analysed using the Lipoprint system
(Quantimetrix, Redondo Beach, CA, USA), according to the manufacturer’s
protocol. Briefly, 25μL of plasma was added to loading buffer in glass gel tubes
and left for 30 minutes to polymerise. Samples were then separated in the
electrophoretic chamber at 3mA per tube for 1-1.5 hours. Following separation
the gels were scanned and the sub-fraction band intensities were obtained
using the supplied software. Ten subclasses of HDL were measured, which
were divided into three groups; HDL large (subclasses 1-3), HDL intermediate
(subclasses 4-6) and HDL small (subclasses 7-10). Dr Steve Pedrini and Dr
Eugene Hone provided the protocol and performed the HDL subfraction
analyses.
2.3.10

Plasma clusterin

Plasma clusterin was measured according to the manufacturer’s protocol using
a commercial kit (Quantikine® ELISA, Human Clusterin Immunoassay, R&D
Systems, Inc., Minneapolis, USA). This sandwich immunoassay kit measures
the amount of clusterin using a specific monoclonal antibody. Briefly, thawed
plasma samples were diluted 1:2000 using Calibrator Diluent RD5T. Working
concentrations of the clusterin standard were prepared from a series of dilutions
with calibrator diluents to a range of 0-200ng/mL. All standards, controls and
plasma samples were run in duplicate. 100μL of RD1-19 assay diluent was
added to the wells of the microplate that were coated with anti-human clusterin
antibody. 50μL of standard, control or sample were loaded into the appropriate
wells. The plates were covered and incubated for two hours at room
temperature on a horizontal orbital microplate shaker. Following incubation
each well was aspirated and washed with wash buffer four times. 200μL of
Clusterin Conjugate was then added and the covered plate incubated at room
temperature for two hours on the shaker. The plates were again aspirated /
washed four times before the addition of 200μL of substrate solution, followed
by further incubation at room temperature for 30 minutes. To terminate the
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enzyme reaction, 50μL of stop solution was added to each well. The optical
density of each well was measured at 450nm using a BMG microplate reader.
Concentrations of Clusterin were determined from a standard curve based on
the supplied reference standards. The sensitivity of the assay is 0.189nM/mL.
The Clusterin assay was performed by Dr Veer Gupta.
2.3.11

Apolipoprotein AI (ApoAI)

Plasma ApoAI was measured as part of the Rules Based Medicine (RBM,
Austin, TX, USA) analysis and biomarker panel used as part of the AIBL study.
Plasma samples were analysed with a 151-analyte multiplex Human Discovery
Map® v1.0 panel. Only ApoAI was selected for use in investigating PLTP
activity levels (see Chapter 5).
2.4

Neuroimaging Biomarkers

2.4.1

Image acquisition

2.4.1.1

Magnetic resonance imaging

Protocol provided by Dr Pierrick Bourgeat of CSIRO, Brisbane for the AIBL study:
“Participants underwent T1 weighted magnetic resonance imaging (MRI) using
the ADNI 3-dimensional (3D) Magnetization Prepared Rapid Gradient Echo
(MPRAGE) sequence, with a 1 x 1 mm in-plane resolution and 1.2 mm slice
thickness, repetition time/echo time/inversion time = 2300 ms/2.98 ms/900 ms,
flip angle 9°, and field of view 240 x 256 and 160 slices.”
2.4.1.2

[11C] Pittsburgh compound-B positron emission tomography

Protocol provided by Dr Victor Villemagne of Austin Health, Heidelberg, Victoria
for the AIBL study: “Participants underwent a [11C] Pittsburgh compound-B
positron emission tomography (PiB PET) scan at Austin Health Centre for PET,
Melbourne or Western Australia PET and cyclotron service, Sir Charles Gairdner
Hospital and Oceanic Medical Imaging, Perth. [11C] PiB production was
performed using a one-step [11C] methyl triflate approach. The average
radiochemical yield was 30% after a synthesis time of 45 minutes with a purity of
> 98% and a specific activity of 30 ± 7.5 GBq/μmol. Each subject received an
intravenous injection of ~370 MBq [11C] PiB over one minute. PET images were
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acquired on a Phillips AllegroTM (Phillips Medical Systems, Eindhoven, The
Netherlands) PET camera, 40-70 minutes post-PiB injection. A transmission scan
was performed for attenuation correction. PET images were reconstructed using
a 3D RAMLA algorithm using a voxel size of 2.0 x 2.0 x 2.0 mm3 (x y z). Summed
images for the 40-70 minute time frame were used.”
2.4.2

Image processing

2.4.2.1

Magnetic resonance imaging tissue segmentation

Protocol provided by Dr Pierrick Bourgeat of CSIRO, Brisbane for the AIBL study:
“For each subject, the T1 weighted images were classified into grey matter, white
matter and cerebrospinal fluid using an implementation of the expectation
maximization segmentation algorithm [459]. Briefly, using a mix of Gaussian
distributions, this algorithm models image intensity histograms. The parameters
of the Gaussian mixture are iteratively updated using an expectation
maximisation approach. In order to provide initialization and spatial consistency
to the expectation maximisation algorithm, an atlas and associated probability
maps of grey matter, white matter and cerebrospinal fluid were spatially
normalized to each individual scan, first through an affine registration, and then
using a diffeomorphic non-rigid registration [460]. The regions of interest (ROI;
hippocampus, anterior cingulate gyrus, posterior cingulate gyrus, temporal lobes
and others) were propagated from the atlas to the T1W to extract the various
regional volumes. To improve the robustness of the approach, it was repeated
nine times, with different elderly atlases, resulting in nine segmentations and nine
ROIs. The segmentations and the ROIs were voted to generate a consensus
grey matter, white matter and cerebrospinal fluid segmentation as well as a
consensus ROI for the investigated brain regions. The grey matter segmentation
was then used to mask out non grey matter voxels from the ROI. Region of
interest volumes were averaged over both hemispheres. The processing of MRIs
was performed by Dr Pierrick Bourgeat of CSIRO, Brisbane. All volumetric
measures of brain regions were corrected for intracranial volume (ICV) using the
following equation:
Adjusted volume = raw volume – b x (ICV – mean ICV); where b is the slope of
the regression of an ROI on ICV.”
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2.4.2.2

Pittsburgh compound-B positron emission tomography
image analysis

Protocol provided by Dr Victor Villemagne of Austin Health, Heidelberg, Victoria
for the AIBL study: “Acquired [11C] PiB PET images were processed using a
semi-automatic ROI method. The semiautomatic method used a preset template
of narrow cortical ROIs that were applied to the PiB scan via placement on the
subject’s co-registered MRI by an operator who was blind to the subject’s clinical
status. Co-registration of each individual’s MRI with the PET images was
performed with SPM5 [Statistical Parametric Mapping 5, University College
London, UK; 461]. The region of interest template was placed on the coregistered MRI and then transferred to the co-registered PET images. Follow-up
PiB images were co-registered with the baseline PiB images and the same ROI
templates were applied to baseline and follow-up scans. Standardised uptake
values (SUV) for PiB were calculated for all brain regions examined and standard
uptake value ratios (SUVR) were generated by dividing all regional SUV by the
cerebellar cortex SUV. The cerebrellar cortex was used as a reference region as
it is relatively devoid of senile plaques and shows no PiB binding in controls or
AD [462, 463]. Region of interest measurements were averaged across both
hemispheres. Neocortical Aβ burden was expressed as the average SUVR of the
area-weighted mean for the following ROIs: frontal (consisting of dorsolateral
prefrontal, ventrolateral prefrontal and orbitofrontal regions), superior parietal,
lateral temporal, lateral occipital and anterior and posterior cingulate. The image
analysis of PiB PET scans was performed by Dr Victor Villemagne and
colleagues of Austin Health, Heidelberg, Victoria.”
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2.5

Statistical Analysis

Statistical analysis of the data will be described in detail in the methods section
of each chapter. All assumptions for statistical tests were considered and met
before detailed analysis was undertaken. All analyses were performed using R
version 3.0.2 (R Development Core team, 2009, Vienna, Austria). Statistical
analyses were performed by Biostatisticians Dr James Doecke and Dr
Samantha Burnham using statistical models previously used for the AIBL study.
Statistical methods utilised for this thesis are summarised in Table 2.3.
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Table 2.3: Summary of statistical methods.

Data to be analysed

Statistical Method Used

Descriptive statistics:
Categorical variables

χ2

Continuous variables

ANOVA

MMSE

Kruskal-Wallace

Mean lipid levels differences

ANOVA

Significant differences in lipid levels

LIMMA

between clinical classifications pre
adjustment for co-variates
Significant differences in lipid levels
between

clinical

GLM

classifications

including adjustment for co-variates
Those lipids which are able to Variable selection
predict clinical classification with the
greatest certainty.
Relationship between lipids selected Partitioning

Around

Medoid

by variable selection

Clustering

(Kaufman

and

Rousseeuw,

1990)

and

Pearson’s correlations
Sensitivity/Specificity

of

predictive ROC curve

lipid panel
Longitudinal lipid data comparing LIMMA, GLM, Multiple regression
baseline to 18 month data
Correlations
other

blood

between
and

PLTP

analysis
and

Pearson’s correlations

neuroimaging

biomarkers
Χ2: Chi squared, ANOVA: Analysis of variance, MMSE: Mini-mental state examination, LIMMA:
Linear Models for Microarray Data, GLM: Generalised Linear Model, ROC: Receiver Operating
Characteristics.
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3.1

Introduction

A huge research effort in the past few decades has lead to a greater
understanding of the patho-physiology of Alzheimer’s disease. However,
despite these great advances many of the fundamental questions regarding AD
remain unanswered. These questions include: what risk factors contribute to
disease and can or how may these risk factors be modified to reduce disease
susceptibility? Can we identify those at risk by investigating biomarkers that
reveal increased susceptibility to disease or indicate accelerated disease
progression? With the identification of lipid biomarkers, can we explain the
aberrant biochemical pathways underlying these findings and use this
information

to

design

prevention

strategies

or

implement

therapeutic

interventions? This study aims to contribute to the existing body of literature to
help address these questions.
The nervous system has the second highest concentration of lipids, exceeded
only by adipose tissue. Lipids in the nervous system also show enormous
structural diversity and lipidomic studies will assist in understanding the
mechanistic significance of lipid diversity and the biology and disease of
neurons. Neurological disorders involve a complex interaction of proteins and
lipids, which lead to the increased formation of protein deposits such as Aβ; a
major component of AD pathology [276].
A key development in the study of lipids and neurodegenerative disease has
been in the advancement of technologies to determine profiles of lipids and their
interacting partners. The improved technology in the field of mass spectrometry
has enabled more specific characterisation of lipid species in larger cohorts.
Three approaches are generally used: “Shotgun lipidomics” uses direct infusion
of the sample with multiple scan modes to provide broad coverage of lipid
species, which are quantitated with the use of internal standards and allows
high sample throughput [381]. A more targeted approach combines liquid
chromatography with multiple reaction monitoring, also allowing precise
quantitation with the use of internal standards [450, 464]. Finally a non-targeted
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approach combines liquid chromatography with high mass accuracy analysis to
profile as many groups of lipids as possible, some sub-species of which may be
unidentified [465]. The method is usually selected after consideration of factors
such as type of sample, sample number to be analysed and scope of the
project. The direct infusion method was chosen for this project due to the high
sample number (>1000) and requirement for broad coverage of lipid species.
Lipidomic research has particular relevance to biomarker development and
therefore this study, especially when there is great overlap with AD and other
conditions involving altered lipid metabolism, such as cardiovascular disease
and diabetes, which are themselves risk factors for AD [270]. Specific lipid
classes and sub-classes are thought to play an important role in AD, where
changes in brain lipid composition have been reported [273]. Lipids are now
considered to play other important roles besides merely serving as stored
energy or the matrix of membranes in which proteins are embedded. The
majority of cellular lipids form the membrane bilayer, whose integrity and
physical characteristics are vital for cellular processes. Membrane lipids are
involved in vesicle fusion, regulation of ion fluxes and create specialised regions
within cells that are involved with cellular communication. They are also very
important signalling molecules via generation of second messengers created by
the actions of a variety of intracellular enzymes. The diversity of lipids that
participate in signalling is highlighted by the multiple integrated roles of
eicosanoids, docosanoids, lysolipids, diacylglycerols, ceramides, phosphatidic
acids and other cell signalling lipids. Neural lipids alter the geometric properties
of membranes and act as ligands for proteins.
As mentioned above, specific lipid classes and sub-classes play an important
role in AD, where changes in brain lipid composition have been reported
involving all classes (cholesterol, sphingolipids, phospholipids and their
metabolites) [273]. Changes in composition and metabolism of several
phospholipids have been described in brain tissue from AD patients, including
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphoinositol (PI)
and plasmalogens [270, 335, 336] and loss of neuronal membrane
phospholipids and associated fatty acids is suggested to be an early event in
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the development of AD [466-468]. Glycerophospholipids are a source of lipid
mediators, including arachidonic acid (AA) and docosahexaenoic acid (DHA),
which are released from membrane phospholipids by the action of
phospholipases. Variations in phospholipid metabolizing enzymes, such as
phospholipase

A2

(PLA2),

phospholipase

C,

phospholipase

D

and

phosphoinositidases have also been reported in AD [342, 343]. Phospholipase
D, which hydrolyses phosphatidylcholine to produce phosphatidic acid (PA) and
choline has been implicated in AD pathology [343]. Post mortem studies of AD
brains compared to control brains have shown elevated levels of phospholipid
degradation

products

such

as

LysoPC,

glycerophosphocholine,

and

glycerophosphoethanolamine [371, 469, 470]. Brain sphingolipid metabolism
has also been shown to be altered in AD [291, 335, 471].
Despite many reports in the literature of animal and tissue studies linking lipids
to AD, few studies have examined cerebrospinal fluid (CSF) or blood for
changes in lipid species. Higher CSF glycerophosphocholine levels were
reported in AD patients compared to age-matched controls [472]. Some studies
have reported a lower LysoPC to PC ratio in the CSF of AD patients compared
to normal controls [371], while a more recent study reported a higher ratio of
LysoPC to PC in AD [375]. These studies were cross-sectional and had low
participant numbers (n=19/19 healthy controls/AD and n=70/40/29 healthy
controls/MCI/AD respectively). Several reports have examined the association
of levels of plasma plasmalogens. A pilot study involving 40 participants
evaluated the relationship between serum total ethanolamine plasmalogen
levels and Alzheimer Disease Assessment Scale–Cognitive (ADAS-Cog)
scores. This study found that ADAS-Cog scores increased significantly in AD
patients with circulating plasmalogen levels that were less than 75% of that of
the age-matched controls at baseline [357]. Further, serum plasmalogen
ethanolamine levels were measured in five independent populations comprising
clinically demented and non-demented subjects. This study showed reduced
serum plasmalogen levels at all stages of dementia [341].
Serum sphingomyelin (SM) and ceramides have been measured in several
studies as part of the longitudinal Women’s Health and Aging study II of
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cognitive impairment (WHASII) [163, 422, 423, 473, 474]. These studies
showed that high ceramides were associated with memory impairment and
hippocampal volume loss and associated with incident dementia when
measured as an outcome. The studies found lower levels of serum ceramides
and SM associated with memory impairment in the cross-sectional data but
higher levels in the longitudinal data, suggesting that serum ceramides and SM
vary according to time of onset of memory impairment. However, the number of
AD cases in this study was low, limited to women and the samples were
collected from individuals in a non-fasted state; a factor that can significantly
influence plasma lipid profiles.
A recent probe into the plasma lipidome of individuals with metabolic syndrome
and obesity; risk factors for AD, showed various changes including increased
LysoPC, decreased ether PLs and significant increases in some PC and PE
species. Additionally several ceramide species were increased [340]. Therefore
the importance of having the neuroimaging data collected as part of the study
utilised in this thesis cannot be overstated as the SUVR shows that abnormal
lipid profiles are likely to be AD related and facilitates delineation of abnormal
lipid profiles associated other age-related co-morbidities that often exist with
AD.
Several reasons can be suggested for the discrepancies reported between
various studies. These include study design, disease classification, analytical
factors, sample type and sample number. However the weight of evidence is
compelling enough to suggest that the delicate equilibrium of phospholipid and
sphingolipid metabolism is disturbed in AD.
The separation of the brain from the periphery presents a particular challenge
when studying the relevance of plasma lipids to neurological disease as some
lipids are transported across the blood brain barrier, while others appear to be
excluded. This separation can be compromised by age-related changes in the
integrity of the blood brain barrier, thereby altering lipid and Aβ kinetics. Chapter
1 described in detail how changes in membrane composition in the brain can
affect Aβ production and promote aggregation and toxicity. Chapter 1 also
described how peripheral lipids and lipoproteins can influence pathological
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processes in the AD brain. High plasma cholesterol has been associated with
increased delivery of peripheral lipoprotein associated Aβ [475]. Additionally,
peripheral lipids, influenced by diet and metabolic hormones will have an effect
on brain biochemistry and vasculature and on increased risk of developing
cardiovascular and metabolic disease with associated abnormal plasma lipid
profiles; all risk factors for AD.
The results from previous studies provide enough optimism to warrant further
investigation of lipid profiles in the highly characterised AIBL cohort. Many
previous studies have targeted specific lipid groups, have not had the benefit of
neuroimaging biomarkers such as MRI and PiB-PET as indicators of AD
pathology, and have been cross sectional in design. The AIBL cohort has
neuroimaging and blood biomarker data and is a longitudinal prospective study.
In addition, the cohort is made up of a large number (n=1112) of well
characterised participants, the blood has been collected in a fasted state and is
enriched with those carrying the APOEε4 allele; a genetic risk factor for AD. In
contrast to other studies, a broad range of lipid species will be measured in
plasma to facilitate identification of a sensitive and specific biomarker panel for
AD. To my knowledge, a study of a large, highly characterised cohort with
biomarker and lifestyle data has not been pursued with respect to biomarker
discovery using such a broad range of lipids.

3.2

Aims

This chapter aims to investigate plasma lipid profiles via a direct infusion with a
multiple scans technique in the highly characterised Australian Imaging,
Biomarkers and Lifestyle study of ageing (AIBL). Differences in lipid profiles
between clinical classifications will be compared to supplementary data
collected as part of this study, including brain amyloid burden and APOEε4
allele carriage. The results will also be assessed for their ability to distinguish
AD patients from cognitively normal individuals and those with mild cognitive
impairment (MCI).
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3.3

Methods

Details of the study population and the methods for sample collection, lipid
extraction, and analysis by electrospray ionisation tandem mass spectrometry
(ESI-MS/MS) have been described in detail in Chapter 2, Sections 2.2 and 2.3.
A total of 189 lipids were measured including sub-species of PE, LysoPE, PC,
Lyso PC, PI, LysoPI, PA, PG, PS, ether PLs, SM and ceramides. This chapter
describes cross sectional results where baseline samples only were used.
The following figure provides a detailed breakdown of the clinical classifications
of participants in the AIBL cohort at baseline.

Figure 3.1: The AIBL cohort at baseline. There were 1,112 baseline samples. These were
classified as 211 AD, 133 MCI and 768 healthy controls. Healthy controls can be further divided
into 372 non-memory complainers (NMC) + 396 subjective memory complainers (SMC).
Psychometric testing, neuroimaging, lifestyle data collection and APOEε4 genotyping were
carried out on the participants and the blood collected was used for lipid profiling.
Schematic adapted from an image provided by the AIBL Study Scientific Management
Committee.
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3.3.1

Statistical analysis

To assess the study population demographics between the healthy controls,
MCI and AD groups, χ2 analyses was used to test the effect of age, gender and
APOEε4 allele status. A Kruskal-Wallis formula was applied to MMSE scores.
Marginalised means and p-values were obtained for the lipid levels using a ttest for two classifications (i.e. HC and AD or HC and MCI) or ANOVA for three
classifications (HC, MCI and AD). Additionally ANOVA was used to test inter
group differences in SUVR and hippocampal volume.
The heatmaps were generated using Matlab version R2006a (Massachusetts,
USA) and R version 3.0.2 was used to calculate the p-values. LIMMA (Linear
Models for Microarray Data) analysis was used to obtain a Q value (false
discovery adjusted value). The fold lipid change was calculated using
unadjusted raw expression values to provide a relative lipid difference between
clinical classifications. A generalised linear model (GLM) was used for those
lipids selected by LIMMA which adjusted for age, gender, APOEε4 allele carrier
status and site of collection (Melbourne or Perth). This GLM determines the
pairwise differences in lipid species between the healthy control, MCI and AD
groups. Using the Bonferroni multiple adjustment approach, the α value for pvalue comparison was 2.65E-4 (0.05/189), where 189 is the number of lipid
species.
Variable selection and prediction of classification analyses were conducted to
choose a short list of lipid biomarkers capable of predicting a diagnosis of AD.
These analyses utilised all 189 lipid species and not those identified by LIMMA
and GLM. The variable selection pipeline utilised creates an importance ranking
for each lipid species by applying four different statistical methods; random
forest, boosted trees, regression trees and LIMMA, while using clinical
classification as a binary outcome factor. The statistical pipeline was run 1000
times and each time a lipid was selected, a frequency score was assigned if it
was chosen from all four or three out of four statistical methods. Those lipids
with the highest frequencies of selection were clustered using Partitioning
Around Medoids (Kaufman and Rousseeuw, 1990) to find a central lipid and
cluster other correlated lipids (from the variable selection) around it: This
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correlates lipids that are related to each other without consideration of clinical
classification. A CLARA (Clustering for Large Applications) algorithm was
applied to create a clusplot of correlated lipids. Standard Pearson’s correlations
were applied to the lipids chosen in the variable selection pathway and these
lipids and R-values were subjected to further statistical assessment using a
stepwise generalised linear model (GLM) to reduce the number of lipids in the
final predictive model. This stepwise GLM algorithm removes lipids from the
predictive model until the lipids left are those giving the best Akaike Information
Criterion (AIC) report, which is a measure of the relative quality of a statistical
model for a given set of data and therefore provides a means for selecting the
best model. Once lipids were selected using the stepwise GLM, a reduced set
of lipids were run using the class prediction statistical pathway. This pathway
includes taking a random sample of the data (comprising 70%) as the training
set, performing the GLM model, and obtaining predicted probabilities for each
participant for the model fit. These predicted probabilities are then used to
predict the remaining 30% of the data as a test set. This class prediction
pathway was iterated through 100 times and then repeated after each individual
lipid removal following assessment of model prediction accuracy. A final panel
is selected that contains the least number of lipids with maximal sensitivity and
specificity for predicting disease classification. Figure 3.2 summarises the
statistical analyses described and used for the study of baseline lipid profiles in
this chapter.
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Figure 3.2: Summary of statistical methods used for analysis of AIBL baseline samples.
ANOVA: Analysis Of Variance, LIMMA: Linear Models for Microarray Data, GLM: Generalised
Linear Model, CLARA: Clustering for Large Applications, sens/spec: Sensitivity and Specificity,
SUVR: Standardised uptake value ratio.
The R statistical software environment, version 3.0.2, was used for all statistical analysis (R
Development Core Team, 2009).
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3.4

Results

The following table describes the demographics of the baseline cohort divided
according to clinical classification.
Table 3.1: AIBL baseline demographics.
Characteristic
Number (n)

HC

MCI

AD

p-value

733

125

204

70.59 (±7.02)

76.09 (±7.58)

78.83 (±8.52)

<0.0001

Gender (F/M)

425/308

71/54

127/77

0.495

ApoE4 (-ve/+ve)

531/202

62/63

76/128

<0.0001

MMSE, score (Mean ±SD)

29 (±1.2)

26 (±2.65)

20 (±5.25)

<0.0001

163

52

49

1.42 (±0.4)

1.88 (±0.58)

2.33 (±0.37)

152

43

36

3.15 (±0.33)

2.93 (±0.38)

2.80 (±0.49)

Age, years (Mean ±SD)

SUVR (n)
SUVR (Mean ±SD)
Hippocampal Volume (n)
Hippocampal Volume (Mean ±SD)

<0.0001
<0.0001

HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s Disease, F: Female, M:
Male, APOEε4: negative or positive for the APOEε4 allele, MMSE: Mini Mental State
Examination, SUVR: Standard Uptake Value Ratio. Hippocampal volume is measured mL. The
characteristics were composed using analysis of variance (ANOVA) to calculate differences for
the continuous variables and X2 for categorical variables. A Kruskal-Wallis formula was applied
to the MMSE scores.

The cohort consisted of 733 healthy controls (HC), 125 MCI and 204 AD
participants. Whilst the number of men and women in each classification did not
significantly differ (p-value = 0.495), significant differences in mean age were
seen in the AD group (p=<0.0001). The AD group are older, which is expected
as AD is an age related disease. It is worthy of note that there are more
APOEε4 +ve individuals in the AIBL cohort compared to epidemiological allele
frequencies reported in other studies (see Table 1.3, Chapter 1). This is
because the AIBL cohort was enriched with APOEε4 allele carriers. As
expected, the mean MMSE score is lower in the MCI and AD groups compared
to healthy controls and cerebral amyloid burden as depicted by mean SUVR is
significantly higher in the MCI and AD groups compared to healthy controls and
significantly higher in the AD group compared to MCI. Predictably, hippocampal
volume is reduced in MCI and AD compared to the HC group.
Of the original 1112 baseline samples a total of 1062 plasma samples were
analysed to profile the lipids by direct flow injection mass spectrometry (ESI
MS/MS), using the ABSciex QTrap 4000 instrument and multi reaction
monitoring (MRM) which fragments the headgroups from their precursor lipids.
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Method details are described in Chapter 2, Sections 2.3.3-2.3.5. The missing
samples are accounted for by failure to extract lipids at the extraction stage or
failure of analysis at the mass spectrometry stage due to poor sample quality.
Table

3.2

lists

the

189

lipid

species

that

were

measured.
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PE

LysoPE

PC

PCp or ether

LysoPC

PI

PE34.2
PE34.1
PE36.5
PE36.4
PE36.3
PE36.2
PE36.1
PE36.0
PE38.7
PE38.6
PE38.5
PE38.4
PE40.6
PE40.5
PE40.4
PE34p.3
PE34p.2
PE36p.4
PE36p.3
PE36p.2
PE36p.1
PE38p.6
PE38p.5
PE38p.1
PE40p.7
PE40p.6
PE40p.5
PE40p.4
PE42p.6
PE42p.5
PE42p.4

LysoPE16.1
LysoPE16.0
LysoPE18.2
LysoPE18.1
LysoPE18.0
LysoPE20.1
LysoPE20.0
LysoPEp16.0
LysoPEp18.1
LysoPEp20.0

PC28.1
PC32.3
PC32.2
PC32.1
PC32.0
PC34.6
PC34.5
PC34.3
PC34.2
PC34.1
PC36.5
PC36.4
PC36.3
PC36.2
PC36.1
PC36.0
PC38.6
PC38.5
PC38.4
PC38.3
PC38.1
PC40.6
PC40.5
PC40.4

PCp32.0
PCp34.2..34.3e
PCp34.1..34.2e
PCp34.0..34.1e
PCp36.4/etherPC
PCp36.3/etherPC
PCp36.2/etherPC
PCp36.1/etherPC
PCp36.0/etherPC
PCp38.5..38.6e
PCp38.4..38.5e
PCp38.3..38.4e
PCp38.2..38.3e
PCp38.1..38.2e
PCp40.6..40.7e
PCp40.5..40.6e
PCp40.4..40.5e
PCp40.3..40.4e
PCp40.2..40.3e
PCp40.1..40.2e
PC30.0e
PC32.0e
PC34.0e

LysoPC14.1
LysoPC14.0
LysoPC16.1
LysoPC16.0
LysoPC18.3
LysoPC18.2
LysoPC18.1
LysoPC18.0
LysoPC20.4
LysoPC20.3
LysoPC16e.1
LysoPC18e.1
LysoPC18e.0
LysoPC22.6
LysoPC22.5
LysoPCp16.2
LysoPCp16.1

PI32.2
PI32.1
PI34.3
PI34.2
PI34.1
PI34.0
PI36.4
PI36.3
PI36.2
PI36.1
PI38.6
PI38.5
PI38.4
PI38.3
PI38.2
PI40.6
PI40.5
PI40.4
PI40.3
PI40.2

Lipid
LysoPI
LysoPI16.1
LysoPI16.0
LysoPI18.2
LysoPI18.1
LysoPI18.0
LysoPI20.4
LysoPI20.3
LysoPI20.2
LysoPI20.1
LysoPI20.0

PG

LysoPG

PS

PA

SM

Cer

PG34.2
PG34.1
PG34.0
PG36.4
PG36.3

LysoPG16.1
LysoPG16.0
LysoPG18.2
LysoPG18.1
LysoPG18.0
LysoPG16.1f
LysoPG16.0f
LysoPG18.2f
LysoPG18.1f
LysoPG18.0f
LysoPG20.4
LysoPG22.6
LysoPG22.5

PS36.2
PS36.1
PS38.6
PS38.5
PS38.4
PS40.6
PS40.5

PA32.2
PA32.1
PA32.0
PA34.2
PA34.1
PA34.0
PA36.1

SM18.16.1
SM18.16.0
SM18.18.1
SM18.18.0
SM18.20.1
SM18.20.0
SM18.22.1
SM18.22.0
SM18.24.1
SM18.24.0

Cer.d18.1.16.0
Cer.d18.1.18.0
Cer.d18.1.20.0
Cer.d18.1.22.0
Cer.d18.1.24.1
Cer.d18.1.24.0
Cer.d18.0.16.0
Cer.d18.0.18.0
Cer.d18.0.20.0
Cer.d18.0.22.0
Cer.d18.0.24.1
Cer.d18.0.24.0

Table 3.2: List of plasma lipid species measured in the AIBL baseline samples.
PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, PI: Phosphatidylinositol, PG:
Phosphatidylglycerol, PS:Phosphatidylserine, PA: Phosphatidic acid, SM: Sphingomyelin,
Cer: Ceramide.
p: vinyl ether bond or plasmalogen, e: ether linkage – can be plasmanyl (vinyl ether) or
plasmenyl (alkyl ether)- (see Figure 1.5), etherPC: where fatty acyl groups cannot be
determined, f: An alternate mass is also detected in Q3 of the mass spectrometer
Numbers represent carbon atoms in acyl chain and number of unsaturated/double
bonds. For example PE38.5 is phosphatidylethanolamine with two acyl chains totalling
38 carbons and 5 unsaturated bonds.
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The mass spectrometer generates electrical signals of each of the lipid species
detected. The signal intensities of the individual lipids are normalised against
the signal intensities of the lipid internal standards for each respective lipid
group, corrected for their respective molecular weights before normalisation to
the sum of all lipid species measured. The lipid levels are expressed as molar
fractions. A heatmap of the baseline results was plotted in Figure 3.3 to enable
visualisation of differences in lipid species between the clinical classification
groups.
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Figure 3.3: Heatmaps of lipid profiles of 1062 samples between clinical
classification groups.
The scale on right side of the charts displays the mean lipid levels expressed as molar
fractions. HC: Healthy Control, MCI: Mild Cognitive Impairment, AD: Alzheimer’s
Disease,
PA:
phosphatidic
acid,
PE:
phosphatidylethanolamine,
PC:
phosphatidylcholine,
PS:
phosphatidylserine,
PI:
phosphatidylinositol,
SM:
sphingomyelin, Cer: ceramide. White colour reflects low levels, while black colour
reflects higher levels.
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The heatmaps depicted in Figure 3.3 showed all the individual lipid species
measured in the HC, MCI and AD groups. The heatmaps show that many of the
PE and PEp species were higher in AD compared to the healthy control group.
Ceramides appear to be higher and SMs lower in the AD group compared to
healthy controls. The abundance of the various lipid species in plasma is quite
different with PC and SM being present in the greatest amounts. To allow this
data to be displayed graphically three separate bar charts, to account for
abundance differences, are depicted in Figure 3.4, showing the non-adjusted
marginalised means of the summed lipid species groups and their significance,
as represented by ANOVA generated p-values, with respect to clinical
classification.
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Figure 3.4: Grouped mean lipid levels differences between clinical classifications. A: PC:
Phosphatidylcholine, SM: Sphingomyelin, PCp: Choline plasmalogen, LysoPC, PI:
Phosphatidylinositol. B: PEp: Ethanolamine plasmalogen, PE: Phosphatidylethanolamine, Cer:
Ceramide, LysoPCp, LysoPE. C: LPI: LysoPI, LysoPEp, LysoPG, PA: Phosphatidic acid, PG:
Phosphatidylglycerol, PS: Phosphatidylserine.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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When lipids are grouped into their respective classes, significant changes were
observed for total PI, total PE, total PC and total SM. Whilst Figure 3.4 shows
the mean total levels for each lipid group, it does not provide information in
relation to sub-species and any significant differences in these lipid sub-species
between clinical classifications. ANOVA analysis of the individual lipid groups
are represented in the following graphs showing how these species levels differ
between clinical classifications. A summary of these results is presented in
Table 3.3 immediately following the graphs in Figures 3.5 to 3.16.
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Figure 3.5A and B: Mean PE levels between clinical classifications.
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD:
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.6A and
classifications.

B:

Mean

Ethanolamine

plasmalogen

levels

between

clinical

PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD:
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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HC
MCI

Figure 3.7: A: Mean Lyso-Phosphatidylethanolamine (LysoPE) and B: Mean Lysoethanolamine plasmalogen levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001

Figure 3.8: Mean Lyso- Phosphatidylinositol (LPI) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05
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Figure 3.9: A: Mean Phosphatidic acid and B: Mean Phosphatidylserine (PS) levels
between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.10: Mean Phosphatidylglycerol (PG) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.11 A and B: Mean Lysophosphatidylglycerol (LPG) levels between clinical
classifications.
LPG16.0, LPG18.2, LPG1.8.1 and LPG18.0 are the “f” species in Figure 3.11B (see Table 3.2).
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.12 A, B and C: Mean Phosphatidylcholine (PC) levels between clinical
classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.13 A, B and C: Mean choline plasmalogen (PCp) levels between clinical
classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.14 A and B: Mean Lysophosphatidylcholine (LPC) levels and C: Mean Lysocholine plasmalogen levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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Figure 3.15: Mean Sphingomyelin (SM) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001

Figure 3.16: Mean Ceramide levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = < 0.05 ** p = < 0.001
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The bar charts in Figures 3.5 to 3.16 show how the non-adjusted marginalised
means of each individual lipid sub-species vary between the healthy controls,
MCI and AD groups. Significant differences, as represented by the p-values
between the lipids sub-species and the clinical classifications, were seen for
many of the lipids, including PE, PC, PI, SM and Ceramide species. A total of
86 out of 189 lipid species measured showed a significant difference with a pvalue of < 0.05 or < 0.001 between HC and AD, HC and MCI or MCI and AD
groups. Table 3.3 lists those lipids that were significantly different between
clinical classifications.
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Table 3.3: List of lipids that were significantly different between clinical classifications.

Lipid – HC vs. AD
p < 0.05
p < 0.001

Lipid – HC vs. MCI
p < 0.05
p < 0.001

p < 0.05

Lipid – MCI vs. AD
p < 0.001

Total PI

Total PE

PE36.1, PE40.6, PE40.5,
PE34p.3, PE34p.2, PE36p.1,
PE38p.5, PE40p.5, LysoPE16.0,
LysoPE18.1p
PC32.1, PC34.2, PC34.3,
PC36.5, PC36.0, PC38.6,
PC38.5, PC40.4, PC 40.6,
PC32.0p, PC34.1p..34.2e,
PC38.2p..38.3e, PCLyso14.1,
PCLyso16.1, PCLyso16.0,
PCLyso18.1, PCLyso22.6,
PI32.1, PI34.1, PI34.2, PI 36.1,
PI36.3, PI36.4, PI38.4, PI40.3,
LysoPG18.0, LysoPG22.5

PE34.2, PE34.1, PE36.4, PE36.3,
PE36.2, PE38.6, PE38.5, PE38.4,
PE36p.2, PE40p.4

PE36.4, PE36.3, PE36.2,
PE38.5, PE38.4,
LysoPE18.1

PE34.2

PE34.1, PE36p.2, LysoPE18.1

PC32.0, PC34.1, PC34.5,
PC34.0p..34.1e, PC34.0e
PC36.4p/etherPC, PC38.1,
PC36.1p/etherPC,
PC36.0p/etherPC,
PC38.5p..38.6e, PC32.0e
PCLyso18e.0
PI34.0

PC32.0, PC34.6, PC34.2,
PC34.5, PC36.0, PC38.1,
PC34.0p..34.1e,
PC38.5p..38.6e,
PC40.1p..40.2e,
PC40.3p..40.4e,
PC40.2p..40.3e
PI32.2, PI34.0

PC34.1, PC38.1p..38.2e

PC34.0e, PC36.0p/etherPC,
PC36.1p/etherPC,
PC34.0p..34.1e, PC38.3p..38.4e,
PC38.1p..38.2e

PG34.2

PG34.0, LysoPG22.5,
LysoPG16.1, LysoPG18.0

PG34.2

SM18.16.1, SM18.20.1,
SM18.22.1, SM18.22.0,
SM18.24.0
Cer.d18.1.24.1, Cer.d18.0.22.0,
Cer.d18.0.20.0

SM18.16.0, SM18.18.0,
SM18.20.0, SM18.22.0,
SM18.22.1

SM18.16.1, SM18.18.1,
SM18.20.1, SM18.24.0

PA36.1
SM18.16.0, SM18.18.0,
SM18.18.1, SM18.20.0,
SM18.24.1
Cer.d18.0.16.0, Cer.d18.0.24.1,
Cer.d18.0.24.0

Total PC, Total SM

LysoPI18.0
LysoPG16.1

Cer.d18.0.22.0

The red text indicates lower mean levels in AD compared to HC, MCI compared to HC and AD compared to MCI. The black text indicates higher mean levels
AD compared to HC, MCI compared to HC and AD compared to MCI.
PI: Phosphatidylinositol, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, SM: Sphingomyelin, PA: Phosphatidic acid, PG: Phosphatidylglycerol, Cer:
Ceramide.
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To further examine the significance of differences in levels observed between
lipid species and clinical classification, a LIMMA model (see Section 3.4.1) was
applied to obtain a false discovery adjusted value for each lipid to exclude any
false associations that may have been included following simple ANOVA.

3.4.1

Linear Models for Microarray Data (LIMMA)

LIMMA (Linear Models for Microarray Data) analysis was used to obtain Q
values (false discovery adjusted values) and Bonferroni correction were used to
generate stricter p-values to exclude some of the 86 lipids species level
differences selected and displayed graphically in Figures 3.5 - 3.16 and in Table
3.3. Using the LIMMA model, 27 out of 86 lipid species levels were significantly
different between healthy controls and AD participants and these lipids are
listed in Table 3.4.
Table 3.4: Linear Models for Microarray Data (LIMMA), listed in order of most to least
significant for Healthy Controls compared to AD.

Lipid
PC.34.0p..34.1e
SM18.20.1
PE34.2
Cer.d18.0.22.0
SM18.24.0
PE38.5
PE38.4
PC34.1
PC34.0e
SM18.22.0
PC38.1
PC.38.5p..38.6e
PE36.2
PC36.0por etherPC

p.value
4.68E-11
3.62E-10
4.23E-10
7.92E-10
1.34E-09
3.59E-09
5.70E-09
9.44E-09
3.07E-08
4.92E-07
6.92E-07
9.58E-07
1.35E-06
1.39E-06

Lipid
PE36.4
PE34.1
PE36.3
PC32.0
PC34.5
PG34.2
SM18.16.1
PE38.6
SM18.22.1
PC.Lyso.18e.0
PC36.4p or etherPC
PC32.0e
PI34.0

p.value
2.30E-06
2.31E-06
3.16E-06
4.73E-06
1.09E-05
2.20E-05
3.64E-05
4.12E-05
5.95E-05
9.64E-05
1.34E-04
1.36E-04
1.98E-04

p-values less than the Bonferroni cut off (0.05/189).
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.
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A fold lipid change was subsequently calculated using unadjusted raw
expression values to provide a relative lipid difference between clinical
classifications. The mean levels, difference in levels between groups, the
directional change i.e. increased or decreased in AD compared to healthy
controls and fold change is shown in Table 3.5.
Table 3.5: Mean value difference in lipid species levels between groups, direction of
change in lipid levels between HC and AD participants and fold change.

Lipid

Mean HC

Mean AD

PE34.2
PE34.1
PE36.4
PE36.3
PE36.2
PE38.6
PE38.5
PE38.4
PC.Lyso.18e.0
PC.34.0p..34.1e
PC36.0p or etherPC
PC32.0e
PC32.0
PC34.0e
PC34.1
Cer.d18.0.22.0
PI34.0
PG34.2
PC36.4p or etherPC
PC38.5p..38.6e
PC34.5
PC38.1
SM18.16.1
SM18.20.1
SM18.22.1
SM18.22.0
SM18.24.0

0.00036
0.00025
0.00065
0.00030
0.00084
0.00120
0.00070
0.00150
0.00032
0.00515
0.00443
0.00160
0.00629
0.00126
0.10666
0.00010
0.00012
9.02E-6
0.00506
0.00329
0.00026
0.00352
0.00217
0.00355
0.02032
0.03332
0.00515

0.00046
0.00031
0.00076
0.00036
0.00100
0.00140
0.00084
0.00182
0.00035
0.00564
0.00473
0.00170
0.00666
0.00137
0.11382
0.00015
0.00010
7.21E-6
0.00470
0.00296
0.00023
0.00329
0.00196
0.00302
0.01922
0.03102
0.00462

Difference Direction
of change
0.00010
↑ in AD
0.00006
↑ in AD
0.00012
↑ in AD
0.00006
↑ in AD
0.00016
↑ in AD
0.00019
↑ in AD
0.00014
↑ in AD
0.00032
↑ in AD
0.00003
↑ in AD
0.00050
↑ in AD
0.00030
↑ in AD
0.00010
↑ in AD
0.00038
↑ in AD
0.00011
↑ in AD
0.00715
↑ in AD
0.00005
↑ in AD
-0.00002
↓ in AD
-1.81E-6
↓ in AD
-0.00037
↓ in AD
-0.00033
↓ in AD
-0.00003
↓ in AD
-0.00024
↓ in AD
-0.00021
↓ in AD
-0.00053
↓ in AD
-0.00110
↓ in AD
-0.00229
↓ in AD
-0.00053
↓ in AD

Fold
Δ
1.288
1.228
1.180
1.200
1.193
1.161
1.207
1.211
1.091
1.096
1.068
1.066
1.060
1.091
1.067
1.435
0.858
0.799
0.927
0.900
0.878
0.933
0.904
0.852
0.946
0.931
0.897

Those lipids in the blue section indicate an increase in the mean lipid levels and those in the
grey section indicate a decrease in mean lipid levels in AD compared to healthy controls.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.
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Table 3.5 shows the mean value, the difference between the mean lipid profile
and the fold change for each of the 27 lipids identified as being significantly
different between HC and AD by LIMMA. 16 lipid species had mean levels
higher and 11 had mean levels lower in AD compared to healthy controls.
Whilst Tables 3.4 and 3.5 compared healthy controls to AD, the following two
tables show the repeat LIMMA analysis for the healthy controls compared to
MCI groups.
Table 3.6: Linear Models for Microarray Data (LIMMA), listed in order of most to least
significant for Healthy Controls compared to MCI.

Lipid
PC34.1
SM18.20.1
SM18.16.1
SM18.24.0
PE34.2

p.value
3.48E-05
9.25E-05
1.55E-04
2.20E-04
2.56E-04

p-values less than the Bonferroni cut off (0.05/189).
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine.

Table 3.6 lists the five lipid species levels that were significantly different
between healthy controls and MCI participants. The mean level, difference in
level between groups, the directional change i.e. increased or decreased in MCI
compared to healthy controls and fold change of these five lipid species is
shown in Table 3.7.
Table 3.7: Mean value difference in lipid species levels between groups, direction of
change in lipid levels between HC and MCI participants and fold change.

Lipid

Mean HC

Mean MCI

Difference

PE34.2
PC34.1
SM18.16.1
SM18.20.1
SM18.24.0

0.00036
0.10666
0.00217
0.00355
0.00515

0.00043
0.11295
0.00193
0.00313
0.00475

0.00007
0.00628
-0.00024
-0.00042
-0.00040

Direction
of change
↑ in MCI
↑ in MCI
↓ in MCI
↓ in MCI
↓ in MCI

Fold
Δ
1.198
1.059
0.892
0.882
0.923

Those lipids in the blue section indicate an increase in the mean lipid levels and those in the
grey section indicate a decrease in mean lipid levels in MCI compared to healthy controls.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine.
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The above table shows the mean value, the difference between the mean lipid
levels and the fold change for each of the five lipids identified as being
significantly different between HC and MCI by LIMMA. Two lipid species had
mean levels higher and three had mean levels lower in MCI compared to
healthy controls.
The LIMMA analysis was repeated comparing lipid species levels between MCI
and AD classifications. Interestingly no significant difference was observed in
the mean levels of lipid species.
3.4.2

Generalised Linear Model (GLM)

The LIMMA analyses, while identifying those lipids species levels that are
significantly different between clinical classifications, do not take into
consideration factors which may influence the significance of the observed
differences. Consequently a generalised linear model (GLM) was created to
control for age, APOEε4 allele carriage status, gender and collection site. The
results from the GLM comparing HC to AD are displayed in Table 3.8.
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Table 3.8: Generalised Linear Modelling (GLM) adjusted for age, sex, APOEε4 allele
status (i.e. carriage or non-carriage of an APOEε4 allele) and sample collection site
(Perth or Melbourne) in the healthy control compared to the AD group.

Lipid

p-value

Age

APOEε4

Sex

Site

SM18.20.1
Cer.d18.0.22.0
PE38.4
PE34.2
PC.34.0p..34.1e
PE38.5
PC34.1
PE36.2
PC34.0e
SM18.16.1
PE34.1

2.65E-06
2.69E-06
3.33E-06
8.98E-06
2.23E-05
3.56E-05
5.84E05
0.00014
0.00016
0.00022
0.00025

1.52E-42
1.37E-40
8.60E-41
6.42E-40
3.61E-36
5.22E-40
9.46E-40
7.38E-42
1.61E-37
1.88E-42
3.86E-41

1.04E-21
3.81E-22
1.97E-22
8.18E-23
7.04E-24
3.67E-22
2.49E-22
9.27E-23
7.96E-24
1.07E-22
5.74E-23

0.061
0.221
0.457
0.345
0.311
0.533
0.123
0.342
0.229
0.146
0.231

0.406
0.010
0.011
0.047
0.041
0.015
0.015
0.025
0.026
0.007
0.028

PI34.0
PC32.0
PG34.2
PE36.4
PC38.5p..38.6e
PC32.0e
SM18.24.0
PC36.0p or ether PC
PE36.3
SM18.22.1
SM18.22.0
PC34.5
PC.Lyso.18e.0
PC38.1
PE38.6
PC36.4p or ether PC

0.00032
0.00038
0.00080
0.00092
0.00105
0.00107
0.00134
0.00240
0.00364
0.00394
0.00411
0.00523
0.00661
0.02124
0.02217
0.08371

1.44E-43
9.00E-40
4.96E-43
2.55E-41
8.52E-41
1.26E-40
5.16E-39
2.21E-39
2.11E-41
1.50E-41
2.51E-40
2.34E-41
2.25E-41
1.02E-39
1.44E-41
3.55E-41

4.77E-23
9.13E-24
5.62E-23
9.50E-23
4.55E-22
1.11E-23
3.18E-22
3.96E-23
1.73E-22
8.31E-23
2.26E-22
2.37E-22
1.17E-22
3.47E-22
2.42E-22
2.38E-22

0.158
0.143
0.344
0.421
0.177
0.120
0.387
0.295
0.328
0.212
0.239
0.151
0.104
0.317
0.467
0.298

0.090
0.027
0.188
0.020
0.007
0.022
0.014
0.018
0.019
0.020
0.022
0.014
0.027
0.007
0.022
0.012

Those lipids above the solid line remain significant (p<0.000265) after adjustment.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.

Table 3.8 shows the p-values for each of the 27 lipids identified by LIMMA as
being significantly different between HC and AD, adjusted through GLM for the
following covariates; age, sex, APOEε4 allele status and collection site. The pvalues for each of the covariates are also shown in the table. The data are
sorted by the strongest p-value for the lipid level post adjustment i.e. where the
levels are most different between the clinical classification groups. The top 11
lipids (above the solid line) in the table remain statistically significant (less than
the Bonferroni cut off value of p<0.000265 (0.05/189)) after adjustment for age,
sex, APOEε4 allele status and collection site. The p-values indicate that neither
site of collection or gender significantly influence the results, but as expected
age and APOEε4 allele carriage do significantly influence the results.
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The GLM was repeated to compare the healthy control and MCI groups
following adjustment of the LIMMA results to control for age, gender, APOEε4
allele status and collection site.
Table 3.9: Generalised Linear Modelling (GLM) adjusted for age, sex, APOEε4 allele
status (i.e. carriage or non-carriage of an APOEε4 allele) and collection site (Perth or
Melbourne) in the healthy control compared to the MCI group.

Lipid

p-value

Age

APOEε4

Sex

Site

SM18.16.1

0.0001

4.20E-15

2.10E-08

0.875

0.216

SM18.20.1
PC34.1
PE34.2
SM18.24.0

0.0007
0.0009
0.0045
0.0269

6.82E-15
3.01E-14
1.48E-14
1.86E-13

3.98E-08
8.72E-08
3.13E-08
2.54E-08

0.682
0.790
0.809
0.761

0.803
0.286
0.472
0.305

Those lipids above the solid line remain significant (p<0.000265) after adjustment.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine.

Table 3.9 shows the p-values for each of the five lipids identified by LIMMA as
being significantly different between HC and MCI, adjusted through GLM for the
same covariates (age, gender, APOEε4 allele status and collection site). The pvalues for each of the covariates are also shown in the table. The data are
again sorted by the strongest p-value for the lipid level post adjustment. Only
one lipid in the table (above the solid line) remained statistically significant (less
than the Bonferroni cut off value of p<0.000265 (0.05/189)) after adjustment for
age, sex, APOEε4 allele status and collection site. The p-values again indicate
that neither site of collection or gender significantly influence the results, but as
expected age and APOEε4 allele carriage do significantly influence the results.
No GLM was created for the MCI compared to AD groups as no lipid species
were found to be significantly different between groups after LIMMA analysis.
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3.4.3.1

Variable selection for HC vs. AD groups

The LIMMA and GLM models assess associations between lipids and clinical
classification, i.e. levels of lipid species that are significantly different between
clinical classifications. Variable selection analysis attempts to identify lipid
species which when considered collectively are able to predict clinical
classification with greatest certainty, i.e. if you measure levels of lipid species x,
y, z you can determine whether an individual would be classified as healthy
control, MCI or AD. As such the level at which clinical classification can be
predicted, is determined by modelling the selected lipids and covariates using
GLM and Receiver Operating Characteristics (ROC) models.
Previous analysis of biomarkers in the AIBL cohort utilised a variable selection
pathway to create lists of biomarkers that were chosen from four separate
selection methods; random forest, boosted trees, regression trees and LIMMA
and used clinical classification as a binary outcome, i.e. HC or AD [476] . In this
study, a variable selection pathway was applied to the 189 lipid species to
create an importance ranking (in addition to generation of p-values), where
1000 iterations were performed to define a list of those lipid species that are
selected most often as differing in levels when comparing clinical classifications.
Each time a lipid was selected a frequency score was assigned if it was chosen
from all four statistical methods or from three out of the four statistical methods.
Table 3.10 lists the lipid species selected most often when comparing the HC
and AD groups. The lipid species that are selected in at least 10% of the 1000
iterations from all four statistical methods are listed in column A and the lipid
species that were selected in at least 10% of the 1000 iterations from three of
the four statistical methods are shown in column B.
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Table 3.10: Lipid Markers selected by the Variable Selection Pathway for HC vs. AD.

List A (4/4)
Lipid
SM18.20.1
Cer.d18.0.22.0
PC34.0e
PC32.0

Frequency (/1000)
610
419
173
108

List B (3/4)
Lipid
PC34.1
Cer.d18.0.22.0
PC34.0e
PC32.0
PC38.5p...38.6e
PC34.0p...34.1e
PE34.2
SM18.20.1
PE38.4
PG34.2
SM18.24.0
PE34.1
PC32.0e
PE38.5
PC36.0p.or.etherPC
SM18.16.1
PI34.0
PE36.4
PE36.3
Cer.d18.0.20.0
PE36.2
Cer.d18.0.24.1

Frequency (/1000)
583
541
539
485
446
432
421
385
375
331
291
285
273
233
231
205
181
173
157
156
144
120

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in
both list A and list B.

Those lipids with the highest frequencies of selection from both lists A and B of
Table 3.10 were clustered using Partitioning Around Medoids (PAM) to find a
central lipid and cluster other correlated lipids around it. This statistical method
correlates lipids that are related to each other without consideration of clinical
classification and is performed to see if lipids can be eliminated from a final
model if they behave in the same way as other lipids in their respective clusters
in terms of predicting clinical classification. A CLARA (Clustering for Large
Applications) algorithm was applied to create a clusplot of correlated lipids
which resulted in the formation of four lipid clusters, listed in Table 3.11 and
represented graphically in Figure 3.17.
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Table 3.11: Four groups of clustered lipids were determined using medoid clustering in
HC vs. AD.

Cluster 1
PE34.2
PE34.1
PE36.4
PE36.3
PE36.2
PE38.5
PE38.4
PE34.1

Cluster 2
PI34.0
PG34.2
PC38.5p..38.6e
SM18.16.1
SM18.20.1
SM18.24.0

Cluster 3
PC34.0p..34.1e
PC36.0p/etherPC
PC32.0e
PC32.0
PC34.0e

Cluster 4
Cer.d18.0.20.0
Cer.d18.0.22.0
Cer.d18.0.24.1

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.

Of the 22 lipids selected by Variable Selection Pathways for HC vs. AD, cluster
1 has eight lipids, cluster 2 has six lipids, cluster 3 has five lipids and cluster 4
has three lipids.

Statistical Component 2

CLARA Cluster Plot

Statistical Component 1

Figure 3.17: Clusplot of correlated lipids showing the 8, 6, 5 and 3 lipids from clusters 1
to 4 respectively.
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The clusplot shows a stronger relationship for the lipids within each of clusters
1, 3 and 4. The lipids in cluster 2 are by contrast more diffuse, suggesting a
weaker intracluster relationship of those lipids. This may be explained by the
fact that clusters 1, 3 and 4 all contain lipids of the same class (PE, PC and
ceramides respectively), whilst cluster 2 is heterogeneous containing one PI
species, one PG species, one ether PC species and three SM species.
Standard Pearson’s correlations were applied to the lipids in each cluster to
explore the directional grouping of the relationship between correlated lipids and
clinical classification. These relationships between the scaled mean expression
for HC and AD groups are shown in Figure 3.18 with the R-values for the lipid
correlations shown in Table 3.12.
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PE 34.2, PE 34.1, PE 36.4,
PE 36.3, PE 36.2, PE 38.5,
PE 38.4

PC34.0p..34.1e,
PC36.0p/etherPC, PC32.0e,
PC32.0, PC34.0e

PI 34.0, PG 34.2
PC38.5p..38.6e, SM18.16.1
SM18.20.1, SM18.24.0

Cer.d18.0.20.0,
Cer.d18.0.22.0,
Cer.d18.0.24.1

Figure 3.18: Correlated lipids between clinical classifications.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. Scaled mean expression is used to enable
graphical representation of lipids that differ in abundance.
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PE34.2
1.000

.1e
therPC
.6e

.0
.0
.1

PE34.1
0.625
1.000

PE36.4
0.640
0.672
1.000

PE36.3
0.643
0.589
0.645
1.000

PE36.2
0.707
0.621
0.626
0.692
1.000

PE38.5
0.483
0.535
0.646
0.554
0.516
1.000

PE38.4
0.538
0.607
0.763
0.583
0.597
0.718
1.000

Pl.34.0
0.131
0.151
0.189
0.069
0.168
0.049
0.050
1.000

PG34.2
0.178
0.198
0.194
0.206
0.198
0.087
0.166
0.258
1.000

PC.34.0p..3
0.162
0.153
0.123
0.118
0.070
0.113
0.058
0.088
-0.040
1.000

PC36.0p.or
0.067
0.086
0.085
0.086
0.017
0.120
0.071
-0.013
0.028
0.696
1.000

PC.38.5p..3
-0.397
-0.331
-0.329
-0.368
-0.428
-0.105
-0.330
-0.137
-0.150
0.017
0.033
1.000

PC32.0
0.062
0.044
0.017
0.006
-0.010
0.019
-0.026
0.096
-0.008
0.750
0.488
0.171
1.000

PC32.0
0.122
0.171
0.153
0.041
0.040
0.133
0.070
0.174
-0.052
0.558
0.172
0.115
0.619
1.000

PC34.0e
0.109
0.124
0.127
0.072
0.026
0.122
0.079
0.098
0.008
0.862
0.744
0.107
0.773
0.574
1.000

PC34.1
0.264
0.336
0.318
0.202
0.221
0.226
0.226
0.215
-0.057
0.351
0.204
-0.327
0.150
0.423
0.272
1.000

SM18.16.1
-0.040
-0.025
-0.012
-0.043
-0.048
-0.081
-0.042
-0.017
0.219
0.073
0.147
0.100
0.123
0.073
0.125
-0.300
1.000

SM18.20.1
-0.050
-0.087
-0.011
-0.020
-0.008
-0.110
-0.081
0.290
0.380
0.026
0.052
-0.083
-0.012
-0.129
0.050
-0.174
0.305
1.000

SM18.24.0
-0.069
-0.068
-0.082
-0.078
-0.047
-0.135
-0.093
0.056
0.301
-0.026
-0.033
0.105
0.104
0.029
0.016
-0.303
0.525
0.348
1.000

Cer.d18.0.
0.070
0.068
0.065
0.098
0.088
0.098
0.084
0.082
0.111
0.077
-0.025
-0.076
0.022
-0.030
0.066
0.140
-0.436
0.164
-0.111
1.000

Cer.d18.0.2 Cer.d18.0.24.1
0.048
-0.020
0.046
0.009
0.035
0.001
0.056
0.016
0.051
0.002
0.075
0.006
0.084
0.031
0.008
0.008
0.047
0.028
0.037
0.004
-0.025
-0.015
-0.045
0.037
-0.004
0.014
-0.076
-0.110
0.006
-0.008
0.119
0.056
-0.419
-0.352
0.104
0.108
-0.141
-0.093
0.804
0.694
1.000
0.786
1.000

Table 3.12: Standard Pearson’s Correlations between 22 lipid species chosen from the variable selection pathway for the HC vs. AD groups.
Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red.

PE34.2
PE34.1
PE36.4
PE36.3
PE36.2
PE38.5
PE38.4
Pl.34.0
PG34.2
PC.34.0p..34.1e
PC36.0p.or.etherPC
PC.38.5p..38.6e
PC32.0e
PC32.0
PC34.0e
PC34.1
SM18.16.1
SM18.20.1
SM18.24.0
Cer.d18.0.20.0
Cer.d18.0.22.0
Cer.d18.0.24.1
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The strongest correlations, as highlighted in red in Table 3.12, are seen
between lipids of the same group. i.e. PEs, PCs or ceramides.
Looking at the directional grouping of the relationship between correlated lipids
and clinical classification as depicted in Figure 3.18, it can be seen that each of
the lipids in each cluster have very similar relationships with each other.
Taking the 22 lipids chosen from the variable selection pathway and factoring in
their correlations as determined by the Pearson’s correlations R-values (see
Table 3.12), the lipids were subjected to further statistical assessment using a
stepwise generalised linear model (GLM) to reduce the number of lipids in the
final predictive model. This GLM algorithm was run repeatedly to remove lipids
from the predictive model until the lipids left were those giving the best Akaike
Information Criterion (AIC) report, which is a measure of the relative quality of a
statistical model for a given set of data and therefore provides a means for
selecting the best model. This stepwise model also factors in covariates of age,
gender, APOEε4 allele status and collection site, as described in the previous
GLM (Table 3.8). This prediction model split the analysis of the 1060 study
participant plasma lipid profiles into a run comprising 70% training (that includes
clinical classification) and 30% test data (blind to clinical classification) and was
repeated over 100 times until the greatest sensitivity and specificity was
achieved. A final panel was selected that contained the least number of lipids
with maximal sensitivity and specificity for predicting clinical classification.
Sensitivity is the ability of a biomarker to correctly identify AD and specificity is
the ability of a biomarker to correctly identify a healthy control. Maximal
sensitivity and specificity (80%) for predicting participants with AD as compared
to healthy controls was attained by variable selection and stepwise GLM with
the following six lipids.
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Table 3.13: List of six lipids yielding maximal sensitivity and specificity between HC and
AD groups.

Lipid
PI.34.0
PC36.0p.or.etherPC
PC38.5p..38.6e
PC32.0
SM18.20.1
Cer.d18.0.22.0
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PI: Phosphatidylinositol.

All of these lipid species were also identified as being significantly different
when assessed by the standard LIMMA analyses.
Figure 3.19 shows a Receiver Operating Characteristic (ROC) curve from the
GLM of the top six lipids including age, gender, APOEε4 allele status and
collection site as covariates.

Figure 3.19: ROC curve of the top six lipids from stepwise GLM showing sensitivity and
specificity of 80% for the HC vs. AD group.
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The ROC curve is a plot of the true positive rate (sensitivity) against the false
positive rate (specificity) of a diagnostic test. The closer the curve follows the
left hand border and then the top border, the more accurate the test. The
accuracy depends on how well the panel of six lipids separates those
participants with AD from healthy controls and is measured by the area under
the ROC curve, which in this case indicates 80%.
3.4.3.2

Variable selection for HC vs. MCI groups

As for the healthy controls vs. AD groups, the variable selection pathway was
repeated for the healthy control vs. MCI groups. This generated a list of lipids
that were chosen from four separate selection methods as previously described
for the HC vs. AD groups. The variable selection pathway was again applied to
the 189 lipid species to create an importance ranking (in addition to generation
of p-values), where 1000 iterations were performed to define a list of those lipid
species that are selected most often as differing in levels when comparing HC
vs. MCI. Each time a lipid was selected a frequency score was assigned if it
was chosen from all four statistical methods or from three out of the four
statistical methods. Table 3.14 lists the lipid species selected most often when
comparing the HC and MCI groups. As before, the lipid species that were
selected in at least 10% of the 1000 iterations from all four statistical methods
are listed in column A and the lipid species that were selected in at least 10% of
the 1000 iterations from three of the four statistical methods are shown in
column B.
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Table 3.14: Lipid Markers selected by the Variable Selection Pathway for HC vs. MCI

List A (4/4)
Lipid
SM18.20.1
Cer.d18.0.22.0
PC34.0e
PC32.0

List B (3/4)

Freq
(/1000)
609
418
173
108

Lipid
PC34.1
PC.38.5p..38.6e
SM18.24.0
SM18.20.1
PE34.2
Cer.d18.0.22.0
PC32.0
PE38.4
SM18.16.1
PC34.0e
PG34.2
PE36.4
PC34.0p..34.1e
PE36.3
PE34.1
PC32.0e
PE38.5

Freq
(/1000)
998
944
863
841
739
708
641
628
612
539
476
467
452
316
291
277
277

Lipid
SM18.18.1
SM18.22.0
PC38.1
LysoPE18.1
PC36.0p.or.etherPC
PI34.0
PE36.2
PC38.1p..38.2e
PE40.4p
SM18.18.0
Cer.d18.0.20.0
SM18.24.1
Cer.d18.0.24.1
LysoPE18.2
LysoPC18.0e
PC34.2

Freq
(/1000)
274
271
249
235
231
224
201
190
177
174
157
149
120
114
108
101

SM: Sphingomyelin, Cer: Ceramide, PC: Phosphatidylcholine, PE: Phosphatidylethanolamine,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in
both list A and list B.

Those lipids with the highest frequencies of selection from both lists A and B of
Table 3.14 were clustered as done previously for the HC vs. AD groups.
Clustering of the lipids for the HC vs. MCI groups resulted in the formation of
four lipid clusters listed in Table 3.15.
Table 3.15: Four groups of clustered lipids were determined using medoid clustering in
HC vs. MCI.

Cluster 1
LysoPE18.2
LysoPE18.1
PE40p.4
PE34.2
PE34.1
PE36.4
PE36.3
PE36.2
PE38.5
PE38.4
PI34.0
PC34.1

Cluster 2
PG34.2
PC38.5p..38.6e
PC38.1
SM18.16.1
SM18.18.1
SM18.18.0
SM18.20.1
SM18.22.0
SM18.24.1
SM18.24.0

Cluster 3
LysoPC18.0e
PC34.0p..34.1e
PC36.0p/etherPC
PC38.1p..38.2e
PC32.0e
PC32.0
PC34.0e

Cluster 4
PC34.2
Cer.d18.0.20.0
Cer.d18.0.22.0
Cer.d18.0.24.1

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.
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Of the 33 lipids selected by Variable selection Pathways for HC vs. MCI, cluster
1 has twelve lipids, cluster 2 has ten lipids, cluster 3 has seven lipids and
cluster 4 has three lipids. A clusplot was generated (Figure 3.20) by plotting the
lipids as clusters of correlations, which revealed that certain lipids fall into
groups.

Statistical Component 2

CLARA Cluster Plot

Statistical Component 1
Figure 3.20: Clusplot of correlated lipids showing the 12, 10, 7 and 4 lipids from clusters
1 to 4 respectively.

The clusplot shows a stronger relationship for the lipids within each of clusters 3
and 4. The lipids in clusters 1 and 2 are by contrast more diffuse, suggesting a
weaker intracluster relationship of those lipids. This may be explained by the
fact that cluster 3 contains all PC species and cluster 4 contains mainly
ceramides. Clusters 1 and 2 are more heterogeneous in terms of the lipid
species they contain.
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Standard Pearson’s correlations were applied to the lipids in each cluster to
explore the directional grouping of the relationship between correlated lipids and
clinical classification. These relationships between the scaled mean expression
for HC and MCI groups are shown in Figure 3.21 with the R-values for the lipid
correlations shown in Table 3.16.
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LysoPE18.2, LysoPE18.1, PE40p.4,
PE34.2, PE34.1, PE36.4, PE36.3,
PE36.2, PE38.5, PE38.4, PI34.0,
PC34.1

PG34.2, PC38.5p..38.6e, PC38.1,
SM18.16.1, SM18.18.1, SM18.18.0,
SM18.20.1, SM18.22.0, SM18.24.1,
SM18.24.0

LysoPC18.0e, PC34.0p..34.1e,
PC36.0p/etherPC, PC38.1p..38.2e,
PC32.0e, PC34.0e

PC34.2, Cer.d18.0.20.0,
Cer.d18.0.22.0, Cer.d18.0.24.1

Figure 3.21: Correlated lipids between clinical classifications.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. Scaled mean expression is used to enable
graphical representation of lipids that differ in abundance. The lipids species highlighted in grey
show a different directional change than the other lipids in the cluster.
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Lyso.PE18.2 Lyso.PE18.1.1 PE40p.4 PE34.2 PE34.1 PE36.4 PE36.3 PE36.2 PE38.5 PE38.4 PI.34.0 PG34.2 PC.Lyso.18e.0 PC.34.0p..34.1e PC36.0p.or.etherPC PC.38.5p..38.6e PC.38.1p..38.2e PC32.0e PC32.0 PC34.0e PC34.2 PC34.1 PC38.1 SM18.16.1 SM18.18.1 SM18.18.0 SM18.20.1 SM18.22.0 SM18.24.1 SM18.24.0 Cer.d18.0.20.0 Cer.d18.0.22.0 Cer.d18.0.24.1
1.000
0.222
0.035 0.383 0.253 0.188 0.362 0.364 0.040 0.112
0.172
0.364
0.169
0.141
0.070
-0.406
0.053
0.114
0.012
0.078
0.192
0.043 -0.024
0.166
0.080
0.068
0.212
0.363
0.140
0.176
0.020
-0.007
-0.019
1.000
0.141 0.160 0.164 0.118 0.114 0.117 0.109 0.135 -0.050
0.118
0.148
0.032
0.023
-0.069
-0.064
0.025
0.034
0.026 -0.016
0.048 -0.041
0.002
0.034
0.034
-0.089
0.011
0.064
0.031
-0.006
0.016
0.012
1.000 0.153 0.193 0.257 0.166 0.140 0.289 0.388 -0.073
0.032
0.177
0.134
0.109
-0.027
0.078
0.083
0.058
0.156 -0.149
0.007
0.089
-0.016
0.009
0.025
-0.061
-0.055
0.054
0.042
0.062
0.051
0.077
1.000 0.613 0.638 0.630 0.693 0.489 0.552
0.153
0.184
-0.018
0.119
0.033
-0.413
-0.073
0.058
0.105
0.058
0.118
0.248 -0.130
0.001
0.016
0.010
-0.034
0.048
0.040
-0.020
0.013
-0.011
-0.051
1.000 0.664 0.568 0.604 0.531 0.588
0.176
0.176
-0.017
0.107
0.049
-0.358
-0.126
0.018
0.157
0.079 -0.046
0.341 -0.144
-0.008
-0.008
-0.028
-0.076
-0.073
0.009
-0.030
0.035
0.014
-0.008
1.000 0.612 0.618 0.653 0.759
0.210
0.173
-0.033
0.095
0.052
-0.352
-0.108
-0.003
0.145
0.087 -0.148
0.322 -0.163
-0.006
0.020
0.015
-0.005
-0.146
0.033
-0.075
0.031
-0.005
-0.028
1.000 0.680 0.552 0.566
0.098
0.189
0.041
0.103
0.070
-0.376
-0.033
0.018
0.032
0.056
0.097
0.194 -0.137
-0.054
-0.063
-0.089
-0.031
-0.016
-0.030
-0.077
0.077
0.038
-0.003
1.000 0.530 0.609
0.154
0.187
-0.025
0.038
0.001
-0.448
-0.102
-0.026
0.027
-0.001
0.141
0.203 -0.124
-0.033
-0.048
-0.049
-0.027
0.055
-0.019
-0.047
0.047
0.020
-0.015
1.000 0.715
0.053
0.078
0.086
0.067
0.084
-0.113
-0.040
-0.016
0.088
0.079 -0.191
0.191 -0.089
-0.094
-0.054
-0.045
-0.122
-0.227
-0.036
-0.119
0.080
0.053
0.004
1.000
0.050
0.144
0.062
0.016
0.024
-0.341
-0.103
-0.059
0.040
0.043 -0.188
0.180 -0.110
-0.038
0.025
0.030
-0.081
-0.126
0.072
-0.057
0.057
0.040
0.012
1.000
0.248
-0.192
0.106
0.002
-0.145
-0.004
0.113
0.221
0.119 -0.049
0.259 -0.065
-0.020
-0.050
-0.007
0.289
0.006
0.048
0.053
0.073
0.026
0.012
1.000
0.049
-0.011
0.078
-0.176
0.085
0.015 -0.060
0.035 -0.172 -0.037
0.026
0.209
0.204
0.160
0.386
0.266
0.290
0.322
0.104
0.052
0.048
1.000
0.293
0.530
0.147
0.339
0.289 -0.064
0.393 -0.101 -0.178
0.058
0.051
0.044
0.036
-0.169
-0.003
-0.023
-0.040
0.089
0.132
0.172
1.000
0.675
0.023
0.447
0.758
0.505
0.848 -0.009
0.302
0.002
0.074
0.081
0.137
0.037
-0.019
0.033
-0.028
0.052
-0.011
-0.046
1.000
0.026
0.558
0.445
0.080
0.733 -0.162
0.137
0.009
0.153
0.209
0.201
0.063
0.008
-0.001
-0.048
-0.022
-0.044
-0.039
1.000
0.193
0.153
0.099
0.094 -0.266 -0.338
0.290
0.073
0.026
0.044
-0.106
-0.104
0.012
0.061
-0.084
-0.020
0.052
1.000
0.312
0.021
0.456 -0.141 -0.329
0.355
0.332
0.321
0.276
0.235
0.162
0.269
0.247
0.072
0.032
0.003
1.000
0.592
0.767
0.070
0.116
0.110
0.111
0.087
0.192
-0.016
0.036
0.092
0.107
0.017
-0.021
-0.005
1.000
0.510 -0.105
0.417
0.050
0.052
-0.001
0.124
-0.145
-0.231
0.010
0.033
-0.065
-0.130
-0.153
1.000 -0.146
0.227
0.031
0.133
0.163
0.232
0.072
-0.031
0.046
0.026
0.047
-0.032
-0.044
1.000
0.060 -0.149
-0.319
-0.329
-0.287
-0.009
0.155
-0.336
-0.179
0.200
0.199
0.147
1.000 -0.306
-0.308
-0.243
-0.186
-0.175
-0.416
-0.252
-0.298
0.126
0.077
0.012
1.000
0.299
0.101
0.224
-0.013
0.163
0.412
0.635
-0.104
-0.096
-0.051
1.000
0.739
0.631
0.293
0.486
0.509
0.534
-0.448
-0.429
-0.350
1.000
0.813
0.379
0.400
0.553
0.414
-0.241
-0.246
-0.208
1.000
0.306
0.358
0.548
0.488
-0.262
-0.292
-0.256
1.000
0.468
0.342
0.333
0.184
0.134
0.113
1.000
0.469
0.563
-0.120
-0.118
-0.126
1.000
0.723
-0.059
-0.064
-0.042
1.000
-0.104
-0.127
-0.094
1.000
0.814
0.712
1.000
0.802
1.000

Table 3.16: Standard Pearson’s Correlations between 33 lipid species chosen from the variable selection pathway for the HC vs. MCI groups.
Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red.

Lyso.PE18.2
Lyso.PE18.1.1
PE40p.4
PE34.2
PE34.1
PE36.4
PE36.3
PE36.2
PE38.5
PE38.4
PI.34.0
PG34.2
PC.Lyso.18e.0
PC.34.0p..34.1e
PC36.0p.or.etherPC
PC.38.5p..38.6e
PC.38.1p..38.2e
PC32.0e
PC32.0
PC34.0e
PC34.2
PC34.1
PC38.1
SM18.16.1
SM18.18.1
SM18.18.0
SM18.20.1
SM18.22.0
SM18.24.1
SM18.24.0
Cer.d18.0.20.0
Cer.d18.0.22.0
Cer.d18.0.24.1
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The strongest correlations, as highlighted in red in Table 3.16, are seen
between lipids of the same group. i.e. PEs, PCs or ceramides. A statistical
correlation between the biologically related SM18.24.0 and PC38.1 is also
shown. SM can be formed by the transfer of phosphocholine to ceramide.
Looking at the directional grouping of the relationship between correlated lipids
and clinical classification as depicted in Figure 3.21, it can be seen that each of
the lipids in clusters 2 and 4 have very similar relationships with each other.
Clusters 1 and 3 have one lipid in each cluster that behaves differently to the
other lipids (highlighted in grey in Figure 3.21). PI34.0 and PC38.1..38.2e levels
are decreased in MCI compared to healthy controls in clusters 1 and 3
respectively.
As per the statistical methodology employed for the HC vs. AD groups, taking
the 33 lipids chosen from the variable selection pathway for HC vs. MCI and
factoring in their correlations as determined by the Pearson’s correlations Rvalues (see Table 3.16), the lipids were subjected to further statistical
assessment using a stepwise generalised linear model (GLM) to reduce the
number of lipids in the final predictive model. The GLM algorithm was run
repeatedly to remove lipids from the predictive model until the lipids left were
those giving the best AIC report, as previously described for the healthy controls
and AD groups. This stepwise model again factors in covariates of age, gender,
APOEε4 allele status and collection site, as described in the previous GLM
(Table 3.9). The prediction model once again split the analysis of the 1060
study participant plasma lipid profiles into a run comprising 70% training and
30% test data and was repeated over 100 times until the greatest sensitivity
and specificity was achieved.
A final panel was selected that contained the least number of lipids with
maximal sensitivity and specificity for predicting clinical classification. In this
case sensitivity represents the ability of a biomarker to correctly identify MCI
and specificity is the ability of a biomarker to correctly identify a healthy control.
Maximal sensitivity and specificity (71%) for predicting participants with MCI as
compared to healthy controls was attained by variable selection and stepwise
GLM with the following four lipids listed in Table 3.17.
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Table 3.17: List of four lipids giving maximal sensitivity and specificity between the HC
and MCI groups.

Lipid
PE34.1
PE34.2
LysoPE18.1
PG34.2
The bolded lipid, PE34.1, was also identified in the standard LIMMA analyses.

Lower sensitivity and specificity is observed for the 4 lipids predicting MCI as
compared to the 6 lipids capable of predicting AD (Table 3.13). This may be due
to the fact that the HC vs. MCI group is less discrete than the HC vs. AD group
with more overlap between profiles. The MCI group is clinically more
heterogeneous and often but not always represents a prodromal stage of AD.
This may explain the sensitivity and specificity of 71% for the HC vs. MCI group
as compared to 80% for the HC vs. AD group.
3.4.4

Correlation with Standardised Uptake Value Ratio (SUVR)

The previous section assessed the ability of a panel of lipids to predict clinical
classification with the aim of identifying a sensitive and specific diagnostic blood
lipid biomarker panel. Cerebral amyloid burden as determined by PiB-PET
neuroimaging, whilst representing a useful AD biomarker is expensive to
perform, requires access to specialist facilities, and is associated with radiation
exposure. Therefore development of a blood based biomarker test to replace
neuroimaging is highly desirable. Consequently, the relationship of the panel of
lipids determined in section 3.4.3 by variable selection analysis was assessed
against neocortical amyloid burden represented as SUVR; an established
neuroimaging biomarker of AD. Each of the 22 lipids (as they sit in the four
clusters) identified in the variable selection pathway (Section 3.4.3) for healthy
controls compared to AD were plotted against categories of baseline SUVR.
Figure 3.22 shows the clusters of correlated lipids compared to baseline SUVR
categories for the healthy controls and AD groups.
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PE 34.2, PE 34.1, PE 36.4,
PE 36.3, PE 36.2, PE 38.5,
PE 38.4

PI 34.0, PG 34.2
PC38.5p..38.6e, SM18.16.1
SM18.20.1, SM18.24.0

PC 34.0p..34.1e, PC32.0e
PC 36.0p/etherPC, PC 32.0,
PC 34.0e

Cer.d18.0.20.0,
Cer.d18.0.22.0
Cer.d18.0.24.1

SUVR category
< 1.3
> 1.3 to < 1.7
1.7 to < 2.0
> 2.0

Interpretation
Individuals with minimal accumulation of Aβ
Includes individuals with borderline transitions
from amyloid -ve to amyloid +ve
Individuals who are definite accumulators, with
increased rate of Aβ accumulation
Individuals with the highest Aβ accumulation
but rate plateaus with saturation between 2-3

Figure 3.22: Clustered and correlated lipids compared with baseline SUVR categories.
The SUVR categories used in this table are those described by Villemagne et al [477].

It is interesting to see that many of the lipids in cluster 1 have a similar profile,
with increased means for those participants with an SUVR of greater than 2. A
standard Pearson’s Correlation test was performed with each of the 22 lipids
that were selected from the variable selection pathway. This analysis shows
146

Chapter 3: Plasma Lipid Profiles in AIBL baseline samples
that the strongest correlation with SUVR was with PE34.2 (R=0.22), which
belongs to cluster 1. However, when the panel of six lipids was assessed for its
relationship with SUVR in the healthy control vs. AD groups no significant
correlation was observed (data not presented). Additionally no figure is
presented for the comparison of the HC vs. MCI groups with SUVR as this also
did not show any significant correlation.
3.5

Discussion

Alterations in lipid metabolism have been demonstrated in a wide variety of
neurological disorders, including Alzheimer’s disease and Parkinson’s disease
[270, 478]. The amyloid precursor protein (APP) and the secretase enzymes
associated with its processing are integral membrane proteins. Therefore the
lipid environment in which these proteins are placed predictably regulate the
processing of APP and formation of Aβ; ultimately influencing AD pathogenesis.
Numerous studies have established and verified this lipid-AD connection, with
cholesterol, phospholipids and sphingolipids all playing a role (described in
detail in Chapter 1). These studies have also given insight into the possible
mechanisms by which lipids influence AD pathology [291, 414, 479, 480].
Changes in lipid species profiles have been reported with significant decreases
in sulphatides in the brain and CSF of those individuals in the early stages of
AD [413, 481]. Significantly increased CSF ceramides were also reported in AD
[413]. Various groups have investigated specific classes of plasma or serum
lipids. Studies demonstrated lower serum total ethanolamine plasmalogen
levels as a predictor of cognitive decline [357] and another study showed
reduced serum plasmalogen levels at all stages of dementia [341]. There have
been inconsistencies in results from studies investigating LysoPC and PC ratios
with some showing elevated ratios [375] and others showing decreased ratios
[371]. Clear outcomes have also not resulted from various sphingolipidomic
studies when serum ceramides and sphingomyelin have been measured for
use as potential biomarkers [163, 422].
The advancement in technologies for lipidomic research has undoubtedly
gained momentum in the past decade and made many of these studies
possible. The current challenge, highlighted by a lack of consistency in previous
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studies, is in the confident characterisation of the various lipid species to help
establish a robust panel of lipid biomarkers that is specific and sensitive enough
to predict clinical classification and possesses sufficient accuracy and precision
in a laboratory setting to be feasible for routine use. The complexity of method
choice used in lipidomic studies and the challenges associated with establishing
large scale highly characterised cohorts can account for many of these
inconsistencies in previous studies. A panel consisting of the least number of
lipid species that achieves maximal sensitivity and specificity is sought as
routine assay feasibility is a consideration, particularly as the increasing
incidence of AD will predictably increase sample numbers requiring analysis.
Therefore the purpose of the study presented in this chapter was to add to the
existing literature by investigating plasma lipid profiles in a highly characterised
cohort, where changes in lipid profiles were compared to supplementary data
collected as part of this study, including brain amyloid burden. The highly
characterised AIBL cohort provides a statistically relevant sample number of
individuals whose clinical classification can be as accurate as possible with the
aid of neuroimaging; helping to address some of the limitations of sample
number with previous studies. The results were assessed for their ability to
distinguish AD from cognitively normal individuals and those with mild cognitive
impairment. The major findings from the study presented in this chapter were:


86 out of 189 plasma lipid species were significantly different when
comparing the unadjusted mean values of the lipid species between
clinical classifications.



Twenty seven lipids were shown to be significantly different between the
healthy control and AD groups by LIMMA analysis when applying a
Bonferroni correction.



11 of these lipids remained significant after adjustment for age, gender,
APOEε4 allele status and collection site when comparing the HC and AD
groups.



Using a variable selection pathway, a panel of six lipids was able to
distinguish healthy controls from AD patients with a sensitivity and
specificity of 80%.
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Five lipid species were shown to be significantly different between the
healthy control and MCI groups by LIMMA analysis when applying a
Bonferroni correction.



One lipid remained significant after adjustment for age, gender, APOEε4
allele status and collection site.



Using a variable selection pathway, a panel of four lipids was able to
distinguish healthy controls from those with MCI with a sensitivity and
specificity of 71%.



The LIMMA and GLM models did not identify any lipids that were
significantly different between the MCI and AD groups.



No significant correlation could be found when comparing SUVR
categories and the results from the panel of six lipids identified by
variable selection for the healthy vs. AD groups.

The heatmaps shown in Figure 3.3, the barcharts in Figures 3.4 - 3.16 and
Table 3.3 showed significant differences between the unadjusted mean lipid
species levels and clinical classification for 86 out of the 189 lipids measured.
This significance was strongest for the greatest number of lipids when
comparing the healthy control and AD groups. When comparing mean levels of
summed lipid groups, statistical significance was only shown for total
Phosphatidylethanolamine (PE) and Phosphatidylinositol (PI) species (p<0.001
and p<0.05 respectively) between the healthy control and AD groups. Between
the healthy control and MCI classifications, statistical significance was only
shown for total Sphingomyelin (SM) and Phosphatidylcholine (PC) species
(p<0.05). Interestingly, no significant summed lipids groups were identified
when comparing the MCI and AD groups. When investigating changes in
summed lipid groups, changes in individual species within a group may be
masked due to the directional change being opposite in effect i.e. some
increased and some decreased, which would neutralise any significance when
looking at the sum of the lipid species within a group. Therefore considering the
individual lipid species within a group will likely provide more meaningful results
in terms of significant different in lipid species levels between clinical
classification.
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When considering the individual lipid species the most significant differences in
levels between clinical classifications were seen with Phosphatidylethanolamine
(PE), Phosphatidylinositol (PI), Phosphatidylcholine (PC), Sphingomyelin (SM)
and ceramide species. Many of the PE species were elevated in AD compared
to healthy controls. Similarly, increases in LysoPC’s and ceramides were seen
in the AD groups compared to healthy controls. The significant PI and SM
species were lower in the AD compared to healthy controls. When comparing
the healthy control and MCI groups, the predominant species that were
significantly different were in the PE and SM groups, with higher and lower
levels respectively in the MCI group. PC species were higher or lower in the
MCI compared to the healthy control groups with the plasmalogen PC species
being lower.
Changes in brain and plasma lipid composition and metabolism have been
previously reported [127, 270, 335, 336, 371, 472] and while direct comparisons of
the results presented here with other studies cannot be made due to study
populations, analytical methodology and sample differences, the changes
described in other studies show some similarity with respect to specific lipid
groups. In agreement with other plasma studies we report reduced
sphingomyelins, increased ceramides and increased LysoPCs in AD. A recent
plasma lipidome study in metabolic syndrome identified increases in PC, PE,
LysoPC and ceramides, with reduced plasmalogen species, suggesting a link
between these lipids in both metabolic syndrome and AD [340]. Cardiovascular
disease, diabetes and metabolic syndrome have all been linked to an increased
risk of AD, and these changes in lipid metabolism which are common to AD and
metabolic syndrome may represent causality or a similarity in metabolic
changes that occur in the different conditions, or a combination of these
possibilities. Longitudinal studies will help characterise more clearly the
relationship between these conditions.
Our study has measured 189 lipids in plasma and has revealed changes in
individual plasma lipid species that have not been simultaneously measured in
previous studies. For example most studies investigating plasmalogen species
have used a more targeted analytical approach which have focused on

150

Chapter 3: Plasma Lipid Profiles in AIBL baseline samples
ethanolamine plasmalogens only and have described reduced levels in AD
[341, 357]. In contrast our study has measured PC and PE plasmalogen and
shows that some are elevated (PE36p.2, PE40p.4, PE34p.3, PE34p.2,
PE36p.1,

PE38p.5,

PE40p.5,

PC34.0p..34.1e,

PC36.1p/etherPC,

PC36.0p/etherPC, PC32.0p, PC34.1p..34.2e) while others are reduced
(LysoPE18.1p, PC36.4p/etherPC, PC38.5p..38.6e, PC32.0e). Interestingly,
none of the species that are increased between the healthy control and AD
groups contain DHA (22.6n-3), while one species that is reduced possibly does
as indicated by an un-saturated bond count of at least 6 (PC38.5p..38.6e). This
may reflect inadequate dietary intakes of polyunsaturated fatty acids or
represent defects in the desaturase or elongase enzymes that produce the long
chain polyunsaturated fatty acids from the essential fatty acids in AD patients. A
more targeted analysis using liquid chromatography coupled with mass
spectrometry would further separate the lipid subspecies and specifically
identify the acyl chains of each species, including those with DHA.
Plasmalogens are abundant in the CNS and ethanolamine plasmalogens make
up 30% of the total brain phospholipids and 90% of the ethanolamine
glycerophospholipid species [339]. Plasmalogens and their precursors are
supplied to the CNS by the liver. Decreased plasmalogen species in neuronal
cell membranes can lead to increased membrane cholesterol as plasmalogen
deficient cells exhibit lower HDL-mediated cholesterol efflux [356, 359]. This
may therefore promote amyloidogenic processing of APP and increase Aβ
generation (described in detail in Chapter 1, Section 1.5.1 and 1.5.2). An
increase in Aβ42 can directly activate sphingomyelinases thereby reducing SM
and elevating ceramide levels (see Chapter 1, Figure 1.13), consistent with the
plasma levels reported in this chapter. The synthesis of plasmalogens is
dependent on peroxisomes to generate the 1-alkyl-glyceryl ether lipid
precursors. The final elongation and desaturation step in the synthesis of DHA
also occurs in peroxisomes and therefore reduced peroxisomal function can be
suggested as a potential reason for reductions in both amongst the AD group.
The significant differences in individual lipid species between clinical
classifications just described were identified from non-adjusted marginalised
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means with an alpha level set at p < 0.05. Stricter criteria for determining any
significant differences were applied using LIMMA analysis to identify those lipid
species with p-values less than the Bonferroni cut off between clinical
classifications. For the healthy control compared to AD group, 27 lipids were
identified and for the healthy control compared to MCI group five lipids were
identified. No lipids were significantly different between the MCI and AD groups.
The lipids identified by LIMMA as being significant between clinical
classifications were subjected to a Generalised Linear Model to control for age,
APOEε4 genotype, gender and collection site. This model selected 11 of the 27
lipids for the healthy control vs. AD groups and one lipid for the healthy control
vs. MCI group, following adjustment. The 11 lipids consisted of five PE species
(PE38.4,

PE34.2,

PE38.5,

PE36.2

and

PE34.1),

three

PC

species

(PC34.0p..34.1e, PC34.1, PC34.0e), two SM species (SM18.20.1 and
SM18.16.1) and one ceramide species (Cer.d18.0.22.0). SM18.16.1, the lipid
identified in the HC vs. MCI groups was also selected in the HC vs. AD analysis
post adjustment for age, gender, APOEε4 allele status and collection site. All
eleven lipids, except the SM species were elevated in the AD group compared
to healthy controls. The SM species were lower in the AD and MCI groups
compared to healthy controls.
The four lipid groups (PE, PC, SM and Ceramide) that showed differences
between HC and AD and the one species that was different between the HC
and MCI groups have a strong biological relationship with each other and the
directional change of these lipids with respect to clinical classification may be
predicted. The interconnection of PE, PC, SM, Ceramide and sterol metabolism
has been depicted in Chapter 1, Figure 1.9. The relative level of the lipid groups
represents a balance between de novo synthesis, remodelling from other lipids,
production of metabolites and breakdown. Production may be increased or
breakdown enhanced by the action of various enzymes upregulated in
response to a range of signals such as inflammatory cytokines, which have
been shown to be upregulated in AD [482, 483]. We have shown that many PE
and a few PC species are increased in AD, which could be an adaptive
response in an attempt to increase precursors for neuronal repair. The elevated
PE species may also be a result of reduced activity of PE methyltransferase
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which converts PE to PC, especially when dietary choline intake is inadequate.
The activity of this enzyme can be affected by nutrient status of the B group
vitamins (see Chapter 1, Section 1.3.5), which may alter PC production and
may reduce the delivery of polyunsaturated fatty acids from the liver to the
peripheral tissues, including the CNS [149, 191]. The phosphocholine group of
PC is transferred to ceramide for SM synthesis [348]. The increased PC,
increased ceramide and reduced sphingomyelin may represent alterations in
this pathway with reduced sphingomyelin synthase activity. Additionally,
sphingomyelinase activity is increased in AD [157] and activated by
inflammatory cytokines and oxidative stress, another likely contributor to AD
pathogenesis [484], which can increase SM breakdown and further increase the
ceramide pool.
From Table 3.8 it can be seen that only one lipid species (PC38.5p..38.6e)
identified as being significantly different by LIMMA and GLM may contain
docosahexaenoic acid (DHA) where levels are reduced in AD compared to
healthy controls. However, PE38.4 and PE38.5 may contain arachidonic acid
(AA, 20.4n-6) and these are increased in the AD group compared to healthy
controls. The balance of omega-3 to omega-6 fatty acid containing
phospholipids may be influenced by factors such as dietary intakes of fatty
acids and other nutrients but also metabolic factors affecting the elongation and
desaturation steps in polyunsaturated fatty acid pathways (see Chapter 1,
Section 1.3.6). Increases in AA containing phospholipids may have implications
in AD pathology (see Chapter 1, Section 1.5.10). Studies investigating lipid
metabolism in the AD brain have confirmed increased membrane turnover and
remodelling with increased expression of enzymes such as cPLA2 (cytosolic
phospholipase A2) and sPLA2 (secretory phospholipase A2) involved with lipid
remodelling [485, 486] and cycloxygenase-2 (COX-2) associated with
neuroinflammation [487]. Ante-mortem PET imaging in AD patients has also
demonstrated increased brain AA metabolism which may increase production of
prostaglandin E2 [488]; a potent inflammatory eicosanoid which also stimulates
Aβ formation through internalisation of the prostaglandin E receptor 4 (EP4)
[489].
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The associations between clinical classification and individual lipid species
explored using LIMMA and GLM models in this chapter are useful in terms of
speculating aberrant pathways that may be present in disease, but in terms of
biomarker discovery, a different statistical approach was required to identify a
panel of lipids that can predict clinical classification with the greatest certainty.
The variable selection pathways, stepwise GLM model and ROC curves
identified a panel of six lipids that gave a sensitivity and specificity of 80% when
comparing healthy controls and AD. These lipids (also identified by the LIMMA
analyses) were PI34.0, PC36.0p/etherPC, PC38.5p..38.6e, PC32.0, SM18.20.1
and

Cer.d18.0.22.0.

The

levels

of

PC36.0p/etherPC,

PC32.0

and

Cer.d18.0.22.0 were increased and PI34.0, PC38.5p..38.6e and SM18.20.1
were decreased in the AD group compared to healthy controls. These six lipids
were selected by statistical models for their ability to predict clinical
classification rather than their ability to explain aberrant pathways which may
explain why none of the PE species were selected when this statistical
modelling was used.
Lower sensitivity and specificity is observed for the 4 lipids predicting MCI as
compared to the 6 lipids capable of predicting AD (Table 3.13). As previously
mentioned, this may be due to the fact that the HC vs. MCI group is less
discrete than the HC vs. AD group with more overlap between profiles. The MCI
group is clinically more heterogeneous and often but not always represents a
prodromal stage of AD. This may explain the sensitivity and specificity of 71%
for the HC vs. MCI group as compared to 80% for the HC vs. AD group.
The correlation between SUVR, a measure of brain amyloid burden and the
lipid panel failed to show any significance in either the HC vs. AD or the HC vs.
MCI groups. This may reflect a limitation of SUVR to distinguish between
clinical classifications when used in isolation i.e. it is more helpful when SUVR
is combined with other measures such as neuropsychological test data. In fact
published data from the AIBL study has shown that approximately 30% of
healthy controls and approximately 60% of MCI participants have a significant
cerebral amyloid burden with a SUVR value of >1.5. This may account for a
lack of correlation. Amyloid deposition is known to start occurring many years
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before symptoms appear, and it has been known for many years that amyloid
burden is a poor indicator of disease severity, even though amyloid deposits do
indicate the presence of AD (symptomatic or pre-clinical stages). The inclusion
of neuropsychological data in future analyses may also have limitations
however. For example, factors known as brain reserve and cognitive reserve
have been shown to influence the appearance or severity of symptoms [490]. In
simple terms, brain reserve can be related to a number of functioning neurons
and healthy brain tissue, whereas cognitive reserve is related to a person’s
resilience and adaptability to change, and may be associated with the number
of synaptic or inter-neuronal connections. These two factors are influenced by
education level and mental activity, and determine the amount of AD-related
neuropathology that can be tolerated before symptoms of AD appear.
Neuropsychological test data were used to categorise the cohort subjects for
this study, and as mentioned above, the SUVR values for many of the subjects,
even in the healthy group, indicate AD pathology is already present. Cognitive
reserve is likely to have influenced the neuropsychological testing. In fact
cognitive reserve is thought to play such an important role in determining
disease severity that it has been suggested that some sort of quantitative
measure of cognitive reserve will help dementia research considerably [491].
Therefore, in future studies, the best approach might be to include all three
factors: SUVR, neuropsychological test results, as well as some measure of
cognitive reserve.
The next step is to analyse the 18 month time point to determine whether the
same lipid species or lipid groups are identified. As the AIBL study is a
prospective longitudinal study, analysis of the 18 month follow up samples will
also enable analysis from a longitudinal perspective to facilitate identification of
plasma lipid species that differ in those participants whose clinical classification
changes during the study and facilitate identification of those lipids that may
contribute to a biomarker panel capable of predicting both clinical classification
and

disease

progression.

This

data

is

presented

in

Chapter

4.
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Chapter 4 – Plasma Lipid Profiles In AIBL 18 month samples
4.1

Introduction

The previous chapter investigated plasma lipid profiles in baseline samples from
the AIBL cohort. This chapter investigates plasma lipid profiles in samples
collected from AIBL participants at the 18 month follow up time point. The aim of
this chapter is to determine whether lipid species identified as being significantly
different in levels between clinical classifications at baseline are also different at
the 18 month time point, thus corroborating the results reported in Chapter 3.
This chapter will also provide a longitudinal perspective to the data through
examination of which lipid species differ in levels between the transition and
non-transition groups i.e. comparing those participants whose clinical
classification changes versus those who remain stable over the 18 month time
frame. Many studies investigating plasma lipid profiles in AD have been cross
sectional in nature. A notable exception is the longitudinal Women’s Health and
Aging study II of cognitive impairment (WHASII), where elevated ceramides
were associated with memory impairment, hippocampal volume loss and
incident dementia [163, 422, 474]. There is a critical need for additional
longitudinal data collected from well-characterised ageing cohorts; the results
reported in this chapter will help address this deficit.
Longitudinal MRI and PiB-PET neuroimaging data is collected as part of the
AIBL study. Whilst this data provides pathological insight, routine use as a
biomarker of AD is unlikely due to the associated costs, radiation exposure and
low accessibility. Furthermore, PiB-PET determined SUVR as an indicator of
brain amyloid burden is limited in its ability to distinguish between clinical
classifications when used in isolation. For example, approximately 30% of
healthy controls and approximately 60% of MCI participants in the AIBL study
have a significant cerebral amyloid burden with a SUVR value of greater than
1.5; therefore combining neuroimaging results with neuropsychological test data
is required to determine clinical status [477]. This highlights the importance of
identifying blood based biomarkers of AD which may supplement or potentially
replace neuroimaging.
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The lipidomic study of the baseline AIBL samples presented in Chapter 3
showed that the mean lipid species levels differed when comparing clinical
classifications for 86 of the 189 lipid species measured. Following adjustment
for age, gender, APOEε4 allele status and collection site, 11 of these lipid
species remained significant when comparing the healthy control and AD
groups, yet only 1 lipid species remained significant when comparing the
healthy control and MCI groups. A variable selection pathway was applied to
choose the least number of lipids which predict clinical classification with the
greatest sensitivity and specificity. A panel of six lipids was selected for the HC
vs. AD groups and a panel of four lipids were selected for the HC vs. MCI
groups, with a sensitivity and specificity of 80% and 71% respectively. When the
panel of six lipids was compared to SUVR, no significant correlation was
identified.
4.2

Aims

The aim of the work in this chapter is to investigate plasma lipid profiles via a
direct infusion with multiple scans technique, using plasma samples obtained as
part of the highly characterised Australian Imaging, Biomarkers and Lifestyle
Study of Ageing (AIBL). This study will analyse samples collected at the 18
month follow up time point. Changes in lipid profiles will be compared to
supplementary data collected as part of the AIBL study: including brain amyloid
burden as measured by PiB-PET determined SUVR. The results will be
assessed for their ability to distinguish AD patients from cognitively normal
individuals and those with mild cognitive impairment (MCI), and will be
compared to the results obtained from the baseline samples (described in
Chapter 3). Additionally, the data will be examined longitudinally to determine if
changes in lipid profiles were reflected by transition to a different clinical
classification within the 18 month follow up period.

4.3

Methods

Details of the study population and the methods for sample collection, lipid
extraction, and analysis by electrospray ionisation tandem mass spectrometry
(ESI-MS/MS) have been described in detail in Chapter 2, Sections 2.2 and 2.3.
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A total of 189 lipids were measured including sub-species of PE, LysoPE, PC,
Lyso PC, PI, LysoPI, PA, PG, PS, ether PLs, SM and ceramides. This chapter
describes results generated following analysis of 18 month follow up AIBL study
samples.
Figure 4.1 provides a detailed breakdown of the clinical classifications of
participants in the AIBL cohort at 18 months.

Figure 4.1: The AIBL cohort at 18 months. There were 968 participants at 18 month follow
up. These participants were classified as 196 AD, 81 MCI and 691 healthy controls (317 nonmemory complainers (NMC) + 374 subjective memory complainers (SMC)). From baseline 115
participants did not return for follow-up: Of these, 28 were deceased and one participant in the
MCI group developed dementia associated with Parkinson’s disease and was therefore
reclassified as non-AD dementia (PDD). Psychometric testing and neuroimaging was performed
on participants, and blood samples collected at 18 months were used for lipid profiling. The
numbers of non-transition and transition participants are indicated on the arrows.
Schematic adapted from an image provided by the AIBL Study Scientific Management
Committee.
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At baseline and the 18 month time points the participants were classed as
healthy control, MCI or AD. Clinical classification of participants at each time
point was determined by a panel of clinicians with experience in diagnosing MCI
and AD. MCI was assigned using the Petersen criteria [456] and AD was
defined using the NINCDS-ARDA criteria [454] as outlined in Chapter 2.

4.3.1 Statistical analysis
As previously described in Chapter 3, the study population demographics were
assessed to compare the healthy controls, MCI and AD groups. χ2 analyses
were used to test the effect of age, gender and APOEε4 allele status. A
Kruskal-Wallis formula was applied to MMSE scores. ANOVA was used to test
inter-group differences in SUVR and hippocampal volume.
Marginalised means and p-values were obtained for the lipid levels using a ttest for two classifications (i.e. HC and AD, HC and MCI or MCI and AD) or
ANOVA for three classifications (HC, MCI and AD).
The heatmaps were generated and LIMMA and GLM analyses performed as
outlined in Chapter 3. Variable selection with clustering and prediction of
classification analyses were also conducted as described in Chapter 3.
Additionally, LIMMA and GLM analysis were performed to assess differences in
plasma lipid species between the transition groups. Figure 4.2 summarises the
statistical analyses used for the study of the 18 month lipid profiles in this
chapter.
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Figure 4.2: Summary of the statistical methods used for analysis of AIBL 18 month
plasma samples.
ANOVA: Analysis Of Variance, LIMMA: Linear Models for Microarray Data, GLM: Generalised
Linear Model, CLARA: Clustering for Large Applications, Sens: Sensitivity, Spec: Specificity.

The R statistical software environment, version 3.0.2, was used for all statistical
analysis (R Development Core Team, 2009).
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4.4 Results
The following table describes the demographics of the 18 month cohort divided
according to clinical classification.
Table 4.1: AIBL 18 month time point demographics.

HC

MCI

AD

686

74

188

71.78 (+ 6.74)

76.72 (+ 7.55)

79.22 (+ 7.93)

<0.0001

Gender (F/M)

403/283

35/39

111/77

0.156

ApoEε4 (-ve/+ve)

502/184

44/30

57/131

<0.0001

29 (+ 1.33)

27 (+ 2.29)

18 (+ 7.1)

<0.0001

152

26

32

1.38 (+ 0.39)

1.82 (+ 0.64)

2.37 (+ 0.44)

143

21

29

3.15 (+ 0.33)

2.93 (+ 0.38)

2.80 (+ 0.49)

Number (n)
Age, years (Mean + SD)

MMSE score (Mean + SD)
SUVR (n)
SUVR (Mean + SD)
Hip Vol (n)
Hip Vol (Mean + SD)

p-value

<0.0001

<0.0001

HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s disease, F: Female, M:
Male, APOEε4 (-ve/+ve): negative or positive for the APOEε4 allele, MMSE: Mini Mental State
Examination, SUVR: Standard Uptake Value Ratio, Hip Vol: Hippocampal volume, measured in
mL. SD: Standard deviation. The characteristics were composed using analysis of variance
(ANOVA) to calculate differences for the continuous variables and X2 for categorical variables. A
Kruskal-Wallis formula was applied to the MMSE scores.

The cohort at 18 month follow up consisted of 686 healthy controls (HC), 74
MCI and 188 AD participants. As was reported for the baseline demographics in
Chapter 3, the number of men and women in each classification did not differ
significantly (p=0.156), but significant differences in mean age were seen
(p<0.001); the AD group is older, which is expected as AD is an age-related
disease. The AIBL cohort was enriched with APOEε4 allele carriers,
consequently

there

are

more

APOEε4

allele

carriers

compared

to

epidemiological allele frequencies previously reported (see Table 1.3, Chapter
1). As expected, and consistent with the baseline cohort demographics
described in Chapter 3, the mean MMSE score is lower in the MCI and AD
groups compared to healthy controls, and cerebral amyloid burden as depicted
by mean SUVR is significantly higher in the AD group compared to the MCI and
healthy control groups. Further, hippocampal volume is reduced in MCI and AD
compared to the healthy control group.
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Of the original 968 follow-up samples, a total of 948 plasma samples were
analysed to profile the lipids by direct flow injection mass spectrometry (ESIMS/MS), using the ABSciex QTrap 4000 instrument and multi reaction
monitoring (MRM) which fragments the headgroups from their precursor lipids.
(Details of methods are outlined in Chapter 2, Sections 2.3.3-2.3.5). The 20
samples that were not successfully analysed failed at either the extraction or the
MS analysis stage. The 189 lipid species measured are outlined in Table 3.2,
Chapter 3.
As with analysis of the baseline samples, the signal intensities of the individual
lipids were normalised against the signal intensities of the lipid internal
standards for each respective lipid group, corrected for their respective
molecular weights before normalisation to the sum of all lipid species measured.
The lipid levels were expressed as molar fractions. A heatmap of the 18 month
lipid profiles was plotted (Figure 4.3) to enable visualisation of differences in
lipid species levels between the healthy control, MCI and AD groups.
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Figure 4.3: Heatmaps of lipid profiles of 948 AIBL study plasma samples collected at the
18 month time point, illustrating differences in lipid species levels between clinical
classification groups. The scale on the right side of the charts displays the mean lipid levels
expressed as molar fractions.
HC: Healthy Control, MCI: Mild Cognitive Impairment, AD: Alzheimer’s Disease, PA:
Phosphatidic acid, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, PS:
Phosphatidylserine, PI: Phosphatidylinositol, SM: Sphingomyelin, Cer: Ceramide. White colour
reflects low levels, while black colour reflects higher levels.
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The heatmaps depicted in Figure 4.3 allow comparison of each lipid species
between the healthy control, MCI and AD groups. However, as previously
mentioned in Chapter 3, they do not allow comparison across lipid species, as
the relative abundance of lipids is only shown within each lipid group. The
heatmaps show differences in many of the PE, PC, SM and ceramide species
between clinical classifications. The abundance of the various lipid species in
plasma is quite different with PC and SM being the most abundant. To allow this
data to be displayed graphically three separate bar charts to account for
abundance differences were created (Figure 4.4), showing the non-adjusted
marginalised means of the summed lipid species groups and their inter-clinical
classification differences, as determined by ANOVA.
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Figure 4.4: Grouped mean lipid levels between clinical classifications. A: PC:
Phosphatidylcholine, SM: Sphingomyelin, PCp: Choline plasmalogen, LysoPC, PI:
Phosphatidylinositol. B: PEp: Ethanolamine plasmalogen, PE: Phosphatidylethanolamine, Cer:
Ceramide, LysoPCp, LysoPE. C: LPI: LysoPI, LysoPEp, LysoPG, PA: Phosphatidic acid, PG:
Phosphatidylglycerol, PS: Phosphatidylserine.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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When lipids are grouped into their respective classes, significant differences in
levels were observed for SM, PEp, PE, Ceramide, LysoPCp, LysoPE, LysoPG
and PG between the healthy control and AD groups. Ceramide, LysoPCp,
LysoPE and PG were also significantly different between the healthy and MCI
groups. Whilst Figure 4.4 shows the mean total levels for each lipid group, it
does not provide information in relation to sub-species or any significant
differences between these sub-species and clinical classification. ANOVA
analysis of the individual lipid groups are represented in the following graphs
(Figures 4.5 to 4.17), and these show how sub-species levels differ between
clinical classifications. A summary of these results is presented in Table 4.2
immediately following Figure 4.17.
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Figure 4.5A and B: Mean PE levels between clinical classifications.
PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD:
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.6A and
classifications.

B:

Mean

Ethanolamine

plasmalogen

levels

between

clinical

PE: Phosphatidylethanolamine, HC: Healthy control, MCI: Mild cognitive impairment, AD:
Alzheimer’s disease. Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.7: A: Mean Lyso-Phosphatidylethanolamine (LPE) and B: Mean Lysoethanolamine plasmalogen (LysoPEp) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.8 A and B: Mean Phosphatidylinositol (PI) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001

Figure 4.9: Mean Lyso- Phosphatidylinositol (LPI) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.10: A: Mean Phosphatidic acid (PA) and B: Mean Phosphatidylserine (PS) levels
between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.11: Mean Phosphatidylglycerol (PG) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.12 A and B: Mean Lysophosphatidylglycerol (LPG) levels between clinical
classifications.
The second LPG 16.1 from Figure 4.12A and LPG16.0, LPG18.2, LPG1.8.1 and LPG18.0 in
Figure 4.12B (see Table 3.2). are the “f” species. HC: Healthy control, MCI: Mild cognitive
impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p=<0.05 **p=<0.001
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Figure 4.13 A, B and C: Mean Phosphatidylcholine (PC) levels between clinical
classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.14 A, B and C: Mean choline plasmalogen (PCp) levels between clinical
classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.15 A and B: Mean Lysophosphatidylcholine (LPC) levels and C: Mean Lysocholine plasmalogen levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p = <0.05 ** p= < 0.001
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Figure 4.16: Mean Sphingomyelin (SM) levels between clinical classifications.
HC: Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p < 0.05 ** p < 0.001
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Figure 4.17A and B: Mean Ceramide (Cer) levels between clinical classifications. HC:
Healthy control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease.
Mean + SEM. Analysis of Variance (ANOVA): * p < 0.05 ** p < 0.001

The bar charts in Figures 4.5 to 4.17 show how the non-adjusted marginalised
means of each individual lipid species vary between the healthy control, MCI
and AD groups. Significant differences between the lipid species and clinical
classifications were seen for many of the lipids including PE, PC, SM and
ceramide species. A total of 110 out of 189 lipid species measured showed a
significant difference (as indicated by a p-value of <0.05 or <0.001) between the
HC and AD, HC and MCI or MCI and AD groups: These results are summarised
in Table 4.2.
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Table 4.2: List of lipids that were significantly different between clinical classifications. (Table legend on following page)

Lipid – HC vs. AD
p < 0.05
p < 0.001

Lipid – HC vs. MCI
p < 0.05
p < 0.001

Total SM, Total PE, Total
LysoPG
PE36.2, PE38.7, PE38.6,
PE40.5, PE40.4, PE34p.3,
PE36p.3, PE36p.2, PE40p.5,
PE42p.5, LysoPE16.1,
LysoPE18.2, LysoPE18.1f

Total PEp, Total Cer, Total
LysoPCp, Total LysoPE, Total PG
PE34.2, PE34.1, PE36.4, PE36.3,
PE36.0, PE38.5, PE38.4, PE36p.4,
PE38p.6, PE38p.5, PE40p.7,
PE40p.6, LysoPE16.0, LysoPE18.1,
LysoPE18.0

Total Cer, Total LysoPCp,
Total LysoPE, Total PG
PE34.1, PE36.0,
LysoPE16.0, LysoPE18.2,
LysoPE18.1, LysoPE18.0

PC30.0e, PC34.3, PC36.5,
PC36.2, PC38.6, PC40.6,
PC36.3p/etherPC,
PC36.1p/etherPC,
PC38.3p..38.4e,
PC40.3p..40.4e, PCLyso16.0,
PCLyso18.2

PC28.1, PC32.0e, PC32.1, PC32.0,
PC34.0e, PC34.5, PC34.1, PC36.3,
PC38.1, PC32.0p, PC34.2p..34.3e,
PC34.0p..34.1e, PC36.4p/etherPC,
PC36.0p/etherPC, PC38.5p..38.6e,
PC38.2p..38.3e, PC40.6p..40.7e,
PC40.2p..40.3e, PC40.1p..40.2e,
PCLyso16.1, PCLyso18.1,
PCLyso18e.1, PCLyso18e.0

PC34.0p..34.1e,
PCLyso16.1, PCLyso18.1,
PCLyso18e.0

PI32.2, PI34.3, PI36.2, PI38.3,
PI38.2, PI40.3, LysoPI16.1,
LysoPI16.0, LysoPI18.1
PS36.2, PS36.1, PS38.6,
PS38.5, PS38.4, PS40.5
LysoPG16.1, LysoPG18.1,
LysoPG18.0, LysoPG16.1f,
LysoPG18.1f
PA34.2, PA36.1
SM18.18.0, SM18.24.1
Cer.d18.1.22.0,
Cer.d18.0.16.0

Lipid – MCI vs. AD
p < 0.05
p < 0.001
PE36.4, PE36.0, PE38p.6,
PE40p.7, PE40p.6

PC32.1, PC32.0, PC34.0e,
PC36.4, PC36.2, PC34.0p..34.1e,
PCLyso18.2

PI38.2, PI40.4, PI40.3

PS38.5, PS38.4, PS40.5
PG34.2, PG34.1, PG36.4, PG36.3,
LysoPG18.2, LysoPG16.0f

PG34.2, PG36.4

PA34.1
SM18.16.0, SM18.20.0,
SM18.22.0, SM18.24.0
Cer.d18.1.16.0, Cer.d18.1.18.0,
Cer.d18.1.20.0, Cer.d18.1.24.1,
Cer.d18.0.18.0, Cer.d18.0.22.0,
Cer.d18.0.24.1

PA36.1

Cer.d18.0.24.0

SM18.20.0

SM18.22.0

Cer.d18.1.16.0, Cer.d18.1.18.0,
Cer.d18.1.22.0, Cer.d18.0.16.0,
Cer.d18.0.18.0, Cer.d18.0.24.1

Cer.d18.1.24.1
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Table 4.2 legend: The red text indicates lower mean levels in AD compared to HC, MCI
compared to HC and AD compared to MCI. The black text indicates higher mean levels in AD
compared to HC, MCI compared to HC and AD compared to MCI.
PI: Phosphatidylinositol, PE: Phosphatidylethanolamine, PC: Phosphatidylcholine, SM:
Sphingomyelin, PA: Phosphatidic acid, PG: Phosphatidylglycerol, Cer: Ceramide.

To test further for significant differences in lipid species levels between clinical
classifications using stricter criteria, a linear Models for Microarray Data
(LIMMA) model was applied to obtain a false discovery adjusted p-value for
each lipid to exclude any false associations identified by simple ANOVA.
4.4.1

Linear Models for Microarray Data (LIMMA) comparing clinical
classifications

LIMMA analysis was used to obtain Q values (false discovery adjusted values),
and Bonferroni comparisons were used to generate p-values to reduce the
number of lipids identified by ANOVA. This model selected 46 out of 189 lipid
species levels that were significantly different between healthy controls and AD
participants and these lipids are listed in Table 4.3.
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Table 4.3: Linear Models for Microarray Data (LIMMA) for 18 month samples for HC vs.
AD.

Lipid
Cer.d18.1.24.1
Cer.d18.1.20.0
PC34.0p..34.1e
PC32.0
PC34.0e
PG34.2
PE36.0
Cer.d18.1.16.0
PG34.1
Cer.d18.1.18.0
PC32.0e
PC34.1
PE38p.6
SM18.22.0
PE40p.6
LysoPE16.0
PE36.4
PC36.0p/etherPC
PE40p.7
LysoPE18.0
PCLyso16.1
PC38.5p..38.6e
PC32.1

p-value
2.22E-21
4.86E-17
1.19E-15
2.85E-13
6.16E-13
1.28E-11
1.66E-11
1.20E-10
1.18E-09
1.54E-09
8.60E-09
1.11E-08
1.37E-08
3.21E-08
4.63E-08
7.89E-08
2.47E-07
2.63E-07
3.15E-07
4.25E-07
5.15E-07
5.47E-07
1.84E-06

Lipid
PC36.4p/etherPC
PE38.5
PC32.0p
PG36.4
PE34.1
PE36.3
Cer.d18.0.18.0
PC34.5
PC40.2p..40.3e
PCLyso18e.1
SM18.16.0
PCLyso18e.0
PC40.6p..40.7e
SM18.20.0
PC38.1
SM18.24.0
PC40.1p..40.2e
LysoPE18.1
PG36.3
PA34.1
PE38.4
PC38.2p..38.3e
PC34.2p..34.3e

p-value
2.46E-06
2.98E-06
8.48E-06
1.03E-05
1.12E-05
1.62E-05
2.00E-05
2.42E-05
2.53E-05
2.74E-05
3.66E-05
4.13E-05
4.94E-05
7.04E-05
8.26E-05
9.81E-05
9.94E-05
1.00E-04
1.50E-04
1.72E-04
2.08E-04
2.40E-04
2.58E-04

Listed in order of most to least significant for p-values less than the Bonferroni cut off
(0.05/189).
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid.

A fold lipid change was subsequently calculated using unadjusted raw
expression values to provide a relative lipid difference between clinical
classifications. The mean levels, difference in levels between groups, the
directional change i.e. increased or decreased in AD compared to healthy
controls and fold change is shown in Table 4.4.
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Table 4.4: Mean value difference in lipid species levels between groups, direction of
change in lipid levels between HC and AD participants and fold change.
Lipid

Mean HC

Mean AD

Difference

LysoPE16.0
LysoPE18.1
LysoPE18.0
PE34.1
PE36.4
PE36.3
PE38.5
PE38.4
PA34.1
PG34.2
PG34.1
PG36.4
PG36.3
PCLyso16.1
PCLyso18e.1
PCLyso18e.0
PC32.0p
PC34.0p..34.1e
PC36.0p/etherPC
PC38.2p..38.3e
PC40.2p..40.3e
PC40.1p..40.2e
PC32.0e
PC32.1
PC32.0
PC34.0e
PC34.1
SM18.16.0
Cer.d18.1.16.0
Cer.d18.1.18.0
Cer.d18.1.20.0
Cer.d18.1.24.1
Cer.d18.0.18.0
PE38p.6
PE40p.7
PE40p.6
PE36.0
PC34.2p..34.3e
PC36.4p/etherPC
PC38.5p..38.6e
PC40.6p..40.7e
PC34.5
PC38.1
SM18.20.0
SM18.22.0
SM18.24.0

4.093E-04
2.047E-04
2.304E-04
3.056E-04
8.717E-04
4.615E-04
1.105E-03
2.305E-03
1.44eE-05
1.913E-05
2.639E-05
1.219E-05
1.264E-05
4.122E-04
7.051E-05
2.568E-04
1.240E-03
4.479E-03
4.169E-03
2.509E-03
7.853E-04
9.318E-04
1.302E-03
9.965E-03
5.407E-03
1.142E-03
8.348E-02
3.361E-02
1.076E-04
4.676E-05
5.192E-05
6.915E-04
9.786E-06
2.498E-03
6.750E-04
1.211E-03
1.514E-03
2.040E-03
3.046E-03
2.551E-03
1.344E-03
1.828E-04
3.476E-03
8.164E-02
6.482E-02
1.164E-02

4.685E-04
2.325E-04
2.593E-04
3.680E-04
1.038E-03
5.443E-04
1.295E-03
2.617E-03
1.607E-05
2.393E-05
3.104E-05
1.393E-05
1.146E-05
4.564E-04
7.656E-05
2.821E-04
1.313E-03
4.953E-03
4.463E-03
2.652E-03
8.387E-04
9.924E-04
1.421E-03
1.108E-02
5.910E-03
1.272E-03
8.897E-02
3.512E-02
1.202E-04
5.421E-05
6.258E-05
8.276E-04
1.139E-05
2.080E-03
5.631E-04
1.008E-03
1.193E-03
1.873E-03
2.745E-03
2.274E-03
1.237E-03
1.591E-04
3.300E-03
7.831E-02
6.134E-02
1.105E-02

5.923E-05
2.781E-05
2.893E-05
6.247E-05
1.666E-04
8.284E-05
1.906E-04
3.117E-04
1.603E-06
4.792E-06
4.645E-06
1.737E-06
1.515E-06
4.427E-05
6.057E-06
2.526E-05
7.320E-05
4.739E-04
2.938E-04
1.429E-04
5.343E-05
6.061E-05
1.189E-04
1.113E-03
5.029E-04
1.305E-04
5.494E-03
1.509E-03
1.263E-05
7.450E-06
1.066E-05
1.362E-04
1.605E-06
-4.188E-04
-1.118E-04
-2.032E-04
-3.215E-04
-1.673E-04
-3.017E-04
-2.771E-04
-1.077E-04
-2.376E-05
-1.760E-04
-3.330E-03
-3.482E-03
-5.871E-04

Direction
change
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↑ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD
↓ in AD

of

Fold Δ
1.145
1.136
1.126
1.204
1.191
1.180
1.173
1.135
1.111
1.250
1.176
1.142
1.120
1.107
1.086
1.098
1.059
1.106
1.070
1.057
1.068
1.065
1.091
1.112
1.093
1.114
1.066
1.045
1.117
1.159
1.205
1.197
1.164
0.832
0.834
0.832
0.788
0.918
0.901
0.891
0.920
0.870
0.949
0.959
0.946
0.950

Those lipids in the blue section indicate an increase in the mean lipid levels and those in the
grey section indicate a decrease in mean lipid levels in AD compared to healthy controls.
HC: Healthy Control, AD: Alzheimer’s disease, Δ: Change, PC: Phosphatidylcholine, SM:
Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI:
Phosphatidylinositol. PA: Phosphatidic acid.
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Table 4.4 shows the mean value, the difference between the mean lipid species
between clinical classifications and the fold change for each of the 46 lipids
identified as being significantly different between HC and AD by LIMMA. 33 lipid
species had mean levels higher and 13 had mean levels lower in AD compared
to healthy controls. Whilst Tables 4.3 and 4.4 compare healthy controls to AD,
LIMMA analysis was also repeated for the healthy controls compared to MCI
and the MCI compared to AD groups. No lipids were identified as being
significantly different following Bonferroni correction between the HC and MCI
groups and only one lipid (Cer.d18.1.24.1) was different (p=6.473E-6) between
the MCI and AD groups: levels of this lipid were higher in AD compared with
MCI.
4.4.2 Generalised Linear Model (GLM) comparing clinical classification
The LIMMA analyses, while identifying those lipid species levels that are
significantly different between clinical classifications, do not take into
consideration factors which may influence the significance of the observed
differences between mean lipid levels. Consequently a generalised linear model
(GLM) was created to control for age, APOEε4 allele carriage status, gender
and sample collection site (which was either Melbourne or Perth). The results
from the GLM comparing the HC and AD groups are displayed in Table 4.5.
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Table 4.5: Generalised Linear Modelling (GLM) for the 18 month samples for HC vs. AD
Lipid
Cer.d18.1.24.1
Cer.d18.1.20.0
PC34.0p..34.1e
PC32.0
Cer.d18.1.18.0
Cer.d18.1.16.0
PG34.2
PC34.0e
PC32.0e
PE36.0
PG34.1
PE38p.6
PCLyso16.1
SM18.16.0
PA34.1
PC32.0p
Cer.d18.0.18.0
PE40p.6
PG36.4
LysoPE18.0
LysoPE16.0
PC40.2p..40.3e
PE40p.7
PC40.1p..40.2e
PC36.4p/etherPC
PC32.1
PG36.3
PE36.4
SM18.22.0
PC34.1
PCLyso18.1e
SM18.20.0
PC40.6p..40.7e
PC36.0p/etherPC
PE36.3
PC34.2p..34.3e
PC38.5p..38.6e
PCLyso18e.0
PE34.1
PE38.5
PC34.5
LysoPE18.1
PC38.2p..38.3e
PE38.4
PC38.1
SM18.24.0

p-value
9.47E-14
1.72E-12
1.28E-07
1.34E-07
4.40E-07
1.01E-06
2.55E-06
4.43E-06
2.31E-05
4.57E-05
8.19E-05
1.12E-04
2.08E-04
2.09E-04
2.18E-04
2.40E-04
2.44E-04
2.49E-04
0.0003
0.0004
0.0005
0.0007
0.0008
0.0011
0.0012
0.0013
0.0031
0.0037
0.0046
0.0049
0.0056
0.0060
0.0085
0.0092
0.0095
0.0098
0.0106
0.0109
0.0118
0.0183
0.0242
0.0351
0.0653
0.0796
0.3542
0.5028

Age
2.63E-23
7.77E-28
1.20E-23
1.57E-25
7.56E-30
1.32E-26
7.73E-29
3.99E-24
1.06E-26
3.07E-29
1.72E-28
5.60E-31
4.70E-31
4.34E-30
5.77E-32
1.15E-29
2.44E-31
5.75E-31
1.84E-31
7.81E-31
2.09E-29
6.55E-31
8.10E-31
1.89E-30
1.12E-30
7.65E-30
2.23E-31
7.20E-29
1.17E-28
2.92E-28
4.26E-30
5.61E-31
1.28E-31
7.60E-29
8.68E-29
7.69E-31
9.41E-31
1.28E-30
1.49E-29
2.89E-29
1.48E-30
9.05E-31
7.40E-31
4.15E-30
1.55E-29
1.35E-29

APOEε4
1.03E-26
2.24E-25
8.18E-28
1.40E-27
4.39E-26
9.33E-27
2.21E-26
4.96E-28
5.05E-28
2.14E-25
3.26E-26
1.51E-25
5.57E-26
5.58E-27
2.51E-26
3.20E-27
3.47E-26
1.63E-25
3.80E-26
2.80E-25
1.65E-25
4.36E-27
1.17E-25
1.99E-27
2.92E-26
7.88E-27
2.32E-26
4.86E-26
8.37E-27
1.06E-26
5.34E-27
1.97E-26
1.06E-25
4.30E-27
7.21E-27
3.71E-27
1.32E-25
1.47E-26
3.25E-26
5.31E-26
1.94E-26
1.12E-25
6.96E-27
2.94E-26
1.00E-26
7.46E-27

Sex
0.180
0.304
0.505
0.303
0.617
0.267
0.513
0.498
0.175
0.501
0.593
0.466
0.518
0.412
0.237
0.383
0.419
0.377
0.353
0.472
0.397
0.484
0.343
0.457
0.865
0.999
0.317
0.833
0.578
0.488
0.231
0.831
0.560
0.634
0.787
0.710
0.629
0.307
0.570
0.934
0.441
0.271
0.519
0.767
0.670
0.633

Site
0.013
0.018
0.200
0.148
0.067
0.027
0.906
0.194
0.172
0.611
0.244
0.714
0.277
0.062
0.103
0.113
0.137
0.486
0.241
0.145
0.079
0.334
0.366
0.215
0.273
0.301
0.218
0.100
0.616
0.498
0.308
0.209
0.248
0.594
0.106
0.387
0.447
0.272
0.106
0.114
0.323
0.149
0.448
0.123
0.214
0.241

Adjusted for age, sex, APOEε4 allele status (i.e. carriage or non-carriage of an APOEε4 allele)
and sample collection site (Perth or Melbourne). Lipids with a statistically significant p-value less
than the Bonferroni cut off (0.05/189) are above the solid black line.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid, APOEε4:
Apolipoprotein E ε4 allele.
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Table 4.5 shows the p-values for each of the 46 lipids identified by LIMMA as
being significantly different between HC and AD, adjusted through GLM for the
following covariates; age, sex, APOEε4 allele status and sample collection site.
The p-values for each of the covariates are also shown in the table. The data
are sorted by the strongest p-value for the lipid level post adjustment i.e. where
the levels are most different between the clinical classification groups. The top
18 lipids (above the solid line) in the table remain statistically significant (less
than the Bonferroni cut off value of p<0.0003 (α of 0.05 / n of 189)) after
adjustment for age, gender, APOEε4 allele status and collection site. The pvalues indicate that neither site of collection or gender significantly influence the
results, but as expected, age and APOEε4 allele carriage do significantly
influence the results.
No GLM was performed to compare the healthy control and MCI groups as no
lipids were identified as being significantly different between these clinical
classifications by LIMMA.
The GLM of the MCI compared to AD groups showed that the Cer.d18.1.24.1
species identified as being significantly different by LIMMA between these
groups, also remained significant (p<0.0003) following adjustment for age,
gender, APOEε4 allele status and sample collection site.
4.4.3. Variable selection for predictive lipid panel
As previously described for the baseline data in Chapter 3, the LIMMA and GLM
models assess associations between lipids and clinical classification, i.e. levels
of lipid species that are significantly different between clinical classifications.
Variable selection analysis attempts to identify lipid species which when
considered collectively are able to predict clinical classification with greatest
certainty. As such, the level at which clinical classification can be predicted, is
determined by modelling the selected lipids and covariates using GLM and
Receiver Operating Characteristics (ROC) models.
As described in Chapter 3, previous analysis of biomarkers in the AIBL cohort
utilised a variable selection pathway to create lists of biomarkers that were
chosen from four separate selection methods; random forest, boosted trees,
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regression trees and LIMMA and used clinical classification as a binary
outcome, i.e. HC or AD [476]. In this study, a variable selection pathway was
applied to the 189 lipid species to create an importance ranking (in addition to
generation of p-values), where 1000 iterations were performed to define a list of
those lipid species that are selected most often as differing in levels when
comparing clinical classifications. Each time a lipid was selected, a frequency
score was assigned if it was chosen from all four statistical methods, or from
three out of the four statistical methods.
4.4.3.1

Variable selection for HC vs. AD groups

Table 4.6 lists the lipid species selected most often when comparing the HC
and AD groups. The lipid species that are selected in at least 10% of the 1000
iterations from all four statistical methods are listed in column A and the lipid
species that were selected in at least 10% of the 1000 iterations from three of
the four statistical methods are shown in column B.
Table 4.6: Lipid Markers selected by the Variable Selection Pathway for HC vs. AD in the
18 month samples.

List A (4/4)
Lipid

Cer.d18.1.24.1
Cer.d18.1.20.0
PC34.0p..34.1e
PG34.2

Frequency (/1000)

766
362
163
127

List B (3/4)
Lipid

Cer.d18.1.20.0
PG34.1
PE36.0
PC34.0p..34.1e
PC32.0
PC34.0e
PG34.2
Cer.d18.1.18.0
SM18.22.0
Cer.d18.1.16.0
Cer.d18.1.24.1
PC32.0e
PC38.5p..38.6e
PC36.4p/etherPC
PE38p.6
PC34.1
LysoPE16.0

Frequency (/1000)

626
466
451
444
444
345
343
334
283
237
230
164
155
140
138
133
125

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol. The lipids highlighted in grey appeared in
both list A and list B.
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Those lipids with the highest frequencies of selection from both lists A and B of
Table 4.6 were clustered using Partitioning Around Medoids (PAM) to find a
central lipid, and then cluster other correlated lipids around it. As described in
Chapter 3, this statistical method correlates lipids that are related to each other
without consideration of clinical classification, and is performed to see if lipids
can be eliminated from a final model if they behave in the same way as other
lipids in their respective clusters in terms of predicting clinical classification. A
CLARA (Clustering for Large Applications) algorithm was applied to create a
clusplot of correlated lipids, which resulted in the formation of four lipid clusters,
listed in Table 4.7 and represented graphically in Figure 4.18.
Table 4.7: Four groups of clustered lipids were determined using medoid clustering when
comparing the HC and AD groups.

Cluster 1
LysoPE16.0
PG34.2
PG34.1
PC34.1

Cluster 2
PE38p.6
PE36.0
PC36.4p/etherPC
PC38.5p..38.6e
SM18.22.0

Cluster 3
PC34.0p..34.1e
PC32.0e
PC32.0
PC34.0e

Cluster 4
Cer.d18.1.16.0
Cer.d18.1.18.0
Cer.d18.1.20.0
Cer.d18.1.24.1

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.

Of the 17 lipids selected by Variable Selection Pathways for HC vs. AD, cluster
1 has 4 lipids, cluster 2 has 5 lipids, cluster 3 has 4 lipids and cluster 4 has 4
lipids.
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Statistical Component 2

CLARA Cluster Plot

Statistical Component 1
Figure 4.18: Clusplot of correlated lipids showing the 4, 5, 4 and 4 lipids from clusters 1
to 4 respectively.

The clusplot shows a stronger relationship for the lipids within clusters 3 and 4.
The lipids in clusters 1 and 2 are by contrast more diffuse, suggesting a weaker
intracluster

relationship

between

those

lipids.

The

strength

of

these

relationships may be explained by the fact that clusters 3 and 4 both contain
lipids of the same class (PC and ceramides respectively), whilst clusters 1 and
2 are more heterogeneous containing a mixture of PG, PE, PC and SM species.
Standard Pearson’s correlations were applied to the lipids in each cluster to
explore the directional relationship between correlated lipids and clinical
classification. These relationships between the scaled mean expression for HC
and AD groups are shown in Figure 4.19 with the r-values for the lipid
correlations shown in Table 4.8.
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LysoPE16.0, PG34.2, PG34.1,
PC34.1

PE38p.6, PE36.0,
PC36.4p/etherPC,
PC38.5p..38.6e, SM18.22.0

PC34.0p..34.1e, PC32.0e,
PC32.0, PC34.0e

Cer.d18.1.16.0, Cer.d18.1.18.0,
Cer.d18.1.20.0, Cer.d18.1.24.1

Figure 4.19: Correlated lipids between clinical classifications.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol. Scaled mean expression is used to enable graphical representation
of lipids that differ in abundance.
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Table 4.8: Standard Pearson’s Correlations between 17 lipid species chosen from the variable selection pathway for the HC vs. AD groups.
A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

1

-0.113130

-0.092540

0.024544

0.291661

0.217801

-0.171040

0.009912

0.182172

0.179702

0.204909

0.043866

-0.005970

0.238777

0.205044

0.293567

0.303768

A

Lyso.PE16.0

1

0.769412

-0.298200

-0.125650

-0.155970

0.534321

0.530812

-0.144360

-0.145240

-0.066340

-0.232740

-0.030280

-0.127930

-0.070670

-0.106140

-0.150560

B

PE38p.6

1

-0.286610

-0.105350

-0.246010

0.415336

0.646169

-0.168570

-0.102940

-0.155530

-0.275870

0.038010

-0.128800

-0.094130

-0.140680

-0.159100

C

PE36.0

1

0.362691

0.061308

-0.152030

-0.194020

0.003428

0.059416

0.031222

0.225135

-0.112510

0.090714

0.108925

0.123625

0.193643

D

PG34.2

1

0.047099

-0.192260

-0.144210

-0.025630

0.145080

0.084246

0.267404

-0.243100

0.128726

0.227648

0.227120

0.303871

E

PG34.1

1

-0.042850

-0.014050

0.788231

0.475870

0.855177

0.302029

-0.079970

0.313523

0.170491

0.204510

0.318756

F

PC.34.0p..34.1e

1

0.693248

0.013221

0.011570

-0.006280

-0.177810

-0.234220

-0.167150

-0.104370

-0.188880

-0.169820

G

PC36.4p.or.ethPC

1

0.067121

0.040785

0.031442

-0.375050

0.032488

-0.015490

-0.046800

-0.079600

-0.052150

H

PC.38.5p..38.6e

1

0.614448

0.783217

0.131912

-0.049800

0.338028

0.128871

0.108996

0.266251

I

PC32.0e

1

0.547570

0.457070

-0.347740

0.190831

0.128015

0.056191

0.204358

J

PC32.0

1

0.275150

-0.166950

0.263676

0.203571

0.195802

0.274928

K

PC34.0e

1

-0.528100

-0.066970

0.057543

0.003977

0.058526

L

PC34.1

1

0.175049

-0.063300

0.046131

-0.053410

M

SM18.22.0

1

0.528673

0.545311

0.626519

N

Cer.d18.1.16.0

1

0.666193

0.595002

O

Cer.d18.1.18.0

1

0.667528

P

Cer.d18.1.20.0

1

Q

Cer.d18.1.24.1

Correlation coefficients (R) for each pairwise correlation are shown. Correlations of greater than 0.5 or less than -0.5 are highlighted in red.
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The strongest correlations, as highlighted in red in Table 4.8 were seen
between lipids of the same class. i.e. PCs, PEs and ceramides. A correlation
was also shown between PC34.1 and SM18.22.0. It is important to note that
sphingomyelin can be formed by the transfer of phosphocholine to ceramide.
Looking at the directional grouping (increased or decreased in AD compared to
HC) of the relationship between correlated lipids and clinical classification as
depicted in Figure 4.19, it can be seen that the lipids in each cluster have a very
similar relationship.
Taking the 17 lipids chosen from the variable selection pathway, and factoring
in their correlations as determined by the Pearson’s correlation R-values (see
Table 4.8), the lipids were subjected to further statistical assessment using a
stepwise generalised linear model (GLM) to reduce the number of lipids in the
predictive model. This methodology was also utilised for the baseline data in
Chapter 3. The GLM algorithm was run repeatedly to remove lipids from the
predictive model until the lipids left were those giving the best Akaike
Information Criterion (AIC) report, which is a measure of the relative quality of a
statistical model for a given set of data, and therefore provides a means for
selecting the best model, as previously described in Chapter 3. This stepwise
model also factors in covariates of age, gender, APOEε4 allele status and
collection site, as described for the previous GLM. This prediction model split
the analysis of the 948 study participant plasma lipid profiles into a run
comprising 70% training (that includes clinical classification) and 30% test data
(blind to clinical classification), and was repeated over 100 times until the
greatest sensitivity and specificity was achieved. A final panel of 9 lipids was
selected that contained the least number of lipids with maximal sensitivity and
specificity for predicting disease classification: these 9 lipids are listed in Table
4.9.
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Table 4.9: List of the nine lipids that yielded maximal sensitivity and specificity between
HC and AD groups at the 18-month follow-up time point.

Lipid
LysoPE16.0
PG34.2
PC34.0p..34.1e
PC38.5p..38.6e
PC32.0e
PC32.0
SM18.22.0
Cer.d18.1.20.0
Cer.d18.1.24.1
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol. Those lipids highlighted in grey were also selected from the baseline
data.

All 9 lipid species were also identified as being significantly different when
assessed

by

the

standard

LIMMA

analyses

(Tables

4.3

and

4.4).

PC38.5p..38.6e and PC32.0 were also selected in the variable selection
pipeline for the baseline data in Chapter 3.
Maximal sensitivity and specificity (80%) for predicting participants with AD as
compared to healthy controls is shown in the Receiver Operating Characteristic
(ROC) curve in Figure 4.20, with respect to the GLM of the top nine lipids
adjusted for age, gender, APOEε4 allele status and collection site.
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Figure 4.20: Receiver Operating Characteristics (ROC) curve of the top nine lipids from
stepwise Generalised Linear Modelling (GLM) showing sensitivity and specificity of 80%
for the HC vs. AD group.

As previously described in Chapter 3, the ROC curve is a plot of the true
positive rate (sensitivity) against the true negative rate (specificity) and is
therefore a measure of the accuracy of a diagnostic test, which in this case is
the ability of the panel of nine lipids to distinguish those participants with AD
from healthy controls. A sensitivity and specificity of 80% for the panel of nine
lipids is indicated by the area under the ROC curve. Although there were only
two lipids (PC38.5p..38.6e and PC32.0) in the predictive panel for the 18 month
data that were also selected in the baseline predictive panel, the remainder
were common to the same classes yet were different sub-species at both time
points. Despite slight differences in the lipids selected at 18 months compared

196

Chapter 4: Plasma Lipid Profiles in AIBL 18 month samples
to baseline, the sensitivity and specificity of the predictive panel remained
unchanged at 80%.
4.4.3.2

Variable Selection for HC vs. MCI groups

As carried out for the healthy controls vs. AD groups, the variable selection
pathway was repeated for the healthy control vs. MCI groups. This generated a
list of lipids that were chosen from four separate selection methods as
previously described for the HC vs. AD groups. Table 4.10 lists the lipid species
selected most often when comparing the HC and MCI groups. As before, the
lipid species that were selected in at least 10% of the 1000 iterations from all
four statistical methods are listed in column A and the lipid species that were
selected in at least 10% of the 1000 iterations from three of the four statistical
methods are shown in column B.
Table 4.10: Lipid Markers selected by the Variable Selection Pathway for HC vs. MCI in
the 18 month samples.

List A (4/4)
Lipid

Frequency (/1000)

List B (3/4)
Lipid

LysoPG16.1
PI38.2
PS38.5
PCLyso16.1
PS36.2

Frequency (/1000)

376
205
173
167
125

PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol.

The variable selection pipeline for the HC vs. MCI groups selected seven lipids
(PI38.2, PS38.5, PA36.1, LysoPE18.1, LysoPE18.0, LysoPE18.2, PG36.4) from
all four statistical methods: the maximum frequency however was 1.5%, thus
too low to be on the list above. The five lipids with the highest frequencies of
selection from list B of Table 4.10 were clustered as previously described: As
too few lipids were selected however, a CLARA (Clustering for Large
Applications) was not generated. Adding the five lipids listed in Table 4.10B to
the predictive GLM/ROC models gave a sensitivity and specificity of just 69%
for distinguishing those participants with MCI from healthy controls following
adjustment for age, gender, APOEε4 allele status and collection site.
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4.4.3.3

Variable selection MCI vs. AD groups

As described previously, the variable selection pathway was repeated for the
MCI vs. AD groups. Table 4.11 lists the lipid species selected most often when
comparing the MCI and AD groups. As before, the lipid species that were
selected in at least 10% of the 1000 iterations from all four statistical methods
are listed in column A and the lipid species that were selected in at least 10% of
the 1000 iterations from three of the four statistical methods are shown in
column B.
Table 4.11: Lipid Markers selected by the Variable Selection Pathway for MCI vs. AD in
the 18 month samples.

List A (4/4)
Lipid

Cer.d18.1.24.1

Frequency (/1000)

377

List B (3/4)
Lipid

Cer.d18.1.20.0
Cer.d18.1.24.1
SM18.22.0
Lyso.PG16.1f
PE40p.4

Frequency (/1000)

325
299
203
112
107

Cer:
Ceramide,
SM:
Sphingomyelin,
PE:
Phosphatidylethanolamine,
LysoPG:
Lysophosphatidylglycerol. The lipid highlighted in grey appeared in both list A and list B.

The variable selection pipeline for the MCI vs. AD groups selected only one lipid
(Cer.d18.1.24.1) from all four statistical methods in at least 10% of the 1000
iterations. Those lipids with the highest frequencies of selection from both lists A
and B of Table 4.11 were clustered as previously described. However, as too
few lipids were once again selected, a CLARA (Clustering for Large
Applications) was not generated. Adding the five lipids listed in Table 4.11 to the
predictive GLM/ROC models also gave a sensitivity and specificity of just 69%
for distinguishing those participants with AD from MCI following adjustment for
age, gender, APOEε4 allele status and collection site.
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4.4.4

Correlation with Standardised Uptake Value Ratio (SUVR)

The previous sections assessed the ability of a panel of lipids to predict clinical
classification as the aim of the study was to develop a sensitive and specific
diagnostic blood biomarker lipid panel. In this section, as with the baseline data,
the relationship of the lipids determined (Section 4.4.4) by variable selection
analysis was assessed against neocortical amyloid burden represented by
SUVR; an established neuroimaging biomarker of AD. Each of the 17 lipids
identified by the variable selection pathway for the healthy control vs. AD
groups (Table 4.6) was plotted by cluster (Table 4.7) against categories of
SUVR measured at the 18 month time point; see Figure 4.21 below.
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LysoPE16.0, PG34.2, PG34.1,
PC34.1

PE38p.6, PE36.0,
PC36.4p/etherPC,
PC38.5p..38.6e, SM18.22.0

PC34.0p..34.1e, PC32.0e,
PC32.0, PC34.0e

Cer.d18.1.16.0, Cer.d18.1.18.0,
Cer.d18.1.20.0, Cer.d18.1.24.1

SUVR category
< 1.3
> 1.3 to < 1.7
1.7 to < 2.0
> 2.0

Interpretation
Individuals with minimal accumulation of Aβ
Includes individuals with borderline transitions
from amyloid -ve to amyloid +ve
Individuals who are definite accumulators, with
increased rate of Aβ accumulation
Individuals who have the highest accumulation
but rate plateaus with saturation between 2-3

Figure 4.21: Clustered and correlated lipids identified by the variable selection pathway
for the healthy control vs. AD groups compared with 18 month SUVR categories.
AD: Alzheimer’s disease, SUVR: Standard uptake value ratio. Aβ: Amyloid Beta. The SUVR
categories used in this table are those described by Villemagne et al. [477].
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Figure 4.21 shows that some of the lipids in each cluster behave in a similar
way when compared to SUVR categories. The lipids levels in clusters 2 and 3
are approximately the same at SUVR of <1.3 and >2. Cluster 4 contains four
ceramide species which show very similar relationships with SUVR, rising
between a SUVR of (> 1.3 to < 1.7) and (1.7 < 2.0), then a sudden decline
between a SUVR of (1.7 < 2.0) and (> 2), the point at which Aβ accumulation
plateaus.
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4.4.5 LIMMA and GLM comparing the transition groups
To assess the lipid profile data longitudinally rather than cross-sectionally, a
LIMMA with Bonferroni comparisons was applied to participants following
classification as either non-transition (classification remained the same:
excepting stable AD), transition (classification changed to a different group) or
stable AD (remained in the AD group) over the 18 month follow up period. The
transition group also included those participants with MCI: “transition” in the
AIBL cohort is defined as transition towards AD or declining mental health as
determined by neuropsychological testing [492]. Table 4.12 shows the
demographics of each classification group for the 948 individuals assessed
longitudinally, i.e. for whom lipid profiles were measured at both baseline and
18 month follow up.
Table 4.12: Demographics of AIBL participants classified as either non-transition,
transition or stable AD over the 18 month follow up period.

Non-transition

Stable AD

Transition

679

155

114

71.76 (+ 6.75)

79.25 (+ 7.96)

77.22 (+ 7.63)

<0.0001

Gender (F/M)

400/279

94/61

55/59

0.077

APOEε4 (-ve/+ve)

498/181

50/105

55/59

<0.0001

29 (+ 1.33)

18 (+ 7.05)

26 (+ 3.06)

<0.0001

149

23

38

1.38 (+ 0.39)

2.37 (+ 0.48)

1.93 (+ 0.63)

140

22

31

3.15 (+ 0.33)

2.80 (+ 0.49)

2.85 (+0.42)

Count (n)
Age, years (Mean +SD)

MMSE (Mean + SD)
SUVR (n)
SUVR (Mean + SD)
Hip Vol (n)
Hip Vol (Mean + SD)

p-value

<0.0001
<0.0001

Non-transition: Classification remained the same (excepting stable AD), Stable AD: Remained
in the AD group, Transition: Classification changed to a different group over the 18 month follow
up period, AD: Alzheimer’s Disease, F: Female, M: Male, APOEε4 (-ve/+ve): Negative or
positive for the Apolipoprotein (APOE) ε4 allele, MMSE: Mini Mental State Examination, SUVR:
Standard Uptake Value Ratio, Hip Vol: Hippocampal volume (measured in mL), SD: Standard
deviation. The characteristics were composed using analysis of variance (ANOVA) to calculate
differences for the continuous variables and X2 for categorical variables. A Kruskal-Wallis
formula was applied to the MMSE scores.

The 948 individuals in whom lipid profiles were measured at both baseline and
18 month follow up consisted of: 679 non-transition, 114 transition and 155
stable AD participants. The number of men and women in each classification
did not significantly differ, but significant differences in mean age, APOEε4
202

Chapter 4: Plasma Lipid Profiles in AIBL 18 month samples
allele status, MMSE, SUVR and hippocampal volume were observed between
groups.
LIMMA analysis of the non-transition vs. stable AD groups identified 44 out of
the 189 lipid species measured that were significantly different in levels
between groups. Table 4.13 lists these lipids.
Table 4.13: Linear Models for Microarray Data (LIMMA) for 18 month samples comparing
the non-transition vs. stable AD groups.

Lipid
Cer.d18.1.20.0
Cer.d18.1.24.1
PC34.0p..34.1e
PC34.0e
PC32.0
PE36.0
Cer.d18.1.16.0
PG34.2
PC34.1
Cer.d18.1.18.0
PG34.1
PC32.0e
LysoPE16.0
PE38p.6
SM18.22.0
PC36.0p/etherPC
PE36.4
PCLyso16.1
LysoPE18.0
PE40p.6
PCLyso18e.1
PC38.5p..38.6e

p-value
3.71E-18
4.43E-18
1.16E-15
5.11E-13
7.53E-12
1.35E-10
2.88E-10
4.02E-10
9.12E-09
9.35E-09
1.43E-08
6.33E-08
6.38e-08
6.53E-08
7.52E-08
7.68E-08
1.61E-07
3.10E-07
4.19E-07
5.37E-07
1.61E-06
1.96E-06

Lipid
PC32.1
PC36.4p/etherPC
PE40p.7
PE38.5
PC40.2p..40.3e
SM18.20.0
PCLyso18.1
SM18.24.0
PCLyso18e.0
PC38.1
PG36.4
PC34.5
LysoPE18.1
PE34.1
PC34.2p..34.3e
PC38.2p..38.3e
PC32.0p
SM18.16.0
PA34.1
Cer.d18.0.22.0
Cer.d18.0.18.0
PE36.3

p-value
2.40E-06
5.03E-06
5.11E-06
5.46E-06
6.30E-06
8.65E-06
1.41E-05
1.56E-05
1.93E-05
2.12E-05
2.96E-05
3.86E-05
4.78E-05
5.30E-05
6.14E-05
6.53E-05
6.68E-05
1.21E-04
1.85E-04
1.86E-04
2.20E-04
2.47E-04

p-values less than the Bonferroni cut off (0.05/189).
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid.

A fold lipid change was subsequently calculated using unadjusted raw
expression values to provide a relative lipid difference between transition
classifications. The mean levels, difference in levels between groups, the
directional change i.e. increased or decreased in stable AD compared to the
non-transition group and fold change is shown in Table 4.14.
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Table 4.14: Mean value difference in lipid species levels between groups, direction of
change in lipid levels between the non-transition and stable AD and groups and fold
change.
Lipid
Mean Non- Mean
Difference
Direction
of Fold Δ
trans
Stable AD
change
LysoPE16.0
4.086E-04
4.734E-04
-6.480E-05 ↑ in stable AD
1.159
LysoPE18.1
2.041E-04
2.355e-04
-3.148E-05 ↑ in stable AD
1.154
LysoPE18.0
2.298E-04
2.610E-04
-3.123E-05 ↑ in stable AD
1.136
PE34.1
3.025E-04
3.672E-04
-6.193E-05 ↑ in stable AD
1.203
PE36.4
8.704E-04
1.053E-03
-1.822E-04 ↑ in stable AD
1.209
PE36.3
4.614E-04
5.374E-04
-7.599E-05 ↑ in stable AD
1.165
PE38.5
1.101E-03
1.300E-03
-1.992E-04 ↑ in stable AD
1.181
PA34.1
1.444E-05
1.616E-05
-1.720E-06 ↑ in stable AD
1.119
PG34.2
1.908E-05
2.376E-05
-4.685E-06 ↑ in stable AD
1.246
PG34.1
2.639E-05
3.106E-05
-4.673E-06 ↑ in stable AD
1.177
PG36.4
1.219E-05
1.395E-05
-1.769E-06 ↑ in stable AD
1.145
PCLyso16.1
4.119E-04
4.610E-04
-4.907E-05 ↑ in stable AD
1.119
PCLyso18.1
3.508E-03
3.824E-03
-3.157E-04 ↑ in stable AD
1.090
PCLyso18e.1
7.030E-05
7.777E-05
-7.467E-06 ↑ in stable AD
1.106
PCLyso18e.0
2.562E-04
2.845E-04
-2.835E-05 ↑ in stable AD
1.111
PC32.0p
1.239E-03
1.310E-03
-7.121E-05 ↑ in stable AD
1.057
PC34.0p..34.1e
4.473E-03
4.988E-03
-5.147E-04 ↑ in stable AD
1.115
PC36.0p/etherPC
4.163E-03
4.496E-03
-3.335E-04 ↑ in stable AD
1.080
PC38.2p..38.3e
2.507E-03
2.676E-03
-1.689E-04 ↑ in stable AD
1.067
PC40.2p..40.3e
7.842E-04
8.462E-04
-6.197E-05 ↑ in stable AD
1.079
PC32.0e
1.301E-03
1.422E-03
-1.211E-04 ↑ in stable AD
1.093
PC32.1
9.970E-03
1.116E-02
-1.190E-03 ↑ in stable AD
1.119
PC32.0
5.406E-03
5.914E-03
-5.080E-04 ↑ in stable AD
1.094
PC34.0e
1.140E-03
1.282E-03
-1.423E-04 ↑ in stable AD
1.125
PC34.1
8.346E-02
8.943E-02
-5.967E-03 ↑ in stable AD
1.071
SM18.16.0
3.359E-02
3.510E-02
-1.512E-03 ↑ in stable AD
1.045
Cer.d18.1.16.0
1.075E-04
1.208E-04
-1.325E-05 ↑ in stable AD
1.123
Cer.d18.1.18.0
4.674E-05
5.437E-05
-7.639E-06 ↑ in stable AD
1.163
Cer.d18.1.20.0
5.182E-05
6.367E-05
-1.185E-05 ↑ in stable AD
1.229
Cer.d18.1.24.1
6.909E-04
8.250E-04
-1.342E-04 ↑ in stable AD
1.194
Cer.d18.0.18.0
9.779E-06
1.128E-05
-1.505E-06 ↑ in stable AD
1.154
Cer.d18.0.22.0
1.732E-05
2.074E-05
-3.417E-06 ↑ in stable AD
1.197
PE38p.6
2.499E-03
2.065E-03
4.341E-04
↓ in stable AD
0.826
PE40p.7
6.751E-04
5.663E-04
1.088E-04
↓ in stable AD
0.839
PE40p.6
1.212E-03
1.010E-03
2.028E-04
↓ in stable AD
0.833
PE36.0
1.514E-03
1.179E-03
3.347E-04
↓ in stable AD
0.779
PC34.2p..34.3e
2.040E-03
1.842E-03
1.976E-04
↓ in stable AD
0.903
PC36.4p/etherPC
3.047E-03
2.729E-03
3.187E-04
↓ in stable AD
0.895
PC38.5p..38.6e
2.549E-03
2.263E-03
2.863E-04
↓ in stable AD
0.888
PC34.5
1.828E-04
1.577E-04
2.508E-05
↓ in stable AD
0.863
PC38.1
3.472E-03
3.267E-03
2.055E-04
↓ in stable AD
0.941
SM18.20.0
8.169E-02
7.767E-02
4.015E-03
↓ in stable AD
0.951
SM18.22.0
6.479E-02
6.111E-02
3.676E-03
↓ in stable AD
0.943
SM18.24.0
1.163E-02
1.092E-02
7.038E-04
↓ in stable AD
0.939
Those lipids in the blue section indicate an increase in the mean lipid levels and those in the
grey section indicate a decrease in mean lipid levels in stable AD compared to the nontransition groups.
Non-trans: Non-transition (classification stayed the same (excepting stable AD) from baseline to
18 month follow up), AD: Alzheimer’s disease, Δ: Change, PC: Phosphatidylcholine, SM:
Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI:
Phosphatidylinositol. PA: Phosphatidic acid.
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The above table shows the mean levels for the groups, the difference between
the group mean lipid species levels, and the fold change for each of the 44
lipids identified as being significantly different between the non-transition and
stable AD groups by LIMMA. For 32 of the lipid species, mean levels were
higher and for 12 of the lipid species, mean levels lower, when comparing the
stable AD group with the non-transition group. The LIMMA analysis, while
identifying 44 lipid species levels that are significantly different between the
non-transition and stable AD groups, does not take into consideration factors
which may influence the significance of the observed differences in mean lipid
levels. Consequently a generalised linear model (GLM) was created to control
for age, APOEε4 allele carriage status, gender and collection site. The results of
the GLM are displayed in Table 4.15.
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Table 4.15: Generalised Linear Modelling (GLM) for the 18 month samples in the nontransition compared to the stable AD group.
Lipid
Cer.d18.1.20.0
Cer.d18.1.24.1
PC34.0p..34.1e
PC32.0
Cer.d18.1.16.0
Cer.d18.1.18.0
PC34.0e
PG34.2
PC32.0e
PE36.0
LysoPE18.0
LysoPE16.0
PCLyso16.1
PG34.1
PE38p.6
PA34.1
PG36.4
SM18.16.0
PC40.2p..40.3e
PE40p.6
PCLyso18e.1
Cer.d18.0.22.0
PC32.0p
PE36.4
PCLyso18.1
PC32.1
Cer.d18.0.18.0
SM18.20.0
PC36.4p/etherPC
PE40p.7
PC34.1
PCLyso18e.0
PC34.2p..34.3e
SM18.22.0
PC36.0p/etherPC
LysoPE18.1
PE34.1
PC38.5p..38.6e
PE38.5
PE36.5
PC34.5
PC38.2p..38.3e
PC38.1
SM18.24.0

p-value
5.29E-14
7.08E-12
8.18E-08
2.07E-07
3.80E-07
4.57E-07
1.93E-06
1.48E-05
3.10E-05
8.48E-05
8.83E-05
9.86E-05
1.31E-04
1.91E-04
2.08E-04
2.26E-04
2.29E-04
2.40E-04
0.0003
0.0005
0.0007
0.0008
0.0008
0.0012
0.0014
0.0017
0.0024
0.0026
0.0026
0.0027
0.0040
0.0043
0.0053
0.0055
0.0068
0.0082
0.0133
0.0134
0.0159
0.0230
0.0238
0.0301
0.1620
0.2443

Age
4.20E-25
1.08E-21
3.45E-21
1.98E-23
2.44E-24
1.26E-27
1.14E-21
9.94E-27
1.35E-24
7.21E-27
2.31E-28
8.56E-27
2.52E-28
4.18E-26
2.00E-28
3.44E-29
5.54E-29
1.46E-27
2.89E-28
1.49E-28
5.07E-27
5.69E-29
3.76E-27
4.06E-26
2.22E-28
3.63E-27
1.46E-28
5.73E-28
4.87E-28
2.16E-28
2.16E-25
7.17E-28
4.90E-28
3.23E-26
5.98E-26
7.06E-28
4.50E-27
3.17E-28
1.14E-26
9.95E-27
5.23E-28
3.59E-28
1.75E-26
1.80E-26

APOEε4
6.31E-21
1.69E-22
2.17E-23
1.98E-23
2.33E-22
6.54E-22
1.13E-23
2.43E-22
1.16E-23
3.02E-21
5.45E-21
3.30E-21
1.36E-21
4.83E-22
2.10E-21
6.13E-22
5.10E-22
8.28E-23
1.33E-22
1.76E-21
1.39E-22
1.68E-22
5.74E-23
8.71E-22
7.42E-22
1.59E-22
5.49E-22
5.77E-22
6.04E-22
1.54E-21
1.95E-22
3.32E-22
9.64E-23
1.72E-22
9.37E-23
2.71E-21
4.88E-22
1.91E-21
9.53E-22
1.18E-22
4.15E-22
1.81E-22
2.67E-22
1.95E-22

Sex
0.246
0.187
0.465
0.269
0.239
0.581
0.456
0.473
0.161
0.446
0.411
0.331
0.463
0.533
0.422
0.213
0.319
0.401
0.429
0.337
0.157
0.355
0.382
0.780
0.128
0.911
0.391
0.800
0.768
0.320
0.423
0.255
0.662
0.504
0.592
0.195
0.512
0.552
0.872
0.692
0.405
0.461
0.670
0.634

Site
0.003
0.005
0.084
0.052
0.006
0.023
0.077
0.633
0.065
0.319
0.046
0.021
0.113
0.095
0.381
0.036
0.098
0.021
0.170
0.236
0.137
0.133
0.044
0.029
0.162
0.123
0.058
0.080
0.119
0.157
0.242
0.115
0.181
0.312
0.332
0.044
0.037
0.209
0.038
0.042
0.147
0.249
0.074
0.094

Adjusted for age, sex, APOEε4 allele status (i.e. carriage or non-carriage of an APOEε4
allele) and sample collection site (Perth or Melbourne). Lipids with a statistically significant pvalue less than the Bonferroni cut off (0.05/189) are above the solid black line.
PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide,
PG: Phosphatidylglycerol, PI: Phosphatidylinositol, PA: Phosphatidic acid. APOEε4:
Apolipoprotein E ε4 allele.
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Table 4.15 shows the p-values for each of the 44 lipids identified by LIMMA as
being significantly different between the non-transition and stable AD groups,
adjusted through GLM for the following covariates; age, sex, APOEε4 allele
status and collection site. The p-values for each of the covariates are also
shown in the table. The data are sorted by the strongest p-value for the lipid
level post adjustment, i.e. where the levels are most different between the
classification groups. The top 18 lipids (above the solid line) in the table remain
statistically significant (less than the Bonferroni cut off value of p<0.0003
(0.05/189)) after adjustment for age, gender, APOEε4 allele status and
collection site. The p-values indicate that neither site of collection or gender
significantly influence the results, but as expected age and APOEε4 allele
carriage do significantly influence the results.
Whilst Tables 4.13 and 4.14 compare the non-transition to stable AD groups,
LIMMA analysis was also repeated for the non-transition compared to transition
groups and the transition compared to the stable AD groups. Three lipids were
identified as being significantly different following Bonferroni correction between
the non-transition and transition groups (PG34.2, PC34.0p..34.1e and PA36.1)
but these did not remain significant following adjustment for age, gender,
APOEε4 allele status and collection site. One lipid (Cer.d18.1.20.0) was
identified by LIMMA as being significantly different between the transition and
stable AD groups, where levels of this lipid were higher in stable AD compared
to the transition group. This difference remained significant after adjusting for
age, gender, APOEε4 allele status and collection site following assessment by
GLM.
The results reported in Tables 4.13, 4.14 and 4.15 and in the above text
examined the relationship between the non-transition, transition and stable AD
groups. These classification groups were defined as described for previous
analysis of data from the AIBL cohort [492]. Using this definition, the transition
group also included those participants with MCI, where “transition” in the AIBL
cohort represents transition towards AD, or declining mental health as
determined by neuropsychological testing. A different analysis was then
undertaken to explore the relationship between lipid profiles and ‘clinical
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classification transition’, i.e. analysis included those individuals classified at
baseline as HC or MCI who had transitioned to MCI classification or AD
diagnosis by the time of the 18 month follow up, yet excluded those participants
who were classified as MCI at both baseline and the 18 month follow up. This
reduced the sample number to n=40. LIMMA analysis identified Cer.d.18.1.24.1
and PG34.2 as being significantly different in those participants who
transitioned by the 18 month follow up. These two lipids remained significant
following adjustment for age, gender, APOEε4 allele status and collection site.
Taking the top markers from the non-transition vs. the transition groups, and
after removing those that were highly correlated the best sensitivity and
specificity (78%) was achieved using Cer.d18.1.24.1, PG34.2, PC32.0,
Cer.d18.0.18.0.
A recent report by Mapstone et al published in Nature Medicine [493] identified
a panel of 10 lipid biomarkers that were able to predict phenoconversion to
either amnestic MCI or AD within 2-3 years with over 90% accuracy. This lipid
panel comprised of 8 PC species (LysoPC18.2, PC36.6, PC38.0, PC38.6,
PC40.1, PC40.2, PC40.6, PCp40.6) and 2 acyl carnitine species (Propionyl AC
and C16.1-OH). Out of the ten lipid species identified in this lipid panel, only
four were measured in our study (PC 38.6, PC40.6, PC40.6p and LysoPC18.2).
Using these four lipids in a model to predict those participants whose clinical
classification transitioned within the 18 month follow up period gave an average
sensitivity of 73.5%.
4.4.6

Comparison of baseline and 18 month data

To enable comparisons between the results obtained in Chapters 3 and 4,
Table 4.16 displays significant differences in lipid species levels and the
predictive lipid panels between clinical classifications for both the baseline and
18 month data. The lipid species which showed different levels when comparing
the original classification groups, as well as transition groups at baseline and at
the 18-month follow-up are also displayed.
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Table 4.16: Summary of the significant differences in lipid species levels following adjustment for age, gender, APOEε4 allele status and collection
site assessed by GLM, and for the predictive lipid panel generated by the variable selection pathways at both baseline and 18 month follow up.

Significant Lipids identified by GLM
18 month

Baseline
HC vs. AD
SM18.20.1,
Cer.d18.0.22.0,
PE38.4,
PE34.2,
PC34.0p..34.1e,
PE38.5,
PC34.1,
PE36.2,
PC34.0e,
SM18.16.1,
PE34.1

HC vs. MCI

MCI vs. AD

SM18.16.1

HC vs. AD

HC vs. MCI
PE34.1, PE34.2,
LysoPE18.1,
PG34.2

HC vs. MCI

Cer.d18.1.24.1,
Cer.d18.1.20.0,
PC34.0p..34.1e,
PC32.0,
Cer.d18.1.18.0
Cer.d18.1.16.0,
PG34.2,
PC34.0e,
PC32.0e.
PE36.0, PG34.1,
PE38p.6,
PCLyso16.1,
SM18.16.0,
PA34.1,
PC32.0p,
Cer.d18.0.18.0,
PE40p.6

Transition groups

MCI vs. AD

NonT vs. St AD

Cer.d18.1.24.1

Cer.d18.1.20.0,
Cer.d18.1.24.1,
PC34.0p..34.1e,
PC32.0,
Cer.d18.1.16.0,
Cer.d18.1.18.0,
PC34.0e,
PG34.2,
PC32.0e, PE36.0,
LysoPE18.0,
LysoPE16.1,
PCLyso16.1,
PG34.1,
PE38p.6, PA34.1,
PG36.4,
SM18.16.0

Variable Selection Pathways For Predictive Model
18 month

Baseline
PI34.0,
PC36.0p/etherPC,
PC38.5p..38.6e,
PC32.0,
SM18.20.1,
Cer.d18.0.22.0

HC vs. AD

MCI vs. AD
Not done

HC vs. AD
LysoPE16.0,
PG34.2,
PC34.0p..34.1e,
PC38.5p..38.6e,
PC32.0e,
PC32.0,
SM18.22.0,
Cer.d18.1.20.0,
Cer.d18.1.24.1

HC vs. MCI
Lyso.PG16.1f,
PI.38.2,
PS.38.5,
PC.Lyso.16.1,
PS.36.2

MCI vs. AD
Cer.d18.1.20.0,
Cer.d18.1.24.1,
SM18.22.0,
Lyso.PG16.1f,
PE40p.4

NonT vs.Tran

Tran vs. St AD
Cer.d18.1.20.0

Sensitivity and Specificity
HC vs. MCI

MCI vs. AD

B/L

HC vs. AD
18

B/L

18

B/L

18

80%

80%

71%

69%

n/d

69%

HC: Healthy control, AD: Alzheimer’s disease, MCI: Mild cognitive impairment, NonT: Non-transition, Tran: Transition, St AD: Stable AD, PC:
Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, Cer: Ceramide, PG: Phosphatidylglycerol, PI: Phosphatidylinositol, B/L: Baseline,
18: 18 months, GLM: Generalised Linear model, APOEε4: Apolipoprotein E ε4 allele, n/d: Not done.
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Table 4.16 summarises the results from analysis of the baseline and 18 month
samples. Lipid sub-species of the same lipid groups were consistently identified
in all comparisons and in the predictive modelling. Of particular note are the
ceramides, sphingomyelins and several ether PC species. There were no
consistent differences in PI, PA, PG or PS species. The only lipids that were
different when considering the HC vs. MCI and MCI vs. AD groups were one
SM species and one ceramide species respectively, probably due to the fact
that there is considerable overlap between these classification groups in terms
of stages of AD pathology. The ability of the predictive model to predict clinical
classifications reliably gave the highest sensitivity and specificity (80%) for the
HC vs. AD groups in both the baseline and 18 month samples, which might be
expected as these groups are much more clinically and pathologically discrete.
However, the lipids that were chosen for the baseline and 18 month panels
differed, with the exception of PC38.5p..38.6e and PC 32.0.
Many lipids identified as being different when considering any change of clinical
classification (transition groups) over the 18 month follow up period were also
identified in the 18 month samples when comparing clinical classifications (see
Table 4.16). There were a few notable differences; e.g. two extra LysoPE
species were identified as differing between the non-transition and stable AD
groups. The greatest differences were observed between the non-transition and
stable AD groups, which again reflects the greater clinical and pathological
separation between these two groups. The only lipid that was different between
the transition and stable AD groups was Cer.d18.1.20.0.
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4.5

Discussion

The aim of the work in this chapter was to investigate plasma lipid profiles in the
18 month time point samples from the AIBL cohort, and to compare the results
with those obtained from analysis of the baseline samples presented in Chapter
3. In addition, plasma lipid profiles were investigated after the cohort was
classified differently, into non-transition, transition and stable AD groups. The
major findings reported in this chapter are as follows:


110 out of 189 plasma lipid species were significantly different when
comparing the unadjusted mean values of the lipid species between
clinical classifications.



46 lipids were significantly different between the healthy control and AD
groups by LIMMA analysis when applying a Bonferroni correction.



18 of these lipids remained significant after adjustment for age, gender,
APOEε4 allele status and collection site when comparing the HC and AD
groups using a GLM.



Using a variable selection pathway, a panel of nine lipids was able to
distinguish healthy controls from AD patients with a sensitivity and
specificity of 80%.



No lipids were identified by LIMMA as being significantly different
between the HC and MCI groups.



Cer.d18.1.24.1 plasma levels were identified by LIMMA as being
significantly different between the MCI and AD groups, and remained
significant following adjustment for age, gender, APOEε4 allele status
and collection site using a GLM.



The variable selection pathways identified a panel of five lipids with a
sensitivity and specificity of 69% for predicting clinical classification when
comparing the HC and MCI groups.



The variable selection pathways identified a panel of five lipids with a
sensitivity and specificity of 69% for predicting clinical classification when
comparing the MCI and AD groups.



No significant correlation could be found when comparing SUVR
categories and the results from the predictive panel identified by variable
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selection for the HC vs. AD groups, although the levels of four ceramide
species showed a distinct relationship with SUVR categories.


After re-classifying at 18 months into non-transition, transition and stable
AD, 44 lipids were significantly different between the non-transition and
stable AD groups by LIMMA analysis, when applying a Bonferroni
correction.



18 of the 44 lipids remained significant after adjustment for age, gender,
APOEε4 allele status and collection site when comparing the nontransition and stable AD groups using a GLM.



No lipids were significantly different between the non-transition and
transition groups following adjustment for age, gender, APOEε4 allele
status and collection site using a GLM.



The plasma levels of Cer.d18.1.20.0 was identified by LIMMA as being
significantly different between the transition and stable AD groups, and
remained significant following adjustment for age, gender, APOEε4 allele
status and collection site using a GLM.

The heatmaps shown in Figure 4.3, the bar charts in Figures 4.4 – 4.17 and
Table 4.2 showed significant differences between the unadjusted mean lipid
species levels and clinical classification for 110 out of the 189 lipids measured
in the 18 month follow up samples. This was more than the 86 species identified
in the baseline samples, although there was considerable overlap between the
species identified at both time points. The differences in levels were greatest
when comparing the healthy control and AD groups. When comparing mean
levels of summed lipids groups, statistical significance was shown for total SM,
PE, LysoPG, PEp, Ceramides, LysoPCp, LysoPE and PG at the 18 month time
point (see Figure 4.4). While differences in total SM and PE were also observed
in the baseline data, the other summed groups identified in the 18 month
samples were not identified as being significantly different between clinical
classifications at baseline. This variation between the baseline and 18 month
results highlights the fact that measuring summed lipid groups has limited ability
to show differences between clinical classifications and its use may be
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restricted to identifying lipid groups that warrant further investigation through
measurement of the individual sub-species within the lipid group.
There were noticeable similarities to the baseline results when considering the
individual lipid species measured at the 18 month time point: the most
significant differences in levels between clinical classifications were seen with
PE, PC, SM, PI and Ceramides. Despite the similarities, a few notable
directional differences between the baseline and 18 month results were
observed in those lipids identified as differing significantly between clinical
classifications. The mean plasma level of PE36.2p was shown to be higher in
AD when compared to HC at the baseline time point, yet at 18 months, PE36.2p
levels were lower in AD when compared to HC. Further, mean plasma levels of
PG34.2, SM18.16.0, SM18.18.0 and SM18.24.1 were lower in AD compared to
HC at baseline, yet were found to be higher in AD compared to HC at 18
months.
In agreement with other studies, some of the similarities observed between the
baseline and 18 month samples involved sub-species of ceramides, choline and
ethanolamine plasmalogens [163, 341, 357, 422]. Despite the similarities there
were differences in some ethanolamine species levels in the 18 month samples
that were not found in the baseline samples; at 18 months, plasma mean levels
of PE38.7, PE36p.4, PE38p.6, PE40p.6 and PE40.7p were shown to be
significantly lower in AD compared to healthy controls. With respect to the
choline plasmalogen species, the baseline and 18 month data showed general
agreement in terms of species that were identified as being significantly
different between clinical classifications. Of note however, in the 18 month
samples, the mean plasma level of PC40.6p..40.7e was identified as being
significantly lower in AD compared to the HC group. Therefore, all of these PE
and PC species which showed reduced mean plasma levels in AD (PE38.7,
PE38p.6, PE40p.6, PE40p.7 and PC40.6p..40.7e) could contain DHA (22:6n-3)
as one of the acyl chains (represented by an unsaturated bond count of 6 or
greater). As previously described for the baseline data, this could reflect
inadequate dietary intakes of omega-3 polyunsaturated fatty acids, or defects in
the desaturase or elongase enzymes required to produce long chain fatty acids
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from their precursor essential fatty acids. Additionally, lower levels of the
ethanolamine plasmalogen species may be a result of elevated ceramides, as it
is also suggested that ceramides can induce a plasmalogen-selective
phospholipase A2 [494], although no significant change in LysoPEp species (a
product of the action of plasmalogen-selective phospholipase A2 on PEp) were
observed.
Furthermore, several of the LysoPE and LysoPC species were elevated in the
AD compared to the healthy control group, which may suggest increased PLA2
activity associated with inflammatory processes [28, 405].
Overall when comparing the baseline and 18 month samples there are many
similarities. Any differences may potentially be explained by analytical factors
and by the fact that the characteristics of the cohort at each time point will differ
slightly: for example, each participant is 18 months older and for those in the
MCI or AD groups, pathological processes have advanced. Cross sectional
analysis of plasma lipid profiles at the 36 month time point may assist in
determining whether these differences are due to changes in lipid profiles within
an individual or due to analytical and sample handling factors.
The significant differences in individual lipid species between clinical
classifications just described were identified from non-adjusted marginalised
means with an alpha level set at 0.05. Stricter criteria for determining any
significant differences were applied using LIMMA analysis to identify those lipids
species with p-values less than the Bonferroni cut off of 0.05/189 (α/n) between
clinical classifications. LIMMA analysis identified 46 differences in the lipids
when comparing HC vs. AD, yet only one significant lipid difference when
comparing MCI vs. AD. No lipids were identified for the HC vs. MCI group.
These lipids identified by LIMMA were then controlled in a GLM for age, gender,
APOEε4 allele status and collection site. A comparison of the adjusted
significant lipids identified in the baseline and 18 month samples is presented in
Table 4.16.
The GLM identified 18 lipid species that remained significant following
adjustment when comparing the HC and AD groups. These 18 lipids consisted
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of five ceramide species (Cer.d18.1.24.1, Cer.d18.1.20, Cer.d18.1.18.0,
Cer.d18.1.16.0 and Cer.d18.0.18.0), six PC species (PC34.0p..34.1e, PC32.0,
PC34.0e, PC32.0e, PCLyso16.1 and PC32.0p), two PG species (PG34.2 and
PG34.1), three PE species (PE36.0, PE38p.6 and PE40p.6) one PA and one
SM species (PA34.1 and SM18.16.0). All mean plasma levels were higher in
AD compared to healthy controls except for PE36.0, PE38p.6 and PE40p.6,
which were lower in AD compared to healthy controls. Two of these species
(PE38p.6 and PE40p.6) may contain DHA as indicated by an unsaturated bond
count of 6. PE38p.6 and PE40p.6 were not significantly different between the
HC and AD groups at baseline. However, the significantly lower plasma levels
of PE38p.6 and PE40p.6 shown in the AD compared to healthy control group
observed at 18 months is in agreement with previous studies showing disease
severity is associated with decreased levels of circulating ethanolamine
plasmalogens [341, 357]. This association with disease severity could also
provide an explanation as to why these lipids were not identified at baseline:
pathology may have progressed sufficiently at the 18 month time point to
enable differences between the AD and HC groups to be determined.
As previously mentioned, several species that were lower in AD compared to
healthy controls possibly contain DHA. This may be explained by inadequate
intakes and/or the presence of abnormal biochemical pathways involving DHA.
While DHA can be obtained from dietary sources, an adequate supply to the
brain also relies on peroxisomal production. The elongation and desaturation of
fatty acids occurs in the endoplasmic reticulum (ER) or microsomes, but the
conversion of eicosapentaenoic acid (EPA, 20:5n-3) to DHA requires a final
additional step that only occurs in peroxisomes [495]. EPA undergoes two
further elongation steps and a final delta-6 desaturation occurs in the ER to
yield tetracosahexaenoic acid (24:6n-3). This very long chain fatty acid is
transported to the peroxisome for a final β-oxidation step to remove 2 carbons
to yield DHA (22:6n-3)[496]. This additional step is suggested as a reason for
inefficient conversion of the essential fatty acid, α-linolenic acid (18:3n-3) to
DHA and why additional dietary intakes of DHA may be required to meet the
needs of the brain. A recent study has shown deficient liver biosynthesis of DHA
in AD patients, as higher levels of the DHA precursor tetracosahexaenoic acid
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(24:6n-3), and lower expression of peroxisomal

D-bifunctional

protein (required

for the conversion of 24:6n-3 to 22:6n-3) were detected in AD patients [497].
Any accumulation of very long chain fatty acids can adversely affect
mitochondrial function [498], and it is important to remember that mitochondrial
dysfunction and oxidative stress are thought to be central to AD pathogenesis.
Additionally, as previously mentioned in Chapter 3, the plasmalogen precursors
(1-alkyl-glyceryl ether lipids) are also synthesised in peroxisomes and
peroxisomal dysfunction in the liver and brain has been reported as a feature of
AD [498, 499].
It is also worthy of note that all of the elevated PC and PE species seen in the
AD group compared to the HC group at both time points contain few
unsaturated bonds and have smaller acyl chain lengths: inferring the intriguing
possibility that abnormal elongase and desaturase enzyme activity could be
present in AD, resulting in a lower than normal production of longer chain
polyunsaturated

fatty

acids

(PUFAs).

This

may

then

have

multiple

consequences including reduced membrane fluidity and an imbalance in PUFAderived signalling molecules such as eicosanoids and docosanoids. Delta 6desaturase acts as a gateway for the flow of fatty acids into the elongation and
desaturation pathways; and the activity of this enzyme may be influenced by
dietary intakes of fatty acids, various nutrients such as zinc, magnesium and
vitamin B6 [224] and metabolic hormones [500, 501]. Insulin is known to affect
activity of both delta 5 and delta 6 desaturases [225] and by reducing the supply
of long chain PUFA to the brain, may represent an additional mechanism by
which metabolic dysfunction and associated insulin resistance could contribute
to AD.
Significant elevations were seen in five species of ceramide in AD compared to
healthy controls and additionally Cer.d18.1.24.1 was also significantly elevated
in AD compared to MCI. The results presented in this chapter are in general
agreement with other reports showing elevated ceramides and reduced SM in
AD compared to HC and MCI [163, 422, 502], although some variation in the
individual sub-species is noted, which may reflect the different methodologies
used in these studies. Sulphatide depletion in the AD cortex has been reported
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[338, 413], and studies have shown that when individual sulphatide species are
measured, the major depleted species contain d18.1.24.1 (nervonic acid),
d18.1.24.1h (α-hydroxynervonic acid) and d18.1.26.1 (hexacosaenoic acid)
[503]. Sulphatides are synthesised from cerebroside (galactosylceramide), with
the

reaction

being

catalysed

by

galactocerebroside

sulphotransferase.

Importantly, activities of this enzyme or the levels of precursor cerebrosides do
not appear to be altered in the AD cortex [335], strongly suggesting that
sulphatide breakdown is the major reason for the observed sulphatide
depletion. As ceramides are a product of sulphatide catabolism, this could
explain the increase in nervonic acid containing Cer.d18.1.24.1. Decreases in
sulphatides in the AD cortex are reflected by large increases in ceramides in
both the cortex and CSF [413, 471, 504]. If increased plasma ceramide levels
parallel those changes observed in the brain and CSF, plasma levels of
Cer.d18.1.24.1 could possibly represent a surrogate measure of sulphatide
status; plasma levels of which are very low and therefore difficult to measure. It
also appears that brain sphingolipid levels vary depending on extent of
neurodegeneration, with the greatest changes occurring in early disease [413].
Figure 4.21 shows the scaled mean expression levels of four ceramides
(Cer.d18.1.16.0, Cer.d18.1.18.0, Cer.d18.1.20.0 and Cer.d18.1.24.1) in the 18
month plasma samples and how the levels relate to SUVR categories, which
are representative of cerebral amyloid burden. There is a clear increase in
levels of all these ceramides between the SUVR categories of (> 1.3 to < 1.7)
and (1.7 to < 2) with 1.5 being considered the cut off between PiB-PET negative
and positive. Interestingly, a dramatic drop in the plasma levels of these
ceramides follows as SUVR reaches a value of > 2. At this more advanced
stage, cerebral amyloid burden is severe and the rate at which further amyloid
accumulation occurs plateaus. The results provide compelling evidence of
abnormal sphingolipid metabolism which warrants further investigation, and the
inclusion of ceramides and sphingomyelins in a potential diagnostic blood
biomarker panel seems justified.
The endogenous ceramide pool consists of production from three main
pathways. The de novo pathway, the sphingomyelinase pathway which
catabolises SM and the salvage pathway which breaks down complex
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sphingolipids such as sulphatides, gangliosides and cerebrosides [505]. In the
de novo pathway ceramides are produced from palmitoyl CoA and serine by the
coordinated action of four enzyme groups; Serine palmitoyltransferase (SPT), 3ketodihydrosphingosine reductase, dihydroceramide synthases (CerS1-6) and
finally dihydroceramide desaturase (DES). The dihydroceramide synthases
(CerS1-6) are specific for fatty acyl chain lengths (CerS1: C18, CerS2: C20-26,
CerS3: C18 and 24, CerS4: C18 and C20, CerS5: C16, and CerS6: C14 and
C16) [506]. The various fatty acyl chains introduced by these specific CerS are
thought to alter membrane dynamics but the exact biological function of the
different species remains to be elucidated. However, the existence of 6 specific
individual CerS enzymes implies the different species are likely to have different
roles [507]. The final step in the synthesis of ceramide is the desaturation of
dihydroceramide by DES. The formation of SM via incorporation of
phosphocholine and complex sphingolipids is then facilitated by the action of
SM synthase and glucosyl or galactosyl ceramide synthases respectively [505].
Ceramides

can

also

be

produced

from

the catabolism

of

SM

via

sphingomyelinase enzymes (SMases). It would appear that sphingolipid
metabolism is regulated by a complex interplay of synthesis from basic
precursors and catabolism of both SM and more complex sphingolipids. Altered
activities of the many enzymes involved in these pathways are emerging as not
only contributors to AD pathology but also potential targets for therapeutic
intervention.
Studies have shown elevated acid SMase activity is associated with an increase
in ceramides, Aβ and phosphorylated tau, as well as an associated reduction in
SM in the AD brain [471]. Serine palmitoyltransferase (SPT), which is the first
enzyme and likely the rate limiting step in the de novo ceramide synthesis
pathway [508] has also recently been shown to be regulated by the APP
intracellular domain (AICD). Increased SPT activity has been demonstrated in
APP knock-in mice missing a functional AICD domain, and increased SPT
activity has also been reported in both familial and sporadic post mortem AD
brains [509]. Inhibition of SPT with L-cycloserine was recently shown to down
regulate production of cortical Aβ42 and hyperphosphorylated tau in a mouse
AD model [510]. Dihydroceramide desaturase (DES), the final enzyme in the de
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novo ceramide synthesis pathway that converts dihydroceramide to ceramide is
receiving attention for its role in sphingolipid metabolism [511]. Dihydroceramide
and dihydrosphingomyelin may interfere with lipid raft processes by increasing
rigidity within these microdomains [512]. APP processing by secretases is
fundamental to AD pathology and inhibition of DES1 has been proposed as a
potential target to reduce secretase activity and therefore Aβ production.
Interestingly, DES regulation has been shown to be influenced by fatty acids in
a cell culture model, with palmitate increasing levels of DES1 mRNA and
therefore increasing ceramide levels, whereas oleate did not induce this
increase [513]: This could represent another link between the protective effects
of the Mediterranean diet, rich in olive oil, on AD and metabolic disease. The
plasma levels of the dihydroceramide species in our study (Cer.d18.0.18.0)
were significantly different between healthy controls and the AD group. The
plasma levels of dihydroceramides or ratio of dihydroceramides to ceramides
may become an important tool for monitoring response to therapy should DES
inhibitors be introduced into any clinical trials.
Another recent study compared the brain levels of six ceramide subspecies,
differing in the length of their acyl moieties, and found elevations in Cer16,
Cer18, Cer20 and Cer24 in AD [514], consistent with our plasma findings.
These authors then investigated the possible mechanisms underlying the
increase in levels of these ceramides by evaluating the expression of acid
SMase, neutral SMase2 (which breaks down SM), UDP-glucose ceramide
glucosyltransferase (UGCG, which catalyses the conversion of ceramides into
glycosphingolipids)

and

galactosylceramidase

(GALC,

which

produces

ceramide from galactosylceramide, a major SL of myelin and precursor for
sulphatides). The results suggested abnormal expression patterns in AD, with
increased expression of GALC, acid SMase and neutral SMase and reduced
expression of UGCG; all of which may increase ceramides [514].
As ceramides can easily cross the blood brain barrier [515], it is possible that
plasma ceramides can influence gene expression changes in the brain, and
elevated ceramides in the brain can influence plasma levels. All these studies
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present intriguing avenues for future research, and the measurement of plasma
ceramide levels will be an important inclusion.
As described in Chapter 3 for the baseline data, a variable selection pathway
was also used in the analysis of the 18 month data, to identify a panel of lipid
biomarkers capable of predicting clinical classification with the greatest
certainty. The variable selection pathways, stepwise GLM and ROC curves
identified a panel of nine lipids that gave a sensitivity and specificity of 80%
when analysing the healthy control and AD groups. These lipids (also identified
by

LIMMA

analyses)

PC38.5p..38.6ePC32.0e,

were

LysoPE16.0,

PC32.0,

PG34.2,

SM18.22.0,

PC34.0p..34.1e,

Cer.d18.1.20.0

and

Cer.d18.1.24.1. All of these lipids, except for PC38.5p..38.6e and SM18.22.0
were elevated in AD compared to healthy controls. The sensitivity and
specificity of the separate lipid panels chosen by variable selection for the HC
and MCI and MCI and AD groups was only 69% however; this may reflect the
fact that MCI is a more clinically heterogeneous group which can often overlap
both the HC and AD groups and often, but not always represents a prodromal
stage of AD.
Whilst the lipids chosen by the statistical pipeline were able to differentiate
between the healthy control and AD groups with a sensitivity and specificity of
80% at both baseline and 18 months, the lipid panels selected at the two time
points were different. Table 4.16 lists the predictive lipid panels for both
baseline and the 18 month time points. Only two of the predictive lipids
(PC38.5p..38.6e and PC32.0) were common to both the baseline and 18 month
time points, however the subclasses identified were very similar, excepting
PI34.0 at baseline and LysoPE at 18 months. The observed differences
between time points may once again be due to analytical and sample handling
factors, or may reflect a difference in the characteristics of the cohort over time,
as previously described. Analysis of samples collected at the 36 month time
point may help to obtain a clearer picture of lipids that are able to predict clinical
classification with the greatest certainty.
The analytical methods chosen for this study were based on the need for
simultaneous quantification of a broad range of lipids in a large number of
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samples. The analytical techniques that were employed have been useful in
identifying which lipids are significantly different between clinical classifications
and to speculate on aberrant pathways that may be present in AD. Further
studies using a more targeted approach with LC separation is warranted,
particularly with the PC, PE, sphingolipids and plasmalogen species, which
appear to offer the best prospect of forming a lipid biomarker panel.
As in the previous chapter, the possibility of correlations between SUVR, a
measure of brain amyloid burden, and lipid species was investigated. When
comparing the predictive lipid panels identified by variable selection, no
significant correlations were identified. However as described earlier, an
intriguing pattern emerged when assessing the relationship of mean ceramide
levels with SUVR (see Figure 4.21). This analysis showed the levels of four
ceramide

species

(Cer.d18.1.16.0,

Cer.d18.1.18.0,

Cer.d18.1.20.0

and

Cer.d18.1.24.1) were relatively low if the SUVR was below 1.7, high at a SUVR
between 1.7 and 2 and yet markedly lower again at a SUVR above 2, at which
stage amyloid accumulation plateaus according to PiB-PET, with saturation
occurring between 2-3 [477]. Statistical significance may not be revealed when
looking at the means of the lipid levels for each SUVR category; however, it
may be useful to investigate how an individual’s lipid levels vary with SUVR, as
this may reveal a significant correlation between these ceramide species and
SUVR.
For the longitudinal study, the diagnostic classifications were revised at the 18
month time point and participants were classified into three groups: nontransition, transition or stable AD (remained in the AD group). The non-transition
group included those participants whose clinical classification was the same at
inception and 18 months (excepting stable AD). The transition group included
those participants whose clinical classification was different at inception and 18
months as well as including the MCI group, who are considered to be in
transition towards AD or declining mental health [492]. The stable AD group
included individuals who were classified as AD at both baseline and 18 month
follow up. The greatest difference in mean lipid species levels was observed
between the non-transition and stable AD groups; these groups are the most
clinically and pathologically discrete. Between the non-transition and stable AD
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groups, 44 lipid species were identified as being significantly different. Following
adjustment for age, gender, APOEε4 allele status and collection site, 18 of
these 44 lipid species remained significant. Most of these lipids were the same
as those identified as being significantly different between the healthy control
and AD group, except PG36.4, LysoPE16.0 and LysoPE18.0, which were
identified as being significantly different between the non-transition and stable
AD groups only.
The ceramide species Cer.d18.1.20.0 was the only lipid to have significantly
different mean plasma levels between the transition and stable AD groups.
Interestingly, a previous study identified elevated plasma levels of very long
chain ceramides as being predictive of memory loss and right hippocampal
volume loss amongst people with MCI [423]. While any association of the very
long chain ceramides with hippocampal volume and cognitive scores was not
assessed in this study, it clearly warrants further investigation. Correlations
between the transition groups and SUVR were not assessed here, as intraindividual levels of cerebral Aβ do not differ significantly between baseline and
18 month time points: This requires evaluation at subsequent time points, which
is beyond the scope of this thesis. As described earlier, however, an intriguing
pattern was uncovered when assessing the relationship between mean
ceramide levels and SUVR cross-sectionally at the18 month follow up (see
Figure 4.21).
When the MCI group was excluded from the analysis and only those
participants whose clinical classification ‘transitioned’ from HC to MCI, HC to AD
or MCI to AD were included, only Cer.d18.1.24.1 and PG34.2 were identified as
being significantly different. Taking the top markers from the non-transition vs.
the transition groups, and after removing those that were highly correlated the
best sensitivity and specificity (78%) was achieved using Cer.d18.1.24.1,
PG34.2, PC32.0, Cer.d18.0.18.0. However the number of participants that were
re-classified at the 18 month follow up (after removing the MCI group) was only
40 and therefore analysis of the samples collected at the 36 month time point
may improve the statistical power of the longitudinal analysis.
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As previously described, a recent report by Mapstone et al published in Nature
Medicine [493] identified a panel of 10 lipid biomarkers that were able to predict
phenoconversion to either amnestic MCI or AD within 2-3 years with over 90%
accuracy. This lipid panel comprised of 8 PC species and 2 acyl carnitine
species; the levels of which were reduced in the plasma of those study
participants who phenoconverted compared to the control group. The levels of
these lipids also remained lower in the converters and in MCI and AD groups
compared to controls. The analytical approach used in this reported study
combined untargeted and targeted analyses facilitating the measurement of a
large number of lipid species. Out of the ten lipid species identified in the lipid
panel, only four were measured in our study (PC 38.6, PC40.6, PC40.6p and
LysoPC18.2); all levels of which were lower in the MCI and AD groups
compared to healthy controls. When these four lipids were used in a prediction
model, a sensitivity and specificity of only 73.5% was achieved. The predictive
ten lipid panel identified in the study by Mapstone et al, predicted conversion
between 2-3 years and therefore analysis of the transition group samples with
the inclusion of the other six lipids measured in their study may become more
relevant in the AIBL 36 month follow up time point.
Plasma lipid profiles are influenced by many factors such as diet, nutrient
status, hormone balance, medication use and the existence of co-morbidities
such as diabetes and cardiovascular disease. The plasma levels of individual
lipid species are also the net result of a complex set of synthesis, metabolic and
catabolic pathways influenced by a myriad of signals and catalytic enzymes. In
addition, lipoprotein metabolism and lipid species are regulated by a number of
proteins including phospholipid transfer protein (PLTP), cholesterylester transfer
protein (CEPT) and lecithin-cholesterol acyl transferase (LCAT). One of these
proteins, PLTP, will be investigated in Chapter 5 for both its relationship to
plasma lipid species levels and its association with clinical classification. PLTP
has been shown to be associated with some features of AD pathology and has
been studied for its role in metabolic and cardiovascular disease: consequently,
correlations between plasma PLTP activity and other AD biomarkers will also be
investigated.
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Chapter 5 - Plasma PLTP Activity
5.1

Introduction

The previous two chapters investigated plasma lipid profiles, their association
with clinical classification and the ability of a panel of lipid species to predict
clinical classification. Plasma lipids are influenced by many factors such as diet,
nutrient status, hormone balance, medication use and the existence of comorbidities such as diabetes and cardiovascular disease; which also happen to
be risk factors for AD.
Phospholipid transfer protein (PLTP) is one of two or more lipid transfer proteins
that are found in plasma, and one of its major roles involves the transfer of
phospholipids from triglyceride-rich lipoproteins to high density lipoprotein
(HDL), thus regulating the size and composition of HDL. Due to its role in
peripheral lipid and lipoprotein metabolism, and its role in other processes that
may influence AD pathology, PLTP may represent a mechanistic link between
abnormal lipid metabolism in the periphery and that of the brain. This chapter
will investigate whether there is any association between plasma PLTP activity
levels and the lipid profiles measured in the previous chapters, whether PLTP
activity levels differ with clinical classification, and whether levels correlate with
those of other biomarkers measured in the AIBL cohort.
PLTP is a ubiquitously expressed protein belonging to the family of
lipopolysaccharide (LPS) binding and lipid transfer genes that includes LPS
binding protein (LBP), neutrophil bactericidal permeability increasing protein
(BPI) and cholesteryl ester transfer protein (CETP) [516-518]. Despite its name,
PLTP is emerging as a multifaceted protein involved in lipoprotein remodelling,
reverse cholesterol transport, phospholipid transfer and immunity. In plasma,
PLTP is mainly associated with high-density lipoproteins (HDL) as mentioned
above, yet in addition to phospholipids, it also efficiently transfers α-tocopherol
(a form of vitamin E), diacylglycerol, lipopolysaccharides, cerebrosides
(monoglycosylceramides; important components of nerve cell membranes) and
other amphiphilic molecules such as Aβ [519, 520]. This multi-functionality
suggests important roles not only in lipoprotein metabolism but also
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inflammation and oxidative stress, which are thought to be involved in AD
pathogenesis [482, 484].
Dietary -tocopherol is incorporated in chylomicrons and transported to the liver
where it is packaged into very low density lipoproteins (VLDL) for release into
the circulation [521]. The tocopherols are important in preventing low density
lipoprotein (LDL) oxidation and subsequent uptake of oxidised LDL by vascular
endothelium [439]. A deficiency of PLTP in PLTP (-/-) transgenic mice has been
shown to result in a reduced delivery of -tocopherol to the brain and an
associated increase in oxidative injury, which may contribute to neurological
dysfunction. This suggests that PLTP is a local transporter of -tocopherol and
that it may transport this antioxidant vitamin across the blood brain barrier
(BBB) [440]. More recent studies of PLTP knockout mice demonstrated that
intracerebral injection of Aβ25-35 oligomers caused memory deficits and
oxidative stress (effects not seen in wild-type mice), and that chronic dietary
supplementation with vitamin E could reduce these symptoms. These studies
demonstrate the importance of PLTP in vitamin E transport and/or delivery to
the brain, and how a PLTP deficiency can lead to an inability to prevent
oxidative damage [522].
PLTP transfers phospholipids from triglyceride-rich and apoB-containing
lipoproteins (chylomicrons and VLDL) to HDL during lipolysis by lipoprotein
lipase. It also facilitates the formation of LDL and maturation of HDL by the
transfer of surface lipids between lipoproteins [523, 524]. Studies have shown
that

PLTP

transfers

all

major

phospholipid

classes

although

phosphatidylethanolamine (PE) is transferred more slowly. Transfer is not
influenced by chain length of the acyl groups or their sn-1 or sn-2 positions on
the phospholipid molecule [437, 525]. Studies into cellular ceramide
homeostasis, have shown that PLTP can also transfer sphingomyelin (SM) from
vesicles to HDL [164]. Evidence suggests that newly synthesised hepatic
ceramides are secreted via VLDL, and PLTP may be one of the proteins that
facilitates the transfer of sphingolipids onto nascent lipoproteins [164, 526, 527].
The physiological relevance of PLTP is highlighted in PLTP-deficient mice,
which demonstrate a total absence of phospholipid transfer from VLDL to HDL
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and subsequently markedly reduced HDL levels [436]. The PLTP gene
promoter region contains response elements for farnesoid X-activated receptor
(FXR), peroxisome proliferator-activated receptor α (PPARα) and the liver Xactivated receptor (LXR); involved in bile acid, fatty acid, glucose and
cholesterol metabolism respectively [528, 529]. A major function of PLTP is in
maintaining the heterogeneity of plasma HDL which therefore facilitates reverse
cholesterol transport due to its ability to generate nascent preβ-HDL. Preβ-HDL
particles are primary acceptors of cell derived cholesterol, and facilitate
cholesterol and phospholipid efflux from peripheral cells via the ATP-binding
cassette transporters ABCA1 and ABCG [442, 530, 531].
Two different forms of PLTP exist in plasma: An active form, measured by its
ability to transfer phosphatidylcholine (PC) to HDL and an inactive form that
lacks this capability [532, 533]. Plasma contains varying amounts of the active
and inactive PLTP forms [518, 534]. Active and inactive PLTP levels also
appear to be tissue-dependent, with no inactive form being detected in CSF or
tear fluid and the majority of the inactive form being present in the vascular
compartment [535-537]. Additionally, plasma levels of the inactive form have
been shown to decrease, and the active form increase in correlation with acute
phase response inflammatory markers, such as C-reactive protein [538, 539];
suggesting that one function of the inactive form is to act as a reserve that may
be converted to the active form in response to changes in the physiological or
pathological landscape. The active form may then transfer more phospholipids
to cells for membrane repair and maintenance of integrity during inflammatory
stress [540, 541]. The complete repertoire of inactive PLTP function is currently
unknown but while it is unable to transfer lipids from PC-containing vesicles to
HDL in vitro or mediate other activities involved with lipoprotein metabolism of
its active counterpart, it can bind lipids with equal capacity and has been shown
to attach strongly to surface phospholipids [542]. It would therefore appear
prudent to suggest that inactive PLTP may activate signal transduction
pathways. In plasma, both forms of PLTP are present in complexes, some of
which are lipid-protein complexes whilst others contain protein only. Studies
using anti-PLTP antibodies and proteomics have identified several proteins in
these

complexes,

including

clusterin

(apoJ),

fibrinogen,

transthyretin,
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plasminogen and apoAI [518, 538]. Some of these proteins are thought to
stabilise or determine lipid transfer activity of PLTP within these complexes and
a large number of these proteins are actually acute phase proteins involved in
inflammatory pathways and compliment activation; suggesting a major role for
PLTP in immunity and inflammation, in addition to its role in lipid transfer [541,
543].
As PLTP is now being shown to play a role in processes other than lipid
transfer, research efforts are changing direction, and the idea that PLTP acts as
a regulator of signal transduction is being actively explored [544, 545]. Initial
studies have shown that both apoAI and PLTP participate in lipid efflux via
ABCA1, but in slightly different ways. The ApoAI pathway utilises lipid-poor HDL
particles whereas PLTP requires the presence of mature, lipidated HDL [544,
546]. PLTP has been shown to bind to and stabilise ABCA1 and at the same
time competitively inhibit apoAI binding to ABCA1, suggesting PLTP mimics
apolipoproteins with respect to the transfer of cellular lipids, particularly
cholesterol. More recent studies have expanded this work and have shown that
like apoAI, PLTP is involved in signal transduction pathways - binding of PLTP
to ABCA1 activates the Janus kinase 2 / Signal Transducer and Activator of
Transcription (JAK2/STAT3) pathway in macrophages, which significantly
reduces secretion of pro-inflammatory markers [518, 547]. Recent evidence has
also demonstrated that in macrophages, PLTP inhibits nuclear factor kappa B
(NFκB); a transcription factor involved in cellular responses to stimuli such as
stress, cytokines, oxidative stress, oxidised-LDL and antigens [548, 549]. These
authors have also shown that PLTP modulates two other ABCA1–independent,
signal transduction pathways in human neuronal cells; the PI3K/Akt/GSK3β
pathway via the insulin receptor and the Dab1-dependent (reelin) pathway
[550]. Collectively, these findings suggest PLTP has the ability to modulate a
selection of cell signalling pathways (irrespective of its lipid transfer properties)
that are linked to many functions in the brain that are adversely affected in AD,
such as plasticity, insulin signalling, tau phosphorylation and neurogenesis.
Neuronal cells require a constant supply of cholesterol and other lipids for
membrane and acetylcholine synthesis and while de novo synthesis of a wide
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range of lipids occurs in neurons there is still a reliance on exogenous sources
contained in lipoproteins, which are bound and internalised from the
extracellular fluid [302, 551]. Excess lipids also need to be eliminated, which
occurs via a bidirectional lipoprotein mediated transport involving apoE [443].
ApoE, the major apolipoprotein synthesised by astrocytes, is usually present in
the CSF in a lipidated state [552], where it exists as cholesterol rich, discoidal
complexes, resembling plasma HDL. These complexes readily target LDL–
receptor related protein (LRP), which is abundantly expressed on the surface of
neurons [302]. As in plasma, CSF lipoproteins can also be remodelled by
lecithin-cholesterol acyltransferase (LCAT) and PLTP; reflecting the key role of
HDL like particles in cholesterol homeostasis within the central nervous system
(CNS) [443]. ApoE secretion by astrocytes is modulated by PLTP and a
correlation between CSF levels of apoE and PLTP has been shown [553]. HDL
and the metabolism of Aβ, the accumulation of which is a key feature of AD
pathology, are also intimately connected [554].
An increase in the production of Aβ occurs in response to higher cellular
cholesterol levels, most likely due to the influence of membrane cholesterol on
lipid rafts and on the activity of APP cleavage enzymes [26] (see Chapter 1,
Section 1.5.1). It has also been suggested that PLTP and apoE-containing HDL
in the brain may exert several neuroprotective effects via suppression of Aβ
production, by activation of reverse cholesterol transport, mediated by ATPbinding cassette (ABC) transporters [555]. Studies have shown that the apoE in
HDL can bind to Aβ and prevent its oligomerisation [554], and that HDL
transports Aβ in both the CSF and plasma and represents a method of
elimination from the brain. PLTP may have a crucial role in this process as it
also transports amphiphillic molecules, such as Aβ.
ApoAI has been shown to be present in the CNS and as this molecule is not
thought to be locally synthesised, it is probably of plasma origin [302]. In
addition to mediating cholesterol removal, ApoAI is considered to be antiinflammatory [556], and may represent the mechanistic link between low
plasma HDL and memory deficits [557].
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Cells of the BBB express several ABC transporters, of which ABCA1 and
ABCB1 play an important role in Aβ removal from the CNS. ABCB1 (also known
as P-glycoprotein 1 and multidrug resistant protein 1) is highly expressed on the
luminal side of endothelial cells within the BBB. Aβ can be transported into the
periphery via Aβ binding to ABCB1 or via LRP-1 (which can bind Aβ directly or
via Aβ ligands, such as apoE) [558, 559]. ABCA1 is expressed in astrocytes
and microglia and at the abluminal side of the endothelium where PLTPmediated lipidation of apoE is enhanced; facilitating Aβ trafficking to the BBB for
elimination via ABCB1 [555].
The widespread distribution of PLTP in the human CNS has been
demonstrated, with synthesis by glia and neurons having been confirmed;
furthermore, a study has reported a significant increase in PLTP in the AD brain
compared to control brain [535]. The authors of this study suggest that an
increase in PLTP levels in brain tissue may represent a compensatory response
to an underlying aberrant metabolic process present in AD [535], and the
accumulation of PLTP in myelin fibres, as shown by immunohistochemistry,
suggest a role for PLTP in preserving the functional and structural integrity of
myelin [535].
Sulphatides are a class of myelin-specialised glycosphingolipids involved in
various cellular processes, including cell growth, protein trafficking, signal
transduction, cell-cell recognition, neuronal plasticity and cellular integrity [270,
421]. Sulphatide levels in the AD brain are markedly reduced [413]. Studies
have shown that apoE is associated with sulphatide transport and mediates
sulphatide homeostasis in the central nervous system through lipoprotein
metabolism pathways. Alterations in apoE mediated sulphatide trafficking have
been shown to deplete sulphatide in the brain [337]. An increased rate of
apoE/sulphatide particle uptake and an increased expression of lipoprotein
receptors can lead to increased degradation of sulphatide-containing apoE
particles, resulting in accelerated sulphatide depletion from the myelin sheath.
[71]. CNS levels of sulphatide have been shown to be apoE isoform-dependent,
the lowest levels being seen with the APOEε4 genotype [71]. Sulphatide
containing apoE-associated particles facilitate Aβ clearance, thus APOEε4
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carriers having the lowest sulphatide levels represent a further mechanism for
APOEε4 increasing the risk for AD [71]. A role for PLTP in Aβ clearance could
be strongly suggested due to its importance in lipid transfer, lipoprotein
metabolism, transport of amphiphilic molecules, and its association with apoE,
in addition to its widespread CNS distribution.
A study of PLTP activity, serum apoE concentration and APOE genotype in a
Finnish population, showed apoE levels to be highest in APOEε2 carriers and
lowest in APOEε4 carriers, yet with no difference observed between the groups
in terms of PLTP activity [534]. However, this study utilised a cognitively normal
population. In another study, CSF PLTP activity levels were shown to be
significantly lower in AD compared to healthy controls, suggesting sequestration
of PLTP in brain tissue [536]. In cognitively normal individuals, a significant
physiological link between CSF levels of PLTP, apoE, APP and tau has also
been demonstrated [553].
The importance of PLTP in lipoprotein metabolism and the discovery of new
roles for this protein have understandably driven research into its association
with cardiovascular, metabolic, inflammatory and neoplastic diseases. However,
due to the complexity of function, tissue specific distribution, genetic
polymorphisms, the regulatory proteins and lipids, and different isoforms, it is
not surprising that determining possible associations with disease has not been
straightforward. A recent comparison of relationships between cardiovascular
disease and plasma PLTP has highlighted inconsistencies, due to conflicting
results [449]. PLTP and cholesteryl ester transfer protein (CETP) are proteins
involved in the exchange of phospholipids and cholesteryl esters (respectively)
between HDL and other lipoproteins, and low CETP and high PLTP activity both
result in higher plasma HDL-cholesterol levels. Activities of both these enzymes
were recently measured in the Framingham Heart Study cohort, which showed
a lower plasma CETP and higher PLTP activity was associated with an
increased risk of cardiovascular disease, but in men only [444]: A gender
difference has not previously been reported in other studies. The relevance of
plasma PLTP activity levels in AD is currently unknown but despite the obvious
caveats, and due to its wide ranging functions involving lipid metabolism,
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inflammation, oxidation and possible removal of Aβ, it is highly likely to play a
significant role and therefore warrants further investigation.
It is known from the literature that PLTP activity levels both influence and are
associated with plasma lipoprotein levels. What is less clear is any association
between plasma lipid species levels (e.g. such as those measured in Chapters
3 and 4) and plasma PLTP activity levels. To our knowledge this is the first
study to investigate any association between plasma lipidomics and PLTP
activity in a highly characterised ageing cohort.
5.2

Aims

This chapter aims to investigate any association of the lipid species levels
measured in Chapter 3 with plasma PLTP activity levels determined using a
commercial assay kit. Differences in PLTP activity levels between clinical
classifications will be compared to supplementary data collected as part of the
AIBL study, including brain amyloid burden as measured by PiB-PET
determined SUVR, and APOEε4 allele status. The results will also be assessed
for correlation with other AD-related blood biomarkers measured in the cohort
including plasma Aβ, ApoE and clusterin levels.
5.3

Methods

Details of the study population and the methods for sample collection,
neuroimaging, lipid extraction, analysis by electrospray ionisation tandem mass
spectrometry (ESI/MS/MS), and determination of plasma PLTP activity levels,
plasma Aβ levels, plasma ApoE levels, clusterin levels and HDL-cholesterol
subfraction levels have been described in detail in Chapter 2, Sections 2.2, 2.3
and 2.4. Plasma PLTP activity levels were measured in a subset of the AIBL
study baseline samples (n=259).
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5.4

Statistical analysis

Pearson’s correlations and logistic regression were used to assess possible
linear relationships between plasma PLTP activity levels and plasma levels of
each of the 189 lipids species measured in Chapter 3. To assess the study
population demographics between the healthy controls, MCI and AD groups, χ2
analyses were used to test the effect of age, gender and APOEε4 allele status.
A Kruskal-Wallis formula was applied to MMSE scores. Marginalised means
and p-values were obtained for the lipid levels using a student’s unpaired t-test
for two classifications (i.e. HC and AD, or HC and MCI) or ANOVA for three
classifications (HC, MCI and AD). Additionally ANOVA was used to test inter
group differences in SUVR and hippocampal volume.
The statistical analysis was performed using R version 3.0.2 (R Development
Core team, 2009, Vienna, Austria) and IBM SPSS Statistics version 22 (SPSS
Inc., Chicago, IL, USA).
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5.5

Results

5.5.1 Correlation of plasma PLTP activity levels with lipid species
Plasma PLTP activity levels were measured in a subset of AIBL study baseline
samples and the activity levels were correlated (independent of clinical
classification) with the mean plasma lipid species levels of 189 lipid species
measured in Chapter 3 (see Table 3.2). Figure 5.1 shows the correlation of the
summed lipid groups with plasma PLTP activity levels; the strongest association
is indicated by a higher adjusted R squared value.

Figure 5.1: Correlation between plasma PLTP activity levels and summed lipid groups.
Pearson’s correlations adjusted for age, gender and APOEε4 allele status.
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM:
Sphingomyelin,
PG:
Phosphatidylglycerol,
PE:
Phosphatidylethanolamine,
PC:
Phosphatidylcholine, PEp: Ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lysoethanolamine
plasmalogen,
PI:
Phosphatidylinositol,
Cer:
Ceramide,
LPI:
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG:
Lysophosphatidylglycerol, LysoPC+P: Lysophosphatidylcholine plus Lyso-choline plasmalogen.

234

Chapter 5 – Plasma PLTP Activity Levels
Plasma PLTP activity levels showed the strongest correlation with the levels of
LysoPE, SM and PG groups; these relationships are statistically significant
(Figure 5.1) (p < 0.05; Pearson’s correlations adjusted for age, gender and
APOE ε4 allele carriage). None of the other lipid groups significantly correlated
with plasma PLTP activity levels. The correlation between plasma PLTP activity
levels and plasma total LysoPE, total SM and total PG levels are shown in
Figure 5.2.

A

.

B
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C

Figure 5.2: Correlation between plasma PLTP activity and plasma lipid levels of (A) Total
LysoPE, (B) Total SM, (C) Total PG. Lipid levels expressed as molar fractions. Pearson’s
correlations, adjusted for age, gender and APOEε4 allele status. p value < 0.05.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, LysoPE:
Lyso-phosphatidylethanolamine, SM: Sphingomyelin. PG: Phosphatidylglycerol.

Figure 5.2A shows a positive correlation between the mean plasma total
LysoPE levels and plasma PLTP activity levels. When mean plasma total
LysoPE levels were measured in the baseline cohort, no significant difference
was observed between clinical classifications (see Figure 3.4B).
Figure 5.2B shows a positive correlation between the mean plasma total SM
levels and plasma PLTP activity levels. When mean plasma total SM levels
were measured in the baseline cohort, a significant difference was observed
between the HC and MCI groups (see Figure 3.4A), where levels were lower in
the MCI group compared to the HC group. Significant differences in the mean
plasma levels of many sub-species of SM were also observed between clinical
classifications with SM species levels lower in the MCI and AD groups
compared to healthy controls (see Figure 3.15).
Figure 5.2C shows a positive correlation between the mean plasma total PG
levels and plasma PLTP activity levels. When mean plasma total PG levels
were measured in the baseline cohort, no significant differences were observed
between clinical classifications (see Figure 3.4C). However, a significant
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difference in the mean plasma level of the PG sub-species PG34.2 was shown
between clinical classifications with PG34.2 lower in the MCI and AD groups
compared to healthy controls (see Figure 3.10).
The association between plasma PLTP activity levels and mean plasma levels
of the individual lipid species was then assessed. Figures 5.3 and 5.4 show the
correlation of the individual 189 lipid species with plasma PLTP activity levels;
the strongest association is indicated by a higher adjusted R squared value.
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Figure 5.3: Correlation between plasma PLTP activity levels and individual lipid species.
Pearson’s correlations adjusted for age, gender, APOE ε4 allele status.
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM:
Sphingomyelin,
PG:
Phosphatidylglycerol,
PE:
Phosphatidylethanolamine,
PC:
Phosphatidylcholine, PEp: ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lysoethanolamine
plasmalogen,
PI:
Phosphatidylinositol,
Cer:
Ceramide,
LPI:
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG:
Lysophosphatidylglycerol.
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Figure 5.4: Correlation between plasma PLTP activity levels and individual lipid species.
Pearson’s correlations adjusted for age, gender, APOE ε4 allele status.
PLTP: Phospholipid transfer protein, LysoPE: Lysophosphatidylethanolamine, SM:
Sphingomyelin,
PG:
Phosphatidylglycerol,
PE:
Phosphatidylethanolamine,
PC:
Phosphatidylcholine, PEp: ethanolamine plasmalogen, PS: Phosphatidylserine, LysoPEp: Lysoethanolamine
plasmalogen,
PI:
Phosphatidylinositol,
Cer:
Ceramide,
LPI:
Lysophosphatidylinositol, PA: Phosphatidic acid, PCp: Choline plasmalogen, LysoPG:
Lysophosphatidylglycerol.
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From the overall model assessing association of the levels of the 189 lipids
against plasma PLTP activity levels (shown in Figures 5.3 and 5.4), the top 5
lipids (SM18.20.1, PCLyso18.2, PC32.2, PCLyso16.0 and PC34.0p..34.1e)
were individually assessed for significant relationships with plasma PLTP
activity using partial Pearson’s correlations.

Figure 5.5: Correlation of SM18.20.1 with plasma PLTP activity levels.
Levels of SM18.20.1 expressed as molar fraction. SM: Sphingomyelin, PLTP: Phospholipid
transfer protein, ρmol/μL/h: Picomole per microlitre per hour.
Pearson’s correlation: *** p < 0.001, adjusted for age, gender, APOE ε4 allele status.

Figure 5.5 shows a significant positive correlation between plasma mean levels
of SM18.20.1 and plasma PLTP activity levels. Interestingly, the mean level of
this sphingomyelin species was also the most significantly different between the
healthy control and AD groups after adjustment for age, gender, APOEε4 allele
status and collection site when assessed by general linear model (GLM) in
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Chapter 3 (see Table 3.8). Additionally, it was one of the lipid species chosen
by the variable selection pipeline for inclusion in the panel for predicting clinical
classification (see Chapter 3, Section 3.4.3.1).
Whilst a positive association between SM18.20.1 and plasma PLTP activity
levels was seen, the other 4 of the top 5 lipids from Figure 5.3 (PCLyso18.2,
PC32.2, PCLyso16.0 and PC34.0p..34.1e) failed to show any statistical
significance (data not presented).
The data presented thus far in this chapter show that plasma PLTP activity
levels are significantly associated with the levels of several lipid groups (total
LysoPE, total SM and total PG) and the levels of a sphingomyelin sub-species
(SM18.20.1), which has also been shown in Chapter 3 to differ in mean plasma
levels between clinical classifications. In the next section, the association
between plasma PLTP activity and clinical classification will be investigated.
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5.5.2 Plasma PLTP activity levels and clinical classification
The PLTP activity data was analysed to determine whether there was any
relationship between activity levels and clinical classification. Table 5.1
describes the demographics of the study population stratified by clinical
classification.
Table 5.1: Demographics of the AIBL baseline sub cohort in which PLTP activity levels
were determined.
Characteristic

HC

MCI

AD

Number (n)

158

38

63

71.58 (± 7.39)

74.71 (± 7.16)

77.03 (± 9.70)

80/78

16/22

41/22

0.0536
< 0.05

Age, years (Mean ± SD)
Gender (F/M)
APOEε4 (-ve/+ve)
MMSE, score (Mean ± SD)
SUVR (n)

91/67

18/20

23/40

29 (± 1.27)

26 (± 3.04)

20 (± 4.84)

p-value
< 0.0001

< 0.0001

158

38

26

SUVR (Mean ± SD)

1.42 (± 0.41)

1.97 (± 0.59)

2.28 (± 0.52)

< 0.0001

PiB status (-ve/+ve)

108/50

10/28

2/24

< 0.0001

145

32

17

3.15 (± 0.33)

2.93 (± 0.38)

2.80 (± 0.49)

Hippocampal Volume (n)
Hippocampal Volume, (Mean ± SD)

< 0.0001

HC: Healthy Controls, MCI: Mild Cognitive Impairment, AD: Alzheimer’s disease, F: Female, M:
Male, APOEε4 (-ve/+ve): Negative or positive for the Apolipoprotein E ε4 allele, MMSE: Mini
Mental State Examination, SUVR: Standard Uptake Value Ratio, PiB status (-ve/+ve):
Pittsburgh Compound B negative (SUVR < 1.5), or positive (SUVR ≥ 1.5), SD: Standard
deviation. Analysis of variance (ANOVA) was used to calculate differences for the continuous
variables and X2 for categorical variables. A Kruskal-Wallis formula was applied to the MMSE
scores. Hippocampal volume measured in mL.

The AIBL study baseline sub cohort (n=259) in which plasma PLTP activity
levels were determined comprised of 158 healthy controls (HC), 38 MCI and 63
AD participants. Whilst the number of men and women in each classification
group did not significantly differ (p=0.0536), the AD group are significantly older
(p < 0.0001), which is expected as AD is an age related disease. The
percentage of APOEε4 allele carriers was significantly different between clinical
classifications (42%, 53% and 63% for the HC, MCI and AD groups
respectively) and is higher than reported epidemiological allele frequencies (see
Table 1.3, Chapter 1) due to deliberate enrichment of the AIBL cohort with
APOEε4 allele carriers. As expected (and partly by definition), the mean MMSE
score is lower in the MCI and AD groups compared to healthy controls and the
cerebral amyloid burden as measured by mean SUVR is significantly higher in
the MCI and AD groups compared to healthy controls and significantly higher in
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the AD group compared to MCI. Predictably, hippocampal volume is reduced in
MCI and AD compared to the HC group.
Plasma PLTP activity levels were measured in the samples obtained from 259
AIBL subjects described above, and the activity means for each of the clinical
classifications are displayed graphically in Figure 5.6.

Figure 5.6: Mean differences in plasma PLTP activity levels between clinical
classifications.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, HC: Healthy
control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease. One way ANOVA: * p < 0.05,
** p < 0.01 with Bonferroni post hoc test.

Figure 5.6 shows that mean plasma PLTP activity levels are lower in MCI and
AD groups compared to HC (p < 0.01, p < 0.05 respectively, using one way
ANOVA with Bonferroni post hoc test). The data was then assessed to
determine whether PLTP activity levels are influenced by gender or APOEε4
allele status. No significant differences were shown between males and females
(data not shown), which is in contrast to the gender difference reported in the
Framingham study [444], where higher plasma PLTP activity was associated
with an increased risk of cardiovascular disease in men only. The relationship
between APOEε4 allele carriage and PLTP activity is explored further in the
following section.
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5.5.3 Plasma PLTP activity levels and APOEε4 allele status
Figure 5.7 shows plasma PLTP activity levels APOEε4 allele and non-allele
carriers.

Figure 5.7: Mean plasma PLTP activity levels in APOEε4 allele carriers compared to
APOEε4 non-carriers.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, APOE E4-:
Apolipoprotein E ε4 allele non-carriers, APOE E4+: Apolipoprotein E ε4 allele carriers. * p <
0.05; student’s unpaired t-test.

Figure 5.7 shows that plasma PLTP activity levels are lower in APOEε4 allele
carriers compared to non-carriers whilst Figure 5.6 demonstrates that plasma
PLTP activity levels are reduced in MCI and AD groups compared to HC. As
observed in Table 5.1, more individuals in the MCI and AD groups carry an
APOEε4 allele, which may account for the observed results in Figure 5.7.
Consequently, the mean plasma PLTP activity level in APOEε4 allele carriers
was assessed when the cohort was stratified by clinical classification.
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Figure 5.8: Mean plasma PLTP activity levels in APOEε4 allele carriers and non-carriers
in each clinical classification group.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, HC: Healthy
control, MCI: Mild cognitive impairment, AD: Alzheimer’s disease, -: APOEε4 allele non-carriers,
+: APOEε4 allele carriers, * p < 0.05; One way ANOVA with Bonferroni post hoc test.

Figure 5.8 illustrates that plasma PLTP activity levels are significantly different
between APOEε4 allele carriers compared to non-carriers within the AD group,
with levels lowest amongst APOEε4 positive individuals. A trend towards lower
plasma PLTP activity levels is also seen amongst APOEε4 allele carriers in the
HC and MCI groups. Having considered the relationship between plasma PLTP
activity levels and APOEε4 allele status, a known genetic risk factor for AD, the
relationship between PLTP activity levels and neuroimaging biomarkers of AD,
such as MRI determined hippocampal volume and PiB-PET determined
cerebral amyloid burden was explored.

5.5.4

Plasma PLTP activity levels and hippocampal volume

Hippocampal atrophy is an end stage feature of AD [560]. To investigate any
association between PLTP activity and hippocampal volume, plasma PLTP
activity levels were compared to MRI-determined hippocampal volume. The
results of this analysis are shown in Figure 5.9.
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Figure 5.9: Correlation of hippocampal volume with plasma PLTP activity levels.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour. Pearson’s
correlation controlled for age, gender, APOEε4 allele status, years of education and intracranial
volume (factors which significantly influence hippocampal volume).

No significant association was seen between plasma PLTP activity levels and
hippocampal volume when all clinical classifications were considered together
(Figure 5.9), or when the PLTP cohort was stratified by APOEε4 allele carriage
or by amyloid status, i.e. PiB-positive or PiB-negative. In each case the
following factors known to significantly influence hippocampal volume were
controlled for; age, gender, APOEε4 allele carriage (except during stratification
by APOEε4 carriage), years of education and intracranial volume. To ensure
that the established relationship between decreased hippocampal volume and
AD was not ‘masking’ any potential relationship between hippocampal volume
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and PLTP activity amongst the HC group, the analysis was repeated for the HC
group alone and for the HC group following stratification by APOEε4 allele
carriage and amyloid status. Once again, no significant association was
observed between hippocampal volume and PLTP activity (data not shown).
It is possible that reduced statistical power due to small sample size may
account for the lack of significance observed (MRI + PLTP cohort; HC n=145,
MCI n=32, AD n=17). However, it is also important to note that hippocampal
atrophy is one of the last clinical manifestations of AD and the significant
reduction in plasma PLTP activity levels observed in the AD and MCI groups
compared to the healthy controls (see Figure 5.6) may be representative of an
ongoing pathological process affecting PLTP levels that precedes, or is
unrelated to end-stage hippocampal atrophy.
As mentioned previously, structural changes in the AD brain such as loss of
hippocampal volume are end stages of the disease spectrum. Functional
changes in the AD brain such as cerebral amyloid deposition predate structural
changes with amyloid deposition, represented by PiB-PET determined SUVR,
commencing approximately 20 years before clinical diagnosis is possible.
Consequently, the relationship between plasma PLTP activity levels and SUVR
was investigated.

5.5.5

Plasma PLTP activity levels and cerebral amyloid burden

The relationship between plasma PLTP activity levels and SUVR, a measure of
PiB-PET determined cerebral amyloid burden was assessed. Figure 5.10 shows
the correlation between plasma PLTP activity levels and SUVR amongst the
PiB-negative (SUVR < 1.5) and PiB-positive (SUVR ≥ 1.5) groups when
controlling for age, gender and APOEε4 allele status.
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Figure 5.10: Correlation of plasma PLTP activity levels with brain amyloid burden
represented by SUVR.
SUVR: Standardised Uptake Value Ratio, PiB: Pittsburgh Compound B, PiB –ve: Individuals
with a SUVR value of < 1.5, PiB +ve: Individuals with a SUVR value of ≥ 1.5, PLTP:
Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour. Pearson’s
correlations adjusted for age, gender and APOEε4 allele status.

No statistical significance was observed when PiB-PET determined SUVR was
plotted as a continuous variable against PLTP activity with the PLTP cohort
stratified by PiB-PET status (independent of clinical classification). Previously
published AIBL data indicate that 98% of the AD group are PiB-positive (mean
SUVR amongst PLTP sub-cohort is 2.28) whilst approximately 30% of healthy
controls have a significant cerebral Aβ burden with an SUVR of > 1.5 [477].
Therefore to investigate the potential of PLTP to distinguish PiB-negative from
PiB-positive ‘cognitively normal’ individuals (i.e. individuals at increased risk of
developing AD) we considered the HC group separately. First, the mean plasma
PLTP activity levels were plotted against SUVR as a categorical variable where
individuals are classified as either PiB-positive or PiB-negative. Figure 5.11
shows the mean difference in plasma PLTP activity levels between the PiBnegative and PiB-positive HCs.
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Figure 5.11: Mean difference in plasma PLTP activity between healthy controls classified
as either PiB-negative or PiB-positive.
PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour, PiB:
Pittsburgh Compound B, SUVR: Standardised Uptake Value Ratio, PiB –ve: Individuals with a
SUVR value of < 1.5, PiB +ve: Individuals with a SUVR value of ≥ 1.5. p > 0.05; student’s
unpaired t-test.

Figure 5.11 shows no significant difference in PLTP activity levels between the
PiB-positive and PiB-negative healthy controls. However, there is a trend
towards lower plasma PLTP activity levels amongst PiB-positive individuals
which may become statistically significant with a larger sample size. To
increase statistical power, we assessed the relationship between PLTP activity
levels and SUVR plotted as a continuous variable among the healthy controls:
The relationship was not significant (data not shown). However, it can be
argued that the PiB-positive individuals within the healthy control group
represent a biologically distinct sub-group within whom the processes
associated with AD pathogenesis are more advanced, and these individuals are
at increased risk of transitioning to AD. Consequently, we further investigated
the association between PLTP activity and SUVR following stratification of the
healthy control cohort by amyloid status i.e. PiB-positive or PiB-negative.
Figure 5.12 shows the correlation of plasma PLTP activity against SUVR plotted
as a continuous variable, following stratification of the HC group into PiBpositive and PiB-negative status.
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A

B

Figure 5.12: Correlation of plasma PLTP activity levels with SUVR in the healthy control
group following stratification into (A) PiB-negative individuals or (B) PiB-positive
individuals. PiB: Pittsburgh Compound B, SUVR: Standardised Uptake Value Ratio, PiBnegative: Individuals with a SUVR value of < 1.5, PiB-positive: Individuals with a SUVR value of
≥ 1.5. PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per hour.
Pearson’s correlations adjusted for age, gender and APOEε4 allele status.
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Figure 5.12A shows a significant negative correlation between plasma PLTP
activity and SUVR amongst PiB-negative HC individuals (p<0.01), where higher
SUVR is associated with lower plasma PLTP activity, whilst figure 5.12B shows
no significant correlation in the PiB-positive HC group (p=0.748).
As SUVR is indicative of cerebral Aβ burden and PLTP is suggested to have a
role in peripheral Aβ metabolism the relationship between plasma PLTP activity
levels and plasma Aβ was also investigated.

5.5.6 Plasma PLTP activity levels and potential blood biomarkers of AD
A recent publication from the AIBL study showed a decrease in the plasma ratio
of Aβ1-42:Aβ1-40 and an inverse correlation with SUVR in AD patients compared
to healthy controls. Additionally a reduction in plasma Aβ1-42 was reported in
MCI and those participants who transitioned from the healthy control to MCI
group [561]. Lower plasma Aβ1-42 levels and plasma ratios of Aβ1-42:Aβ1-40 in AD
compared to healthy controls have also been reported in other studies [562]. A
relationship between lipoprotein metabolism, Aβ and PLTP was described at
the beginning of this chapter and therefore the association between plasma
PLTP activity levels and plasma Aβ1-42 as well as the ratio of Aβ1-42:Aβ1-40 in
plasma was investigated. The results are shown in Figure 5.13.
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A

B

Figure 5.13: Correlation of (A) plasma Aβ1-42 and (B) plasma ratio of Aβ1-42:Aβ1-40 with
plasma PLTP activity levels.
Aβ: Amyloid beta, PLTP: Phospholipid transfer protein, ρmol/μL/h: Picomole per microlitre per
hour. Pearson’s correlations adjusted for age, gender and APOEε4 allele status; p < 0.05.
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Figures 5.13A and 5.13B show significant positive correlations between plasma
Aβ1-42 and the ratio of Aβ1-42:Aβ1-40 with plasma PLTP activity levels
respectively, i.e. lower plasma PLTP activity levels are associated with lower
plasma Aβ1-42 and a lower Aβ1-42:Aβ1-40 ratio. This is consistent with Figure 5.6
where plasma PLTP activity levels were shown to be significantly lower in AD
patients compared to healthy controls.
A weakly statistically significant (p=0.049) positive correlation was also
observed between Aβn-42 and plasma PLTP activity levels (data not
presented).
Additionally, plasma PLTP activity levels were also compared to plasma apoE,
clusterin (apoJ) and apoAI levels, with no significant correlation observed for
any of these blood biomarkers (data not shown). Plasma HDL-cholesterol
subfraction levels were also compared to plasma PLTP activity levels, yet no
significant relationship observed (data not shown). In the case of plasma HDLcholesterol subfractions, the results are likely to be influenced by medication
use (e.g. statins); a factor that was not controlled for during this analysis.

5.6

Discussion

Differences in plasma lipid species between clinical classifications were
investigated in Chapters 3 and 4 for their potential use as blood biomarkers to
reliably differentiate those with AD and MCI from healthy controls. By measuring
the plasma levels of many different lipid species, some insight into ADassociated aberrant biochemical pathways can also be obtained. However,
when using blood to investigate processes that are brain-related, a major
assumption is that processes in the brain correlate with those in the periphery,
and while this has been shown for some markers, it has also been shown not to
apply to others. AD is a chronic age related progressive disease in which coexistence of other age related factors, impacting lipid metabolism, is inevitable:
These factors include dietary intakes, digestive capacity, nutrient status,
hormone balance, the existence of co-morbidities and medication use. These
factors present a major challenge when studying blood lipid biomarkers as
considerable interference from systemic metabolic dysfunction may be present.
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The purpose of the study presented in this chapter was to measure the activity
levels of a protein (PLTP) that potentially connects plasma lipids to some
features of AD pathology, to determine if there is any correlation between PLTP
and established blood and neuroimaging markers of AD. Research investigating
the relationship between AD and PLTP activity is relatively new and so a pilot
study was undertaken on a subset of the baseline AIBL cohort to determine
whether the results justified analysis in a larger sample size. According to a
recent report, the sensitivity and specificity of clinically diagnosing AD is 80%,
with neuroimaging biomarkers not improving this accuracy [563]. The lipid
panels identified in Chapters 3 and 4 were also able to distinguish AD from
healthy controls with a sensitivity and specificity of 80%. Plasma PLTP activity
was investigated to determine whether there was any merit in its measurement
in the AIBL cohort and whether it may show potential in terms of improving the
sensitivity and specificity of a diagnostic biomarker panel. The major findings
from the study presented in this chapter were:


A significant positive correlation was seen between plasma PLTP activity
levels and the plasma mean total LysoPE, total SM and total PG species.



A significant positive correlation was seen between plasma PLTP activity
levels and the lipid SM18.20.1, the levels of which were shown in
Chapter 3 to differ significantly between clinical classifications; this lipid
was also later chosen in the variable selection pathway for predicting
clinical classification (Figure 3.15 and Section 3.4.3.1).



Plasma PLTP activity levels were significantly lower in the MCI and AD
groups compared to healthy controls.



When comparing the cohort as a whole, APOEε4 allele carriers had
significantly lower mean plasma PLTP activity levels than non-carriers.



When stratified by clinical classification, only in the AD group did the
APOEε4 allele carriers have significantly lower plasma PLTP activity
levels than non-carriers.



No significant correlation was seen between plasma PLTP activity levels
and hippocampal volume.



When investigating the cohort as a whole, no significant correlation was
seen between plasma PLTP activity levels and cerebral amyloid burden
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amongst PiB-positive or PiB-negative individuals. However, when the
healthy control group was stratified into PiB-positive and PiB-negative, a
significant negative correlation was observed between SUVR and PLTP
activity levels amongst the PiB-negative group.


Significant positive correlations were observed between PLTP activity
levels and Aβ1-42 levels in plasma, as well as between PLTP activity
levels and Aβ1-42:Aβ1-40 ratios in plasma.

Statistically significant positive correlations were seen between plasma PLTP
activity levels and the mean total levels of LysoPE, SM and PG. The total levels
of LysoPE did not significantly differ between clinical classifications when
assessed in Chapter 3. However, the mean plasma level of LysoPE16.0, the
most abundant LysoPE species (see Chapter 3), was higher in AD compared to
healthy controls. On the other hand, no correlation was observed between
LysoPE16.0 and plasma PLTP activity levels in this chapter.
A statistically significant association was seen between plasma PLTP activity
levels and plasma mean total SM as well as levels of the SM species
SM18.20.1. Figures 5.2B and 5.5 show that lower plasma PLTP activity levels
are associated with lower total SM, and lower SM18.20.1 respectively. When
mean plasma SM species levels were assessed in Chapter 3 all sub-species
measured were significantly different between clinical classifications with mean
plasma levels lower in the AD and MCI groups compared to the HC group.
Studies into cellular ceramide homeostasis have shown that PLTP can transfer
sphingomyelin (SM) from vesicles to HDL [164]. There is also evidence to
suggest that newly synthesised hepatic ceramides are secreted via VLDL, and
PLTP is believed to be one of the proteins that facilitates the transfer of
sphingolipids onto nascent lipoproteins [164, 526, 527]. A reduction in this
PLTP mediated secretion may adversely affect SM levels as SM are
synthesised from newly synthesised ceramides. Other evidence that PLTP
influences ceramide/VLDL production comes from studies of PLTP-deficient
mice, which show an impairment in hepatic secretion of VLDL, whereas an
overproduction of PLTP in mice has been shown to lead to excessive hepatic
VLDL production [564, 565]. All these studies indicate that changes in PLTP
255

Chapter 5 – Plasma PLTP Activity Levels
levels may influence several aspects of sphingolipid metabolism, and thus lower
PLTP activity may be reducing the transfer of sphingomyelin (SM) from vesicles
to lipoproteins such as HDL, leading to reduced plasma SM levels seen in this
study. Conversely, the ceramide pool can be elevated by the breakdown of
other sphingolipids and therefore ceramide levels may be unaffected by a
reduction in PLTP activity (see Chapter 4, Section 4.5). Further analysis of
plasma PLTP activity levels and plasma sphingolipid levels in a larger sample
number is required to investigate the potential of PLTP and sphingolipids as a
combined blood biomarker panel, for the purpose of distinguishing between
clinical classifications.
Plasma PLTP activity levels were significantly lower in the MCI and AD groups
compared to the healthy control group. In other studies, AD patients have been
shown to have lower CSF PLTP activity [535, 536]; showing a level of
agreement between studies, if one assumes plasma PLTP activity levels
parallel CSF levels. Due to the role of PLTP in lipoprotein metabolism and
reverse cholesterol transport, PLTP has been extensively studied for its role in
cardiovascular disease (CVD) and other metabolic diseases, such as diabetes
[444, 445, 520, 566], where plasma PLTP activity levels have been reported to
be elevated. The AIBL recruitment process excludes potential participants with
a history of insulin dependent or uncontrolled diabetes, or a history of CVD or
recent cardiovascular event and therefore the potential influence of these comorbidities on PLTP activity levels in our study should have been minimised.
The link between atherosclerosis and PLTP levels was suggested by studies of
various mouse models which reported a marked reduction in HDL as a result of
increased PLTP expression [567]. On the other hand, PLTP expression in
macrophages has been shown in animal studies to reduce atherosclerosis
[568], suggesting that protective or disease-promoting effects may be tissue
specific. Nevertheless, most but not all studies suggest elevated plasma PLTP
activity levels are associated with an increased risk of CVD. The results
presented in this chapter show reduced plasma PLTP activity levels in AD
compared to healthy controls which may appear counter-intuitive given that
CVD is proposed to contribute to the development of AD. There are, however,

256

Chapter 5 – Plasma PLTP Activity Levels
several potential explanations for our findings: Firstly, the cohorts are
significantly different in terms of age (cohorts investigating CVD are usually
comprised of younger participants compared to studies of AD), although PLTP
activity is also suggested to increase with age [518]. Secondly, there is a
suggested correlation between plasma PLTP activity levels and the acute
phase response protein, C-reactive protein (CRP) [539], which is reportedly
elevated in CVD. CVD may involve a more acute type of inflammatory
response, reflected in an elevated CRP and PLTP, whereas in AD more chronic
inflammatory processes are present which are not reflected by a peripheral
increase in acute inflammatory markers. Therefore, it may be that different
factors in AD and CVD are influencing plasma PLTP activity levels. It would be
interesting to investigate plasma PLTP activity in the context of other forms of
dementia, specifically vascular dementia, to determine whether the differences
shown in this study between clinical classifications are driven by specific
features of AD pathology. As mentioned previously, the relationship between
PLTP activity and vascular disease is neither predictable nor straightforward:
Some studies have shown an association between elevated PLTP activity and
coronary artery disease as well and left ventricular dysfunction [445, 569], while
others have shown reduced PLTP activity is associated with peripheral vascular
disease [447].
Significantly lower plasma PLTP activity levels were found in APOEε4 allele
carriers compared to non-carriers, in the cohort as a whole. When the cohort
was stratified according to clinical classification, the significance between
carriers and non-carriers remained in the AD group (see Figure 5.8). A study of
PLTP activity, serum apoE concentration and APOEε4 in a Finnish population
showed serum apoE levels to be highest in those carrying an APOEε2 allele
and lowest in those carrying an APOEε4 allele but failed to show a difference in
PLTP activity [534], however this study utilised a ‘cognitively healthy’ population
with an age range of 30-94. Our study reports lower PLTP activity levels in
APOEε4 allele carriers, and a published study from the AIBL cohort has
described significantly lower plasma total apoE levels in patients with AD and
specifically those carrying the APOEε4 allele. This study also demonstrated an
APOEε4 gene dose effect in further reducing plasma apoE levels [84]. ApoE
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complexes with, and stabilises its activity, and therefore a role for the regulation
of plasma PLTP activity by apoE is suggested [570]; the results presented in
this chapter are consistent with this suggestion.
As mentioned previously, pathological changes in the AD brain such as cerebral
amyloid deposition (which can be quantitated by SUVR) predate the onset of
clinical symptoms. Brain atrophy in selected regions such as the hippocampus
has also been shown, mostly by structural magnetic resonance (MRI), to
predate symptom onset [560]. The entorhinal cortex is the first region to display
atrophy in AD, this is followed by atrophy in the hippocampus, amygdala and
parahippocampal gyrus [571]. The next region to display atrophy includes the
posterior cingulate cortex; eventually the atrophy becomes generalised to the
temporal neocortex and neocortical association areas [572]. Thus, the
neuroimaging
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assessment using MRI could be used for early diagnosis and disease
monitoring. However, the MRI technique is time-consuming and requires
expensive technology, and a blood biomarker test would clearly be preferable.
In our study, no significant correlation was found between hippocampal volume
and plasma PLTP activity levels. Unfortunately, hippocampal volume data was
only available for 17 out of 63 AD participants in whom PLTP activity levels
were measured; an increased sample size is required to confirm any lack of
correlation.
When the whole cohort was divided into two groups - the PiB-negative and PiBpositive groups - no relationship could be observed between plasma PLTP
activity levels and cerebral amyloid burden as measured by SUVR. However
when the HC group was stratified into PiB-positive or PiB-negative, a significant
negative correlation was observed between SUVR and PLTP activity levels
amongst the PiB-negative group. This correlation was ‘masked’ when the PiBnegative and PiB-positive groups were considered collectively, and as referred
to in earlier text, may be due to different biochemical processes occurring in the
pathologically distinct groups. This result could reflect the suggested roles of
PLTP in Aβ metabolism, as lower plasma PLTP activity may reduce Aβ removal
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from the brain to the periphery for degradation. A significant positive correlation
was observed between plasma PLTP activity levels and plasma Aβ1-42, as well
as the ratio of plasma Aβ1-42:Aβ1-40, which is consistent with a role for PLTP in
the transfer and metabolism of Aβ. Plasma levels of Aβ1-42 and the plasma ratio
of Aβ1-42:Aβ1-40 were recently shown in the AIBL study to be lower in AD; these
Aβ measures also showed a negative correlation with SUVR. The correlation
reported in this chapter between plasma PLTP activity levels and both plasma
(positive correlation) and cerebral Aβ (negative correlation) strengthens the
hypothesis that PLTP may be involved in Aβ transport from the brain. The
“peripheral sink” hypothesis assumes that a balance exists between peripheral
and brain levels of soluble Aβ, and posits that efficient removal of Aβ from the
periphery (by enzymatic breakdown or tissue uptake followed by breakdown)
should help decrease brain levels of Aβ. According to the hypothesis, a
disruption or decrease in clearance from the brain contributes to cerebral
retention of Aβ, Aβ aggregation and amyloid formation [573, 574]. This
hypothesis remains controversial, as pharmacological intervention efforts to
reduce peripheral and cerebral Aβ have sometimes reduced Aβ in one or both
compartments. However, the animal models or people in most of these
pharmacological trials have not shown significant cognitive improvement [16,
575, 576]. A recent animal study using the Aβ degrading enzyme neprilysin,
showed an effective degradation of Aβ in the periphery but no alteration in brain
or CSF Aβ levels [577]. Some studies have shown promise however, for
example intravenous application of a form of low-density lipoprotein receptorrelated protein-1 (LRP) in an AD mouse model was found to reduce Aβ
accumulation and aggregation in the brains of the mice, and also was shown to
improve their learning and memory [578]. The concept of improving clearance
of brain Aβ via increasing Aβ removal from the periphery is a relatively new
idea, and although many trials have not yet shown symptom improvement, as
one review has suggested - it may take longer than expected in ongoing trials
for such neurobiological effects to translate into measurable clinical
improvements [579]. However, whilst such studies are still debating whether
the “peripheral sink” hypothesis offers an effective therapy for AD, the results do
not dispute suggested roles of PLTP in Aβ metabolism, transport and removal
from the brain, or its potential use as a biomarker of AD. A very recent study of
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PLTP-deficient mice has found that a lack of PLTP causes an increase in
cerebral and hippocampal Aβ1-42 levels and a decrease in cerebral Aβ1-40 levels.
The PLTP deficiency also increased brain expression of γ-secretase catalytic
units and decreased the content of apo E, and was found to impair learning and
memory in the mice [580]. Collectively, studies such as these together with the
findings reported in this chapter suggest that the relationship between PLTP,
peripheral and cerebral Aβ warrants further investigation.
No significant correlations were seen when plasma PLTP activity levels were
compared with plasma apoE, clusterin (apoJ) or apoAI levels. The plasma HDLcholesterol subfractions also failed to show significance when compared with
PLTP activity levels. It should be noted however, that the use of medications
such as statins and fibrates which would have been likely to impact on such an
association was not included as a covariate during analysis, and thereby
represents a limitation and significant caveat when interpreting the results of
this aspect of the study. Indeed, a recent investigation, as part of the Diabetes
Atorvastatin Lipid Intervention study (DALI), showed that PLTP activity and
plasma apoE were both lowered by treatment with Atorvastatin over a 30 week
period [581]. Furthermore, fibrates (PPARα activators) also lower plasma
triglyceride and can increase HDL-cholesterol levels. In PLTP studies utilising
‘healthy’ cohorts, the level of triglycerides has been the parameter that has
consistently contributed to variations in plasma PLTP activity levels, which is
likely due to its role in transferring lipids from apoB containing lipoproteins [518,
534]. Thus, a logical recommendation for future investigation is controlling for
medications that can potentially affect biomarker levels.
A genetic polymorphism has been identified in the PLTP gene (rs7679) and
interestingly this has been shown to predict both serum triglyceride levels as
well as mRNA PLTP expression in the liver [582]. The rs7679 T allele was
shown to be associated with increased PLTP expression, increased plasma
HDL and lower plasma triglycerides. Another study showed higher PLTP
activity, higher plasma HDL and lower plasma triglycerides were associated
with the T allele, suggesting a cardioprotective effect of increased PLTP activity
[583]; adding to the confusion surrounding the influence of PLTP on
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cardiovascular disease. The association of AD with this rs7679 polymorphism
and other variants of the PLTP gene should be investigated in future studies; if
any of these genetic variants can predict PLTP activity, this may circumvent
methodological disparities associated with measurement of PLTP and thereby
enhance comparability of results between cohorts.
The results presented in this chapter strongly suggest a relationship between
PLTP activity levels, certain plasma lipid species levels, cerebral and plasma
Aβ levels. In the quest to identify a sensitive and specific blood biomarker for
AD, plasma PLTP activity levels may prove to be an important additional
measurement, and PLTP warrants further assessment both cross-sectionally
and longitudinally.
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6.1

Introduction

Over the past few decades the role of lipids in brain biochemistry and the
involvement of particular lipid species in the pathological processes associated
with AD have been more clearly defined. A key protein central to AD pathology
is the transmembrane protein APP. Processing of this protein, which appears to
be highly regulated by the membrane lipid environment, leads to the production
of the Aβ peptide which is neurotoxic when its levels are elevated. Undoubtedly,
progress in lipid research and our understanding of AD pathology has been
driven by advances in technologies enabling the more precise investigation of
the lipidome; the repertoire of lipid species present in cells and tissues. The
specific type, concentration and flux of these lipid species present at a given
time or associated with a pathological state are the net result of gene and
protein expression, which are influenced by the cellular environment. Abnormal
lipid metabolism, involving cholesterol, phospholipids and sphingolipids has
emerged as a key component of the pathological processes leading to the
development of AD. While selected factors, including abnormal lipid metabolism
have been identified as key features of AD pathology, it is unlikely that any of
these factors is the sole disease causing culprit. It is more reasonable to
assume, due to the highly integrated nature of metabolic pathways, that these
multiple factors work together in response to perhaps a series of insults that
eventually lead to AD. Lipidomic studies, therefore, are vital for gaining a
greater understanding of disease mechanisms, aberrant biochemical pathways,
and importantly for biomarker discovery. The identification of sensitive and
specific biomarkers is a priority not only in terms of early AD diagnosis, but to
assist in the validation and monitoring of clinical interventions that target these
aberrant pathways and their associated lipids and proteins. The results
presented in this thesis add to the existing body of knowledge and open new
avenues of exploration in the pursuit of diagnostic tests and therapeutic
strategies for AD.
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The challenge for future research is to answer the following questions with more
certainty:


What factors control lipid metabolism, how are they integrated, and which
signals go wrong in AD?



How does this lead to amyloid deposition, tau pathology and
neurodegeneration; the hallmarks of AD?



Is abnormal lipid metabolism a driver or is it influenced by aberrant
upstream signals that effect cell metabolism, cell survival and DNA
repair?



How can this information be used to diagnose, prevent and treat AD?

When considering the measurement of blood lipids, the influence of dietary and
lifestyle factors cannot be ignored. Diet and lifestyle factors have an effect on
the complex network of hormones and transcription factors that orchestrate
metabolism and influence anti-ageing and pro-survival proteins. Such proteins
include the sirtuins and other metabolic sensors such as PPAR-gamma
coactivator 1 α (PGC1) and adenosine monophosphate kinase (AMPK), which
allow proper adaptation to energy requirements and environmental challenges.
The existence of these factors may be a major reason why the identification of
highly specific and sensitive blood lipid biomarkers has been difficult in AD due
to the interference of plasma abnormal lipid profiles associated with metabolic
dysfunction and other co-morbidities.
A highly complex relationship between AD pathology and lipid metabolism
exists and this association was investigated by measuring plasma lipid species
to identify which lipids groups were significantly different between clinical
classifications and if these lipids correlated with other AD biomarkers. The
ability of certain plasma lipids species to predict clinical classification and
disease progression was also assessed. Additionally, the activity of the lipid
transfer protein PLTP was measured in plasma and assessed for its association
with plasma lipid profiles, clinical classification and other AD biomarkers.
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6.2

Plasma lipid
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In Chapters 3 and 4, 189 plasma lipid species were investigated to determine
their feasibility as blood biomarkers for AD. Following complex statistical
modelling, several lipids were identified as differing significantly in levels
between clinical classifications, after adjustment for age, gender, APOEε4 allele
status and collection site in samples collected at both baseline and the 18
month follow up. Further, lipid panels were determined at baseline and the 18month follow up which could distinguish between healthy control and AD
participants with a sensitivity and specificity of 80%, which compares to the
current sensitivity and specificity of both clinical diagnosis and neuroimaging
biomarkers for diagnosing AD [563]. Lipid panels identified at both time points
for their ability to distinguish MCI from healthy controls, and AD patients from
MCI, demonstrated reduced sensitivity (69% and 71% respectively), possibly
due to the heterogeneity of the MCI group. The lipids selected at baseline and
18 months for inclusion in the HC vs. AD panel were not the same (excepting 2
lipids), and although the change in characteristics of the cohort between
baseline and 18 months may explain the differences, further work is
recommended to improve the diagnostic utility of the blood lipid biomarker
panels presented in this thesis. The analytical platform chosen for this study
simultaneously identified a broad range of lipids (189 species) in a large cohort
(n=1112) at two time points. While this has been extremely useful in identifying
lipids that differ with clinical classification, and providing information that can
contribute to an understanding of altered lipid metabolism in AD, the lipid panels
as they stand cannot be used in a routine setting for the diagnosis of AD.
However these results have generated many future research avenues to
pursue, for example they have provided a selection of lipid groups which should
be investigated for biomarker discovery by a more targeted analytical approach.
A recent study by Mapstone et al. [493] has just reported the identification of a
panel of ten lipid biomarkers that predicted conversion to either amnestic mild
cognitive impairment or AD within a 2-3 year timeframe, with greater than 90%
accuracy. Using a combination of untargeted and targeted lipidomic
methodologies, eight PC species and two acyl carnitine species were identified
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for inclusion in the panel. As part of our study acyl carnitines were not
measured, and only four of the PC species identified by Mapstone et al. were
measured. Additionally, analysis of the transition group data reported in this
thesis was undertaken at 18 months, whilst according to the report by Mapstone
et al, phenoconversion occurred on average at 2.1 years. The results presented
in this thesis agree with the report by Mapstone et al. showing lower mean
plasma levels of the four PC species measured (PC38.6, PC40.6, PC40.6p and
LysoPC18.2) between the HC and AD groups and analysis of AIBL samples at
additional time points may identify important lipids able to predict transition
groups.
The lipid differences that were noted between clinical classifications were not
identical at the two time points; however similarities exist in terms of sub-class,
acyl chain length and number of unsaturated bonds. In addition, the relative
levels of some species compared to others enabled plausible explanations of
the biological relationships and allowed speculation of possible interference in
the lipid pathways by dietary and metabolic factors.
In general agreement with other studies, the major lipids that were shown to
differ between clinical classifications at either or both time points were several
PE, PC, plasmalogen, sphingomyelin and ceramide species. Of note was the
directional change (increased or decreased) with clinical classifications of the
various species differing in acyl chain length and degree of saturation in the PE
and PC species. The majority of species levels that were increased in AD and
MCI compared to healthy controls in the PE and PC groups had shorter chain
lengths and less saturated bonds: this may suggest abnormalities with the
desaturase and elongation enzymes required to produce long chain
unsaturated fatty acids from shorter omega-3 or omega-6 precursors, including
the essential fatty acids, linoleic and α-linolenic acids. It may also suggest
essential fatty acid deficiency (and therefore reduced production of AA (20.4n6) and DHA (22.6n-3)) or a combination of fatty acid deficiency and reduced
enzyme activity. If abnormal desaturase or elongase activity exists, shorter
chain fatty acids with few saturated bonds would accumulate. However, if the
desaturase and elongation activities were normal yet there was a deficiency of
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essential fatty acids, the unsaturated mead acid (22.3n-9) would accumulate in
plasma. The preferred substrates of the delta 6 and delta 5 desaturase
enzymes are omega-3 and omega-6 fatty acids which produce the long chain
polyunsaturated fatty acids. If there is a deficiency in the essential fatty acids
(18.2n-6 and 18.3n-3), the desaturase and elongase enzymes are then free to
act on their less preferred fatty acid substrates, omega-9 series (18.1n-9).
Consequently, mead acid accumulates which acts as a marker for essential
fatty acid deficiency.
While inferences can be made from the lipid species identified in Chapters 3
and 4, the analytical platform used does not allow precise determination of the
fatty acid composition of all species when two fatty acids are present in a
particular phospholipid species. For example, PE38.4 indicates two fatty acids
with a combined total of 38 carbon chains and 4 unsaturated bonds, which is
likely but not certain to be 18.0 at sn-1 and 20.4 at sn-2. Further studies are
needed to identify the individual acyl groups in the lipid species, which will also
determine whether abnormal desaturase and elongase activities or essential
fatty acid deficiencies are the cause of reduced acyl chain length and
desaturation in the PE and PC species. A more targeted analysis coupling
chromatography to mass spectrometry and the measurement of plasma fatty
acids will meet this need. Such information would possibly lead to increased
sensitivity and specificity of a plasma lipid biomarker panel when added to those
lipid subspecies identified in Chapters 3 and 4.
Interestingly a recent study has shown an upregulation of stearoyl-CoA
desaturase (SCD) in the AD brain, and increased nervonic (24.1n-9) acid;
resulting in an increased ratio of monounsaturated fatty acid to saturated fatty
acid [584]. This is interesting for several reasons. The first step in the synthesis
of nervonic acid (22.1n-9), a crucial component of myelin sphingolipids including
sulphatide, is the desaturation of stearic (18.0) to produce oleic acid (18.1n-9).
Oleic acid is then elongated to form nervonic acid. The authors found no
increase in nervonic acid containing sphingolipids, and subsequently concluded
that the reported increase in nervonic acid was unlikely to result from
sphingolipid breakdown and was more likely due to upregulation of SCD,
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although they were unable to exclude sampling effects. Chapter 4 of this thesis
showed plasma ceramide containing nervonic acid (C.d18.1.24.1) to be one of
the lipids with the greatest difference in levels between the healthy control and
AD groups and was later selected in the statistical model for predicting AD. It is
certainly feasible that the increase in C.d18.1.24.1 seen in our AD patients
results from both breakdown of sulphatide and increased de novo synthesis of
nervonic acid containing ceramide. Sulphatide is a crucial component of myelin
and its degradation appears to be accelerated in AD, thus it is also possible that
there is a compensatory increase in nervonic acid production to supply
precursors for synthesis. The authors reporting upregulation of SCD in the AD
brain also reported elevated mead acid (22.3n-9). Mead acid is the only
polyunsaturated fatty acid that can be synthesised de novo, with SCD being the
rate limiting enzyme. When DHA deficiency is present in the brain, mead acid
production may be increased as a compensatory mechanism to maintain a
minimum unsaturation level of fatty acids in the membrane to preserve function.
Assuming that these changes are related to plasma lipid species, their
measurement may contribute to a biomarker panel that reflects an aberrant
brain pathway. As previously mentioned, a future addition to the lipid
biomarkers measured in Chapters 3 and 4 will be the measurement of both
mead and nervonic acids as components of plasma fatty acid profiling.
The results of Chapters 3 and 4 also provide several indicators of peroxisomal
dysfunction, a reported feature of AD [498]. These indicators include the
decrease in plasma ether lipid species containing greater than six unsaturated
bonds (DHA, 22.6n-3) in the AD group compared to healthy controls; the supply
of both the plasmalogen precursors (1-alkyl-glyceryl ether lipids) and the final
desaturation step in DHA production which is carried out in peroxisomes. Again,
plasma fatty acid profiling, including measurement of the peroxisomal DHA
precursor tetracosahexaenoic acid (24.6n-3) and targeted lipidomics for
plasmalogen species, will assist in determining the utility of peroxisomal
dysfunction and specific plasmalogen species as sensitive and specific AD
biomarkers.
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In agreement with other studies, the plasma lipid profiles reported in Chapters 3
and

4

showed

significant

changes

in

sphingolipids

between

clinical

classifications [163, 422, 423, 474]. Generally, the sphingomyelin species levels
were decreased and the ceramide species were elevated in AD. Ceramide is
the central sphingolipid from which other complex sphingolipids (including
sphingomyelin (SM), cerebrosides and gangliosides) are derived. The reduced
sphingomyelin species seen in AD may result from decreased synthesis via SM
synthase or increased catabolism via SMases or a combination of both. As
described in detail in Chapter 1 (Section 1.5.4), a tight connection exists
between cholesterol and sphingomyelin, and a reduction in sphingomyelin has
consequences for membrane biology and APP processing. Furthermore,
reduced sulphatides have been reported at an early stage of disease in the AD
brain [413]. The increase in ceramide species in AD may be a net result of
increased de novo synthesis from serine and palmitoyl CoA and increased
catabolism of sphingomyelin and sulphatide. In agreement with previous reports
[163, 502], this study reports a reduction in plasma sphingomyelin levels in AD
patients. As previously mentioned, the ceramide containing nervonic acid
C.d18.1.24.1 was one of the lipids with the greatest difference in levels between
clinical classifications and was also selected as part of the predictive panel in
Chapter 4: this data may represent an intriguing link to brain sulphatide
degradation.
When the ceramide containing nervonic acid C.d18.1.24.1 and three other
ceramides chosen in the HC vs. AD predictive panel were compared with SUVR
categories, used as a measure of cerebral amyloid burden (see Chapter 4,
Figure 4.21), mean plasma levels of all four lipid species rose with the SUVR up
to a value of 2, this was followed by a marked decline in levels when the SUVR
levels were greater than 2. This striking relationship may suggest that plasma
ceramides increase as the rate of Aβ accumulation increases in the brain and
then decline as the Aβ accumulation rate plateaus: This warrants further
investigation both through validation in other cohorts and through studying the
correlation between intra-individual rates of Aβ accumulation and ceramide
species in this cohort.
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The results presented in this thesis show that markers of sphingolipid
metabolism have the potential to be sensitive and specific biomarkers for AD.
Studies have shown that there are several enzymes involved in sphingolipid
metabolism which have altered activities in AD resulting in accumulation of
ceramides and alterations in other specific sphingolipids [471, 511, 514].
Potential therapeutic targets for AD are emerging from these studies and
measurement of plasma sphingolipids will provide a valuable tool to assess
efficacy and monitor progress of therapeutic interventions. A more targeted
approach

coupling

chromatography

with

mass

spectrometry

for

sphingolipidomic studies would enable identification of specific species and
their ratios which may facilitate discovery of more sensitive and specific
biomarkers.

For

example

the

measurement

of

sphinganine

and

dihydroceramide may provide information on the de novo ceramide synthesis
pathway and the relative activity of the enzymes serine-palmitoyl transferase
(SPT) and dihydroceramide desaturase (DES); the activities of which are
reportedly altered in AD, thereby identifying them as potential therapeutic
targets for reducing ceramides.

6.3

Plasma PLTP activity levels and their association with plasma
lipid species and clinical classification

Phospholipid Transfer Protein (PLTP) in involved in lipoprotein metabolism and
lipid transfer and has suggested roles in processes involved with AD pathology,
including Aβ metabolism. Therefore, any association of PLTP with the lipid
species measured in Chapters 3 and 4, clinical classification and other AD
biomarkers was investigated, to determine whether PLTP shows promise as a
potential biomarker of AD. Plasma PLTP activity, measured in a subset of the
AIBL baseline samples, correlated with several of the lipid species measured in
Chapters 3 and 4 as well as with other AD biomarkers. Plasma PLTP activity
levels showed the strongest correlation with mean plasma levels of SM18.20.1;
this lipid species was also shown in Chapter 3 to be lower in the AD group
compared to healthy controls. The relationship of PLTP with individual lipid
species should be reassessed when PLTP activity measurement is undertaken
in the entire baseline cohort and when the 18 month samples are assessed.
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Plasma PLTP activity levels were measured and found to be lower in the MCI
and AD groups compared to the healthy controls. Additionally, PLTP activity
levels were lower in APOEε4 allele carriers compared to non-carriers. However,
no correlation was observed between plasma apoE levels and PLTP activity.
When comparing PLTP activity levels with neuroimaging results, no significant
correlation was observed with hippocampal volume or PiB-PET determined
SUVR as a marker of cerebral amyloid burden, when assessing all clinical
classifications together. To investigate the potential of PLTP to distinguish PiBnegative from PiB-positive ‘cognitively normal’ individuals (i.e. individuals at
increased risk of developing AD, or in the early pre-symptomatic stages of AD)
the HC group was investigated further. Following stratification into PiB-positive
and PiB-negative groups, a significant negative correlation was observed
between PLTP activity and SUVR in the PiB-negative HC group, suggesting
that PLTP activity may be indicative of cerebral amyloid load in the early stages
of Aβ deposition; an effect which diminishes as SUVR increases beyond a
certain point.
Interestingly, of all the blood biomarkers assessed for their relationship with
plasma PLTP activity levels (Aβ, apoE, clusterin and HDL subfractions) only
plasma Aβ showed a significant positive correlation, with lower plasma PLTP
levels associated with lower plasma Aβ1-42 and the plasma ratio of Aβ1-42:Aβ1-40.
Lower levels of both these Aβ measurements have been reported in AD in the
AIBL study [561], which is in agreement with a suggested role for PLTP in Aβ
metabolism.
Collectively, the results of PLTP activity measurement in the healthy control
group of the baseline AIBL samples clearly suggest further investigation of this
protein is warranted. Assessing a larger sample number longitudinally will assist
with determining PLTP’s potential as a biomarker of AD. How plasma PLTP
activity levels and SUVR vary for a particular individual over time should also be
investigated.

271

Chapter 6 – General Discussion and Future Directions
6.4

Future directions

Plasma lipid profiles show great potential as blood biomarkers of AD, with the
lipid panels identified in Chapters 3 and 4 distinguishing AD patients from
healthy controls with a sensitivity and specificity of 80%. The analytical platform
used in this study enabled the simultaneous measurement of 189 plasma lipid
species in each sample. The method confers the advantages of facilitating the
identification of both differences in individual lipid species between clinical
classifications, and also patterns within related groups, such as the
sphingolipids; therefore directing future investigations to specific lipid targets.
The shotgun lipidomics method allows high sample throughput but suffers from
a compromise in the resolution, which may be addressed by a more targeted
approach utilising chromatographic separation prior to MS analysis. However,
before any further analyses are undertaken, the AIBL study has a wealth of
existing biomarker and lifestyle data that will continue to accumulate and
assessment of this data in the context of the plasma lipid profiles measured in
this study is required.
The results presented in this thesis have also opened up many areas of
potential future investigation, which may contribute towards the identification of
a sensitive and specific plasma AD biomarker panel that can be used in a
routine diagnostic laboratory setting; a necessity given the predicted marked
increase in the number of AD cases. Such lipidomic studies will likely lead to a
greater understanding of the pathological processes involved in AD and may
identify novel targets for which therapeutic interventions are directed. The
following summarises suggested areas for further investigation:


To improve the diagnostic sensitivity and specificity of the existing lipid
profiles, assessing ratios of lipid species may provide additional
information. The ratio of ceramides to sphingomyelin with same acyl
chain and the ratio of dihydroceramides to ceramides, may provide
information regarding SMases and dihydroceramide desaturase (DES)
respectively. The ratio of LysoPLs with their corresponding PL may be
altered by abnormal phospholipase activity, which is also reported in AD.
Additionally, the saturated to unsaturated ratio of the acyl species of the
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phospholipids may indicate problems with fatty acid metabolism. The
ratio of PE to PC species may indicate abnormal methylation patterns
and reduced choline availability, which is required for the synthesis of
both SM and acetylcholine.


Plasma fatty acid analysis will enable identification of important
polyunsaturated fatty acids such as DHA and also reveal whether there
is an essential fatty acid deficiency or abnormal metabolism involving
desaturase and elongase enzymes. Additionally measurement of
nervonic (24.1n-9), mead (22.3n-9) and tetracosahexaenoic (24.6n-3)
acids, which have been shown to be altered in AD, may be useful
additions to existing lipid profiles.



LC-MS/MS analysis of sphingolipids is justified as many ceramide and
sphingomyelin species were significantly different between clinical
classifications and changes in sphingolipids have been reported to
predict memory impairment [163]. Additionally in light of the recent report
by Mapstone et al, more targeted analysis of PC species with the
addition of acyl carnitines may identify an accurate panel for predicting
phenoconversion.



Chapter 1 described the interconnection of cholesterol, sphingolipid and
phospholipid metabolism, which suggest that the measurement of
cholesterol metabolites such as oxysterols may improve the sensitivity
and specificity of a lipid biomarker panel.



Determining PLTP activity levels within the entire baseline cohort is
recommended, as the pilot study reported in Chapter 5 showed
promising results. PLTP activity should also be assessed longitudinally
and compared to intra-individual SUVR. Additionally, the potential of
PLTP as an AD biomarker should be explored, both in combination with
plasma Aβ, and also as a component of a potential biomarker panel
including

inflammatory

markers.

Ceramides

are

connected

to
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inflammatory cytokines and insulin resistance [207, 265] and as a role for
PLTP in inflammatory signalling is suggested; an intriguing relationship
may be uncovered. The combined measurement of specific ceramide
species, inflammatory markers and PLTP could form an additional
biomarker panel.

6.4

Limitations

This thesis had the aim of identifying a sensitive and specific blood biomarker
panel for AD and reports the association of plasma lipid profiles and a lipid
transfer protein with clinical classification and various other AD biomarkers.
However, several limitations should be considered when interpreting the
findings.
Although samples were analysed at two time points in the AIBL cohort, further
longitudinal analysis is required. Whilst the baseline and 18 month lipid species
results were compared, the characteristics of the cohort changed over the 18
month period in terms of age, disease progression and non-returning
participants: Factors which must be considered when comparing the cross
sectional results at both baseline and 18 months. When analysing the data
longitudinally over 18 months, statistical power was limited in the context of
clinical classification transition, as only 54 of the participants who returned at 18
months transitioned to MCI or AD. It is likely that analysis of samples collected
at additional time points (i.e. 36 and 54 months) will reveal greater diversity in
the lipid profiles of individuals transitioning between clinical classifications,
compared to those who remain within their original classification group, thereby
facilitating the identification of a more sensitive and specific biomarker panel for
predicting clinical classification transition.
‘True comparison’ of the data collected at each of the two time points may also
have been affected by sample handling, as storage of the two sample sets
differed. The 18 month samples were stored in liquid nitrogen until the lipids
were extracted whereas the baseline samples, while initially stored in liquid
nitrogen, were stored for several years at -80°C prior to lipid extraction. The
effect of -80°C versus liquid nitrogen storage on lipid profiles was not tested.
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A “shotgun” lipidomics method was used for this study which simultaneously
measured a large number of lipid species with high throughput. This method
may have had lower resolution compared to a more targeted approach, and
therefore the measurement of some less abundant lipid species may have been
compromised. However, this analytical platform forms a solid foundation to
indicate which lipid species may need further investigation for their association
with AD.
When investigating plasma PLTP activity, only a sub-set of the cohort was
assessed. This analysis should be extended to include the whole cohort to
improve the power of the study.

6.5

Conclusion

The results presented in this thesis indicate that levels of several plasma lipids
significantly differ between healthy control, MCI and AD individuals and that
further investigation using complimentary lipidomic analytical approaches may
reveal highly sensitive and specific blood biomarkers for predicting AD. The
analytical platform chosen for this study was based on simultaneously
identifying a broad range of lipids (189 species) in a large cohort (n >1000).
Several lipid species were identified in both the baseline and 18 month samples
as being different between clinical classifications and a panel of lipids was
identified at each time point that was able to distinguish participants with AD
from healthy controls with a sensitivity and specificity of 80%. While this is
extremely useful in identifying lipids that differ with clinical classification and
providing information that can contribute to an understanding of altered lipid
metabolism in AD, the lipid panels as they stand cannot be used in a routine
setting for the diagnosis of AD. However several specific lipid species, in
particular ceramides and sphingomyelins showed great potential as blood AD
biomarkers;

therefore

further,

more

targeted

lipidomic

studies

are

recommended. In addition the results from the measurement of plasma PLTP
activity revealed some important associations with other AD biomarkers which
warrant further investigation.
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